BENZENE A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R EFERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright ©2004 by ICON Group International, Inc. Copyright ©2004 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1 Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Benzene: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-84351-1 1. Benzene-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International, Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on benzene. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes&Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON BENZENE ................................................................................................... 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Benzene ......................................................................................... 4 E-Journals: PubMed Central ....................................................................................................... 38 The National Library of Medicine: PubMed ................................................................................ 46 CHAPTER 2. NUTRITION AND BENZENE ......................................................................................... 93 Overview...................................................................................................................................... 93 Finding Nutrition Studies on Benzene ........................................................................................ 93 Federal Resources on Nutrition ................................................................................................... 98 Additional Web Resources ........................................................................................................... 99 CHAPTER 3. ALTERNATIVE MEDICINE AND BENZENE ................................................................. 101 Overview.................................................................................................................................... 101 National Center for Complementary and Alternative Medicine................................................ 101 Additional Web Resources ......................................................................................................... 106 General References ..................................................................................................................... 108 CHAPTER 4. DISSERTATIONS ON BENZENE ................................................................................... 111 Overview.................................................................................................................................... 111 Dissertations on Benzene ........................................................................................................... 111 Keeping Current ........................................................................................................................ 113 CHAPTER 5. CLINICAL TRIALS AND BENZENE ............................................................................. 115 Overview.................................................................................................................................... 115 Recent Trials on Benzene ........................................................................................................... 115 Keeping Current on Clinical Trials ........................................................................................... 116 CHAPTER 6. PATENTS ON BENZENE.............................................................................................. 119 Overview.................................................................................................................................... 119 Patents on Benzene .................................................................................................................... 119 Patent Applications on Benzene ................................................................................................ 136 Keeping Current ........................................................................................................................ 176 CHAPTER 7. BOOKS ON BENZENE ................................................................................................. 177 Overview.................................................................................................................................... 177 Book Summaries: Online Booksellers......................................................................................... 177 Chapters on Benzene .................................................................................................................. 180 CHAPTER 8. PERIODICALS AND NEWS ON BENZENE ................................................................... 183 Overview.................................................................................................................................... 183 News Services and Press Releases.............................................................................................. 183 Academic Periodicals covering Benzene .................................................................................... 185 CHAPTER 9. RESEARCHING MEDICATIONS .................................................................................. 187 Overview.................................................................................................................................... 187 U.S. Pharmacopeia..................................................................................................................... 187 Commercial Databases ............................................................................................................... 188 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 191 Overview.................................................................................................................................... 191 NIH Guidelines.......................................................................................................................... 191 NIH Databases........................................................................................................................... 193 Other Commercial Databases..................................................................................................... 195 APPENDIX B. PATIENT RESOURCES ............................................................................................... 197 Overview.................................................................................................................................... 197 Patient Guideline Sources.......................................................................................................... 197 Finding Associations.................................................................................................................. 199
viii Contents
APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 201 Overview.................................................................................................................................... 201 Preparation................................................................................................................................. 201 Finding a Local Medical Library................................................................................................ 201 Medical Libraries in the U.S. and Canada ................................................................................. 201 ONLINE GLOSSARIES................................................................................................................ 207 Online Dictionary Directories ................................................................................................... 208 BENZENE DICTIONARY ............................................................................................................ 211 INDEX .............................................................................................................................................. 283
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with benzene is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about benzene, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to benzene, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on benzene. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to benzene, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on benzene. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON BENZENE Overview In this chapter, we will show you how to locate peer-reviewed references and studies on benzene.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and benzene, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “benzene” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Occupational Factors and Renal Disease Source: Renal Failure. 16(4): 425-434. 1994. Contact: Available from Marcel Dekker, Inc. 270 Madison Avenue, New York, NY 10016. (212) 696-9000. Summary: This review article investigates the possible relationship between occupational factors and renal disease. The authors note that the male-to-female ratio of patients requiring dialysis treatment commonly approaches 2 to 1. They propose that environmental factors, particularly occupational exposure to hydrocarbons, may account for the excessive number of male patients. The term 'hydrocarbon' refers to the aliphatic, alicyclic, aromatic, and halogenated hydrocarbons; glycols; and organic solvents. Hydrocarbons have long been known to be neurotoxicants, affecting both
4
Benzene
peripheral and central nervous systems. Although benzene and its derivatives have a known association with uroepithelial tumors, there is now a considerable body of evidence suggesting a possible role for hydrocarbons in the development of nonneoplastic renal diseases. The authors present an epidemiological case for such an association and critically review the relevant literature. 64 references. (AA-M). •
Solvent Exposure As a Risk Factor for Alzheimer's Disease: A Case-Control Study Source: American Journal of Epidemiology. 141(11): 1059-1071. November 1995. Summary: This study investigated whether a history of organic solvent exposure is associated with increased risk of Alzheimer's disease (AD). The study base included about 23,000 people 60 years old and older from the local membership of a health maintenance organization in Seattle, Washington. About 193 cases of probable AD were identified and selected for the study in addition to 243 control subjects, randomly selected from the study base, who were free of dementia. Proxy informants provided specific solvent exposure history and job descriptions likely to involve solvent use as part of a comprehensive risk factor interview. The results suggest that kappa statistics indicated substantial agreement for control-control proxy solvent responses. History of exposure to one or more solvent groups (benzene and toluene; phenols and alcohols; ketones; and other solvents) yielded an adjusted AD odds ratio of 2.3; among males only, it increased to 6.0. The authors suggest that past exposure to organic solvents may be associated with onset of AD. 7 tables, 48 references. (AA-M).
Federally Funded Research on Benzene The U.S. Government supports a variety of research studies relating to benzene. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to benzene. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore benzene. The following is typical of the type of information found when searching the CRISP database for benzene: •
Project Title: A PF-GC FOR ENVIRONMENTAL HEALTH BREATH ASSESSMENT Principal Investigator & Institution: O'brien, Robert J.; Voc Technologies, Inc. 19251 Se Highway 224 Clackamas, or 970158845 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 30-SEP-2002
2 Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
Studies
5
Summary: Pneumatic Focusing Gas Chromatography (PFGC, patent pending) has achieved a limit of detection of 20 parts per trillion (0.8 pmol/liter) for benzene in ambient air in Portland OR. PFGC has a FID for universal hydrocarbon detection. Major endogenous compounds in human breath are methane, methanol, ethanol, acetone, methyl acetate, and isoprene. Their concentrations range from 80 nmol/L for methane to 400 pmol/L or less for methyl acetate. More than 1000 additional compounds have been reported present in human breath, many originating in the inhaled air. Exposure to toxics such as BTEX or other industrial chemicals will evidence itself in breath as well as in the ambient air environment. PFGC can detect the compounds already established in breath and ambient air with better sensitivity and lower cost than current instrumental methods. PFGC has the potential to standardize the methodology of breath analysis research. The goal of Phase I is to modify 3 commercial gas chromatographs for pneumatic focusing and demonstrate their performance in single and dual-column modes. Specific capillary column choice for resolution and selectivity will be evaluated. Performance will be evaluated with simultaneous indoor air/breath analysis for assessment of toxic exposure and uptake through the lungs of volatile organic compounds. PROPOSED COMMERCIAL APPLICATION: Potential commercial applications include breath analysis for exposure assessment onsite, and in standard monitoring profiles, as a research tool of human and other organismal exposure and metabolic studies, and for life insurance screening for passive markers of drug use, tobacco smoking, and as a toxic chemical exposure assessment tool. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: APPLICATION OF CRYSTALLOGRAPHIC TECHNIQUES Principal Investigator & Institution: Glusker, Jenny P.; Senior Member; Institute for Cancer Research Philadelphia, Pa 19111 Timing: Fiscal Year 2002; Project Start 01-APR-1976; Project End 30-APR-2004 Summary: Three aspects of chemical carcinogenesis will be investigated: the structural effect on DNA of alkylation by a bulky activated carcinogenic polycyclic aromatic hydrocarbon (PAH) and the reason that it escapes enzymatic repair, the roles played by various metal ions in biochemical reactions that control growth and other cellular processes that are affected by cancer, and the types of reactions (particularly isomerizations) that free radicals can undergo readily in a biological setting. Results from these proposed studies will increase our understanding on a molecular scale of a wide range of processes involved in cancer, and will help in the design of chemotherapeutic agents to combat it. Structural studies of PAH-DNA adducts and their interactions with repair enzymes will allow us to identify the specific type of DNA lesion that results in progression of the carcinogenic process. In addition to structural studies, model building will be coupled with energy calculations to study these DNA lesions. Some ab initio molecular orbital studies of reaction pathways in the metabolism of benzene and phenol will also be carried out. In proposed studies of metal ions, their coordination geometry and preferred ligands in biological systems and their effects on the ligands that they bind will be analyzed from structural data retrieved from the Cambridge Crystallographic Database and the Protein Databank. The energetic consequences of deviations from these preferred modes will be determined by ab initio molecular orbital calculations. The aim is to derive a series of rules on the different ways a given metal can behave in the environments found in biological systems. Conclusions will be tested in structural studies of enzymes (porphobilinogen synthase and ubiquitin hydrolase) and by studies of the binding of metal ions to D-xylose isomerase, an enzyme with two metal binding sites. Reactions of free radicals, causative agents in some forms
6
Benzene
of cancer, will be investigated by ab initio molecular orbital calculations to assess energy barriers to various reaction pathways. Initially, the B12-mediated reactions of the enzymes diol dehydrase and ethanolamine-ammonia lysase will be studied together with some structural work, but we will then proceed to other free-radical reactions such as those involving hydroxyl radicals and semiquinones that are relevant to cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ASSESSMENT NAPTHALENE
OF
DERMAL
EXPOSURE
TO
BENZENE
&
Principal Investigator & Institution: Nylander-French, Leena A.; Assistant Professor; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, Nc 27599 Timing: Fiscal Year 2002 Summary: Dermal exposure to allergenic and carcinogenic agents that may interact directly or indirectly (via electrophilic metabolites) with the skin is poorly understood and investigated. A major limitation to our understanding and development of this area of research has been the absence of non-invasive device and/or associated methodology to determine chemical specific skin exposure. New methods to determine the threshold dose to induce adverse effects under environmental and occupational exposure conditions are needed. We propose to test the hypothesis that very low levels of dermal exposure to benzene and naphthalene can be directly detected using samples of the keratinized epidermis removed by tape stripping. Subsequent extraction of the epithelium removed may then be analyzed for benzene or naphthalene by analytical chemical for recent exposures. Enzyme-linked immunosorbent assay (ELISA) methods may be used for quantification for protein adducts as biomarkers for low level chronic exposures and for correlation of dermal and systemic exposure. First, we will develop and use a non-invasive tape-stripping technique coupled with analytical chemistry methods to measure dermal exposure to benzene and naphthalene in two selected populations of workers. Secondly, we will investigate the potential relationship between dermal exposure in systems exposure to benzene and naphtalene in these exposed populations. Finally, we will develop an ELISA method for quantification of dermal exposure to benzene using polyclonal antibodies produced to protein adducts of benzene metabolites. Benzene is metabolized by cytochrome P450 CYP2E1 to benzene oxide and other electrophilic species, which may be used for measuring adduction to keratin (dermal exposure) to human serum albumin (systemic exposure). The results obtained by these proposed studies will increase our knowledge of the significance and the role of dermal exposure and the internal dose received to both the skin and internal tissues. In addition, the potential health effects (allergic contact dermatitis, cancer, etc.) that may result due to dermal exposure can be examined and correlated exposures. Ultimately, the procedures and methods developed in this study may be used as a as a model non-invasive skin-sampling procedure that reliably and reproducibly determines dermal exposure to environmental toxicants. Through reliable exposure assessment, strategies for minimizing exposure and, thus, preventing adverse health effects, can be developed and implemented. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ASSESSMENT OF HUMAN VOC EXPOSURE NEAR SUPERFUND SITES Principal Investigator & Institution: Thrall, Karla D.; Oregon Health & Science University Portland, or 972393098
Studies
7
Timing: Fiscal Year 2002 Summary: The research in this proposal to provide a fundamental understanding of the influence of route of reexposure on the total body burden and internal target tissue dosimetry of commonly encountered. Superfund contaminants, including trichloroethylene, perchloroethylene, 1,1- dichloroethylene, vinyl chloride, toluene, xylene, benzene, diethylbenzene isomers, and chloroform. Furthermore, since this research will involved extension of existing physiologically based pharmacokinetic models to describe the brain dosimetry following exposures, this effort will enhance the ability to accurately extrapolate animal studies to relevant human exposure scenarios and improve hazard and risk assessments. Exposure assessment studies will be conducted with human volunteers using a novel real-time breath analysis system to determine the uptake of any of the nine potential contaminants of study from tap water by each of three routes: inhalation, ingestion, and dermal contact. This data will be coupled with physiologically based pharmacokinetic (PBPK) modeling to determine the uptake kinetics and brain dosimetry. The resultant data from these comprehensive research projects within this Superfund program focused on development of biomarkers of susceptibility and response in potentially exposed populations. The specific research objectives are: 1. To generate physiologically based pharmacokinetic models to describe target organ dosimetry by route exposure. 2. To use the models to predict human dosimetry under environmentally relevant exposure conditions at characterized field study locations. 3. To conduct field studies to provide actual exposure assessments and target organ dose estimates by each route of exposure. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BENZENE METABOLITES AND HEMATOTOXICITY Principal Investigator & Institution: Monks, Terrence J.; Professor and Chair; Div/Pharmoacology & Toxicology; University of Texas Austin 101 E. 27Th/Po Box 7726 Austin, Tx 78712 Timing: Fiscal Year 2002; Project Start 01-JUN-2000; Project End 31-MAY-2005 Summary: (Adapted from applicant's abstract): Benzene, a major industrial chemical and environmental pollutant, causes a variety of hematological disorders in man, including aplastic anemia, myelodysplastic syndrome, and acute myelogenous leukemia. While it is clear that benzene must be metabolized to cause its acute hematotoxic effects, no single metabolite of benzene reproduces these effects in vivo. Coadministration of hydroquinone (HQ) and phenol (PHE), however, does lead to bone marrow suppression in rodents. A pharmacokinetic interaction between these two benzene metabolites results in increased concentrations of both metabolites in bone marrow. Peroxidase and/or phenoxy-radical mediated oxidation of HQ then initiates redox cycling and formation of the reactive electrophile, 1,4-benzoquinone, which is considered the ultimate hematotoxic metabolite of benzene. However, 1,4benzoquinone readily undergoes glutathione (GSH) conjugation to form 2-(glutathion-Syl)hydroquinone, 2,5-bis-(glutathion-S-yl)hydroquinone, 2,6-bis-(glutathion-Syl)hydroquinone, and 2,3,5-tris-(glutathion-S-yl)hydroquinone. Preliminary data indicate that these GSH conjugates are present in the bone marrow of rats and mice following coadministration of hydroquinone and phenol. Moreover, the majority of HQGSH conjugates present in bone marrow are formed in situ and are metabolized to more reactive thiol conjugates via a previously unidentified mercapturic acid pathway. Because these quinol-thioether metabolites have enhanced capability to both redox cycle and arylate tissue macromolecules, we hypothesize that quinol-thioether metabolites contribute to benzene-mediated hematotoxicity and that the mechanism(s) likely
8
Benzene
involve the production of reactive oxygen species and/or interaction with proteins that specifically recognize GSH/cysteine and GSH/cysteine containing molecules. Such metabolite specific interactions interfere with growth- and differentiation-related signaling. We therefore propose to (i) assess the acute hematotoxicity of HQ-GSH conjugates in rodent hematopoietic tissue, (ii) determine changes in the production and/or function of hematopoietic growth factors in response to HQ-GSH conjugates, (iii) test the hypothesis that metabolite-induced changes in gamma-glutamyl transpeptidase activity (GGT), dipeptidase activity, cysteine transport, and GSH concentrations, precipitate sphingolipid turnover, the generation of ceramide and the induction of apoptosis, and (iv) test the hypothesis that specific proteins involved in the synthesis (GST), transport (GS-X pump), and metabolism (GGT, dipeptidases) of the peptidyl leukotrienes are targets of HQ-GSH conjugates and interfere with granulocytic cell differentiation. Because benzene reduces the number of myeloid stem cells in bone marrow and induces incomplete granulocytic differentiation, our studies will provide a comprehensive understanding of the mechanisms by which reactive polyphenolic metabolites of benzene cause perturbations in growth- and differentiation-related signaling and how such changes culminate in benzene-mediated hematotoxicity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BIOCHEMICAL MECHANISM OF EXOCYCLIC ADDUCTS IN CANCER Principal Investigator & Institution: Singer, B A.; Faculty Scientist; Cell and Molecular Biology; University of Calif-Lawrenc Berkeley Lab Lawrence Berkeley National Laboratory Berkeley, Ca 94720 Timing: Fiscal Year 2002; Project Start 15-FEB-1988; Project End 31-MAR-2005 Summary: (Provided by Applicant): Many environmental and industrial chemicals, found to be mutagenic/carcinogenic when metabolized, form exocyclic derivatives of nucleic acid bases. The chemicals in this category to be studied include two metabolites of benzene, 2-hydroxy-p-benzoquinone and Z,Z-muconaldehyde, and glycidaldehyde, a carcinogenic metabolite from the widely used glycidol ethers. These metabolites will all react with DNA bases, resulting in structures which have additional 5 or 6membered ring(s) between the 1, N6 of A, the 3, N4 of C and the 1, N2 of G. These adducts, when incorporated into DNA, will be studied in terms of resulting changes in nucleic acid conformation using thermodynamics, molecular modeling and NMR. Concurrently, their mutagenic potential will be assessed by measuring the extent and type of base incorporation opposite the adducts and subsequent lesion bypass in replication using both prokaryotic and eukaryotic DNA polymerases. Experimentally, we will synthesize modified deoxynucleosides and their phosphoramidites which will be site-specifically incorporated into defined oligomers with differing flanking sequences since it is known that the sequence context is an important variable in biochemical functions. For replication studies, a primer extension assay with a 32P-label will be followed by gel electrophoresis for analysis of mispairing. Structural studies will be carried out using thermodynamics, NMR and molecular modeling. Such approaches should yield information on the relationship of adduct structure to DNA duplex stability and local conformational alterations, as well as probable biological relevance of these adducts on the basis of in vitro mutagenic findings. By using these exocyclic adducts, which have incremental changes in chemical structure, information will be gained on how structure affects function. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
9
Project Title: BIOMARKERS OF BENZENE EXPOSURE AND GENOTOXICITY Principal Investigator & Institution: Smith, Martyn T.; Professor; Environmental Health Sciences; University of California Berkeley Berkeley, Ca 94720 Timing: Fiscal Year 2002; Project Start 01-AUG-1993; Project End 31-MAR-2004 Summary: Benzene is an important industrial chemical (greater than 2 billion pounds produced annually in U.S.) And component of gasoline. It is also an established human leukemogen. The shape of the dose-response curve for benzene-induced leukemia at exposures below 10 ppm is highly controversial and a key public policy and risk assessment issue involving potentially billions of dollars. Conventional epidemiology and toxicology studies are unlikely to resolve this controversy. Work performed to date on this grant has led to the development of a mechanistically- relevant biomarker that should be sufficiently sensitive to shed light on the dose-response curve in the low dose region. This biomarker is the simultaneous detection of leukemia-specific aberrations in chromosomes 5, 7, 8 and 21 by fluorescence in situ hybridization in metaphase cells. We propose to examine this and other biomarkers in the blood of 300 workers exposed to a wide range of benzene concentrations (0.5 to greater than 10 ppm) and 150 unexposed matched controls. The first year will be devoted to the collection of these biological samples with detailed exposure information and sophisticated sample processing such that many new endpoints can be examined. Prior work on this grant has also shown that specific chromosomal translocations related to leukemogenesis can be detected by the reverse transcriptase-polymerase chain reaction (RT-PCR) in benzene- exposed workers. Recent advances in kinetic real-time PCR now make it possible to quantitate accurately the level of various chromosome translocations. We propose to use quantitative realtime PCR to measure levels of the translocations t(8;21), t(9;22), t(11q23) and t(14;18) in the peripheral blood lymphocytes and granulocytes of workers exposed to benzene and unexposed controls. Our studies to date also suggest that individuals differ in their susceptibility to benzene toxicity in relation to their folate status and genetic make-up. We therefore propose to further examine the role folate, vitamin B12, and various genetic polymorphisms play in individual susceptibility to benzene-induced chromosome damage. These studies will contribute to our understanding of the mechanism of benzene-induced leukemia, the risk benzene poses at low doses, and factors associated with susceptibility to this compound. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: BIOMARKERS OF EXPOSURE USING ACCELERATOR MASS SPECTROMET Principal Investigator & Institution: Turtletaub, Kenneth W.; University of California Berkeley Berkeley, Ca 94720 Timing: Fiscal Year 2002 Summary: The scope of this proposal is to develop a novel and ultra sensitive method for the measurement of DNA adducts quantitatively in humans and to study the degree of benzene and trichloroethylene (TCE) macromolecular adduct formation and repair in adults and children at concentrations equivalent yo human exposure levels. Benzene and TCE are important toxicants in the workplace and are ubiquitous in the environment. Importantly, there may be age- and gender-specific sensitivity to these agents, which requires study to understand the risks posed to children as opposed to adults. Our goal for this project is to develop and validate a method in animals that will have the capacity to quantitatively measure adducts from benzene and TCE exposure in humans and to understand the relationship between age and gender on the dose
10
Benzene
reaching the target tissues and the resultant levels of macromolecular adducts that are formed at doses equivalent to those encountered around superfund waste sites. Specifically, we will: 1. Develop and validate an accelerator mass spectroscopy-based isotope "post-labeling" assay. This assay will involve chemical acylation of nucleosides or nucleotides, will be quantitative, and will have detection limits in the low attomole range (equivalent to approximately 1 adducts/10/12 nucleotides). This is a continuation of the development of this technology for broad use in toxicology research. 2. Apply this isotope post-labeling-AMS assay in pilot studies using a mouse model to explore age and gender effects on benzene and TCE DNA adduct formation and clearance. 3. Conduct a pilot study with human sperm from benzene exposed workers to assess the mean level and variation in DNA adduct levels. We will correlate DNA adduct levels with exposure dose, subject age, blood protein adducts, and markers of chromosomal damage measured by other projects in this program. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BIOMARKERS NEURODEGENERATION
OF
NEUROTOXICANT
EXPOSURE
&
Principal Investigator & Institution: Sabri, Mohammad I.; Oregon Health & Science University Portland, or 972393098 Timing: Fiscal Year 2002 Summary: Superfund sites commonly contain organic solvents with neurotoxic potential. These substances include aromatic hydrocarbons, such as benzene and toluene and aliphatic hydrocarbons, such as 2-butanone (methyl ethyl ketone). Neurotic benzene derivatives, such as a 1,2- diethylbenzene (1,2-DEB) and its putative metabolite 1,2-diacetylbenzene (1,2-DAB), cause a blue-green coloration (chromogenicity) of tissues and urine. The chromogenic compound 1,2-DAB is a potent neurotoxicant that induces neuropathological changes (neurofilament-filled giant axonal swellings) comparable to those found in humans and animals repeatedly exposed to the aliphatic hydrocarbon solvent n-hexane or its keto metabolite 2,5-hexanedione (2,5-HD), respectively. In concert with components of the Analytical Core, we will use male and female young adult rats, and biochemical, analytical, and morphological methods, to test the following hypotheses: (a) that a relationship exists between the structural and toxicological properties of 1,2-DAB and 2,5-HD, (b) that the chromogenic and neurotoxic properties of 1,2-DAB are directly interrelated, (c) that 1,2-DAB is the neurotoxic metabolic of 1,2DEB, and (d) that 2-butanone and toluene, which respectively enhance and suppress the neurotoxic potential of n-hexane by altering its metabolism to 2,5-HD, modulate the neurotoxic potency of 1,2-DEB by altering its metabolism to 1,2-DAB. The major goal of this research project is to determine if the urinary chromogen (known to form in humans as well as rodents) can be used as a sensitive and specific biomarker of exposure to, and impending neuropathic effect of, aromatic hydrocarbons with neurotoxic potential. This biomarker may prove to be less invasive and more sensitive than an existing red blood cell spectrin-based biomarker of exposure to aliphatic gamma-diketones (2,5-HD). This project will also support studies in a companion research project (see Withers and Wallace, A4) that seek to determine if 1,2-DAB impacts brain development and plasticity. The long-term objective is to develop an ultrasensitive biomarker of exposure to non-chlorinated organic solvents that can be used to identify individuals/populations at risk for neurotoxicity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
11
Project Title: BIOTRANSFORMATION OF BENZENEARSONATES BY HUMAN ENZYMES Principal Investigator & Institution: Bayse, Gladys S.; Spelman College 350 Spelman Ln Sw Atlanta, Ga 303144399 Timing: Fiscal Year 2002 Summary: The long-term objectives of this project are to characterize the metabolism and assess the potential toxic effects n humans of the benzenearsonate additives in poultry and swine feed. Such information would provide the basis for consideration of potential metabolic or disease impact in humans, upon ingestion of these compounds. The benzene-arsonates, arsanilic acid (4-aminobenzenearsonic acid) and roxarsone (4hydroxy-3-nitrobenzenearsonic acid) are reactive compounds, with their phenolic aromatic amine, and aromatic nitro groups. Chronic exposure of humans to such compounds in the food supply is a matter of serious cancer, since structurally similar compounds are metabolized to active electrophiles which react with protein and DNA molecules to form tissue toxins or mutagens. Surprisingly, it appears that little attention has been given to analyzing human biotransformation of benzenearsonate compounds from consumed meat. An expanded study of the study of the action of human enzymes in biotransformations of the benzenearsonates will be undertaken, using human liver, including microsomes, the post-mitochondrial S9 fraction, several individual cytochrome P450 isoforms, flavin monoozygenases (FMO), and human cells in culture. Additional studies of the inhibitor roles of these benzenearsonates will be pursued as well, with attention given to the acid and alkaline phosphatase systems in human cell culture. Protein tyrosine phosphatases (PTPases) will also be investigated as benzenearsonate inhibition targets. The PTPases occur as both cytoplasmic and integral membrane enzymes with cell growth inhibition and tumor suppression characteristics. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CELL CYCLE DISRUPTION BY HYDROQUINONE AND CATECHOL Principal Investigator & Institution: Mccue, Jesica M.; Medicine; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, Co 800450508 Timing: Fiscal Year 2002; Project Start 01-JUN-2002 Summary: (Adapted from the Applicant's Abstract): Among the environmental immunotoxicants, benzene and its derivatives are produced in the greatest quantities have the widest human exposure, particularly as a result of cigarette smoking. Of these, hydroquinine (HQ) and catechol are potent inhibitors of several T cell responses in vitro. The long term objective of this research is to determine how HQ and catechol suppress cellular immunity by elucidating mechanisms by which exposure to these benzene derivatives affect human lymphocyte function. The hypothesis to be tested in this study is that HQ and catechol disrupt T cell responses by interfering with the normal sequence of cell cycle progression. In order to determine the molecular mechanisms of action of these phenolic compounds, the following specific aims will be undertaken using normal, human lymphocytes: Examine the kinetics and dose range of HQ- and catechol-induced cell cycle block. Determine the effects of acute exposure in vitro to HQ and catechol on IL-2 independent induction of competence by evaluating events that regulate T cell cycle entry (or G0 exit). Evaluate the effects of acute exposure in vitro to HQ and catechol on events that regulate IL-2 dependent G1 phase progression and cell survival. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
12
•
Benzene
Project Title: CHAR OF LOW BARRIER HYDROGEN BONDS IN SERINE PROTEASES & MODEL COMPOUNDS Principal Investigator & Institution: Frey, Perry A.; University of Wisconsin Madison 750 University Ave Madison, Wi 53706 Timing: Fiscal Year 2002 Summary: The goal of this project is the characterization of low-barrier hydrogen bonds in serine proteases and model compounds utilizing NMR spectroscopic techniques. Chymotrypsin, with various inhibitors (including N-acetyl-L-leucyl-L-phenylalanyltrifluoromethyl ketone) will be studied by proton NMR to evaluate the low-field chemical shifts in buffer solutions such as acetate, formate and succinate. The deuterium chemical shift values of chymotrypsin amd chymotrypsin complexed with specific inhibitors are also of interest, and will be examined. A series of acetic acid derivatives in 1:1 complexes with N-methylimidazole is also under investigation. These complexes are proposed to model the histidine-aspartate coupling in chymotrypsin and will be studied by proton and deuterium NMR in order to examine the low-field chemical shift values. Other intramolecular model compounds will be studied to examine the low-field chemical shifts. The model compounds will be prepared in solvents such a chloroform, methylene chloride and benzene. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CHECKPOINTS, DNA REPAIR & HUMAN CARCINOGENESIS Principal Investigator & Institution: Kaufman, William K.; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, Nc 27599 Timing: Fiscal Year 2002 Summary: This project concerns the roles of cell cycle checkpoint and DNA repair genes in protecting human cells from mutations and chromosomal aberrations induced by Superfund carcinogens. The "guardian of the genome" and tumor suppressor gene, p53, is now known to coordinate a complex set of checkpoint and DNA repair responses in carcinogen- damaged cells. Sone of the signals to activated p53 function come from the ATM kinase gene product. ATM also signals to p53-independent cell cycle checkpoints. Cells lacking p53 or ATM gene function display genetic instability and increased susceptibility to malignant transformation. Such cells provide a window to the systems of response to DNA damage that protect against human carcinogenesis. One human carcinogen found in many Superfund waste-sites is vinyl chloride (VC). Although not directly reactive with DNA, after absorption and metabolic activation to form chloroethylene oxide (CEO), mutagenic etheno adducts are produced on DNA bases. A subfraction of people exposed to VC in the workplace expressed high frequencies of hprt mutations in blood lymphocytes, while the majority of VC-exposed people did not. We will test whether this elevated mutation frequency is associated with a DNA repair defect by assessing CEO-induced genotoxicity in lymphoblastoid lines derived from sensitive and resistant people. Superfund waste-site carcinogens such as benzene and benzo[a]pyrene can be metabolized within cells to produce reactive electrophiles such as benzene- diolepoxide, respectively, as well as reactive oxygen species (ROS). The electrophiles and ROS both may attack DNA producing mutations and chromosomal aberrations. This project will determine whether p53 and ATM protect against genotoxicity by CEO, ROS, and diolepoxides. Enhanced risk of development of breast cancer has been linked to mutations in genes that participate in DNA repair including p53 and ATM. This project will employ a functional assay for DNA repair capacity in peripheral and lymphocytes that measures rejoining of radiation-induced chromatid
Studies
13
breaks. This assay will be used in a case- control study to test the hypothesis that development of breast cancer is associated with a defect in DNA repair. Sensitive cells identified in our case control study will be available as immortalized lines to determine whether hypersensitivity extends to ROS induced by Superfund carcinogens. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CORE--BIOMARKER LABORATORY Principal Investigator & Institution: Holland, Nina T.; University of California Berkeley Berkeley, Ca 94720 Timing: Fiscal Year 2002 Summary: In order to support the Superfund Program, we propose to establish a Biomarker laboratory Core that will combine the resources and facilities at the School of Public Health, UC Berkeley, the Laboratory of Molecular Epidemiology, UCSF, and Children's Hospital Oakland Research Institute. The main goal of the new Biomarker Core is to facilitate the collection, processing, and analysis of samples for epidemiological Projects 1-5 using established molecular and cytogenetic methods of analysis and to assure appropriate handling, storing, banking, and testing of these specimens. This core will be involved in the acquisition of handling, storing, banking, and testing of these specimens. This core will be involved in the acquisition of specimens from childhood leukemia cases and healthy controls of different ethnic backgrounds (with Projects #1-2); arsenic exposed children and adults from India and/or Chile (with Project #3); and benzene exposed workers from China (with Projects #4- 5). Laboratory protocols for sophisticated sample processing, including cryopreservation and storage in liquid nitrogen, will be established for cord blood, peripheral blood, buccal and urothelial cells, and sperm specimens. Routine characterization of these biological samples will include DNA/RNA isolation and storage; mutational analysis of the N- RAS gene; genotyping of a panel of cancer susceptibility genes; characterization of the cytogenetic traits in childhood leukemia cases by reverse-transcriptase PCR and fluorescence in situ hybridization; and analysis of cytogenetic damage in different cell types by the micronucleus assay. A computer database will be created to manage sample tracking, recovery, and transmission throughout the core and the Superfund program. These services will greatly enhance the ability of the epidemiological Projects #1-5 to achieve their goals. Establishing a biomarker core for laboratory analysis is an efficient use of resources of the Superfund program as UCB, UCSF and CHORI collaborators are already capable of performing all of the assays required and can do so without incurring the expenses of an outside laboratory. A unique bank of tissues and DNA/RNA samples will be established from children and adults of different ethnic background for use in future of cancer risk from genetic and environmental factors. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CORE--MOLECULAR EPIDEMIOLOGY Principal Investigator & Institution: Hertz-Picciotto, Irva; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, Nc 27599 Timing: Fiscal Year 2002 Summary: We propose to establish a Molecular Epidemiology Core to support Projects 1,2 and 3. The Core will build upon existing expertise and facilities in the Department of Epidemiology in three areas: collecting and archiving biologic samples from large, population-based epidemiologic studies; high throughput PCR-based genotyping to
14
Benzene
detect polymorphisms in carcinogen metabolism and DNA repair genes; design and implementation of epidemiologic studies incorporating biomarkers. For Project 1, the Core will provide DNA, red blood cells, and plasma samples from 435 controls from a population-based case-control study of breast cancer in North Carolina. Plasma samples have previously been characterized for PCB levels. The Core will optimize procedures for extraction of DNA and proteins from these samples in order to investigate the relationship between PCB exposure and levels of oxidative stress (AP sites, TG adducts, M1G adducts, oxidized proteins). The Core will conduct assays for metabolism genes and DNA repair genes which modulate endogenous levels of ROS and confer susceptibility to exogenous sources of oxidative DNA damage. For Project 2, the Core will maintain and archive immortalized cell lines from participants in a hospital-based case-control study of breast cancer who have been characterized with a variety of DNA repair and metabolism genes in order to investigate the genetic basis for radiation hypersensitivity. For Project 3, the Core will conduct genotyping assays for metabolism genes which contribute to variability in levels of benzene, benzene metabolites and reactive intermediates in human populations. For Projects 1, 2 and 3, the Core will assist in the implementation of population-based studies incorporating biomarkers, including study design, power calculations, identifying appropriate populations, addressing issues of bias, and obtaining IRB approval. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CYTOCHROME P450 SUBSTRATE SITING AND MOTION Principal Investigator & Institution: Mcdermott, Ann E.; Professor; Chemistry; Columbia Univ New York Morningside 1210 Amsterdam Ave, Mc 2205 New York, Ny 10027 Timing: Fiscal Year 2002; Project Start 30-SEP-2000; Project End 31-AUG-2004 Summary: Rationalization and prediction of hydroxylation products of cytochrome P450 is crucial for understanding the mechanism of this enzyme and for understanding drug metabolism, but remains generally enigmatic. We propose studies of orientation of substrates in the enzyme pocket, and motion of substrates in the enzyme pocket, by new magnetic resonance methods. A longstanding hypothesis states that, counter to typical enzymological dogma, many substrates bound to the active site of (mammalian or prokaryotic) cytochrome P450 rotate rapidly on the timescale of enzymatic turnover; this putative motion might actually be reasonable and even needed for turnover, since the substrate pocket appears to be rather hydrophobic and chemically "featureless". If this motion does indeed occur, it would have important implications for understanding hydroxylation preferences. We have performed preliminary studies of substrate siting and motion for adamantane bound to the resting state of CP450cam, using deuterium magic angle spinning (MAS) SSNMR spectroscopy. These preliminary data support the hypothesis of extensive motion. On this preliminary basis we propose to conduct more detailed studies with medicinally relevant systems. In this preliminary study, competitive displacement and Curie-law temperature dependence of isotropic shifts were used to verify location at the active site. Simulation of deuterium spinning sideband intensities allowed us to determine the strengths of the electron-nuclear dipolar hyperfine coupling, the strength of the effective deuterium quadrupolar splitting (which serves as measure of local motion) and the Euler angles describing the mutual orientation of the dipolar and quadrupolar tensors. Simulations of analogous data from model compounds are reported in a recent publication; RMS agreements of approximately 5 percent are possible, and the simulations are used to determine distances to a precision of 0.5 Angstrom units up to a maximum "capture radius" of 7 Angstrom units, and angles were determined to within 20 degrees. Simulations of the
Studies
15
data for enzyme-bound adamantane indicated an average metal-deuterium distance of 6.0 (+/- 0.2) Angstrom units and clear-cut evidence of a rapid high- symmetry motion. Computational and experimental improvements for analysis of the line-shape and spinning side-band intensities are proposed. We propose to characterize substrate motion for additional substrates (camphor, benzene, toluene, xylene, nicotine and warfarin), and an additional stable intermediate of the enzymatic cycle. Substrate geometry relative to the heme and substrate motion will be studies for the mammalian P450 enzyme using a membrane-mimic environment (DMPC/DHPC bicelles); information about substrate geometries is unavailable from crystallographic studies at present. Studies involving microbial detoxification enzymes with similar chemical mechanisms are also planned. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DETECT, ID & CHARACTERIZE BENZENE ADDUCTED MOUSE LIVER & BONE MARROW PROTEINS Principal Investigator & Institution: Burlingame, Alma L.; Professor; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 941222747 Timing: Fiscal Year 2002 Summary: By combining the ability of accelerator mass spectrometry to detect low levels of 14C with the high sensitivity of high energy collision-induced dissociation analysis for peptide sequence determination, we have developed a novel approach to detect and characterize proteins withadducted xenobiotic compounds. In the present study, we are trying to identify benzene-protein adducts purified from mouse liver and bone marrow cells. Benzene is a commonly occurring toxic compound and is present in combustion products, gasoline and tobacco smoke. It is known that chronic exposure to benzene leads to degeneration of the bone marrow and leukemia. Further, it has also been shown that benzene-protein adducts are formed via metabolism of benzene. Bioactivation of benzene occurs in the liver through oxidation by P450to phenol. However, several other reactive metabolites are formed as well, such as benzoquinones, catechol hydroquinone and muconaldehyde. The hematotoxic effect of benzene has been attributed to these benzene intermediates rather than benzene or phenol. The aim of this workis to characterize the protein adducts formed with benzene and to elucidate their possible importance for the development of leukemia and other benzene-induced pathological conditions. Crude liver homogenates obtained from mice injected with low amounts (500 ng/kg body weight) of 14C-benzene are fractionated by SDS-PAGE and the 14Cenriched proteins are detected by accelerator MS. The proteins of interest are subjected to in-gel trypsin digestion and the extracted peptides sequenced by high energy CID analysis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DETERMINANTS FOR CHROMOSOMALLY DEFECTIVE HUMAN SPERM Principal Investigator & Institution: Wyrobek, Andrew; University of California Berkeley Berkeley, Ca 94720 Timing: Fiscal Year 2002 Summary: Evidence for male-mediated developmental toxicity derives from strong animal data and from several epidemiological studies that exposures of fathers to environmental toxicants are associated with adverse consequences to the fetus and offspring. The proposed research will investigate the roles of specific paternal host
16
Benzene
factors and environmental risk factors for the transmission of chromosomal defects via sperm. Chromosomally defective sperm are detrimental to the developing embryo and live-born child resulting in spontaneous abortions and birth defects. Two promising sperm FISH methods have been recently developed to detect human sperm carrying abnormal numbers of chromosomes (aneuploidy) or structurally defective chromosomes (partial chromosomal duplications, deletions, or breakage). Studies with these sperm methods indicate that chromosomally defective sperm are inducible after exposures to certain drugs, both in murine and human studies; however, the utility of the genetic biomarkers in sperm in the assessment of reproductive hazards in occupationally or environmentally exposed populations remains to be proven. In addition, the modifying effects of host factors are not known. The objectives of the proposed research are to investigate the relationship of age and diet on sperm chromosomal defects in healthy non-smoking men and to determine if occupational exposure to benzene is associated with increases in the proportions of chromosomally defective sperm and with reduced semen quality. The specific aims are to: (a) characterize the relationship between age and chromosomal defects in sperm of approximately 100 healthy men aged approximately 20-80y, contrasting the age-defects on chromosome structure defects in sperm against numerical defects and semen quality; (b) examine the associations between diet and chromosomally abnormal sperm utilizing food- frequency questionnaire and seminal measurements of specific nutrients; and (c) investigate the effects of moderate-to-high occupational exposure to benzene (at or above US permissible levels) on chromosomal defects in sperm and semen quality for a group of approximately 50-benzene- exposed Chinese workers and approximately 40 unexposed controls. We will also compare the semen effects of benzene against its chromosome toxicity to lymphocytes We propose to investigate benzene because it is an important Superfund chemical, a proven human leukemogen, and occupational exposure induces chromosomal damage in lymphocytes. This project will contribute towards understanding male reproductive human health, specifically: (a) the importance of age and diet as paternal risk factors for chromosomally defective sperm, and (b) whether these genetic biomarkers in human sperm can be used as early warning signals for the identification of paternally mediated embryo-toxicity and teratogenicity due to exposure to Superfund chemicals. This project also has the exciting potential of identifying benzene as a human germinal mutagen, which would be extreme importance in assessing health risk to the unborn near Superfund sites. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DEVELOPMENT AND APPLICATION OF BIOMARKERS OF EXPOSURE Principal Investigator & Institution: Rappaport, Steve M.; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, Nc 27599 Timing: Fiscal Year 2002 Summary: Although it has been known for decades that benzene is a human carcinogen, the mechanism by which benzene causes human diseases is still unknown. One reason for this lack of understanding is the complex metabolism of benzene, which gives rise to many electrophilic intermediates capable of binding with macromolecules [notably, 1, 2- and 1,4-benzoquinone (BQ), benzene oxide (BO), benzene diol (epoxide (BDE), 1,2- and 1,4-benzoquinone (BQ) and the muconaldehydes (MAHs)]. In addition, some metabolites generate reactive oxygen species (ROS) which can also cause toxic effects. We previously developed cysteinyl protein adducts as biomarkers of exposure to BO and the BQs and now propose to extend the work to include BDE and the MAHs.
Studies
17
We will also apply existing methods to measure benzene and its metabolites in human urine and protein adducts associated with ROS in vivo (lysine adducts of malondialdehyde and 4-hydroxynonenal, the principal aldehyde product of lipid peroxidation). Armed with a comprehensive set of benzene biomarkers, we will explore the shapes of the gamut of exposure biomarker relationships in 1225 persons, about half of whom were occupationally exposed to benzene over a wide range of air levels (0.1 > 100 pp,). This will allow us to investigate the kinetics of the various metabolic routes. We will use these biomarkers to explore the magnitudes of inter-individual variability in human metabolism and to evaluate the association between biomarkers and genotypic expression of several enzymes involved in benzene metabolism (CYP4502E1, GSTT1 & GSTM1, NQO1, EH and MPO). We will also employ protein adducts to study the disposition of reactive benzene metabolites in rats and to compare the doses of these short-lived compounds in humans and rats, thereby improving quantitative risk assessment. Finally, we will use samples of blood and urine from unexposed persons to investigate the sources of background adducts of BO, the BQs and, potentially, to BDE and the MAHs. Collectively, these studies will provide information with which to characterize human metabolism of benzene, particularly in the critical range of benzene exposure below 10 ppm. Such information will be immensely valuable to those engaged in risk assessment and to researchers investigating the mechanism of benzene's particularly in the critical range of benzene exposure below 10 ppm. Such information will be immensely valuable to those engaged in risk assessment and to researchers investigating the mechanism of benzene's human health effects. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DEVELOPMENT OF COCAINE ABUSE TREATMENT AGENTS Principal Investigator & Institution: Ojo, Babatunde; Savannah State University Savannah, Ga 31404 Timing: Fiscal Year 2002 Summary: The overall goal of this proposed research is to synthesize and pre- clinically evaluate several new series of reversible and irreversibly binding cocaine antagonists in the methylphenidate class of stimulant agents. Extensive structural modifications involving the piperidine, ester moiety and aromatic ring of methylphenidate will be examined. It is anticipated that these structural modifications will provide therapeutic agents which inhibit cocaine binding, but spare dopamine uptake. The syntheses of desbenzene methylphenidate and a novel class of methylphenidate-like analogs (with piperidine ring replacement) are also proposed. These compounds will be evaluated in rats striatal tissue sin vitro for activity at the cocaine binding site using the [3H]WIN 35, 428 radioreceptor assay and for their ability to block synaptosomal [3H] dopamine transport. The ability to antagonize the behavioral effects of cocaine mediated through central dopaminergic pathways will be assessed utilizing tests which measure locomotor activity, cocaine discrimination and rotation following unilateral nigrostriatal lesions. Compounds which exhibit partial agonist or antagonist activity in the behavioral testings will be further evaluated ex vivo in the [3H]WIN 35, 428 and [3H] dopamine transport assays to obtain a better understanding of their interactions with the dopamine uptake complex in vivo. Computational modeling studies will be initiated to rationalize the biological significance of discrimination ratio (DR). Correlation between potency, dopamine uptake, DR, and the computational chemical analyses will be used to establish new structure activity relationships and hence, identify compounds which may be useful in directing efforts to develop medications for cocaine abuse. Successful completion of this research program will result in drugs with therapeutic
18
Benzene
potential against the reinforcing and addicting properties of cocaine. Ultimately, this work could serve as a significant contribution to the solution of cocaine addiction problem, a major continuing problem in the United States. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ENZYME REPAIR OF EXOCYCLIC ADDUCTS Principal Investigator & Institution: Hang, Bo; Staff Scientist; Cell and Molecular Biology; University of Calif-Lawrenc Berkeley Lab Lawrence Berkeley National Laboratory Berkeley, Ca 94720 Timing: Fiscal Year 2003; Project Start 05-SEP-1996; Project End 31-MAR-2006 Summary: (provided by applicant): The primary focus of this renewal proposal is on how repair enzymes process specific exocyclic DNA adducts, which are formed by diverse environmental mutagens/carcinogens including vinyl compounds, glycidyl ethers, chlorohydroxyfuranones, benzene and therapeutic nitrosoureas such as BCNU or formed by endogenous processes. Unrepaired adducts can block replication or cause mutation since many of these exocyclic adducts are miscoding lesions. The exocyclic adducts to be studied are structurally related but with differing features. Our central hypothesis is that such ring structural features, formed by different carcinogens, will determine specific enzymatic recognition and the type of repair. On this basis, we hope to identify and characterize new repair activities or novel repair enzymes. The proposed approaches from biochemistry and structural studies attempt to define specific structural features or rules that are essential for enzymatic recognition or repair efficiency. In addition, protein-protein interactions in glycosylase excision of exocyclic adducts will be investigated. By using in vitro biochemical approaches and specific oligonucleotides containing a single site-directed adduct, we wish to carry out the following specific aims: (1) To identify DNA glycosylases/endonucleases acting on newly synthesized exocyclic adducts; (2) To examine the initial recognition by mismatch repair (MMR) pathway of the available exocyclic adducts as these lesions form similar structures to mismatches; (3) To explore the potential pathway for p-benzoquinone adduct repair using an in vitro substitution methodology; (4) To study how and to what extent the DNA glycosylases excising exocyclic adducts interact with other cellular proteins such as 5'AP endonucleases, XPG protein and the MMR binding proteins; and (5) Structural studies, such as molecular modeling of damaged DNA/glycosylase complexes, will be performed to aid in understanding how repair enzymes interact with such adducted DNA. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: FOLDING OF UNNATURAL OLIGOMERS: HOLLOW HELICES Principal Investigator & Institution: Gong, Bing; Associate Professor; Psychology; State University of New York at Buffalo Suite 211 Ub Commons Amherst, Ny 14228 Timing: Fiscal Year 2002; Project Start 01-AUG-2000; Project End 31-JUL-2005 Summary: The proposed research involves the design of a novel class of oligomers that automatically fold into helices with large (10 Angstrom units to 30 Angstrom units) tubular cavities. Such hollow helices are suggested as potential prototypes of functional models for pore-forming protein and peptide toxins. The oligomers consist of benzene rings linked by amide groups. The backbone of an oligomer is curved due to the incorporation of intramolecular hydrogen bonds that rigidify the amide linkages. As a result, a backbone that is long enough will fold back on itself, leading to a left- or righthanded helical conformation. The helix formed is further stabilized by stacking of the
Studies
19
aromatic rings of neighboring spiral turns. Such a backbone- based helical programming will lead to helices whose folded conformation is resilient toward structural variation of the side groups that determine the outside surface properties. The interior of a helix is featured by the amide-O atoms, which makes the tubular cavities rather hydrophilic. The internal diameters of the helices are adjustable by combining meta- and paradisubstituted benzene rings or by using larger aromatic rings such as derivatives of naphthalene and anthracene. Preliminary results from ab initio calculations, 1H-NMR and X-ray crytsallography have clearly established the feasibility of the proposed research. These helices, as nanotubes, can be used as artificial pore-forming agents that can be easily functionalized. Molecular gatekeepers based on these nanotubes can be designed by including biochemical, chemical, and physical switches into the structures. The design of pore-forming drugs, drug carriers and sensitive membrane-bound sensors can be envisioned. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENOMICS OF AML-M3: PROGRESSION FACTORS Principal Investigator & Institution: Ley, Timothy J.; Washington University Lindell and Skinker Blvd St. Louis, Mo 63130 Timing: Fiscal Year 2003; Project Start 19-SEP-2003; Project End 31-AUG-2007 Summary: The goal of this project is to define the genomic changes that cooperate with t(15; 17) to cause progression of Acute Promyelocytic Leukemia (APL). To study this question, we developed a mouse model of APL. In mice that express both PMLRARalpha (PR) and RARalpha-PML (RP) in early myeloid cells, progression to APL is usually associated with the acquisition of an interstitial deletion of chromosome 2 (del 2), which also occurs in mice that develop radiation or benzene-induced AML. We propose to define the importance of del 2 for APL progression, as follows: Specific Aim 1: We will define the minimal reqion of chromosome 2 relevant for APL progression using high-resolution Comparative Genomic Hybridization and RNA Array techniques. We will precisely define del 2 in PR/RP mice using long oligomer arrays and comparative genomic hybridization (CGH). The same arrays will be used to search for microdeletions, and genes that are silenced in tumors that contain del 2. These regions will be the first to be resequenced in Aim 2. Specific Aim 2: We will define the genetic alterations within del 2 that contribute to APL progression. Total exonic sequencing of the most relevant genes within the del 2 interval will be performed in a series of tumors with and without del 2. If mutant genes are identified, their human homologues will be resequenced in human APL samples. Verified mutations will be assessed biologically in appropriate mouse models. Specific Aim 3: We will establish the relevance of del 2 for APL progression by recreating the deletion in mice using homologous recombination and Lox P-Cre technology. We will define the endpoints of the minimal deletion in Specific Aim 1, and target Lox P sites to its ends. We will remove the region from chromosome 2 in embryonic stem cells (or adult mice) with Cre recombinase, and make adult mice that are heterozygous for del 2. The del 2 mice will be intercrossed with hCGPML-RARalpha mice to assess the contribution of del 2 to APL progression. Additional mutations will be made as required to further define the critical regions within del 2. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HEMATOTOXIC EFFECTS OF BENZENE AND DOXORUBICIN Principal Investigator & Institution: Walsh, Anne C.; Wadsworth Center Empire State Plaza Albany, Ny 12237
20
Benzene
Timing: Fiscal Year 2002; Project Start 01-AUG-1991; Project End 31-AUG-2004 Summary: (Adapted from the Investigator's Abstract) The benzene metabolite hydroquinone (HQ) and the antitumor agent doxorubicin (DX) are chemically-related compounds that cause hematotoxicity through a mechanism that is likely to involve oxidative stress. Tumor Necrosis Factor-a (TNF) is capable of directly protecting human hematopoietic stem/progenitor cells (HPC) from numerous oxidative stress-inducing hematotoxic agents, including HQ and DX. TNF also affects normal HPC proliferation and differentiation and may stimulate myelodysplastic and leukemic HPC to proliferate. However, the mechanism by which TNF affects the biological activities of HPC remains largely unknown. It is hypothesized that the TNF-induced genes that have been identified by differential display reverse transcription PCR and RNase protection analyses encode products that are important in the protective (or other biological) effects of TNF on human HPC. The specific aims, research design and methods are: 1) to determine whether the TNF-induced genes identified are preferentially expressed in primitive or committed HPC by RNase protection on double purified HPC. Full-length cDNAs of these TNF-induced genes will be isolated by 5' rapid amplification of cDNA ends. The promoter regions will also be isolated by subcloning these sequences from human genomic bacterial artificial chromosomes. Sequencing and DNA database searches with the coding and promoter regions of the induced genes will be done to gain insight into the functions of the products of the unknown genes and to identify putative transcriptional regulatory sequences. 2) to assess the involvement of the TNFinduced genes in protection of HPC from HQ or DX using antisense methods to selectively inhibit gene expression in HPC or by transiently transfecting a leukemic cell line, not normally protected by TNF, or purified HPC with vectors expressing candidate protective genes to determine whether resistance to HQ or DX can be conferred. 3) to create profiles of the expression levels of known genes in HPC treated with TNF and/or HQ or DX, using DNA array technology. The long-term objectives of this proposal are to determine what TNF-activated genes and biochemical pathways are involved in protection of human HPC from hematotoxic agents. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HUMAN DOSIMETRY FOR ASSESSMENT OF EXPOSURE TO VOLATILE COMPOUNDS Principal Investigator & Institution: Kalman, David A.; University of Washington Grant & Contract Services Seattle, Wa 98105 Timing: Fiscal Year 2002 Summary: The objective of this project is understand the extent to which humans absorb, metabolize, and eliminate volatile organic compounds to which they may be exposed as a result of environmental contamination. Of special interest to us is the range of normal variation in these processes, and the factors which influence this variation. To better understand the underlying physiology, this project has as one of its central features the development and validation of a detailed mathematical mode of absorption, metabolism, and elimination processes in humans. Our past success in using this model to describe the operation of these processes for toluene, with very good accuracy, leads us to anticipate that this model will be able to describe the behavior of other solvents with different biological and chemical properties. Most important, the model relies on only a few readily measured individual characteristics (e.g. body fat composition, height, simple measurements of metabolic rate such as respiratory ventilation rate) to predict the individual's response. The results of this study will therefore support
Studies
21
relatively accurate health risk assessments and epidemiologic studies, without requiring complex or detailed input data. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HUMAN GENETICS, ENVIRONMENTAL INTERACTIONS Principal Investigator & Institution: King, Mary-Claire; American Cancer Society Professor; University of California Berkeley Berkeley, Ca 94720 Timing: Fiscal Year 2002 Summary: There is no text on file for this abstract. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: IN VIVO GENTOXICITY TO HEMOPOIETIC STEM CELLS Principal Investigator & Institution: Pallavicini, Maria G.; Professor; Laboratory Medicine; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 941222747 Timing: Fiscal Year 2002; Project Start 01-JUN-1998; Project End 30-NOV-2003 Summary: (Adapted from the investigator's abstract). The long term health effects of exposure to environmental contaminants are major public concerns. Occupational or environmental exposure to radiation, fuel hydrocarbons, and polychlorinated biphenyls is associated with increased risk of malignancy, particularly leukemia. However, assessment of the genotoxic and carcinogenic potential of environmental contaminants is difficult. Uncertainties in physical exposure and variations in physiologic response among individuals complicates risk assessment. Cross-species data extrapolation from in vitro and in vivo animal model systems is problematic. Fortunately, recent advances in molecular and cellular methodologies and in vivo models promise to alleviate some of these limitations. Molecular cytogenetics facilitates detection of translocations using fluorescence in situ hybridization. Immune -deficient mice transplanted with human cord blood cells (HU-mice) maintain high levels of persistent multi-lineage hematopoiesis, thereby providing opportunities to evaluate molecular and functional changes in human hemopoietic cells exposed to genotoxins in vivo. HU-mice should allow assessment of genotoxin effects on human hemopoietic stem cells (hsc) in vivo. We propose a novel approach to assess genomic and cellular changes in human hsc exposed to environmental contaminants in vivo. specifically, we will determine whether human hsc in HU-mice exposed to single and intermittent low doses of radiation or chemicals provide a read-out assay useful to estimate exposure. Specifically, we will 1) determine whether the frequency of genetically-damaged human hsc in an optimized HU-mouse model reflects in vitro exposure to radiation or benzene. 2) establish the relationship between in vivo radiation and benzene exposure and frequency of genetically damaged human hsc. 3) Test the hypothesis that intermittent, low dose in vivo exposure of human has to a genotoxin with concomitant hematotoxicity will result in more genomic damage than dose-equivalent single exposures. These studies will establish the usefulness of the HU-mouse model to increase understanding of the relationship between genotoxin dose and genetic damage in human hsc- an important component of risk assessment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
22
•
Benzene
Project Title: MECHANISM(S) OF CHEMICAL LEUKEMOGENESIS Principal Investigator & Institution: Irons, Richard D.; Pathologist/Scientist; Pharmaceutical Sciences; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, Co 800450508 Timing: Fiscal Year 2002; Project Start 30-SEP-1993; Project End 30-APR-2004 Summary: (Adapted from the Investigator's Abstract) The purpose of this continuing project is to better understand the roles of altered hematopoietic stem or progenitor cell (HPC) differentiation and cytogenetic damage in early events in the development of acute myelogenous leukemia (sAML) following treatment with alkylating chemotherapeutic agents or benzene. Consistent with emerging models of carcinogenesis, sAML is an evolutionary process involving selection of clonal cytogenetic events in HPC together with microenvironmental changes in stromal cells that ultimately contribute to the development of myelodysplasia (MDS) and sAML. During the previous funding period a multistep model for the evolution of sAML was developed in which drug- induced alterations in HPC proliferation lead to development of a distinct pattern of clonal cytogenetic abnormalities (C.A.) and progressive dysplastic changes that select for the emergence of the malignant cell phenotype. Using this model as a hypothesis, the pattern of expression of genes known to be involved in regulation of normal hematopoiesis will be compared between normal human bone marrow (BM) cells and BM treated with alkylating agents in vitro. Treatment related changes in transcriptional regulation of gene expression occurring in purified subpopulations of human CD34+ BM cells in liquid culture will be assessed using a variety of molecular biology techniques and correlated with flow cytometric analysis of cell phenotype, clonogenic function in HPC, and cytokine production in stromal cells. Fluorescence in situ hybridization also will be used to evaluate the potential of individual agents to produce C.A. in specific sub-populations of CD34+ human BM cells. Finally, patterns of gene expression will be correlated with genotype, phenotype and functional clonogenic response in BM cells obtained from patients with MDS or evolving sAML. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MICROWAVE REMEDIATION
TECHNOLOGY
FOR
SUPERFUND
SITE
Principal Investigator & Institution: Cha, Chang Y.; Cha Corporation 372 W Lyon St Laramie, Wy 82072 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-JUL-2004 Summary: (provided by applicant): CHA Corporation has developed a microwavebased air purification technology that can be effectively utilized to recover chemicals from soil vapors produced during hazardous site remediation without using a catalytic oxidizer. A field-ready prototype microwave treatment system will be designed, constructed, and tested in the laboratory during the first year of work. In the second year, the prototype microwave system will be transported to the Superfund site for a field demonstration. The prototype microwave system will be operated at the Superfund site to recover benzene and other chemicals in the soil vapors. Using the field demonstration test results, technical and economic feasibility of the microwave technology for hazardous waste site remediation will be assessed. If the microwave technology is successfully demonstrated for recovering chemicals including benzene from soil vapors, the technology will be ready to be commercialized for Superfund site remediation. Therefore, the main objective of Phase 2 of the proposed project is to
Studies
23
perform a commercial demonstration for this Superfund site remediation. A successful application of microwave technology for Superfund site remediation will provide significant energy savings and economic and environmental benefits to industrial sites and military bases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MODULATION OF CIGARETTE SMOKE INDUCED OXIDATIVE DAMAGE Principal Investigator & Institution: Fiala, Emerich S.; Chief, Division of Molecular Biology; Institute for Cancer Prevention 1 Dana Rd Valhalla, Ny 10595 Timing: Fiscal Year 2002 Summary: Previously, we found that inhalation of cigarette smoke by guinea pigs fed a diet deficient in ascorbic acid (AA), induced nitric oxide synthase (iNOS), and increased the respiratory levels of 3-nitrotyrosine (3-NT) and 8-oxodeoxyguanosine (8-oxo-dG). All of these effects, indicative of inflammation and of protein and DNA damage, were significantly decreased in guinea pigs fed a diet high in AA. The work proposed here is a logical extension of these findings. We postulate that cigarette smoke-derived oxidants, probably H2O2 and/or peroxynitrite, activate the transcription factors NFkappaB and AP-1, and that this is an anti- apoptotic, tumor promoting event. We further propose that the activation of NF-kappaB and AP-1 will be inhibited by anti-oxidants, specifically AA, vitamin E, and the tea polyphenol, (-)-epigallocatechin gallate, given singly or in combination in the diet. To test these hypotheses, we propose short term (approximately 40 day) cigarette smoke inhalation studies in which we determine changes in the levels of DNA 8-oxo-dG, 8- nitroguanine and selected etheno adducts, and the modulation of NF- kappaB, AP-1, c-myc, matrix metalloproteinase-9, iNOS, 3NT, cell proliferation and apoptosis in the guinea pig respiratory system, and the effects on these factors by dietary antioxidants. Specific Aim 1 will furnish basic information on the time courses of formation and loss of 8- oxo-dG, ethene adducts and 8-nitroguanine in lung DNA, The studies in Specific Aims 2 and 3 will give information on the degree of activation of inflammation- and tumor promotion-related transcription factors NFkappaB, AP-1 and c-myc, and on the consequences of such activation, including induction of matrix metalloproteinase-9 and iNOS, the appearance of 3-NT in protein, appearance of 8-oxo-dG, ethano adducts and 8-nitroguanine in lung DNA, and in changes in cell proliferation and apoptosis. Studies will then be undertaken to determine how these molecular marker changes in cell proliferation and apoptosis. Studies will then be undertaken to determine how these molecular markers are affected by dietary antioxidants, and whether the effects of the antioxidants, when given in combination, are either null, additive, or synergistic. As Specific Aim 2, we will continue the development of a method for the quantitative determination of 3-NT. The extension of this method, which has a sensitivity in the femtomol range for 3-NT (a marker for peroxynitrite-induced damage to proteins), to the array of 8- nitroguanine (a marker of peroxynitrite-induced damage to DNA), and to nitrated benzene metabolites generated in Project 2, will also be examined under this Aim. The results of our studies will read to a better understanding of the relationship of chronic respiratory inflammation to cigarette smoke-induced cancers, and the influence of dietary anti- oxidants. We expect that conclusions drawn into our research will be directly translatable to simple dietary intervention strategies in those smokers unable to quit. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
24
•
Benzene
Project Title: MOLECULAR CHARACTERIZATION OF AQUIFER MICROBIAL COMMUNI* Principal Investigator & Institution: Scow, Kate M.; Land, Air and Water Resources; University of California Davis Sponsored Programs, 118 Everson Hall Davis, Ca 95616 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-JUL-2005 Summary: Numerous groundwater aquifers are contaminated with organic and inorganic pollutants. Directly monitoring biodegrading microbial communities could guide decisions about treatment and facilitate monitoring of remediation. A common, but not well-investigated, challenge at Superfund sites is managing remediation of mixtures of contaminants. Superfund chemicals, toluene, benzene and xylene, along with fuel oxygenates, comprise mixed contaminants associated with petroleum pollution. Our aim is to adapt and develop molecular tools to assess the behavior of microbial communities associated with mixtures of pollutants. The underlying hypothesis that will guide our technology development is that microbial community structure (diversity and numbers of total bacteria, certain anaerobic toluene/xylene degraders, and denitrifiers) and community functions (e.g. rates of utilization of pollutants as e donors, use of electron acceptors) when exposed to mixtures of contaminants will not behave as predicted from behavior on single contaminants. We will focus on toluene and xylene biodegradation under nitrate reducing conditions, but also consider interactions of these processes with other BTEX compounds and the fuel additives, methyl tertiary butyl ether (MTBE) and ethanol. Our study system will be groundwater aquifer microbial communities, in microcosm and controlled field studies. Questions to be addressed include: 1) Are differences in biodegradation rates of contaminants, alone versus mixed with other chemicals, associated with differences in diversity and numbers of total bacteria, toluene/xylene degraders, and denitrifiers? 2) Do the same microbial populations use multiple contaminants? 3) Do readily degradable (e.g., ethanol) and recalcitrant (e.g., MTBE) fuel additives alter the biodegradation of BTEX under anaerobic conditions? We will use DGGE analysis and real-time quantitative PCR, targeting primers for enzymes involved in contaminant degradation (bssA) and nitrate reduction (nirS and nirK) and total bacterial cells (universal bacterial 16S rDNA). We will measure the accumulation of carbon from 14C labeled compounds (toluene, MTBE) into cellular constituents (PLFA, determine signature lipids/markers) of microbial communities using GC-MS and AMS (at Lawrence Livermore National Lab) in artificial mixes of bacterial strains and in microcosms. We will conduct studies in microcosms and across pollutant gradients (of BTEX, BTEX + MTBE or ethanol) at a field site containing a petroleum spill (with BTEX and MTBE) at Vandenberg Air Force Base in CA. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MOLECULAR EPIDEMIOLOGY OF ACUTE MYELOGENOUS LEUKEMIA Principal Investigator & Institution: Strom, Sara S.; Assistant Professor; University of Texas Md Anderson Can Ctr Cancer Center Houston, Tx 77030 Timing: Fiscal Year 2003; Project Start 05-AUG-2003; Project End 30-APR-2008 Summary: Little is known about the epidemiologic risk factors associated with the development of acute myelogenous leukemia (AML), and less is known about the role that genetic susceptibility plays in the development of AML. We propose to conduct a population-based study to investigate genetic susceptibility in adult AML patients, both de novo and treatment-related in a well-defined geographical area. Using a case-control
Studies
25
design, we will prospectively enroll 400 patients from the greater Houston area (Harris and surrounding counties) and 800 healthy controls. Controls will be recruited using random digit dialing, and will be matched to the cases by age, gender, and ethnicity. Epidemiological and demographic information will be obtained through personal interviews, and will be integrated with clinical information, cytogenetic data, and genotypic markers. Blood specimens will be collected on all participants, who will be genotyped for markers associated with activation and detoxification of chemical carcinogens, including chemotherapy drugs. Polymorphisms in genes such as cytochrome p450 (CYP2E1), glutathione S-transferases (GSTT1, GSTM1, GSTP1 ), epoxide hydrolase (HYL1), NADPH-quinone oxidoreductase (NQO1), and myeloperoxidase (MPO) will be analyzed. This study will provide insight into the role that these susceptibility markers, along with clinical epidemiological, and cytogenetic factors, play in the identification of people at risk of developing AML. Understanding how genetic predisposition and exogenous exposures interact to determine AML susceptibility will allow the development of prevention strategies in the future. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR CATECHOL/SEMIQUINOE/QUINONE
ORIGIN
OF
CANCER--
Principal Investigator & Institution: Cavalieri, Ercole L.; Associate Professor; None; University of Nebraska Medical Center Omaha, Ne 681987835 Timing: Fiscal Year 2002; Project Start 30-SEP-1991; Project End 31-DEC-2003 Summary: The results of our studies of the most potent carcinogenic aromatic hydrocarbon dibenzo[alpha,1]pyrene have provided critical information on the mechanism of tumor initiation. We have discovered that there is a correlation between depurinating adducts and oncogenic mutations, suggesting that these adducts are the primary culprit in the tumor initiation process and represent a common denominator for recognizing the potential of a chemical to initiate cancer. Oxidation of the carcinogenic 4-catechol estrogens (CE) produces depurinating adducts after reaction with DNA, whereas the noncarcinogenic 2-CE yield only stable adducts. These results form the basis to investigate initiation of cancer by the pathway of oxidative activation of catechols yields semiquinones yields quinones for CE in breast cancer, benzene in leukemia and dopamine in Parkinson's disease. We propose to (1) synthesize the 4hydroxyestradiol (4-OHE2)-1-C8Ade adduct by reaction of semiquinone (E2-SQ) anion radical with dA or Ade and determine whether it is formed, along with other already determined depurinating CE adducts, by enzymic oxidation of 4-OHE2; (2) determine the mammary carcinogenicity in female ACI rats of (a) 2-OHE1 or 2 and 4-OHE1 or 2 by subdorsal implantation in silastic tubing and (b) 2-OHE2, 4-OHE2 and their quinones (with or without equimolar E2) by repeated application to six teats; (3) determine the levels of depurinating CE-DNA adducts and CE-N-acetylcysteine [N(Ac)Cys] adducts in the urine of female ACI rats treated with CE or CE quinones; (4) determine the levels of these adducts in urine specimens from women with and without breast cancer; (5) synthesize adducts by reaction of the quinones of catechol, hydroquinone and dopamine with dG, dA, Ade, GSH, Cys and N(Ac)Cys; and (6) identify and quantify the depurinating and stable adducts formed by reaction of catechol quinone, 1,4benzoquinone and dopamine quinone with DNA or GSH and by reaction of enzymeactivated catechol, hydroquinone and dopamine with DNA or GSH. By accomplishing these aims, we will gain evidence that this pathway of oxidation of catechols (amines and estrogens) to form depurinating DNA adducts is the common denominator for
26
Benzene
triggering cancer and other diseases. In addition, we will identify biomarkers for use in diagnosis and in studies of prevention of breast cancer and other diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MUTAGENESIS AND CARCINOGENESIS Principal Investigator & Institution: Smith, Allan; University of California Berkeley Berkeley, Ca 94720 Timing: Fiscal Year 2002 Summary: This is the largest of the research cores, consisting of nine investigators working on various aspects of mutagenesis and carcinogenesis. It brings together toxicologists, molecular biologists, epidemiologist and geneticists. The multidisciplinary projects range in scope from studies on DNA damage through human population studies on biomarkers and cancer risk. The core leader is Dr. Allan Smith. Accomplishments from his laboratory include evidence for genotoxic effects in exfoliated bladder epithelial cells in human population exposed to arsenic in drinking water. Other accomplishments of this core include findings by Dr. Ames that oxidative DNA damage plays a major role in aging and cancer, that mitochondria are an important source of these oxidants, and that dietary antioxidant can protect against oxidative damage in humans. New Salmonella tester strains (Ames II test) have also been developed. New fluorescent labels for analysis of nucleic acid have been developed by Dr. Alexander Glazer. Dr. Lois Gold, in collaboration with Dr. Bruce Ames, has developed ranking schemes and databases for carcinogenic agents to which humans are exposed. Dr. Alexander Karu has developed immunoassays to detect PCBs and PAHs. Dr. Stuart Linn has added to our knowledge of the steps involved in oxidative DNA damage. Dr. Martyn Smith has new findings on the genotoxic effects of benzene metabolites, as well as development of a FISH technique for micronuclei in exfoliated bladder experiments which was used in the studies of Dr. Allan Smith. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NEURAL ACTIONS OF TOLUENE Principal Investigator & Institution: Woodward, John J.; Professor; Physiology and Neuroscience; Medical University of South Carolina 171 Ashley Ave Charleston, Sc 29425 Timing: Fiscal Year 2002; Project Start 15-APR-2002; Project End 28-FEB-2007 Summary: (provided by applicant): Volatile solvents such as toluene, benzene and trichloroethane are widely distributed in a variety of products encountered in both industrial and home settings. These include glues, thinners, rubber cements, aerosol sprays, nail polish removers, correction fluid and dry cleaning solvents. Although the occupational hazards of exposure to these solvents have been previously examined in a variety of toxicological studies, the cellular and molecular sites of action that account for their intoxicating effects are virtually unknown. Surveys of drug use show that a significant percentage of the population has used volatile solvents for their intoxicating properties and such use is especially prevalent among adolescents and teens who may have easy access to these products. Previous behavioral studies show that toluene and other abused volatile solvents display actions similar to that observed for CNS depressants such as ethanol, barbiturates, benzodiazepines, and anesthetics. Thus, we hypothesize that abused solvents, like other CNS depressants, may exert some of its neurobehavioral effects by altering the function of specific ion channels that are involved in mediating and modulating neuronal transmission. We have generated data
Studies
27
to support this hypothesis and have demonstrated that toluene and other volatile solvents inhibit the function of recombinant and native NMDA and acetylcholine receptors expressed in oocytes and cultured neurons. This inhibition was dosedependent and was influenced by the subunit composition expressed. In contrast to ethanol, toluene had negligible effects on currents mediated by non-NMDA receptors or on G-protein coupled potassium channels. These results suggest that abused solvents may show greater selectivity than alcohol with respect to their ability to modulate the activity of neuronal ion channels. Studies outlined in this proposal will test this hypothesis by determining the sensitivity of recombinant and native ion channels to toluene and other volatile solvents that are subject to abuse. Two-electrode voltageclamp and patch-clamp electrophysiology will be used to analyze the solvent sensitivity of recombinant ionotropic receptors expressed in oocytes and HEK cells. The molecular sites of action for toluene will be explored by testing whether sites known to regulate the alcohol/anesthetic sensitivity of these channels also regulate solvent sensitivity. Finally, the relevance of the findings obtained in recombinant receptor systems will be assessed by measuring the effects of toluene and other abused solvents on ion channels expressed in cultured brain neurons using whole-cell patch clamp and calcium imaging. Results obtained from these studies outlined are expected to greatly expand our knowledge of the cellular and molecular targets of these important drugs of abuse. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEUROTOXIC SUPERFUND CHEMICALS AND BIOMAKERS Principal Investigator & Institution: Spencer, Peter S.; Professor; Director and Senior Scientist; None; Oregon Health & Science University Portland, or 972393098 Timing: Fiscal Year 2002; Project Start 01-JUN-2000; Project End 31-MAR-2005 Summary: Cross-disciplinary and interdependent research will be undertaken to investigate several classes of Superfund-relevant chemicals that exert toxic or mutagenic effects on biological systems, notably the mammalian brain and other parts of the developing and adult nervous system. Research will be focused on mixtures of organochlorine and benzene- related solvents, their biodegradation products and associated metabolites. Three non-biomedical projects will investigate important aspects of the microbial degradation of these environmental toxicants. One focuses on enhancing in situ anaerobic biodegradation processes in groundwater (Project B1), a second examines methods to enhance in situ aerobic co- metabolism of these chemicals (Project B2), and the third investigates the nature and requirements of the microbial community involved in the breakdown process (Project B3). Four biomedical projects address the detection and health impact of animal and human exposure to low concentrations of these hazardous chemical species. One study will develop data-driven models to examine how Superfund-derived chemical enter the human brain (Project A1); another will develop a sensitive biomarker of neurotoxicant exposure based on structure-activity relationships (Project 2). The third will address molecular mechanisms underlying the neurotoxic and neuro-oncogenic properties of Superfund chemical metabolites (Project A3). The fourth will investigate subtle impacts of chemical exposure on the development and adaptability of the immature brain (Project A4). A communitybased project (Core C1) will seek to model neurobehavioral tests to disadvantaged pediatric populations exposed to Superfund chemicals with neurotoxic potential. Two Research Support Cores provide powerful, state-of-the-art technical support (Core D1), and next-generation mass spectroscopy (D3). The Outreach Core will assess the impact of Internet-based education on communities in remote locations that are at high risk for exposure to neurotoxicants in water and other media. Graduate students entering the
28
Benzene
Training Core will select from a wide range of biomedical and non- biomedical research opportunities that will provide them with a unique cross-disciplinary training. In sum, this program of research seeks innovative methods to promote microbial degradation and thereby reduce exposure to hazardous chemicals, to develop hazardous sensitive methods to detect their presence in environmental media and mammalian species, and to define their potential adverse effects on the developing and mature nervous system. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEW CYCLIZATION METHODS AND MULTICOMPONENT COUPLINGS Principal Investigator & Institution: Montgomery, John; Professor; Chemistry; Wayne State University 656 W. Kirby Detroit, Mi 48202 Timing: Fiscal Year 2003; Project Start 01-JAN-1998; Project End 31-DEC-2006 Summary: (provided by applicant): The primary objective of this proposal is to develop powerful methods for the synthesis of complex molecules. The new methods to be specifically addressed during this project period will rely on the catalytic generation and functionalization of nickel metallacycles. A new synthetic strategy employing sequential nickel-catalyzed reactions will be developed that should provide access to a variety of carbocyclic and heterocyclic aromatic substructures. Other new cyclization methods that utilize allene precursors and vinylzirconium precursors will be developed. The efforts in synthetic methodology development should provide fundamentally new solutions to a variety of synthetic problems.The aims of this proposal also include the total syntheses of biologically interesting natural products utilizing new reactions developed in this program. The target molecules that will be pursued include testudinariols A and B, domoic acid, isodomoic acids G and H, serratezomine A, and pumiliotoxin 341A. These problems in total synthesis will allow us to pursue solutions to numerous substantial synthetic challenges including the generation of densely functionalized five and six membered rings that possess multiple contiguous stereocenters, the stereoselective generation of tri- and tetrasubstituted alkenes, and the stereoselective creation of quaternary carbon centers. Furthermore, the synthesis of preparative quantities of these biologically interesting natural products and closely related late stage intermediates will allow evaluation of their utility as potential pharmaceutical agents and as research tools in pharmacology. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NQO1 IN PROTECTION AGAINST BENZENE TOXICICITY Principal Investigator & Institution: Ross, David; Professor; Pharmaceutical Sciences; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, Co 800450508 Timing: Fiscal Year 2003; Project Start 15-JUL-1998; Project End 30-NOV-2007 Summary: (provided by applicant): The homozygous NQO1*2 polymorphism results in a total lack of NQO1 activity due to accelerated degradation of the mutant NQO1*2 protein by the ubiquitin/proteasomal pathway. The NQO1*2 polymorphism has been found to be a risk factor for benzene-induced myeloid toxicity but also for childhood and adult de-novo leukemias and secondary leukemias arising as a result of chemotherapy. The mechanisms underlying the protective effects of NQO1 against benzene-induced myelotoxicity and both de-novo and secondary leukemias were puzzling since NQO1 was not expressed in aspirated human bone marrow cells or human bone marrow CD34+ progenitor cells, the target cell for induction of both
Studies
29
aplastic anemia and leukemia. However, we observed that NQO1 was present in human bone marrow endothelial cells (HBMEC), which are not harvested by bone marrow aspiration. In the present application, we wish to explore the potential role of NQO1 in HBMEC in protection against benzene induced aplastic anemia and have established HBMEC cultures in our lab for this purpose. We propose a mechanism whereby HBMEC exposed to benzene metabolites produce increasing amounts of endothelial IL8 (elL8) which results in apoptosis of neighboring hematopoietic cells and myeloid progenitor cells resulting in aplastic anemia. We will also examine the mechanism underlying the lack of expression of NQO1 in human myeloid cells at the transcriptional level by characterizing cis acting DNA sequences and trans acting nuclear protein-DNA interactions that modulate NQO1 expression. One of the major tumor suppressor genes characterized in mammalian systems is p53 and a high percentage of leukemias contain mutations or allelic losses of p53. In preliminary data, we demonstrate that NQO1 forms a protein complex with wild type p53. We propose to examine whether the interaction of NQO1 and p53 is specific for wild type p53 and whether it has consequences for p53 stability and p53-dependent transcriptional activation of downstream genes. If NQO1 stabilizes p53 and the interaction has functional consequences, this would provide a mechanism for the increased incidence of leukemia of diverse origin that has been associated with a lack of NQO1 protein due to the NQO1*2 polymorphism. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SYNTHESIS
ORGANOCATALYSIS:
A
STRATEGY
FOR
ASYMMETRIC
Principal Investigator & Institution: Macmillan, David W.; None; California Institute of Technology Mail Code 201-15 Pasadena, Ca 91125 Timing: Fiscal Year 2002; Project Start 01-JUN-2002; Project End 31-MAY-2006 Summary: The objective of this research proposal is to invent new catalytic synthetic methods or strategies that allow enantioselective access to structural and stereochemical motifs, which although common among anti-viral, anti-cancer anti- bacterial and antiinflammatory medicinal agents, cannot be readily accessed using conventional methods. In this endeavor, we target processes that are readily applied within the related discipline of enantioselective catalysis and therefore will have a direct and immediate impact on the production of single enantiomer drugs with established biological importance. Our intent is to develop synthetic methods of broad utility and function that will ultimately provide new chemical tools for the diverse range of biomedical researchers that utilize molecule construction. As a consequence, this core research will prove valuable to a number of wide-ranging therapeutical areas. Over the last 30 years, enantioselective catalysis has become one of the most important frontiers in exploratory organic synthetic research with widespread application in biomedical settings. Surprisingly, however, relatively few asymmetric transformations have been reported which employ organic molecules as reaction catalysts (organocatalysis) despite the widespread availability of organic chemicals in enantiopure form and the attendant potential for savings in cost, time, energy, operational complexity and chemical waste This proposal outlines the development of an innovative and general strategy for organocatalysis that enables simple chiral amines to function as asymmetric catalysts for a wide range of transformations that traditionally utilize Lewis acids. We further describe a catalyst design endeavor that should provide an inexpensive, robust amine catalyst that provides high levels of asymmetric induction across a broad spectrum of chemical processes. During the tenure of this granting period we hope to demonstrate the value of this new chemical strategy in the context of the first examples of
30
Benzene
enantioselective organocatalytic (1) intermolecular Diels-Alder reactions, (2) intramolecular Diels-Alder reactions, (3) 1,3-dipolar cycloadditions, (4) Benzene alkylations, (5) Pyrrole alkylations, (6) Indole alkylations, (7) Furan alkylations, (8) Michael Additions, (9) Mukaiyama-Michael Additions, (10) Vinylogous Michael Additions and (10) Intramolecular Ene reactions. The pyrroloindolines and bispyrroloindolines represent a diverse family of structurally complex polyindoline alkaloids that exhibit remarkable biological properties across a broad spectrum of pharmacological screens (anti-cancer, anti-inflammatory, neuroactivity receptors: cholecystokinin, substance P and neurokinin 1). This proposal outlines an innovative application of our iminium activation strategy towards the one step enantioselective cascade synthesis of bispyrroloindoline architecture. Having demonstrated the feasibility of this transformation, we hope to determine the scope of this catalytic tandem reaction methodology for the production of a range of bispyrroloindoline alkaloids. To exemplify the value of this innovative asymmetric catalytic methodology we will pursue the highly expeditious synthesis of (+)-pseudophrynamine A; a constituent of the dendrobatid amphibians. This new chemical tool will be further employed for the five step asymmetric synthesis of (+)-chimonanthine, a complex alkaloid that will serve as an architectural template to launch a variety of subsequent complex target syntheses endeavors. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: OXIDATIVE ACTIVATION OF QUINONES AND MUTAGENESIS Principal Investigator & Institution: Chakravarti, Dhrubo; University of Nebraska Lincoln Lincoln, Ne 685880430 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2007 Summary: (provided by applicant): Carcinogen-induced DNA depurination plays a central event in the initiation of cancer. Apurinic sites formed by carcinogens in this manner are mutated by errorprone repair. Studies indicate a remarkable similarity in the enzymatic (redox) mechanisms for the conversion of several carcinogens (diethylstilbestrol, hexestrol and benzene) and suspected agents for the initiation of neurodegenerative diseases (dopamine) into DNA-reactive metabolites. These chemicals primarily form DNA depurinating adducts. On the basis of these shared similarities, we hypothesize that these carcinogens (diethylstilbestrol and benzene) and dopamine cause disease through specific mutagenesis, induce mutations by error-prone repair. To examine this hypothesis, we have chosen three model systems (mouse skin H-ras, rat bone marrow N-ras and rat brain protein kinase C-gamma) to study the mechanism of mutagenesis by these agents. We have also noted that during the repair of carcinogeninduced DNA depurination, the level of AP endonuclease protein increases five-fold over untreated tissue levels. AP endonuclease is a multifunctional protein, with apurinic/apyrimidinic site incision activity (DNA repair) and a reducing activity on various transcription factors (redox activity). The redox status of AP endonuclease protein determines its ability to participate in DNA repair. We hypothesize that AP endonuclease induction plays important regulatory role in carcinogen-induced apurinic site repair. To examine these hypotheses, we propose four specific aims. In Specific Aim 1, we propose to examine the induction of mutations by the quinone of diethylstilbestrol in the mouse skin H-ras gene as a reporter system. In Specific Aim 2, we propose to examine induction of mutations by the quinone of benzene in the rat bone marrow Nras model system for leukemia. In Specific Aim 3, we propose to examine induction of mutations by the quinone of dopamine in rat brain protein kinase C-gamma model system for neurodegenerative diseases. In Specific Aim 4, we propose to examine the
Studies
31
induction of AP endonuclease by these chemicals in the model tissues, determine the apurinic/apyrimidininc site incision activity and the redox status of AP endonuclease protein. In summary, the proposed studies (Specific Aims 1-3) will provide experimental evidence on the central role of apurinic site induction plays in causing various diseases. Experiments proposed in Specific Aim 4 will examine the redox status of AP endonuclease and its role in apuinic site misrepair. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PILOT STUDY--MODELS DRINKING H2O
OF ORGANIC COMPOUNDS
IN
Principal Investigator & Institution: Gurian, Patrick L.; University of Texas El Paso El Paso, Tx 79968 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAY-2007 Summary: (provided by applicant): Drinking water is an important source of exposure to environmental contaminants. Many organic compounds commonly found in drinking water (e.g., benzene, chloroform) are believed to be carcinogenic. Understanding current national exposures and the costs of reducing these exposures will allow us to prioritize among different health risks and focus efforts on those areas likely to have the greatest public health benefits. The specific objectives of this project are to develop joint statistical models of the concentrations of organic contaminants in U.S. drinking water, to estimate human exposure to these contaminants from drinking water, and to estimate the cost-effectiveness of efforts to reduce these exposures. Multivariate statistical models of organic contaminant concentrations in U.S. drinking water will be estimated using data in one or more publicly available databases on drinking water quality. A crossvalidation approach will be used to identify the multivariate statistical model with the greatest predictive power. Predictions from the selected model will be used in conjunction with information on the distribution of the population served by public water supplies in the U.S. to develop a national distribution of human exposure to these contaminants. The cost-effectiveness of risk mitigation options will be estimated by a statistical simulation of the effects of potential future drinking water standards. Finished water concentrations at each of the nation's approximately 55,000 community water systems will be simulated from statistical concentrations exceeding their potential future standards, the costs and exposure reductions achieved by additional treatment processes will be simulated. Incorporating joint models of contaminant occurrence in such benefit-cost models is important because treatments implemented to reduce exposure to one contaminant often affect the concentrations of other contaminants. This project will develop more accurate models of current human exposures to organic contaminants in drinking water and will also improve estimates and benefits of reducing human exposure to these contaminants. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PREVENTION OF QUINONE TOXICITY AND MUTAGENICITY Principal Investigator & Institution: Jaiswal, Anil Kumar.; Associate Professor; Pharmacology; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2002; Project Start 01-AUG-1996; Project End 31-JUL-2005 Summary: Studies on the mechanisms that detoxify chemicals and protect cells against toxicity, mutagenicity and cancer are highly significant for human health. Two cytosolic proteins [NAD(P)H:quinone oxidoreductase 1 (NQO1) and NRH:quinone oxidoreductase 2 (NQO2)], with the expected function of quinone detoxification, were
32
Benzene
cloned and sequenced. Cellular studies showed that NQO1 and NQO2 reduced the DNA binding and mutagenicity of quinones. Knockout NQO1 -/- mice were produced using target gene disruption. The NQO1 -/- mice were born normal and reproduced the same as the wild-type NQO1 +/+ mice. However, NQO1 -/- mice exhibited a significant reduction in abdominal adipose tissue, bone marrow hyperactivity and hyperplasia. The NQO1 -/- mice, upon exposure to benzo(a)pyrene, developed skin tumors at a higher frequency, when compared with the wild-type mice. NQO1 and NQO2 were found to be differentially expressed among various mouse tissues. The mouse NQO2 cDNA and gene were cloned and sequenced. A targeting construct to generate NQO2 -/- mice was prepared. One of the major goals of this proposal is to extend our studies on the NQO1 /- mice. We will determine the susceptibility of NQO1 -/- mice to benzo(a)pyrene, benzene and their quinone metabolites induced carcinogenicity when compared with wild-type NQO +/+ mice and investigate the role of NQO1 in the accumulation of abdominal adipose tissue. In addition, we will generate knockout NQO2 -/- mice that do not express NQO2 and compare the sensitivity of these mice, to that of mice expressing NQO2, following carcinogen exposure. We also plan to generate double knockout mice that do not express both NQO1 and NQO2 and determine the susceptibility of double knockout mice to chemical carcinogens when compared with wild-type and single knockout mice. To this effect, we will expose the NQO1 -/- and NQO +/+ mice to chemicals and analyze the development skin and tissue specific tumors. To investigate the mechanism of reduced abdominal adipose tissue in NQO1 -/mice, we plan to analyze the ratio of reduced and oxidized cytosolic NAD(P) from livers an kidneys of NQO1 -/- and NQO1 +/+ mice. This ratio plays a role in regulation of gluconeogenesis and fatty acid biosynthesis. NQO1 utilizes NAD(P)H and may participate in maintaining a balance between reduced and oxidized forms of NAD(P). We will use gene targeting and homologous recombination to generate NQO2 -/- mice deficient in NQO2. The NQO1 -/- mice will be bred with the NQO2 -/- mice to produce NQO1 -/-/NQO2 -/- double knockout mice. NQO2 -/- and double knockout mice, along with wild-type mice, will be exposed to quinones and precursors and analyzed for DNA/membrane damage and the development of skin and tissue specific tumors. Upon completion, these studies will provide significant information on the in vivo function of NQO1 and NQO2, as well as their role in chemical carcinogenesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RADIOIODINATED LIGANDS FOR IMAGING ABETA PLAQUES Principal Investigator & Institution: Kung, Hank F.; Professor of Radiology & Pharmacology; Radiology; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2002; Project Start 15-SEP-2002; Project End 31-AUG-2007 Summary: (provided by applicant): Alzheimer's disease (AD) is a neurodegenerative disease of the brain characterized by dementia, cognitive impairment and memory loss. Formation and accumulation of aggregates of &-amyloid (AB) peptides in the brain are critical factors contributing to the development and progression of AD. Currently, early appraisal of clinical symptoms for diagnosis of AD is often difficult and unreliable. Therefore, there is an urgent need for in vivo imaging agents, which can specifically demonstrate the location and density of amyloid plaques in the brain. The objective of this project is to develop potential 1-123 labeled diagnostic imaging agents specific for detection of AB plaques. Recent advances in developing tracers for binding A13 plaques suggest that there are specific and saturable binding sites on the aggregates of At3 that can be selectively labeled and imaged in vivo. The proposed agents are derivatives of
Studies
33
stilbenes containing a p-MezN-, -SH, -SMe, -0Me or -OH group on one of the benzene rings, while radioactive iodine can be attached to the other benzene ring without affecting the binding affinity. They are simple, relatively small, neutral and lipophilic. On the basis of their exquisitely high binding affinity to At3140 aggregates (Ki at the range of 0.1-40 nM), they are suitable candidates as A&-plaque-selective imaging agents. They also showed ability to penetrate the intact blood-brain barrier, an essential prerequisite for a useful plaque-imaging agent. The proposed synthesis and methodology provide a framework to test the hypothesis that small probes can be used to detect At3 plaques in vivo. The proposed compounds are innovative and carefully crafted to meet the stringent requirements for t3-amyloid imaging agents. Together with the compelling preliminary data presented in this project we believe that At3 plaque-selective imaging agents can be successfully developed. The At3-plaque-specific imaging agents will be useful for early detection or monitoring the progression and effectiveness of treatment of AD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REACTIVE METABOLITES AND DRUG TOXICITY Principal Investigator & Institution: Hanzlik, Robert P.; Professor; Medicinal Chemistry; University of Kansas Lawrence Youngberg Hall Lawrence, Ks 660457563 Timing: Fiscal Year 2002; Project Start 01-AUG-1978; Project End 31-MAR-2004 Summary: Many simple organic molecules containing phenyl substituents or benzene rings become cytotoxic upon biotransformation to reactive electrophilic metabolites. Prime examples include halothane, acetaminophen and bromobenzene (BB). Their hepatotoxicity is correlated with covalent binding of reactive metabolites to cellular proteins. As a start toward elucidating the biochemical mechanism(s) of their cytotoxicity we identified the structures of ten adducts of BB metabolites to protein-SH groups; most arose via quinone metabolites, but we also found that BB-3,4-oxide (BBO), thought to be the primary "toxic" metabolite of BB, alkylates histidine and lysine as well as cysteine residues of rat liver proteins. Key questions concerning the mechanism of cell injury by reactive metabolites include the identity of the proteins they target and the functional consequences of their covalent modification. We recently identified several rat liver proteins targeted by BB metabolites. One was a nonspecific esterase also known to be a target for metabolites of halothane and molinate. Another, surprisingly, was epoxide hydrolase, which is supposed to detoxify BBO. To address the mechanism of BB-induced cytotoxicity it is essential to expand this list by identifying other liver proteins targeted by BB metabolites. In doing so we will emphasize mitochondrial proteins but will continue to explore cytosolic and microsomal proteins. To facilitate recognition of BBO adducts, we raised antibodies to p-bromophenyl-cysteine and demonstrated their utility for western blotting; we will now develop antibodies to pbromophenyl-histidine and p-bromophenyl-lysine as well. These antibodies, coupled with [C14]-BB, will give us a broad and powerful means for finding and identifying those proteins of greatest toxicological interest. Very little is known about the chemistry and consequences of protein adduction by reactive metabolites. Thus we will elucidate in detail the specific site(s), metabolite(s) and linkage(s) involved in adduct formation for select BB target proteins. For those target proteins which are enzymes, we will evaluate the effect of adduction on catalytic activity to assess its potential contribution to cell injury. Comparing the proteins modified by bromobenzene to those modified by other small bioactivated toxins may reveal the existence, or the lack of, a "common pathway" for chemically-induced cytotoxic responses. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
34
•
Benzene
Project Title: RE-ENGINEERING THE DIAMETER OF THE DOUBLE HELIX Principal Investigator & Institution: Kool, Eric T.; Professor; Chemistry; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2002; Project Start 01-AUG-2001; Project End 31-JUL-2005 Summary: This proposal is aimed at expanding or contracting the diameter of the DNA helix, and studying the effects on its pairing properties. The normal C1'-C1' distance in B-form DNA is ca. 10.7 Angstrom units. It is proposed that DNA bases of varying length be synthesized and their base pairing thermodynamics tested in helices consisting entirely of such "stretched" or "compressed" base pairs. Taking inspiration from an extended adenine compound originally synthesized by Leonard, we will accomplish the length variation of the nucleobases by addition or removal of the width of one benzene ring. Thus, the dimensions will be varied in 2.4 Angstrom units increments. This work will address some important basic scientific questions, by providing new insight into the physical origins of DNA helix stability, and the role that electrostatics and base stacking play in it. It will also provide useful data regarding the effects of steric size and shape of the nucleobase on polymerase replication of DNA. Finally, the project will explore the viability of an alternative genetic system, giving insight into how our natural genetic system evolved. For sequence-generalizable hybridization, designs of four 2.4 Angstrom units extended DNA bases are proposed. It is hypothesized that DNA strands completely comprised of such analogues will be competent in hybridizing to natural RNA or DNA complements. Moreover, it is predicted that because of greatly enhanced base stacking, the binding will exhibit higher affinity and pairing specificity than natural DNA does. Further, a number of these extended bases are expected to be fluorescent, allowing for the possibility that they can act as self-reporters of helix formation. These enhanced properties are likely to be of significant utility in many nucleic acid hybridization applications, such as in synthetic DNA microarrays. In the term covered by this proposal, the aims are to (1) evaluate two compressed thymine analogues in 8.4 Angstrom units helices; (2) study an expanded deoxyadenosine analogue in 10.7 and 13.0 Angstrom units helices, and evaluate polymerase enzyme activity; (3) test generalizability of pairing with analogues of four expanded bases in 10.7, 13.0 and 15.4 Angstrom units helices; and (4) study the structure and fluorescence properties of single nucleosides and of helices comprised of these modified- sized bases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ROLE OF PEROXYNITRITE IN BENZENE INDUCED TOXICITY Principal Investigator & Institution: Melikian, Assieh A.; Institute for Cancer Prevention 1 Dana Rd Valhalla, Ny 10595 Timing: Fiscal Year 2002 Summary: Benzene is a known leukemia-inducing agents in humans and multi-site carcinogen in rodents. It is present in tobacco smoker and also a major environmental pollutant. About 60% of smoking-related acute myeloid leukemia mortality is attributed to benzene. The molecular mechanisms responsible for benzene-induced toxicity and carcinogenicity are not well defined; however, metabolism is a pre-requisite for its biological effects. The cytochrome P4502E1 activation of benzene is considered the dominant pathway in productive active metabolites. The CYP2E1 pathways alone is insufficient to explain the mechanism of benzene toxicity. Thus, other cellular processes participate in the biological activation of benzene. There is mounting evidence to suggest that bone marrow depression is associated with increased production of reactive oxygen species and nitric oxide (.NO) by bone marrow. On the basis of our preliminary
Studies
35
studies we hypothesize that (a) superoxide generated in redox cycling of ringhydroxylated metabolites reacts with. NO (induced by benzene metabolites) to form peroxynitrite. Peroxynitrite can damage DNA directly, or modify benzene and its primarily metabolites non- enzymatically to more toxic hydroxylated and nitrated products. Therefore, peroxynitrite, may in part, be responsible for the toxicity of benzene. (b) Further activation of primary may also contribute to benzene toxicity. These hypotheses will be tested by formulating the following Specific Aims. (1) Demonstrate that peroxynitrite is the primary causative agent in DNA strand breakage induced by the synergistic interaction of ring-hydroxylated benzene metabolites with an NO-donor compound in plasmid DNA in vitro. (2) Investigate catalytic role of myeloperoxidase in generating reactive benzene metabolites and study the involvement of these metabolites in DNA damage and cell toxicity in vitro. 3 (I) Extend information obtained from Aims 1 and 2 to in vivo B6C3F1 mice. Determine dose-dependent effects of benzene and its metabolites in formation and persistence of oxidized DNA bases and co-valent DNA adducts as well as production of 3-nitro tyrosine and etheno-base adducts and their relationships with cytotoxicity. 3 (II) Investigate whether C57BI/6AiTAC (KO)Nos2 mice (deficient in iNOS) are protected against benzene induced bone marrow suppression. The results of this study will provide detailed information on the mechanisms and the nature of the DNA lesions that are responsible for benzene toxicity; such knowledge is of paramount importance for risk assessment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SIMULATION AND PREDICTION OF PROTEIN FOLDING Principal Investigator & Institution: Levitt, Michael; Professor; Structural Biology; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2002; Project Start 01-JUL-1989; Project End 30-JUN-2007 Summary: (provided by applicant): The long-term aim of this project is to fold proteins "in silico". The proposed research involves a variety of different theoretical and computational methods as well as a collaboration with an experimentalist with whom we have a longstanding relationship. The five specific aims are to be achieved by answering these questions: 1. How accurately do all-atom simulations reproduce the hydrophobic interactions? Encouraged by the ability of molecular dynamics with simple all-atom energy functions to reproduce the hydrophobic interaction quantitatively, we will investigate the effect of temperature and pressure on our calculations. We will also examine the time-averaged arrangement of water molecules around a benzene molecule. 2. How do short chains of connected hydrophobic amino acids collapse? Having reproduced the clustering behavior of small hydrophobic molecules in molecular dynamics simulations, we plan to examine the role of the polypeptide chain in hydrophobic collapse by extending our techniques to short artificial sequences of the form GGGhGhGGGhhhGhhGGGhGG (h is a hydrophobic amino acid). 3. Do alphahelix unfolding simulations agree in detail with experiment? Working with our experimental collaborator, Dr. William Eaton, we plan to study the rate of helix unfolding. This will involve new experimental work as well as massive amounts of computer time. With the help of Dr. Vijay Pande, we will deploy Encad as a massively parallel simulation system via the folding@home client-server scheme. 4. Can simulated annealing minimization with special potentials generate better decoys? With our greater understanding of the need to develop a potential that captures the free-energy of a protein, we plan to develop terms for solvation and cooperativity. Use of a fast simulated annealing code will enable different potentials to be prototyped and tested rapidly. 5. Can decoy discrimination be improved by better clustering and the use of
36
Benzene
sequence homologues3 Discrimination of near-native folds from less good structures has become increasingly important with our expanding ability to generate native-like decoy sets. We propose new methods involving homologous sequences, non-linear mapping of conformation space and robust clustering. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TOBACCO CARCINOGENESIS AND CHEMOPREVENTION Principal Investigator & Institution: El-Bayoumy, Karam E.; Director of Research; Institute for Cancer Prevention 1 Dana Rd Valhalla, Ny 10595 Timing: Fiscal Year 2002; Project Start 17-JUN-1996; Project End 28-FEB-2006 Summary: Smokers are the largest population exposed to known carcinogens. Besides containing carcinogenic agents such as the tobacco-specific nitrosamines [TSNA, e.g., 4(methylnitrosamino)-1-(3-pyridyl)-1- butanone, (NNK)], the polycyclic aromatic hydrocarbons [e.g., benzo[a]pyrene, (BaP))] and benzene, cigarette smoke is also a rich source of free radical species that are capable of inducing oxidative stress. Free radicals represent a serious threat to cellular components. Although significant progress has been made toward explaining the causal association of cigarette smoking and cancers, several important academic and cancer control issues remain to be addressed. This Program consists of 4 Projects and a CORE. In contrast to extensively studied genotoxic agents, such as NNK and B[a]P, there is a lack of information on the molecular mechanisms by which reactive oxidative species (RO2)- induced oxidative damage occurs in vivo. Thus, Project 1 will test the hypothesis that an inflammatory response to cigarette smoke in the guinea pig respiratory system contributes to the tumor promotion phase of lung carcinogenesis by inhibiting apoptosis through pathways involving activation of the transcriptional nuclear factor-Kappa B (NF-kappaB) and activator protein-1 (AP-1) and that this process can be modulated by dietary anti-oxidants (vitamins and EGCG, a polyphenolic compound in tea). The results should provide a strong rationale for dietary recommendations to smokers who are unable to quit. The molecular mechanisms responsible for the induction of bone marrow toxicity and leukemia by benzene remain to be defined. Thus, in model studies, Project 2 will test the hypothesis that a superoxide, generated via redox cycling of ring-hydroxylated derivatives of benzene, reacts with nitric oxide to form peroxynitrite; the latter may be responsible for the toxicity of benzene and tobacco-associated leukemia in smokers. Project 3 combines the most sensitive analytical tools with molecular and clinical investigations to test the hypothesis that critical events required for the development of cervical cancer are genetic damage and mutations of p53 induced by tobacco carcinogens combined with HPV-induced deactivation of p53 and inhibition of apoptosis. Primary prevention techniques must continue to take a prominent role in our efforts to reduce tobacco-related cancers. However, such efforts showed limited success in the past and, chemopreventive approaches can provide complementary strategies. One of the most exciting clinical trials in the U.S.A. is the recent study demonstrating that supplementation of human nutrition with selenium-enriched yeast significantly reduces lung cancer incidence and mortality. The chemopreventive efficacy depends on the structure of the selenium-containing compound; not the element per se. Thus, Project 4 will test the hypothesis that selenium may, in part, inhibit lung carcinogenesis by inhibiting NF-kappaB; thereby down-regulating COX- 2 and LOX activities and inducing apoptosis. In summary, this Program Project proposes to resolve critical problems in tobacco carcinogenesis and provide insights into mechanisms and optimal models of intervention by modulation of smoke carcinogens and by nutritional supplements, i.e., selenium compounds, vitamins, and EGCG.
Studies
37
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: METABOLISM
TOXICOLOGICAL
SIGNIFICANCE
OF
ALKYLBENZENE
Principal Investigator & Institution: Backes, Wayne L.; Professor; Pharmacology; Louisiana State Univ Hsc New Orleans New Orleans, La 70112 Timing: Fiscal Year 2003; Project Start 05-AUG-2002; Project End 30-APR-2007 Summary: (provided by applicant): The long-term objective of this proposal is to supply information that will aid in identifying conditions under which individuals may be susceptible to alkylbenzene-induced toxicity. Alkylbenzenes are produced in extensive quantities throughout the world. Simple aromatic hydrocarbons (e.g. benzene, toluene, and ethylbenzene) are major components of unleaded gasoline and are also used in the production of a wide variety of consumer products. The P450 system is responsible for both aliphatic and aromatic hydroxylation of the aromatic hydrocarbons, with several forms, CYP1A2, CYP2B4, and CYP2E1, being implicated in hydrocarbon metabolism. The toxicity from many of the hydrocarbons is known to be due to bioactivation of a small percentage of the parent compound to reactive intermediates. This process requires a functional interaction between P450 and the flavoprotein NADPHcytochrome P450 reductase. However, total P450 levels exceed those of reductase by a ratio of 20:1. In addition, there are multiple forms of P450, each having their own reductase binding characteristics and substrate dependencies. This raises the question: "How does a single reductase supply electrons to all the P450s?" A second question is: "Can one P450 influence the function of a second P450?" The proposed studies are designed to address questions related to the organization of P450 and reductase, focusing on the metabolism of alkylbenzenes. During the prior grant period, we identified important interactions among CYP2B4, CYP1A2 and reductase that have a substantial effect on substrate metabolism. The results are consistent with the formation of a CYP1A2-CYP2B4 complex having unusual reductase binding characteristics. We now propose to characterize these interactions, and to identify the region(s) responsible for the interactions among these proteins. We also intend to examine P450-P450 interactions in the CYP2E1/CYP1A2/reductase, and CYP2E1/CYP2B4/reductase systems, and to focus on the ability of these interactions to alter not only metabolism of hydrocarbons and other substrates, but also generation of reactive oxygen. These studies will increase our understanding of how the P450 electron transport chain is organized, and will provide new important information on the role of the P450 system in the bioactivation of aromatic hydrocarbons and the generation of reactive oxygen - a process that can have a significant influence on chemical toxicity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: V-HA-RAS TRANSGENE EXPRESSION IN TGAC MICE Principal Investigator & Institution: Nwosu, Veronica C.; North Carolina Central University 160 Alexander-Dunn Bidg. Durham, Nc 27707 Timing: Fiscal Year 2002; Project Start 01-JUN-1977; Project End 31-DEC-2005 Summary: The broad long term objective of this study is to better understand benzene toxicity relative to hematopoiesis and v-Ha-ras transgene activation in bone marrow cells and hematopoietic progenitor cells (HPC) that lead to the onset of leukemia. The vHa-ras transgenic Tg.AC mouse is used to investigate environmental determinants of carcinogenesis. The transgene construct is composed of a zeta-globin promoter fused to a v-Ha-ras coding sequence and a 3'SV40 polyadenylation sequence. Procedures for
38
Benzene
clonal selection of murine HPC from bone marrow cells using defined culture media for quantification and characterization of erythroid and myeloid lineage of HPC are evaluated. Transgene expression in bone marrow cells and HPC derived from them is assayed by RT-PCR. The effect of benzene on hematopoiesis and transgene expression is studied by exposing groups of experimental and control mice to benzene (34 mg/kg body weight/day) in their drinking water for extended time periods. It is hypothesized that benzene will have a significant negative effect on hematopoiesis and will activate transgene expression beyond basal levels. It is also hypothesized that benzene toxicity cooperates with the expressed transgene to drive selection proliferation and differentiation of transformed neoplastic HPC. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “benzene” (or synonyms) into the search box. This search gives you access to fulltext articles. The following is a sample of items found for benzene in the PubMed Central database: •
A Chromosomally Based tod-luxCDABE Whole-Cell Reporter for Benzene, Toluene, Ethybenzene, and Xylene (BTEX) Sensing. by Applegate BM, Kehrmeyer SR, Sayler GS.; 1998 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=106455
•
A cluster of bacterial genes for anaerobic benzene ring biodegradation. by Egland PG, Pelletier DA, Dispensa M, Gibson J, Harwood CS.; 1997 Jun 10; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=21076
•
A new condensing reagent, 1-(2,4,6-triisopropylbenzenesulfonyl)-5-(pyridin-2yl)tetrazolide and its use in the synthesis of lambda cro binding heptadecanucleotide on a polymer support. by Ohtsuka E, Tozuka Z, Iwai S, Ikehara M.; 1982 Oct 25; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=326913
•
A Novel 2-Aminomuconate Deaminase in the Nitrobenzene Degradation Pathway of Pseudomonas pseudoalcaligenes JS45. by He Z, Spain JC.; 1998 May 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=107194
•
A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H:quinone oxidoreductase 1 (NQO1) to benzene toxicity. by Moran JL, Siegel D, Ross D.; 1999 Jul 6; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=22203
3 4
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
Studies
39
•
An unusual mechanism for the major human apurinic /apyrimidinic (AP) endonuclease involving 5[prime prime or minute] cleavage of DNA containing a benzene-derived exocyclic adduct in the absence of an AP site. by Hang B, Chenna A, Fraenkel-Conrat H, Singer B.; 1996 Nov 26; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=19409
•
Anaerobic Benzene Biodegradation Linked to Nitrate Reduction. by Burland SM, Edwards EA.; 1999 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=91057
•
Anaerobic Benzene Degradation in Petroleum-Contaminated Aquifer Sediments after Inoculation with a Benzene-Oxidizing Enrichment. by Weiner JM, Lovley DR.; 1998 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=106118
•
Anaerobic degradation of alkylated benzenes in denitrifying laboratory aquifer columns. by Kuhn EP, Zeyer J, Eicher P, Schwarzenbach RP.; 1988 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=202478
•
Anaerobic Degradation of Ethylbenzene by a New Type of Marine Sulfate-Reducing Bacterium. by Kniemeyer O, Fischer T, Wilkes H, Glockner FO, Widdel F.; 2003 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=143655
•
Anaerobic Degradation of the Benzene Nucleus by a Facultatively Anaerobic Microorganism. by Taylor BF, Campbell WL, Chinoy I.; 1970 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=247568
•
Anaerobic Oxidation of o-Xylene, m-Xylene, and Homologous Alkylbenzenes by New Types of Sulfate-Reducing Bacteria. by Harms G, Zengler K, Rabus R, Aeckersberg F, Minz D, Rossello-Mora R, Widdel F.; 1999 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=91135
•
Analysis of cumene (isopropylbenzene) degradation genes from Pseudomonas fluorescens IP01. by Habe H, Kasuga K, Nojiri H, Yamane H, Omori T.; 1996 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=168274
•
BACTERIAL OXIDATION OF BENZENE. by Marr EK, Stone RW.; 1961 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=279025
•
Benzene Induces Gene-Duplicating but not Gene-Inactivating Mutations at the Glycophorin A Locus in Exposed Humans. by Rothman N, Haas R, Hayes RB, Li G, Wiemels J, Campleman S, Quintana PJ, Xi L, Dosemeci M, Titenko-Holland N, Meyer KB, Lu W, Zhang LP, Bechtold W, Wang Y, Kolachana P, Yin S, Blot W, Smith MT.; 1995 Apr 25; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=42104
•
Benzene, NQO1, and genetic susceptibility to cancer. by Smith MT.; 1999 Jul 6; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=33590
•
Benzene-Induced Uncoupling of Naphthalene Dioxygenase Activity and Enzyme Inactivation by Production of Hydrogen Peroxide. by Lee K.; 1999 May 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=93710
40
Benzene
•
Biodegradation of 1,2,3- and 1,2,4-Trichlorobenzene in Soil and in Liquid Enrichment Culture. by Marinucci AC, Bartha R.; 1979 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=243591
•
Biodegradation of mixtures of substituted benzenes by Pseudomonas sp. strain JS150. by Haigler BE, Pettigrew CA, Spain JC.; 1992 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=195761
•
Biodegradation of n-Alkylcycloalkanes and n-Alkylbenzenes via New Pathways in Alcanivorax sp. Strain MBIC 4326. by Dutta TK, Harayama S.; 2001 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=92823
•
Biotransformation of benzothiophene by isopropylbenzene-degrading bacteria. by Eaton RW, Nitterauer JD.; 1994 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=205597
•
Carbon and Hydrogen Isotopic Fractionation during Anaerobic Biodegradation of Benzene. by Mancini SA, Ulrich AC, Lacrampe-Couloume G, Sleep B, Edwards EA, Sherwood Lollar B.; 2003 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=152413
•
Characterization and expression of the plasmid-borne bedD gene from Pseudomonas putida ML2, which codes for a NAD+-dependent cis-benzene dihydrodiol dehydrogenase. by Fong KP, Goh CB, Tan HM.; 1996 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=178396
•
Characterization of a novel TOL-like plasmid from Pseudomonas putida involved in 1,2,4-trimethylbenzene degradation. by Bestetti G, Galli E.; 1987 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=212019
•
Characterization of a plasmid-specified pathway for catabolism of isopropylbenzene in Pseudomonas putida RE204. by Eaton RW, Timmis KN.; 1986 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=213428
•
Chlorobenzene degradation by bacteria isolated from contaminated groundwater. by Nishino SF, Spain JC, Belcher LA, Litchfield CD.; 1992 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=195663
•
cis-Chlorobenzene Dihydrodiol Dehydrogenase (TcbB) from Pseudomonas sp. Strain P51, Expressed in Escherichia coli DH5[alpha](pTCB149), Catalyzes Enantioselective Dehydrogenase Reactions. by Raschke H, Fleischmann T, Van Der Meer JR, Kohler HP.; 1999 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=91711
•
Cloning and characterization of plasmid-encoded genes for the degradation of 1,2dichloro-, 1,4-dichloro-, and 1,2,4-trichlorobenzene of Pseudomonas sp. strain P51. by van der Meer JR, van Neerven AR, de Vries EJ, de Vos WM, Zehnder AJ.; 1991 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=207149
Studies
41
•
Cloning, sequencing, and expression of isopropylbenzene degradation genes from Pseudomonas sp. strain JR1: identification of isopropylbenzene dioxygenase that mediates trichloroethene oxidation. by Pflugmacher U, Averhoff B, Gottschalk G.; 1996 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=168215
•
Coexistence of different pathways in the metabolism of n-propylbenzene by Pseudomonas sp. by Jigami Y, Kawasaki Y, Omori T, Minoda Y.; 1979 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=243586
•
Combination of the tod and the tol pathways in redesigning a metabolic route of Pseudomonas putida for the mineralization of a benzene, toluene, and p-xylene mixture. by Lee JY, Jung KH, Choi SH, Kim HS.; 1995 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=167492
•
Complete mineralization of benzene by aquifer microorganisms under strictly anaerobic conditions. by Edwards EA, Grbic-Galic D.; 1992 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=195836
•
Construction and Use of an ipb DNA Module To Generate Pseudomonas Strains with Constitutive Trichloroethene and Isopropylbenzene Oxidation Activity. by Berendes F, Sabarth N, Averhoff B, Gottschalk G.; 1998 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=106411
•
Construction of chlorobenzene-utilizing recombinants by progenitive manifestation of a rare event. by Krockel L, Focht DD.; 1987 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=204131
•
Degradation of 1,2,3,4-Tetrachlorobenzene by Pseudomonas chlororaphis RW71. by Potrawfke T, Timmis KN, Wittich RM.; 1998 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=106552
•
Degradation of 1,2,4-Trichloro- and 1,2,4,5-Tetrachlorobenzene by Pseudomonas Strains. by Sander P, Wittich RM, Fortnagel P, Wilkes H, Francke W.; 1991 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=182966
•
Degradation of 1,4-dichlorobenzene by a Pseudomonas sp. by Spain JC, Nishino SF.; 1987 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=203802
•
Degradation of 1,4-dichlorobenzene by Alcaligenes sp. strain A175. by Schraa G, Boone ML, Jetten MS, van Neerven AR, Colberg PJ, Zehnder AJ.; 1986 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=239236
•
Degradation of benzene, toluene, ethylbenzene, and xylenes (BTEX) by the lignindegrading basidiomycete Phanerochaete chrysosporium. by Yadav JS, Reddy CA.; 1993 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=202186
42
Benzene
•
Degradative capacities and 16S rRNA-targeted whole-cell hybridization of sulfatereducing bacteria in an anaerobic enrichment culture utilizing alkylbenzenes from crude oil. by Rabus R, Fukui M, Wilkes H, Widdle F.; 1996 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=168167
•
Directed Evolution of Biphenyl Dioxygenase: Emergence of Enhanced Degradation Capacity for Benzene, Toluene, and Alkylbenzenes. by Suenaga H, Mitsuoka M, Ura Y, Watanabe T, Furukawa K.; 2001 Sep 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=95430
•
Evidence of Two Oxidative Reaction Steps Initiating Anaerobic Degradation of Resorcinol (1,3-Dihydroxybenzene) by the Denitrifying Bacterium Azoarcus anaerobius. by Philipp B, Schink B.; 1998 Jul 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=107334
•
Evolution of a Pathway for Chlorobenzene Metabolism Leads to Natural Attenuation in Contaminated Groundwater. by van der Meer JR, Werlen C, Nishino SF, Spain JC.; 1998 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=106626
•
Fate of the Benzene Ring of Linear Alkylbenzene Sulfonate in Natural Waters. by Larson RJ, Payne AG.; 1981 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=243749
•
Friedel-Crafts Phenylethylation of Benzene and Toluene with [alpha]- and [beta]Phenylethyl Chlorides: [pi]-Aryl Participation in Polarized Donor-Acceptor [beta]Phenylethylating Complexes Distinct from Phenonium Ions ([sigma] Complexes). by Olah GA, Hamanaka S, Wilkinson JA, Olah JA.; 1992 Feb 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=48355
•
Fungal Metabolism of n-Alkylbenzenes. by Fedorak PM, Westlake DW.; 1986 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=238889
•
Genetic and Molecular Organization of the Alkylbenzene Catabolism Operon in the Psychrotrophic Strain Pseudomonas putida 01G3. by Chablain PA, Zgoda AL, Sarde CO, Truffaut N.; 2001 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=92599
•
Genetic organization and regulation of a meta cleavage pathway for catechols produced from catabolism of toluene, benzene, phenol, and cresols by Pseudomonas pickettii PKO1. by Kukor JJ, Olsen RH.; 1991 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=208133
•
Identification and characterization of a transmissible linear plasmid from Rhodococcus erythropolis BD2 that encodes isopropylbenzene and trichloroethene catabolism. by Dabrock B, Kesseler M, Averhoff B, Gottschalk G.; 1994 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=201402
Studies
43
•
Identification of Chlorobenzene Dioxygenase Sequence Elements Involved in Dechlorination of 1,2,4,5-Tetrachlorobenzene. by Beil S, Mason JR, Timmis KN, Pieper DH.; 1998 Nov 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=107608
•
In Vitro Studies on the Initial Reactions of Anaerobic Ethylbenzene Mineralization. by Johnson HA, Spormann AM.; 1999 Sep 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=94085
•
Incorporation of Oxygen from Water into Toluene and Benzene during Anaerobic Fermentative Transformation. by Vogel TM, Grbi`c-Gali`c D.; 1986 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=203449
•
Influence of Side-Chain Substituents on the Position of Cleavage of the Benzene Ring by Pseudomonas fluorescens. by Seidman MM, Toms A, Wood JM.; 1969 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=249834
•
Inhibition of alkylbenzene biodegradation under denitrifying conditions by using the acetylene block technique. by Hutchins SR.; 1992 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=183109
•
Inhibition of pure cultures of methanogens by benzene ring compounds. by Patel GB, Agnew BJ, Dicaire CJ.; 1991 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=183906
•
Initial reactions in anaerobic ethylbenzene oxidation by a denitrifying bacterium, strain EB1. by Ball HA, Johnson HA, Reinhard M, Spormann AM.; 1996 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=178416
•
Mechanism of ATP-driven electron transfer catalyzed by the benzene ring-reducing enzyme benzoyl- CoA reductase. by Unciuleac M, Boll M.; 2001 Nov 20; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=61090
•
Metabolism of Benzene, Toluene, and Xylene Hydrocarbons in Soil. by Tsao CW, Song HG, Bartha R.; 1998 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=90944
•
Microbial Communities Associated with Anaerobic Benzene Degradation in a Petroleum-Contaminated Aquifer. by Rooney-Varga JN, Anderson RT, Fraga JL, Ringelberg D, Lovley DR.; 1999 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=91456
•
Microbial degradation of 1,3-dichlorobenzene. by de Bont JA, Vorage MJ, Hartmans S, van den Tweel WJ.; 1986 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=239096
•
Microbial metabolism of haloaromatics: isolation and properties of a chlorobenzenedegrading bacterium. by Reineke W, Knackmuss HJ.; 1984 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=239681
44
Benzene
•
Mineralization of Linear Alkylbenzene Sulfonate by a Four-Member Aerobic Bacterial Consortium. by Jimenez L, Breen A, Thomas N, Federle TW, Sayler GS.; 1991 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=182987
•
Modeling the Complexation of Substituted Benzenes by a Cyclophane Host in Water. by Jorgensen WL, Nguyen TB.; 1993 Feb 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=45839
•
Modulation of Affinity of a Marine Pseudomonad for Toluene and Benzene by Hydrocarbon Exposure. by Law AT, Button DK.; 1986 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=238903
•
Mossbauer and electron paramagnetic resonance studies of chloroperoxidase following mechanism-based inactivation with allylbenzene. by Debrunner PG, Dexter AF, Schulz CE, Xia YM, Hager LP.; 1996 Nov 12; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=23999
•
Nucleotide sequence analysis of genes encoding a toluene/benzene-2-monooxygenase from Pseudomonas sp. strain JS150. by Johnson GR, Olsen RH.; 1995 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=167614
•
Nucleotide sequencing and characterization of the genes encoding benzene oxidation enzymes of Pseudomonas putida. by Irie S, Doi S, Yorifuji T, Takagi M, Yano K.; 1987 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=213923
•
Parallel Characterization of Anaerobic Toluene- and Ethylbenzene-Degrading Microbial Consortia by PCR-Denaturing Gradient Gel Electrophoresis, RNA-DNA Membrane Hybridization, and DNA Microarray Technology. by Koizumi Y, Kelly JJ, Nakagawa T, Urakawa H, El-Fantroussi S, Al-Muzaini S, Fukui M, Urushigawa Y, Stahl DA.; 2002 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=126768
•
Phylogenetic Analysis of an Anaerobic, Trichlorobenzene-Transforming Microbial Consortium. by von Wintzingerode F, Selent B, Hegemann W, Gobel UB.; 1999 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=91014
•
Potentiation of DNA Adduct Formation in HL-60 Cells by Combinations of Benzene Metabolites. by Levay G, Bodell WJ.; 1992 Aug 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=49654
•
Rapid Benzene Degradation in Methanogenic Sediments from a PetroleumContaminated Aquifer. by Weiner JM, Lovley DR.; 1998 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=106255
•
Reductive dechlorination of hexachlorobenzene to tri- and dichlorobenzenes in anaerobic sewage sludge. by Fathepure BZ, Tiedje JM, Boyd SA.; 1988 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=202451
Studies
45
•
Shedding light on anaerobic benzene ring degradation: a process unique to prokaryotes? by Harwood CS, Gibson J.; 1997 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=178697
•
Spontaneous deletion of a 20-kilobase DNA segment carrying genes specifying isopropylbenzene metabolism in Pseudomonas putida RE204. by Eaton RW, Timmis KN.; 1986 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=213470
•
Structural analysis of the binding modes of minor groove ligands comprised of disubstituted benzenes. by Hawkins CA, Watson C, Yan Y, Gong B, Wemmer DE.; 2001 Feb 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=29609
•
Substrate interactions during aerobic biodegradation of benzene. by Arvin E, Jensen BK, Gundersen AT.; 1989 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=203250
•
Substrate Interactions during the Biodegradation of Benzene, Toluene, Ethylbenzene, and Xylene (BTEX) Hydrocarbons by the Fungus Cladophialophora sp. Strain T1. by Prenafeta-Boldu FX, Vervoort J, Grotenhuis JT, van Groenestijn JW.; 2002 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=123968
•
Substrate interactions of benzene, toluene, and para-xylene during microbial degradation by pure cultures and mixed culture aquifer slurries. by Alvarez PJ, Vogel TM.; 1991 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=183908
•
Synergistic Action of the Benzene Metabolite Hydroquinone on Myelopoietic Stimulating Activity of Granulocyte/Macrophage Colony-Stimulating Factor in vitro. by Irons RD, Stillman WS, Colagiovanni DB, Henry VA.; 1992 May 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=48937
•
The Alkene Monooxygenase from Xanthobacter Strain Py2 Is Closely Related to Aromatic Monooxygenases and Catalyzes Aromatic Monohydroxylation of Benzene, Toluene, and Phenol. by Zhou NY, Jenkins A, Chan Kwo Chion CK, Leak DJ.; 1999 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=91225
•
The Benzene Metabolite p-Benzoquinone Forms Adducts with DNA Bases that are Excised by a Repair Activity from Human Cells that Differs from an Ethenoadenine Glycosylase. by Chenna A, Hang B, Rydberg B, Kim E, Pongracz K, Bodel WJ, Singer B.; 1995 Jun 20; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=41607
•
The Branched-Chain Dodecylbenzene Sulfonate Degradation Pathway of Pseudomonas aeruginosa W51D Involves a Novel Route for Degradation of the Surfactant Lateral Alkyl Chain. by Campos-Garcia J, Esteve A, Vazquez-Duhalt R, Ramos JL, Soberon-Chavez G.; 1999 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=91560
46
Benzene
•
The effect of ferredoxin(BED) overexpression on benzene dioxygenase activity in Pseudomonas putida ML2. by Tan HM, Joannou CL, Cooper CE, Butler CS, Cammack R, Mason JR.; 1994 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=205386
•
The Xenobiotic Compound 1,4-Bis[2-(3,5-Dichloropyridyloxy)]Benzene Is an Agonist Ligand for the Nuclear Receptor CAR. by Tzameli I, Pissios P, Schuetz EG, Moore DD.; 2000 May 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=85552
•
Toluene and ethylbenzene oxidation by purified naphthalene dioxygenase from Pseudomonas sp. strain NCIB 9816-4. by Lee K, Gibson DT.; 1996 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=168101
•
Toluene-Degrading Bacteria Are Chemotactic towards the Environmental Pollutants Benzene, Toluene, and Trichloroethylene. by Parales RE, Ditty JL, Harwood CS.; 2000 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=92264
•
Transformation of Chlorinated Benzenes and Toluenes by Ralstonia sp. Strain PS12 tecA (Tetrachlorobenzene Dioxygenase) and tecB (Chlorobenzene Dihydrodiol Dehydrogenase) Gene Products. by Pollmann K, Beil S, Pieper DH.; 2001 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=93129
•
Transformation of toluene and benzene by mixed methanogenic cultures. by GrbicGalic D, Vogel TM.; 1987 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=203647
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with benzene, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “benzene” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for benzene (hyperlinks lead to article summaries):
6 PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
Studies
47
•
A combination of the micronucleus assay and a FISH technique for evaluation of the genotoxicity of 1,2,4-benzenetriol. Author(s): Chung HW, Kang SJ, Kim SY. Source: Mutation Research. 2002 April 26; 516(1-2): 49-56. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11943610&dopt=Abstract
•
A comparative study between 10 per cent sulfur ointment and 0.3 per cent gamma benzene hexachloride gel in the treatment of scabies in children. Author(s): Singalavanija S, Limpongsanurak W, Soponsakunkul S. Source: J Med Assoc Thai. 2003 August; 86 Suppl 3: S531-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14700144&dopt=Abstract
•
A note on myeloperoxidation index and its correlation to the biomarker, urine trans, trans-muconic acid level, in the subjects occupationally exposed to benzene. Author(s): Wiwanitkit V, Soogarun S, Suwansaksri J. Source: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2004 February; 18(2): 369. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14671636&dopt=Abstract
•
A quantitative structure-activity relationship analysis on a series of alkyl benzenes metabolized by human cytochrome p450 2E1. Author(s): Lewis DF, Sams C, Loizou GD. Source: Journal of Biochemical and Molecular Toxicology. 2003; 17(1): 47-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12616646&dopt=Abstract
•
A review of quantitative studies of benzene metabolism. Author(s): Lovern MR, Cole CE, Schlosser PM. Source: Critical Reviews in Toxicology. 2001 May; 31(3): 285-311. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11405442&dopt=Abstract
•
Actual commuter exposure to methyl-tertiary butyl ether, benzene and toluene while traveling in Korean urban areas. Author(s): Lee JW, Jo WK. Source: The Science of the Total Environment. 2002 May 27; 291(1-3): 219-28. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12150439&dopt=Abstract
•
Airborne concentrations of benzene and mineral spirits (stoddard solvent) during cleaning of a locomotive generator and traction motor. Author(s): Madl AK, Paustenbach DJ. Source: Journal of Toxicology and Environmental Health. Part A. 2002 December 13; 65(23): 1965-79. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12490042&dopt=Abstract
48
Benzene
•
Airborne concentrations of benzene due to diesel locomotive exhaust in a roundhouse. Author(s): Madl AK, Paustenbach DJ. Source: Journal of Toxicology and Environmental Health. Part A. 2002 December 13; 65(23): 1945-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12490041&dopt=Abstract
•
Albumin adducts of benzene oxide and 1,4-benzoquinone as measures of human benzene metabolism. Author(s): Rappaport SM, Waidyanatha S, Qu Q, Shore R, Jin X, Cohen B, Chen LC, Melikian AA, Li G, Yin S, Yan H, Xu B, Mu R, Li Y, Zhang X, Li K. Source: Cancer Research. 2002 March 1; 62(5): 1330-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11888901&dopt=Abstract
•
Ambient air levels and occupational exposure to benzene, toluene, and xylenes in northwestern Italy. Author(s): Bono R, Scursatone E, Schiliro T, Gilli G. Source: Journal of Toxicology and Environmental Health. Part A. 2003 March 28; 66(6): 519-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12712594&dopt=Abstract
•
An online automatic sample cleanup system for the quantitative detection of the benzene exposure biomarker S-phenylmercapturic acid in human urine by electrospray ionization tandem mass spectrometry. Author(s): Liao PC, Li CM, Lin LC, Hung CW, Shih TS. Source: Journal of Analytical Toxicology. 2002 May-June; 26(4): 205-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12054360&dopt=Abstract
•
Analysis of benzene, toluene, ethylbenzene and m-xylene in biological samples from the general population. Author(s): Perbellini L, Pasini F, Romani S, Princivalle A, Brugnone F. Source: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 2002 October 5; 778(1-2): 199-210. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12376127&dopt=Abstract
•
Anti-androgenic activity of substituted azo- and azoxy-benzene derivatives. Author(s): Takahashi H, Ishioka T, Koiso Y, Sodeoka M, Hashimoto Y. Source: Biological & Pharmaceutical Bulletin. 2000 November; 23(11): 1387-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11085374&dopt=Abstract
Studies
49
•
Antitumor agents. Part 3: synthesis and cytotoxicity of new trans-stilbene benzenesulfonamide derivatives. Author(s): Yang LM, Lin SJ, Hsu FL, Yang TH. Source: Bioorganic & Medicinal Chemistry Letters. 2002 April 8; 12(7): 1013-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11909706&dopt=Abstract
•
Application of statistical models to estimate the correlation between urinary benzene as biological indicator of exposure and air concentrations determined by personal monitoring. Author(s): Tolentino D, Zenari E, Dall'Olio M, Ruani G, Gelormini A, Mirone G. Source: Aiha Journal : a Journal for the Science of Occupational and Environmental Health and Safety. 2003 September-October; 64(5): 625-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14521437&dopt=Abstract
•
Assessing health risk from benzene pollution in an urban area. Author(s): Carletti R, Romano D. Source: Environmental Monitoring and Assessment. 2002 December; 80(2): 135-48. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12449321&dopt=Abstract
•
Assessing the health risks of benzene: a report on the benzene state-of-the-science workshop. Author(s): Krewski D, Snyder R, Beatty P, Granville G, Meek B, Sonawane B. Source: Journal of Toxicology and Environmental Health. Part A. 2000 November; 61(56): 307-38. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11086936&dopt=Abstract
•
Assessment of the correlation between exposure to benzene and urinary excretion of t, t-muconic acid in workers from a petrochemical plant. Author(s): Panev T, Popov T, Georgieva T, Chohadjieva D. Source: International Archives of Occupational and Environmental Health. 2002 October; 75 Suppl: S97-100. Epub 2002 September 10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12397418&dopt=Abstract
•
Association of genetic polymorphisms in CYP2E1, MPO, NQO1, GSTM1, and GSTT1 genes with benzene poisoning. Author(s): Wan J, Shi J, Hui L, Wu D, Jin X, Zhao N, Huang W, Xia Z, Hu G. Source: Environmental Health Perspectives. 2002 December; 110(12): 1213-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12460800&dopt=Abstract
50
Benzene
•
Attomole detection of in vivo protein targets of benzene in mice: evidence for a highly reactive metabolite. Author(s): Williams KE, Carver TA, Miranda JJ, Kautiainen A, Vogel JS, Dingley K, Baldwin MA, Turteltaub KW, Burlingame AL. Source: Molecular & Cellular Proteomics : Mcp. 2002 November; 1(11): 885-95. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12488464&dopt=Abstract
•
Benzene and leukemia. Author(s): Snyder R. Source: Critical Reviews in Toxicology. 2002 May; 32(3): 155-210. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12071572&dopt=Abstract
•
Benzene and lymphohematopoietic malignancies in humans. Author(s): Hayes RB, Songnian Y, Dosemeci M, Linet M. Source: American Journal of Industrial Medicine. 2001 August; 40(2): 117-26. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11494338&dopt=Abstract
•
Benzene and naphthalene in air and breath as indicators of exposure to jet fuel. Author(s): Egeghy PP, Hauf-Cabalo L, Gibson R, Rappaport SM. Source: Occupational and Environmental Medicine. 2003 December; 60(12): 969-76. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14634191&dopt=Abstract
•
Benzene and total hydrocarbons exposures in the downstream petroleum industries. Author(s): Verma DK, Johnson DM, Shaw ML, des Tombe K. Source: Aihaj : a Journal for the Science of Occupational and Environmental Health and Safety. 2001 March-April; 62(2): 176-94. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11331990&dopt=Abstract
•
Benzene emitted from glowing charcoal. Author(s): Olsson M, Petersson G. Source: The Science of the Total Environment. 2003 March 1; 303(3): 215-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12606161&dopt=Abstract
•
Benzene exposure and hematopoietic mortality: A long-term epidemiologic risk assessment. Author(s): Rinsky RA, Hornung RW, Silver SR, Tseng CY. Source: American Journal of Industrial Medicine. 2002 December; 42(6): 474-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12439870&dopt=Abstract
Studies
51
•
Benzene exposure assessment for use of a mineral spirits-based degreaser. Author(s): Fedoruk MJ, Bronstein R, Kerger BD. Source: Applied Occupational and Environmental Hygiene. 2003 October; 18(10): 764-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12959887&dopt=Abstract
•
Benzene exposure measurement in shoe and glue manufacturing: a study to validate biomarkers. Author(s): Qu Q, Cohen BS, Shore R, Chen LC, Li G, Jin X, Melikian AA, Yin S, Yan H, Xu B, Li Y, Mu R, Zhang X, Li K. Source: Applied Occupational and Environmental Hygiene. 2003 December; 18(12): 98898. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14612295&dopt=Abstract
•
Benzene exposure monitoring of Tunisian workers. Author(s): Chakroun R, Kaabachi N, Hedhili A, Feki M, Nouaigui H, Ben Laiba M, Mebazaa A. Source: Journal of Occupational and Environmental Medicine / American College of Occupational and Environmental Medicine. 2002 December; 44(12): 1173-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12500460&dopt=Abstract
•
Benzene in gasoline and crude oil: occupational and environmental implications. Author(s): Verma DK, des Tombe K. Source: Aiha Journal : a Journal for the Science of Occupational and Environmental Health and Safety. 2002 March-April; 63(2): 225-30. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11975660&dopt=Abstract
•
Benzene in the environment: an assessment of the potential risks to the health of the population. Author(s): Duarte-Davidson R, Courage C, Rushton L, Levy L. Source: Occupational and Environmental Medicine. 2001 January; 58(1): 2-13. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11119628&dopt=Abstract
•
Benzene metabolism in rodents at doses relevant to human exposure from urban air. Author(s): Turteltaub KW, Mani C. Source: Res Rep Health Eff Inst. 2003 February; (113): 1-26; Discussion 27-35. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12675491&dopt=Abstract
•
Benzene metabolites antagonize etoposide-stabilized cleavable complexes of DNA topoisomerase IIalpha. Author(s): Baker RK, Kurz EU, Pyatt DW, Irons RD, Kroll DJ. Source: Blood. 2001 August 1; 98(3): 830-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11468185&dopt=Abstract
52
Benzene
•
Benzene: a case study of the control of a carcinogen in New South Wales. Author(s): Brotherton J. Source: New South Wales Public Health Bulletin. 2002 September-October; 13(9-10): 20911. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12555112&dopt=Abstract
•
Benzene-extracted components are important for the major activity of diesel exhaust particles: effect on interleukin-8 gene expression in human bronchial epithelial cells. Author(s): Kawasaki S, Takizawa H, Takami K, Desaki M, Okazaki H, Kasama T, Kobayashi K, Yamamoto K, Nakahara K, Tanaka M, Sagai M, Ohtoshi T. Source: American Journal of Respiratory Cell and Molecular Biology. 2001 April; 24(4): 419-26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11306435&dopt=Abstract
•
Benzene-induced myelodysplastic syndrome. Author(s): Chen YH, Su WL, Liou SH. Source: The Journal of the American Board of Family Practice / American Board of Family Practice. 2001 January-February; 14(1): 71-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11206698&dopt=Abstract
•
Benzene's adverse effects. Microarray's reveal breadth of toxicity. Author(s): Medlin J. Source: Environmental Health Perspectives. 2003 August; 111(11): A590-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12940287&dopt=Abstract
•
Biological monitoring of exposure to benzene in petrol pump workers and dry cleaners. Author(s): Verma Y, Rana SV. Source: Ind Health. 2001 October; 39(4): 330-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11758996&dopt=Abstract
•
Biological monitoring of exposure to benzene in traffic policemen of north India. Author(s): Verma Y, Kumar A, Rana SV. Source: Ind Health. 2003 July; 41(3): 260-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12916757&dopt=Abstract
•
Biological monitoring of workers exposed to ethylbenzene and co-exposed to xylene. Author(s): Jang JY, Droz PO, Kim S. Source: International Archives of Occupational and Environmental Health. 2001 January; 74(1): 31-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11196078&dopt=Abstract
Studies
53
•
California perspective on the assessment of benzene toxicological risks. Author(s): Zeise L, McDonald TA. Source: Journal of Toxicology and Environmental Health. Part A. 2000 November; 61(56): 479-83. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11086956&dopt=Abstract
•
Cancer mortality among workers with benzene exposure. Author(s): Ireland B, Collins JJ, Buckley CF, Riordan SG. Source: Epidemiology (Cambridge, Mass.). 1997 May; 8(3): 318-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9115030&dopt=Abstract
•
Capillary electrophoresis determination of urinary muconic acid as a biological marker for benzene in cigarette smoke. Author(s): Coutrim MX, Jager AV, de Carvalho LR, Tavares MF. Source: J Capillary Electrophor. 1997 January-February; 4(1): 39-45. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9384719&dopt=Abstract
•
Carcinogenic effects of benzene: Cesare Maltoni's contributions. Author(s): Mehlman MA. Source: Annals of the New York Academy of Sciences. 2002 December; 982: 137-48. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12562633&dopt=Abstract
•
Carcinogenic effects of benzene--a status update and research needs to improve risk assessments: US EPA perspective. Environmental Protection Agency. Author(s): Sonawane B, Bayliss D, Valcovic L, Chen C, Rodan B, Farland W. Source: Journal of Toxicology and Environmental Health. Part A. 2000 November; 61(56): 471-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11086954&dopt=Abstract
•
Carcinogenic potential of benzene and toluene when evaluated using cyclindependent kinase activation and p53-DNA binding. Author(s): Dees C, Askari M, Henley D. Source: Environmental Health Perspectives. 1996 December; 104 Suppl 6: 1289-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9118908&dopt=Abstract
•
Characterization and mechanisms of chromosomal alterations induced by benzene in mice and humans. Author(s): Eastmond DA, Schuler M, Frantz C, Chen H, Parks R, Wang L, Hasegawa L. Source: Res Rep Health Eff Inst. 2001 June; (103): 1-68; Discussion 69-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11504146&dopt=Abstract
54
Benzene
•
Characterization of genetic instability in radiation- and benzene-induced murine acute leukemia. Author(s): Rithidech K, Dunn JJ, Bond VP, Gordon CR, Cronkite EP. Source: Mutation Research. 1999 July 16; 428(1-2): 33-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10517976&dopt=Abstract
•
Childhood cancer and possible exposure to benzene from traffic and petrol stations. Author(s): Jarvholm B, Forsberg B. Source: Occupational and Environmental Medicine. 2000 July; 57(7): 500-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10917714&dopt=Abstract
•
Chromosome damage from biological reactive intermediates of benzene and 1,3butadiene in leukemia. Author(s): Smith MT. Source: Advances in Experimental Medicine and Biology. 2001; 500: 279-87. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11764955&dopt=Abstract
•
Clinical features of hematopoietic malignancies and related disorders among benzene-exposed workers in China. Benzene Study Group. Author(s): Linet MS, Yin SN, Travis LB, Li CY, Zhang ZN, Li DG, Rothman N, Li GL, Chow WH, Donaldson J, Dosemeci M, Wacholder S, Blot WJ, Hayes RB. Source: Environmental Health Perspectives. 1996 December; 104 Suppl 6: 1353-64. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9118920&dopt=Abstract
•
Coast Guard exposure to gasoline, MTBE, and benzene vapors during inspection of tank barges. Author(s): Davenport AC, Glynn TJ, Rhambarose H. Source: Aihaj : a Journal for the Science of Occupational and Environmental Health and Safety. 2000 November-December; 61(6): 865-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11192221&dopt=Abstract
•
Comparison of the mutations induced by p-benzoquinone, a benzene metabolite, in human and mouse cells. Author(s): Nakayama A, Koyoshi S, Morisawa S, Yagi T. Source: Mutation Research. 2000 October 31; 470(2): 147-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11027969&dopt=Abstract
•
Construction of a database of benzene biological monitoring. Author(s): Pople JE, Ball RL, Padgett MJ, Aston JP. Source: Toxicology Letters. 2002 August 5; 134(1-3): 301-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12191892&dopt=Abstract
Studies
55
•
Critical literature review of determinants and levels of occupational benzene exposure for United States community-based case-control studies. Author(s): van Wijngaarden E, Stewart PA. Source: Applied Occupational and Environmental Hygiene. 2003 September; 18(9): 67893. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12909536&dopt=Abstract
•
Customer exposure to MTBE, TAME, C6 alkyl methyl ethers, and benzene during gasoline refueling. Author(s): Vainiotalo S, Peltonen Y, Ruonakangas A, Pfaffli P. Source: Environmental Health Perspectives. 1999 February; 107(2): 133-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9924009&dopt=Abstract
•
Cytochromes P450 involved with benzene metabolism in hepatic and pulmonary microsomes. Author(s): Powley MW, Carlson GP. Source: Journal of Biochemical and Molecular Toxicology. 2000; 14(6): 303-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11083083&dopt=Abstract
•
Cytogenetic changes in subjects occupationally exposed to benzene. Author(s): Kasuba V, Rozgaj R, Sentija K. Source: Chemosphere. 2000 February; 40(3): 307-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10665421&dopt=Abstract
•
Cytogenetic findings on shoe workers exposed long-term to benzene. Author(s): Tunca BT, Egeli U. Source: Environmental Health Perspectives. 1996 December; 104 Suppl 6: 1313-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9118912&dopt=Abstract
•
Cytotoxic 1,4-bis(2-oxo-1-cycloalkylmethylene)benzenes and related compounds. Author(s): Dimmock JR, Jha A, Kumar P, Zello GA, Quail JW, Oloo EO, Oucharek JJ, Pasha MK, Seitz D, Sharma RK, Allen TM, Santos CL, Manavathu EK, De Clercq E, Balzarini J, Stables JP. Source: European Journal of Medicinal Chemistry. 2002 January; 37(1): 35-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11841873&dopt=Abstract
•
Degradation of sodium 4-dodecylbenzenesulphonate photoinduced by Fe(III) in aqueous solution. Author(s): Mailhot G, Asif A, Bolte M. Source: Chemosphere. 2000 August; 41(3): 363-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11057598&dopt=Abstract
56
Benzene
•
Dermal absorption of benzene: implications for work practices and regulations. Author(s): Kalnas J, Teitelbaum DT. Source: International Journal of Occupational and Environmental Health : Official Journal of the International Commission on Occupational Health. 2000 April-June; 6(2): 114-21. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10828140&dopt=Abstract
•
Detection of chromosome-specific aneusomy and translocation by benzene metabolites in human lymphocytes using fluorescence in situ hybridization with DNA probes for chromosomes 5, 7, 8, and 21. Author(s): Chung HW, Kim SY. Source: Journal of Toxicology and Environmental Health. Part A. 2002 March; 65(5-6): 365-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11936217&dopt=Abstract
•
Detection of DNA damage in human lymphocytes by alkaline single cell gel electrophoresis after exposure to benzene or benzene metabolites. Author(s): Andreoli C, Leopardi P, Crebelli R. Source: Mutation Research. 1997 June 9; 377(1): 95-104. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9219584&dopt=Abstract
•
Determination of benzene and its metabolites: application in biological monitoring of environmental and occupational exposure to benzene. Author(s): Ong CN, Lee BL. Source: Journal of Chromatography. B, Biomedical Applications. 1994 October 3; 660(1): 1-22. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7858701&dopt=Abstract
•
Determination of benzene in urine by static headspace gas chromatography. Author(s): Skender L, Brcic I, Zuzul S. Source: Arh Hig Rada Toksikol. 2002 September; 53(3): 197-202. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12557472&dopt=Abstract
•
Determination of firefighter exposure to polycyclic aromatic hydrocarbons and benzene during fire fighting using measurement of biological indicators. Author(s): Caux C, O'Brien C, Viau C. Source: Applied Occupational and Environmental Hygiene. 2002 May; 17(5): 379-86. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12018402&dopt=Abstract
Studies
57
•
Determination of leukemogenic benzene exposure concentrations: refined analyses of the Pliofilm cohort. Author(s): Schnatter AR, Nicolich MJ, Bird MG. Source: Risk Analysis : an Official Publication of the Society for Risk Analysis. 1996 December; 16(6): 833-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8972111&dopt=Abstract
•
Determination of low concentrations of benzene in urine using multi-dimensional gas chromatography. Author(s): Ljungkvist G, Larstad M, Mathiasson L. Source: The Analyst. 2001 January; 126(1): 41-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11205510&dopt=Abstract
•
Determination of specific mercapturic acids as an index of exposure to environmental benzene, toluene, and styrene. Author(s): Maestri L, Ghittori S, Imbriani M. Source: Ind Health. 1997 October; 35(4): 489-501. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9348721&dopt=Abstract
•
Determination of S-phenylmercapturic acid in urine as an indicator of exposure to benzene. Author(s): Ghittori S, Imbriani M, Maestri L, Capodaglio E, Cavalleri A. Source: Toxicology Letters. 1999 September 5; 108(2-3): 329-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10511279&dopt=Abstract
•
Determination of the urinary benzene metabolites S-phenylmercapturic acid and trans,trans-muconic acid by liquid chromatography-tandem mass spectrometry. Author(s): Melikian AA, O'Connor R, Prahalad AK, Hu P, Li H, Kagan M, Thompson S. Source: Carcinogenesis. 1999 April; 20(4): 719-26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10223205&dopt=Abstract
•
Determination of urinary t-t muconic acid as biomarker of environmental benzene intake and its interference factors. Author(s): Valente T, Medico L, Chiapperini D, Bonsignore AD. Source: Ann Chim. 2002 September; 92(9): 911-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12407914&dopt=Abstract
•
Development and validation of a competitive immunoassay for urinary Sphenylmercapturic acid and its application in benzene biological monitoring. Author(s): Aston JP, Ball RL, Pople JE, Jones K, Cocker J. Source: Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals. 2002 March-April; 7(2): 103-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12101630&dopt=Abstract
58
Benzene
•
Development of liquid chromatography-electrospray ionization-tandem mass spectrometry methods for determination of urinary metabolites of benzene in humans. Author(s): Melikian AA, Meng M, O'Connor R, Hu P, Thompson SM. Source: Res Rep Health Eff Inst. 1999 June; (87): 1-36: Discussion 37-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10500979&dopt=Abstract
•
Differential cleavage of oligonucleotides containing the benzene-derived adduct, 1,N6-benzetheno-dA, by the major human AP endonuclease HAP1 and Escherichia coli exonuclease III and endonuclease IV. Author(s): Hang B, Chenna A, Sagi J, Singer B. Source: Carcinogenesis. 1998 August; 19(8): 1339-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9744526&dopt=Abstract
•
DNA adduct formation in the bone marrow of B6C3F1 mice treated with benzene. Author(s): Pathak DN, Levay G, Bodell WJ. Source: Carcinogenesis. 1995 August; 16(8): 1803-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7634407&dopt=Abstract
•
DNA damage by ethylbenzenehydroperoxide formed from carcinogenic ethylbenzene by sunlight irradiation. Author(s): Toda C, Uchida T, Midorikawa K, Murata M, Hiraku Y, Okamoto Y, Ueda K, Kojima N, Kawanishi S. Source: Biochemical and Biophysical Research Communications. 2003 May 16; 304(4): 638-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12727201&dopt=Abstract
•
Does benzene cause multiple myeloma? An analysis of the published case-control literature. Author(s): Bezabeh S, Engel A, Morris CB, Lamm SH. Source: Environmental Health Perspectives. 1996 December; 104 Suppl 6: 1393-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9118925&dopt=Abstract
•
Dose-response nonlinearities for benzene revisited: a reply to Crump et al. Author(s): Cox LA Jr, Ricci PF. Source: Risk Analysis : an Official Publication of the Society for Risk Analysis. 1993 October; 13(5): 485-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8259437&dopt=Abstract
Studies
59
•
Effect of benzene, toluene, xylene on the semen quality and the function of accessory gonad of exposed workers. Author(s): Xiao G, Pan C, Cai Y, Lin H, Fu Z. Source: Ind Health. 2001 April; 39(2): 206-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11341554&dopt=Abstract
•
Effect of benzene, toluene, xylene on the semen quality of exposed workers. Author(s): Xiao G, Pan C, Cai Y, Lin H, Fu Z. Source: Chinese Medical Journal. 1999 August; 112(8): 709-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11601277&dopt=Abstract
•
Enhanced benzene-induced DNA damage in PMA-stimulated cells in vitro and in LPS-treated animals. Author(s): Tuo J, Loft S, Poulsen HE. Source: Free Radical Biology & Medicine. 1999 April; 26(7-8): 801-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10232822&dopt=Abstract
•
Enhancement of myeloid cell growth by benzene metabolites via the production of active oxygen species. Author(s): Wiemels J, Smith MT. Source: Free Radical Research. 1999 February; 30(2): 93-103. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10193577&dopt=Abstract
•
Environmental and biological monitoring of benzene during self-service automobile refueling. Author(s): Egeghy PP, Tornero-Velez R, Rappaport SM. Source: Environmental Health Perspectives. 2000 December; 108(12): 1195-202. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11133401&dopt=Abstract
•
Environmental benzene exposure assessment for parent-child pairs in Rouen, France. Author(s): Kouniali A, Cicolella A, Gonzalez-Flesca N, Dujardin R, Gehanno JF, Bois FY. Source: The Science of the Total Environment. 2003 June 1; 308(1-3): 73-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12738202&dopt=Abstract
•
Environmental use of diffusive samplers: evaluation of reliable diffusive uptake rates for benzene, toluene and xylene. Author(s): Brown RH. Source: Journal of Environmental Monitoring : Jem. 1999 February; 1(1): 115-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11529070&dopt=Abstract
60
Benzene
•
Estimating mean exposures from censored data: exposure to benzene in the Australian petroleum industry. Author(s): Glass DC, Gray CN. Source: The Annals of Occupational Hygiene. 2001 June; 45(4): 275-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11378148&dopt=Abstract
•
Estimation of human exposure to styrene and ethylbenzene. Author(s): Tang W, Hemm I, Eisenbrand G. Source: Toxicology. 2000 April 3; 144(1-3): 39-50. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10781869&dopt=Abstract
•
Estimation of trace amounts of benzene in solvent-extracted vegetable oils and oil seed cakes. Author(s): Masohan A, Parsad G, Khanna MK, Chopra SK, Rawat BS, Garg MO. Source: The Analyst. 2000 September; 125(9): 1687-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11064941&dopt=Abstract
•
Ethylbenzene and xylene from Sarstedt Monovette serum gel blood-collection tubes. Author(s): Streete PJ, Flanagan RJ. Source: Clinical Chemistry. 1993 June; 39(6): 1344-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8504548&dopt=Abstract
•
Evaluation of benzene exposure in children living in Campania (Italy) by urinary trans,trans-muconic acid assay. Author(s): Amodio-Cocchieri R, Del Prete U, Cirillo T, Agozzino E, Scarano G. Source: Journal of Toxicology and Environmental Health. Part A. 2001 May 25; 63(2): 7987. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11393801&dopt=Abstract
•
Exposure to benzene and risk of leukemia among shoe factory workers. Author(s): Seniori Costantini A, Quinn M, Consonni D, Zappa M. Source: Scand J Work Environ Health. 2003 February; 29(1): 51-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12630436&dopt=Abstract
•
Exposure to benzene in fuel distribution installations: monitoring and prevention. Author(s): Peretz C, Froom P, Pardo A, Goren A. Source: Archives of Environmental Health. 2000 November-December; 55(6): 439-46. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11128883&dopt=Abstract
Studies
61
•
Exposure to benzene in urban workers: environmental and biological monitoring of traffic police in Rome. Author(s): Crebelli R, Tomei F, Zijno A, Ghittori S, Imbriani M, Gamberale D, Martini A, Carere A. Source: Occupational and Environmental Medicine. 2001 March; 58(3): 165-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11171929&dopt=Abstract
•
Exposure to benzene, occupational stress, and reduced birth weight. Author(s): Chen D, Cho SI, Chen C, Wang X, Damokosh AI, Ryan L, Smith TJ, Christiani DC, Xu X. Source: Occupational and Environmental Medicine. 2000 October; 57(10): 661-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10984337&dopt=Abstract
•
Exposure to carbon monoxide, methyl-tertiary butyl ether (MTBE), and benzene levels inside vehicles traveling on an urban area in Korea. Author(s): Jo WK, Park KH. Source: Journal of Exposure Analysis and Environmental Epidemiology. 1998 AprilJune; 8(2): 159-71. Erratum In: J Expo Anal Environ Epidemiol 1998 July-September; 8(3): 441. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9577748&dopt=Abstract
•
Exposure to methyl tert-butyl ether and benzene among service station attendants and operators. Author(s): Hartle R. Source: Environmental Health Perspectives. 1993 December; 101 Suppl 6: 23-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8020445&dopt=Abstract
•
Exposure to methyl tertiary butyl ether and benzene in close proximity to service stations. Author(s): Jo WK, Oh JW. Source: J Air Waste Manag Assoc. 2001 August; 51(8): 1122-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11518287&dopt=Abstract
•
Exposures to jet fuel and benzene during aircraft fuel tank repair in the U.S. Air Force. Author(s): Carlton GN, Smith LB. Source: Applied Occupational and Environmental Hygiene. 2000 June; 15(6): 485-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10853289&dopt=Abstract
62
Benzene
•
Failure of urinary trans,trans-muconic acid as a biomarker for indoor environmental benzene exposure at PPB levels. Author(s): Sanguinetti G, Accorsi A, Barbieri A, Raffi GB, Violante FS. Source: Journal of Toxicology and Environmental Health. Part A. 2001 August 24; 63(8): 599-604. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11549119&dopt=Abstract
•
Feasibility of urinary trans, trans-muconic acid determination using high performance liquid chromatography for biological monitoring of benzene exposure. Author(s): Wiwanitkit V, Suwansaksri J, Nasuan P. Source: J Med Assoc Thai. 2001 June; 84 Suppl 1: S263-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11529343&dopt=Abstract
•
Formation of hemoglobin and albumin adducts of benzene oxide in mouse, rat, and human blood. Author(s): Lindstrom AB, Yeowell-O'Connell K, Waidyanatha S, McDonald TA, Golding BT, Rappaport SM. Source: Chemical Research in Toxicology. 1998 April; 11(4): 302-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9548800&dopt=Abstract
•
Formation of nitrated and hydroxylated aromatic compounds from benzene and peroxynitrite, a possible mechanism of benzene genotoxicity. Author(s): Tuo J, Wolff SP, Loft S, Poulsen HE. Source: Free Radical Research. 1998 April; 28(4): 369-75. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9684981&dopt=Abstract
•
Gamma benzene hexachloride neurotoxicity. Author(s): Sarkar M, Sarkar AK, Biswas SK. Source: Indian Pediatrics. 1993 November; 30(11): 1358-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7518805&dopt=Abstract
•
Gamma benzene hexachloride resistant scabies. Author(s): Judd LE. Source: N Z Med J. 1993 February 24; 106(950): 61-3. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7679786&dopt=Abstract
•
Gasoline-contaminated ground water as a source of residential benzene exposure: a case study. Author(s): Lindstrom AB, Highsmith VR, Buckley TJ, Pate WJ, Michael LC. Source: Journal of Exposure Analysis and Environmental Epidemiology. 1994 AprilJune; 4(2): 183-95. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7549473&dopt=Abstract
Studies
63
•
GC/MS determination of N-phenylvaline, a possible biomarker for benzene exposure in human hemoglobin by the “N-alkyl Edman method”. Author(s): Bader M, Lehnert G, Angerer J. Source: International Archives of Occupational and Environmental Health. 1994; 65(6): 411-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8034366&dopt=Abstract
•
Gender differences in hematopoietic and lymphoproliferative disorders and other cancer risks by major occupational group among workers exposed to benzene in China. Author(s): Li GL, Linet MS, Hayes RB, Yin SN, Dosemeci M, Wang YZ, Chow WH, Jiang ZL, Wacholder S, Zhang WU, et al. Source: J Occup Med. 1994 August; 36(8): 875-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7807268&dopt=Abstract
•
Genetic polymorphisms influence variability in benzene metabolism in humans. Author(s): Rossi AM, Guarnieri C, Rovesti S, Gobba F, Ghittori S, Vivoli G, Barale R. Source: Pharmacogenetics. 1999 August; 9(4): 445-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10780264&dopt=Abstract
•
Genetic susceptibility to benzene and shortened gestation: evidence of geneenvironment interaction. Author(s): Wang X, Chen D, Niu T, Wang Z, Wang L, Ryan L, Smith T, Christiani DC, Zuckerman B, Xu X. Source: American Journal of Epidemiology. 2000 October 15; 152(8): 693-700. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11052546&dopt=Abstract
•
Genitoanocrural porokeratosis following chronic exposure to benzene. Author(s): Trcka J, Pettke-Rank CV, Brocker EB, Hamm H. Source: Clinical and Experimental Dermatology. 1998 January; 23(1): 28-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9667106&dopt=Abstract
•
Genotoxic effects in workers exposed to benzene: with special reference to exposure biomarkers and confounding factors. Author(s): Bogadi-Sare A, Brumen V, Turk R, Karacic V, Zavalic M. Source: Ind Health. 1997 July; 35(3): 367-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9248220&dopt=Abstract
•
Genotoxic effects in workers exposed to low levels of benzene from gasoline. Author(s): Nilsson RI, Nordlinder RG, Tagesson C, Walles S, Jarvholm BG. Source: American Journal of Industrial Medicine. 1996 September; 30(3): 317-24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8876800&dopt=Abstract
64
Benzene
•
Geographical distribution of benzene in air in northwestern Italy and personal exposure. Author(s): Gilli G, Scursatone E, Bono R. Source: Environmental Health Perspectives. 1996 December; 104 Suppl 6: 1137-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9118883&dopt=Abstract
•
Glutathione S-transferase (GST) M1 and GST T1 genotypes and hematopoietic effects of benzene exposure. Author(s): Hsieh LL, Liou SH, Chiu LL, Chen YH. Source: Archives of Toxicology. 1999 March; 73(2): 80-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10350187&dopt=Abstract
•
Hairy cell leukaemia and occupational exposure to benzene. Author(s): Clavel J, Conso F, Limasset JC, Mandereau L, Roche P, Flandrin G, Hemon D. Source: Occupational and Environmental Medicine. 1996 August; 53(8): 533-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8983464&dopt=Abstract
•
Headspace solid-phase microextraction for the determination of benzene, toluene, ethylbenzene and xylenes in urine. Author(s): Fustinoni S, Giampiccolo R, Pulvirenti S, Buratti M, Colombi A. Source: J Chromatogr B Biomed Sci Appl. 1999 February 19; 723(1-2): 105-15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10080638&dopt=Abstract
•
Hematologic effects of benzene. Job-specific trends during the first year of employment among a cohort of benzene-exposed rubber workers. Author(s): Cody RP, Strawderman WW, Kipen HM. Source: J Occup Med. 1993 August; 35(8): 776-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8229327&dopt=Abstract
•
Hematological changes among Chinese workers with a broad range of benzene exposures. Author(s): Qu Q, Shore R, Li G, Jin X, Chen LC, Cohen B, Melikian AA, Eastmond D, Rappaport SM, Yin S, Li H, Waidyanatha S, Li Y, Mu R, Zhang X, Li K. Source: American Journal of Industrial Medicine. 2002 October; 42(4): 275-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12271475&dopt=Abstract
•
Hematological changes of children exposed to volatile organic compounds containing low levels of benzene. Author(s): Lee CR, Yoo CI, Lee JH, Kim SR, Kim Y. Source: The Science of the Total Environment. 2002 November 1; 299(1-3): 237-45. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12462588&dopt=Abstract
Studies
65
•
Hematopoietic malignancies and related disorders among benzene-exposed workers in China. Author(s): Travis LB, Li CY, Zhang ZN, Li DG, Yin SN, Chow WH, Li GL, Dosemeci M, Blot W, Fraumeni JF Jr, et al. Source: Leukemia & Lymphoma. 1994 June; 14(1-2): 91-102. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7920231&dopt=Abstract
•
Hematotoxocity among Chinese workers heavily exposed to benzene. Author(s): Rothman N, Li GL, Dosemeci M, Bechtold WE, Marti GE, Wang YZ, Linet M, Xi LQ, Lu W, Smith MT, Titenko-Holland N, Zhang LP, Blot W, Yin SN, Hayes RB. Source: American Journal of Industrial Medicine. 1996 March; 29(3): 236-46. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8833776&dopt=Abstract
•
Hemoglobin and albumin adducts of benzene oxide among workers exposed to high levels of benzene. Author(s): Yeowell-O'Connell K, Rothman N, Smith MT, Hayes RB, Li G, Waidyanatha S, Dosemeci M, Zhang L, Yin S, Titenko-Holland N, Rappaport SM. Source: Carcinogenesis. 1998 September; 19(9): 1565-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9771926&dopt=Abstract
•
Human health risk assessment and management in hazardous waste site contaminated by polychlorinated benzenes. Author(s): Dura G, Laszlo E, Horvath A. Source: Cent Eur J Public Health. 2000 July; 8 Suppl: 47-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10943459&dopt=Abstract
•
Hydroquinone, a benzene metabolite, increases the level of aneusomy of chromosomes 7 and 8 in human CD34-positive blood progenitor cells. Author(s): Smith MT, Zhang L, Jeng M, Wang Y, Guo W, Duramad P, Hubbard AE, Hofstadler G, Holland NT. Source: Carcinogenesis. 2000 August; 21(8): 1485-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10910948&dopt=Abstract
•
Hydroquinone, a bioreactive metabolite of benzene, inhibits apoptosis in myeloblasts. Author(s): Hazel BA, Baum C, Kalf GF. Source: Stem Cells (Dayton, Ohio). 1996 November; 14(6): 730-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8948030&dopt=Abstract
66
Benzene
•
Hydroquinone, a reactive metabolite of benzene, inhibits NF-kappa B in primary human CD4+ T lymphocytes. Author(s): Pyatt DW, Stillman WS, Irons RD. Source: Toxicology and Applied Pharmacology. 1998 April; 149(2): 178-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9571986&dopt=Abstract
•
Hyperphosphorylation of p53 induced by benzene, toluene, and chloroform. Author(s): Dees C, Travis C. Source: Cancer Letters. 1994 September 15; 84(2): 117-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8076368&dopt=Abstract
•
Identification of benzene oxide as a product of benzene metabolism by mouse, rat, and human liver microsomes. Author(s): Lovern MR, Turner MJ, Meyer M, Kedderis GL, Bechtold WE, Schlosser PM. Source: Carcinogenesis. 1997 September; 18(9): 1695-700. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9328163&dopt=Abstract
•
In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Author(s): Taavitsainen P, Juvonen R, Pelkonen O. Source: Drug Metabolism and Disposition: the Biological Fate of Chemicals. 2001 March; 29(3): 217-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11181487&dopt=Abstract
•
Increased aneusomy and long arm deletion of chromosomes 5 and 7 in the lymphocytes of Chinese workers exposed to benzene. Author(s): Zhang L, Rothman N, Wang Y, Hayes RB, Li G, Dosemeci M, Yin S, Kolachana P, Titenko-Holland N, Smith MT. Source: Carcinogenesis. 1998 November; 19(11): 1955-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9855009&dopt=Abstract
•
Increased gene expression in human promyeloid leukemia cells exposed to trans,trans-muconaldehyde, a hematotoxic benzene metabolite. Author(s): Ho TY, Witz G. Source: Carcinogenesis. 1997 April; 18(4): 739-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9111208&dopt=Abstract
•
Increased levels of alpha-class and pi-class glutathione S-transferases in cell lines resistant to 1-chloro-2,4-dinitrobenzene. Author(s): Wareing CJ, Black SM, Hayes JD, Wolf CR. Source: European Journal of Biochemistry / Febs. 1993 October 15; 217(2): 671-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8223610&dopt=Abstract
Studies
67
•
Increased translocations and aneusomy in chromosomes 8 and 21 among workers exposed to benzene. Author(s): Smith MT, Zhang L, Wang Y, Hayes RB, Li G, Wiemels J, Dosemeci M, Titenko-Holland N, Xi L, Kolachana P, Yin S, Rothman N. Source: Cancer Research. 1998 May 15; 58(10): 2176-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9605763&dopt=Abstract
•
Indicators of benzene emissions and exposure in Bangkok street. Author(s): Leong ST, Laortanakul P. Source: Environmental Research. 2003 July; 92(3): 173-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12804513&dopt=Abstract
•
Indirect validation of benzene exposure assessment by association with benzene poisoning. Author(s): Dosemeci M, Yin SN, Linet M, Wacholder S, Rothman N, Li GL, Chow WH, Wang YZ, Jiang ZL, Dai TR, Zhang WU, Chao XJ, Ye PZ, Kou QR, Fan YH, Zhang XC, Lin XF, Meng JF, Zho JS, Blot WJ, Hayes RB. Source: Environmental Health Perspectives. 1996 December; 104 Suppl 6: 1343-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9118918&dopt=Abstract
•
Induction of micronuclei and aneuploidy by the quinone-forming agents benzene and o-phenylphenol. Author(s): Eastmond DA. Source: Toxicology Letters. 1993 April; 67(1-3): 105-18. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8451753&dopt=Abstract
•
Industrial sources of benzene exposure? Author(s): Rosebrook DD, Worm GH. Source: Environmental Health Perspectives. 1993 April 22; 101(1): 13-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8513754&dopt=Abstract
•
Influence of culture conditions on the DNA-damaging effect of benzene and its metabolites in human peripheral blood mononuclear cells. Author(s): Fabiani R, De Bartolomeo A, Rosignoli P, Scamosci M, Lepore L, Morozzi G. Source: Environmental and Molecular Mutagenesis. 2001; 37(1): 1-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11170236&dopt=Abstract
•
Inhalation toxicokinetics of 1,2,4-trimethylbenzene in volunteers: comparison between exposure to white spirit and 1,2,4-trimethylbenzene alone. Author(s): Jarnberg J, Johanson G, Lof A, Stahlbom B. Source: The Science of the Total Environment. 1997 June 20; 199(1-2): 65-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9200848&dopt=Abstract
68
Benzene
•
Inter-individual variability of benzene metabolism to trans,trans-muconic acid and its implications in the biological monitoring of occupational exposure. Author(s): Gobba F, Rovesti S, Borella P, Vivoli R, Caselgrandi E, Vivoli G. Source: The Science of the Total Environment. 1997 June 20; 199(1-2): 41-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9200846&dopt=Abstract
•
Interleukin 1 alpha hematological examination in mechanics exposed to low benzene concentrations. Author(s): Hotz P, Carbonnelle P, Scheiff JM, Tschopp A, Lauwerys R. Source: International Archives of Occupational and Environmental Health. 1998 February; 71(1): 19-28. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9523245&dopt=Abstract
•
Investigation of benzene-DNA adducts and their detection in human bone marrow. Author(s): Bodell WJ, Levay G, Pongracz K. Source: Environmental Health Perspectives. 1993 March; 99: 241-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8319633&dopt=Abstract
•
Investigation of the role of the 2',3'-epoxidation pathway in the bioactivation and genotoxicity of dietary allylbenzene analogs. Author(s): Guenthner TM, Luo G. Source: Toxicology. 2001 March 7; 160(1-3): 47-58. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11246123&dopt=Abstract
•
Investigations of benzene exposure, benzene poisoning, and malignancies in China. Author(s): Wong O. Source: Regulatory Toxicology and Pharmacology : Rtp. 2002 February; 35(1): 126-35. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11846642&dopt=Abstract
•
Iodopyridine-for-iodobenzene substitution for use with low molecular weight radiopharmaceuticals: application to m-iodobenzylguanidine. Author(s): Vaidyanathan G, Zalutsky MR, DeGrado TR. Source: Bioconjugate Chemistry. 1998 November-December; 9(6): 758-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9815170&dopt=Abstract
•
Is benzoquinone the prohapten in cross-sensitivity among aminobenzene compounds? Author(s): Lisi P, Hansel K. Source: Contact Dermatitis. 1998 December; 39(6): 304-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9874021&dopt=Abstract
Studies
69
•
Issues for discussion: benzene-induced leukemia--human studies. Author(s): Bayliss D, Sonawane B. Source: Journal of Toxicology and Environmental Health. Part A. 2000 November; 61(56): 467-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11086953&dopt=Abstract
•
Lack of correlation between environmental or biological indicators of benzene exposure at parts per billion levels and micronuclei induction. Author(s): Violante FS, Sanguinetti G, Barbieri A, Accorsi A, Mattioli S, Cesari R, Fimognari C, Hrelia P. Source: Environmental Research. 2003 March; 91(3): 135-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12648475&dopt=Abstract
•
Lack of sensitivity of urinary trans,trans-muconic acid in determining low-level (ppb) benzene exposure in children. Author(s): Barbieri A, Accorsi A, Raffi GB, Nicoli L, Violante FS. Source: Archives of Environmental Health. 2002 May-June; 57(3): 224-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12507175&dopt=Abstract
•
Lack of specificity of trans,trans-muconic acid as a benzene biomarker after ingestion of sorbic acid-preserved foods. Author(s): Weaver VM, Buckley T, Groopman JD. Source: Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2000 July; 9(7): 749-55. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10919747&dopt=Abstract
•
Leukemia after exposure to benzene: temporal trends and implications for standards. Author(s): Finkelstein MM. Source: American Journal of Industrial Medicine. 2000 July; 38(1): 1-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10861761&dopt=Abstract
•
Leukemia and cumulative exposure to butadiene, styrene and benzene among workers in the synthetic rubber industry. Author(s): Macaluso M, Larson R, Delzell E, Sathiakumar N, Hovinga M, Julian J, Muir D, Cole P. Source: Toxicology. 1996 October 28; 113(1-3): 190-202. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8901898&dopt=Abstract
70
Benzene
•
Leukemia in relation to occupational exposures to benzene and other agents: a casecontrol study nested in a cohort of gas and electric utility workers. Author(s): Guenel P, Imbernon E, Chevalier A, Crinquand-Calastreng A, Goldberg M. Source: American Journal of Industrial Medicine. 2002 August; 42(2): 87-97. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12125084&dopt=Abstract
•
Leukemia mortality by cell type in petroleum workers with potential exposure to benzene. Author(s): Raabe GK, Wong O. Source: Environmental Health Perspectives. 1996 December; 104 Suppl 6: 1381-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9118924&dopt=Abstract
•
Leukemia risk associated with benzene exposure in the Pliofilm cohort. Author(s): Paxton MB. Source: Environmental Health Perspectives. 1996 December; 104 Suppl 6: 1431-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9118929&dopt=Abstract
•
Leukemia risk associated with benzene exposure in the pliofilm cohort. II. Risk estimates. Author(s): Paxton MB, Chinchilli VM, Brett SM, Rodricks JV. Source: Risk Analysis : an Official Publication of the Society for Risk Analysis. 1994 April; 14(2): 155-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8008924&dopt=Abstract
•
Leukemia risk associated with benzene exposure in the pliofilm cohort: I. Mortality update and exposure distribution. Author(s): Paxton MB, Chinchilli VM, Brett SM, Rodricks JV. Source: Risk Analysis : an Official Publication of the Society for Risk Analysis. 1994 April; 14(2): 147-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8008923&dopt=Abstract
•
Leukemia risk associated with low-level benzene exposure. Author(s): Glass DC, Gray CN, Jolley DJ, Gibbons C, Sim MR, Fritschi L, Adams GG, Bisby JA, Manuell R. Source: Epidemiology (Cambridge, Mass.). 2003 September; 14(5): 569-77. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14501272&dopt=Abstract
•
Levels of benzene in unleaded petrol. Author(s): Deschamps F. Source: Occupational Medicine (Oxford, England). 1994 July; 44(3): 165. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7919303&dopt=Abstract
Studies
71
•
Limitations to benzene cancer risk assessment by Cox and Ricci. Author(s): Crump K, Allen B, Clewell H. Source: Risk Analysis : an Official Publication of the Society for Risk Analysis. 1993 April; 13(2): 145-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8502787&dopt=Abstract
•
Liquid chromatographic-tandem mass spectrometric urine assay for a highly metabolized cyclic ureidobenzenesulfonamide: issues concerning assay specificity and quality control preparation. Author(s): Fisher AL, DePuy E, Shih T, Stearns R, Lee Y, Gottesdiener K, Flattery S, De Smet M, Keymeulen B, Musson DG. Source: Journal of Pharmaceutical and Biomedical Analysis. 2001 December; 26(5-6): 739-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11600286&dopt=Abstract
•
Liquid/air partition coefficients of the trimethylbenzenes. Author(s): Jarnberg J, Johanson G. Source: Toxicology and Industrial Health. 1995 January-February; 11(1): 81-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7652753&dopt=Abstract
•
Lymphocyte phenotype analysis and chromosome aberration frequency of workers occupationally exposed to styrene, benzene, polycyclic aromatic hydrocarbons or mixed solvents. Author(s): Biro A, Pallinger E, Major J, Jakab MG, Klupp T, Falus A, Tompa A. Source: Immunology Letters. 2002 April 22; 81(2): 133-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11852118&dopt=Abstract
•
Lymphohaematopoeitic cancer mortality among workers with benzene exposure. Author(s): Collins JJ, Ireland B, Buckley CF, Shepperly D. Source: Occupational and Environmental Medicine. 2003 September; 60(9): 676-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12937190&dopt=Abstract
•
Lymphohaematopoietic malignancies and quantitative estimates of exposure to benzene in Canadian petroleum distribution workers. Author(s): Schnatter AR, Armstrong TW, Nicolich MJ, Thompson FS, Katz AM, Huebner WW, Pearlman ED. Source: Occupational and Environmental Medicine. 1996 November; 53(11): 773-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9038803&dopt=Abstract
72
Benzene
•
Mammalian enzymatic repair of etheno and para-benzoquinone exocyclic adducts derived from the carcinogens vinyl chloride and benzene. Author(s): Singer B, Hang B. Source: Iarc Sci Publ. 1999; (150): 233-47. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10626224&dopt=Abstract
•
Matrix interferences in the analysis of benzene in urine. Author(s): Perbellini L, Buratti M, Fiorentino ML, Fustinoni S, Pasini F, Magnaghi S. Source: J Chromatogr B Biomed Sci Appl. 1999 March 19; 724(2): 257-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10219666&dopt=Abstract
•
Measurement of benzene in human breath associated with an environmental exposure. Author(s): Yu R, Weisel CP. Source: Journal of Exposure Analysis and Environmental Epidemiology. 1996 JulySeptember; 6(3): 261-77. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8889948&dopt=Abstract
•
Measurement of benzene in the workplace and its evolution process, Part I: Overview, history, and past methods. Author(s): Verma DK, des Tombe K. Source: American Industrial Hygiene Association Journal. 1999 January-February; 60(1): 38-47. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10028615&dopt=Abstract
•
Measurement of benzene in the workplace and its evolution process, Part II: Present methods and future trends. Author(s): Verma DK, des Tombe K. Source: American Industrial Hygiene Association Journal. 1999 January-February; 60(1): 48-56. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10028616&dopt=Abstract
•
Measurement of DNA repair deficiency in workers exposed to benzene. Author(s): Hallberg LM, el Zein R, Grossman L, Au WW. Source: Environmental Health Perspectives. 1996 May; 104 Suppl 3: 529-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8781377&dopt=Abstract
•
Measurement of the urinary benzene metabolite trans,trans-muconic acid from benzene exposure in humans. Author(s): Yu R, Weisel CP. Source: Journal of Toxicology and Environmental Health. 1996 August 9; 48(5): 453-77. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8751835&dopt=Abstract
Studies
73
•
Mechanistic considerations in benzene physiological model development. Author(s): Medinsky MA, Kenyon EM, Seaton MJ, Schlosser PM. Source: Environmental Health Perspectives. 1996 December; 104 Suppl 6: 1399-404. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9118926&dopt=Abstract
•
Meta-analysis of multiple myeloma and benzene exposure. Author(s): Sonoda T, Nagata Y, Mori M, Ishida T, Imai K. Source: J Epidemiol. 2001 November; 11(6): 249-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11769942&dopt=Abstract
•
Metabolic polymorphisms and urinary biomarkers in subjects with low benzene exposure. Author(s): Verdina A, Galati R, Falasca G, Ghittori S, Imbriani M, Tomei F, Marcellini L, Zijno A, Vecchio VD. Source: Journal of Toxicology and Environmental Health. Part A. 2001 December 21; 64(8): 607-18. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11766168&dopt=Abstract
•
Metabolism of benzene in human liver microsomes: individual variations in relation to CYP2E1 expression. Author(s): Nedelcheva V, Gut I, Soucek P, Tichavska B, Tynkova L, Mraz J, Guengerich FP, Ingelman-Sundberg M. Source: Archives of Toxicology. 1999 February; 73(1): 33-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10207612&dopt=Abstract
•
Methodological issues in biomonitoring of low level exposure to benzene. Author(s): Lagorio S, Crebelli R, Ricciarello R, Conti L, Iavarone I, Zona A, Ghittori S, Carere A. Source: Occupational Medicine (Oxford, England). 1998 November; 48(8): 497-504. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10024724&dopt=Abstract
•
Modeling annual benzene, toluene, NO2, and soot concentrations on the basis of road traffic characteristics. Author(s): Carr D, von Ehrenstein O, Weiland S, Wagner C, Wellie O, Nicolai T, von Mutius E. Source: Environmental Research. 2002 October; 90(2): 111-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12483801&dopt=Abstract
74
Benzene
•
Modulation of the toxicity and macromolecular binding of benzene metabolites by NAD(P)H:Quinone oxidoreductase in transfected HL-60 cells. Author(s): Wiemels J, Wiencke JK, Varykoni A, Smith MT. Source: Chemical Research in Toxicology. 1999 June; 12(6): 467-75. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10368308&dopt=Abstract
•
Molecular analysis of mutations induced by a benzene metabolite, p-benzoquinone, in mouse cells using a novel shuttle vector plasmid. Author(s): Nakayama A, Kawanishi M, Takebe H, Morisawa S, Yagi T. Source: Mutation Research. 1999 July 21; 444(1): 123-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10477346&dopt=Abstract
•
Molecular cytogenetic analysis of buccal cells and lymphocytes from benzeneexposed workers. Author(s): Surralles J, Autio K, Nylund L, Jarventaus H, Norppa H, Veidebaum T, Sorsa M, Peltonen K. Source: Carcinogenesis. 1997 April; 18(4): 817-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9111220&dopt=Abstract
•
Molecular models of benzene leukemogenesis. Author(s): Irons RD. Source: Journal of Toxicology and Environmental Health. Part A. 2000 November; 61(56): 391-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11086945&dopt=Abstract
•
Mortality among benzene-exposed workers in China. Author(s): Hayes RB, Yin SN, Dosemeci M, Li GL, Wacholder S, Chow WH, Rothman N, Wang YZ, Dai TR, Chao XJ, Jiang ZL, Ye PZ, Zhao HB, Kou QR, Zhang WY, Meng JF, Zho JS, Lin XF, Ding CY, Li CY, Zhang ZN, Li DG, Travis LB, Blot WJ, Linet MS. Source: Environmental Health Perspectives. 1996 December; 104 Suppl 6: 1349-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9118919&dopt=Abstract
•
Multiple myeloma and benzene exposure in a multinational cohort of more than 250,000 petroleum workers. Author(s): Wong O, Raabe GK. Source: Regulatory Toxicology and Pharmacology : Rtp. 1997 October; 26(2): 188-99. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9356282&dopt=Abstract
•
Myelofibrosis and benzene exposure. Author(s): Tondel M, Persson B, Carstensen J. Source: Occupational Medicine (Oxford, England). 1995 February; 45(1): 51-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7703476&dopt=Abstract
Studies
75
•
NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Author(s): Nebert DW, Roe AL, Vandale SE, Bingham E, Oakley GG. Source: Genetics in Medicine : Official Journal of the American College of Medical Genetics. 2002 March-April; 4(2): 62-70. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11882782&dopt=Abstract
•
National Association of Medical Examiners Pediatric Toxicology (PedTox) Registry Report 3. Case submission summary and data for acetaminophen, benzene, carboxyhemoglobin, dextromethorphan, ethanol, phenobarbital, and pseudoephedrine. Author(s): Hanzlick R. Source: The American Journal of Forensic Medicine and Pathology : Official Publication of the National Association of Medical Examiners. 1995 December; 16(4): 270-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8599337&dopt=Abstract
•
Needs for research on benzene metabolism and dosimetry. Author(s): Schlosser PM. Source: Journal of Toxicology and Environmental Health. Part A. 2000 November; 61(56): 373-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11086941&dopt=Abstract
•
New PBPK model applied to old occupational exposure to benzene. Author(s): Sherwood RJ, Sinclair GC. Source: American Industrial Hygiene Association Journal. 1999 March-April; 60(2): 25965. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10222577&dopt=Abstract
•
Nitric oxide as a mediator of benzene-induced hematosuppression and toxicity. Author(s): Laskin DL, Heck DE, Punjabi CJ, Laskin JD. Source: Journal of Toxicology and Environmental Health. Part A. 2000 November; 61(56): 413-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11086947&dopt=Abstract
•
Non-amidine-containing 1,2-dibenzamidobenzene inhibitors of human factor Xa with potent anticoagulant and antithrombotic activity. Author(s): Masters JJ, Franciskovich JB, Tinsley JM, Campbell C, Campbell JB, Craft TJ, Froelich LL, Gifford-Moore DS, Hay LA, Herron DK, Klimkowski VJ, Kurz KD, Metz JT, Ratz AM, Shuman RT, Smith GF, Smith T, Towner RD, Wiley MR, Wilson A, Yee YK. Source: Journal of Medicinal Chemistry. 2000 June 1; 43(11): 2087-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10841787&dopt=Abstract
76
Benzene
•
Non-Hodgkin's lymphoma and exposure to benzene in a multinational cohort of more than 308,000 petroleum workers, 1937 to 1996. Author(s): Wong O, Raabe GK. Source: Journal of Occupational and Environmental Medicine / American College of Occupational and Environmental Medicine. 2000 May; 42(5): 554-68. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10824308&dopt=Abstract
•
Non-Hodgkin's lymphoma and exposure to benzene in petroleum workers. Author(s): Goldstein BD, Shalat S. Source: Journal of Occupational and Environmental Medicine / American College of Occupational and Environmental Medicine. 2000 December; 42(12): 1133-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11125674&dopt=Abstract
•
Non-linear production of benzene oxide-albumin adducts with human exposure to benzene. Author(s): Rappaport SM, Yeowell-O'Connell K, Smith MT, Dosemeci M, Hayes RB, Zhang L, Li G, Yin S, Rothman N. Source: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 2002 October 5; 778(1-2): 367-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12376141&dopt=Abstract
•
Novel inhibitors of the sodium-calcium exchanger: benzene ring analogues of Nguanidino substituted amiloride derivatives. Author(s): Rogister F, Laeckmann D, Plasman P, Van Eylen F, Ghyoot M, Maggetto C, Liegeois J, Geczy J, Herchuelz A, Delarge J, Masereel B. Source: European Journal of Medicinal Chemistry. 2001 July-August; 36(7-8): 597-614. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11600230&dopt=Abstract
•
NTP Technical Report on the metabolism, toxicity and predicted carcinogenicity of diazoaminobenzene (CAS No. 136-35-6). Author(s): Ress NB; National Toxicology Program. Source: Toxicity Report Series. 2002 September; (73): 1-23, A1-C6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12370695&dopt=Abstract
•
Occupational paternal exposure to benzene and risk of spontaneous abortion. Author(s): Strucker I, Mandereau L, Aubert-Berleur MP, Deplan F, Paris A, Richard A, Hemon D. Source: Occupational and Environmental Medicine. 1994 July; 51(7): 475-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8044247&dopt=Abstract
Studies
77
•
On the carcinogenic risk evaluation of diesel exhaust: benzene in airborne particles and alterations of heme metabolism in lymphocytes as markers of exposure. Author(s): Muzyka V, Veimer S, Schmidt N. Source: The Science of the Total Environment. 1998 June 30; 217(1-2): 103-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9695175&dopt=Abstract
•
Optimization issues in physiological toxicokinetic modeling: a case study with benzene. Author(s): Woodruff TJ, Bois FY. Source: Toxicology Letters. 1993 August; 69(2): 181-96. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8212060&dopt=Abstract
•
Overview of benzene-induced aplastic anaemia. Author(s): Smith MT. Source: European Journal of Haematology. Supplementum. 1996; 60: 107-10. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8987251&dopt=Abstract
•
Overview of the toxicology of benzene. Author(s): Snyder R. Source: Journal of Toxicology and Environmental Health. Part A. 2000 November; 61(56): 339-46. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11086937&dopt=Abstract
•
Oxidative DNA damage and apoptosis induced by benzene metabolites. Author(s): Hiraku Y, Kawanishi S. Source: Cancer Research. 1996 November 15; 56(22): 5172-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8912853&dopt=Abstract
•
Oxidative modifications produced in HL-60 cells on exposure to benzene metabolites. Author(s): Rao NR, Snyder R. Source: Journal of Applied Toxicology : Jat. 1995 September-October; 15(5): 403-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8666725&dopt=Abstract
•
Particle-bound benzene from diesel engine exhaust. Author(s): Muzyka V, Veimer S, Shmidt N. Source: Scand J Work Environ Health. 1998 December; 24(6): 481-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9988090&dopt=Abstract
78
Benzene
•
Partition coefficients for benzene in human skin. Author(s): Sinclair GC, Wester RC, Maibach HI. Source: Aiha Journal : a Journal for the Science of Occupational and Environmental Health and Safety. 2002 November-December; 63(6): 685-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12570074&dopt=Abstract
•
Partitioning of benzene in blood: influence of hemoglobin type in humans and animals. Author(s): Wiester MJ, Winsett DW, Richards JH, Doerfler DL, Costa DL. Source: Environmental Health Perspectives. 2002 March; 110(3): 255-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11882476&dopt=Abstract
•
p-Benzoquinone, a reactive metabolite of benzene, prevents the processing of preinterleukins-1 alpha and -1 beta to active cytokines by inhibition of the processing enzymes, calpain, and interleukin-1 beta converting enzyme. Author(s): Kalf GF, Renz JF, Niculescu R. Source: Environmental Health Perspectives. 1996 December; 104 Suppl 6: 1251-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9118901&dopt=Abstract
•
Personal exposure to benzene and the influence of attached and integral garages. Author(s): Mann HS, Crump D, Brown V. Source: J R Soc Health. 2001 March; 121(1): 38-46. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11329696&dopt=Abstract
•
Personal exposure to benzene, toluene and xylene in different microenvironments at the Mexico City metropolitan zone. Author(s): Ortiz E, Alemon E, Romero D, Arriaga JL, Olaya P, Guzman F, Rios C. Source: The Science of the Total Environment. 2002 March 27; 287(3): 241-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11993966&dopt=Abstract
•
Personal exposure to different levels of benzene and its relationships to the urinary metabolites S-phenylmercapturic acid and trans,trans-muconic acid. Author(s): Melikian AA, Qu Q, Shore R, Li G, Li H, Jin X, Cohen B, Chen L, Li Y, Yin S, Mu R, Zhang X, Wang Y. Source: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 2002 October 5; 778(1-2): 211-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12376128&dopt=Abstract
•
Personal reflections on 50 years of study of benzene toxicology. Author(s): Parke DV. Source: Environmental Health Perspectives. 1996 December; 104 Suppl 6: 1123-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9118881&dopt=Abstract
Studies
79
•
Petroleum worker studies and benzene risk assessment. Author(s): Schnatter R. Source: Journal of Toxicology and Environmental Health. Part A. 2000 November; 61(56): 433-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11086949&dopt=Abstract
•
Pharmacokinetics of and monoamine oxidase B inhibition by (E)-4-fluoro-betafluoromethylene benzene butanamine in man. Author(s): Dulery BD, Schoun J, Zreika M, Dow J, Huebert N, Hinze C, Haegele KD. Source: Arzneimittel-Forschung. 1993 March; 43(3): 297-302. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8489556&dopt=Abstract
•
Physiologically based modeling of 1,2,4-trimethylbenzene inhalation toxicokinetics. Author(s): Jarnberg J, Johanson G. Source: Toxicology and Applied Pharmacology. 1999 March 15; 155(3): 203-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10079206&dopt=Abstract
•
Physiologically based pharmacokinetic modeling of a ternary mixture of alkyl benzenes in rats and humans. Author(s): Tardif R, Charest-Tardif G, Brodeur J, Krishnan K. Source: Toxicology and Applied Pharmacology. 1997 May; 144(1): 120-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9169076&dopt=Abstract
•
Platelet aggregation inhibiting and anticoagulant effects of oligoamines, XX: 4,4',4''(1,3,5)-benzene-tris-sydnone imines. Author(s): Rehse K, Martens A. Source: Archiv Der Pharmazie. 1993 April; 326(4): 217-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8494483&dopt=Abstract
•
Population toxicokinetics of benzene. Author(s): Bois FY, Jackson ET, Pekari K, Smith MT. Source: Environmental Health Perspectives. 1996 December; 104 Suppl 6: 1405-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9118927&dopt=Abstract
•
Possible genotoxicity in low level benzene exposure. Author(s): Karacic V, Skender L, Bosner-Cucancic B, Bogadi-Sare A. Source: American Journal of Industrial Medicine. 1995 March; 27(3): 379-88. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7747744&dopt=Abstract
80
Benzene
•
Possible mechanisms of carcinogenesis after exposure to benzene. Author(s): Golding BT, Watson WP. Source: Iarc Sci Publ. 1999; (150): 75-88. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10626210&dopt=Abstract
•
Potential biomarkers of benzene exposure. Author(s): Medeiros AM, Bird MG, Witz G. Source: Journal of Toxicology and Environmental Health. 1997 August 29; 51(6): 519-39. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9242226&dopt=Abstract
•
Presence of antibodies to heat stress proteins in workers exposed to benzene and in patients with benzene poisoning. Author(s): Wu T, Yuan Y, Wu Y, He H, Zhang G, Tanguay RM. Source: Cell Stress & Chaperones. 1998 September; 3(3): 161-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9764756&dopt=Abstract
•
Protein adducts as dosimeters of human exposure to styrene, styrene-7,8-oxide, and benzene. Author(s): Rappaport SM, Yeowell-O'Connell K. Source: Toxicology Letters. 1999 September 5; 108(2-3): 117-26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10511253&dopt=Abstract
•
Protein adducts of 1,4-benzoquinone and benzene oxide among smokers and nonsmokers exposed to benzene in China. Author(s): Yeowell-O'Connell K, Rothman N, Waidyanatha S, Smith MT, Hayes RB, Li G, Bechtold WE, Dosemeci M, Zhang L, Yin S, Rappaport SM. Source: Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2001 August; 10(8): 831-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11489749&dopt=Abstract
•
Radioiodinated styrylbenzene derivatives as potential SPECT imaging agents for amyloid plaque detection in Alzheimer's disease. Author(s): Kung MP, Hou C, Zhuang ZP, Skovronsky DM, Zhang B, Gur TL, Trojanowski JQ, Lee VM, Kung HF. Source: Journal of Molecular Neuroscience : Mn. 2002 August-October; 19(1-2): 7-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12212796&dopt=Abstract
Studies
81
•
Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. Author(s): Zhuang ZP, Kung MP, Hou C, Skovronsky DM, Gur TL, Plossl K, Trojanowski JQ, Lee VM, Kung HF. Source: Journal of Medicinal Chemistry. 2001 June 7; 44(12): 1905-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11384236&dopt=Abstract
•
Re: Benzene and lymphohematopoietic malignancies in humans. Hayes et al. Am. J. Ind. Med. 40:117-126, 2001. Author(s): Robbins A. Source: American Journal of Industrial Medicine. 2001 December; 40(6): 714-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11757049&dopt=Abstract
•
Re: Benzene and the dose-related incidence of hematologic neoplasms in China. Author(s): Wong O. Source: Journal of the National Cancer Institute. 1998 March 18; 90(6): 469-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9521175&dopt=Abstract
•
Re: Benzene and the dose-related incidence of hematologic neoplasms in China. Author(s): Niazi GA, Fleming AF. Source: Journal of the National Cancer Institute. 1997 November 19; 89(22): 1728-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9390548&dopt=Abstract
•
Recent developments in benzene risk assessment. Author(s): Kacew S, Lemaire I. Source: Journal of Toxicology and Environmental Health. Part A. 2000 November; 61(56): 485-98. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11086957&dopt=Abstract
•
Recent developments in the understanding of benzene toxicity and leukemogenesis. Author(s): Snyder R. Source: Drug and Chemical Toxicology. 2000 February; 23(1): 13-25. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10711386&dopt=Abstract
•
Recent findings and new initiatives for epidemiologic research on benzene. Author(s): Wong O. Source: Journal of Toxicology and Environmental Health. Part A. 2000 November; 61(56): 457-66. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11086952&dopt=Abstract
82
Benzene
•
Reconstruction of benzene exposure for the Pliofilm cohort (1936-1976) using Monte Carlo techniques. Author(s): Williams PR, Paustenbach DJ. Source: Journal of Toxicology and Environmental Health. Part A. 2003 April 25; 66(8): 677-781. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12746133&dopt=Abstract
•
Red blood cell glycerol lysis and hematologic effects in occupational benzene exposure. Author(s): Bogadi-Sare A, Turk R, Karacic V, Zavalic M, Trutin-Ostovic K. Source: Toxicology and Industrial Health. 1997 July-August; 13(4): 485-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9249930&dopt=Abstract
•
Relationship between environmental exposure to toluene, xylene and ethylbenzene and the expired breath concentrations for gasoline service workers. Author(s): Chen ML, Chen SH, Guo BR, Mao IF. Source: Journal of Environmental Monitoring : Jem. 2002 August; 4(4): 562-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12196001&dopt=Abstract
•
Relationships between smoking habits, smoking-associated hematological changes, and urinary benzene metabolites. Author(s): Haufroid V, Hotz P, Carbonnelle P, Lauwerys R. Source: Journal of Toxicology and Environmental Health. 1997 September; 52(1): 1-17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9269319&dopt=Abstract
•
Report on the workshop entitled: “Modeling chemically induced leukemia-implications for benzene risk assessment”. Author(s): Smith MT, Fanning EW. Source: Leukemia Research. 1997 May; 21(5): 361-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9225061&dopt=Abstract
•
Resonance light-scattering method for the determination of BSA and HSA with sodium dodecyl benzene sulfonate or sodium lauryl sulfate. Author(s): Liu R, Yang J, Sun C, Wu X, Li L, Li Z. Source: Analytical and Bioanalytical Chemistry. 2003 September; 377(2): 375-9. Epub 2003 July 08. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12851737&dopt=Abstract
•
Retrospective estimation of exposure to benzene in a leukaemia case-control study of petroleum marketing and distribution workers in the United Kingdom. Author(s): Lewis SJ, Bell GM, Cordingley N, Pearlman ED, Rushton L. Source: Occupational and Environmental Medicine. 1997 March; 54(3): 167-75. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9155777&dopt=Abstract
Studies
83
•
Retrospective exposure assessment for benzene in the Australian petroleum industry. Author(s): Glass DC, Adams GG, Manuell RW, Bisby JA. Source: The Annals of Occupational Hygiene. 2000 June; 44(4): 301-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10831734&dopt=Abstract
•
Review of epidemiologic evidence on benzene and lymphatic and hematopoietic cancers. Author(s): Savitz DA, Andrews KW. Source: American Journal of Industrial Medicine. 1997 March; 31(3): 287-95. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9055951&dopt=Abstract
•
Rheological behaviour of red blood cells suspended in hemoglobin solutions. In vitro study comparing dextran-benzene-tetra-carboxylate hemoglobin, stroma free hemoglobin and plasma expanders. Author(s): Menu P, Longrois D, Faivre B, Donner M, Labrude P, Stoltz JF, Vigneron C. Source: Transfusion Science. 1999 February; 20(1): 5-16. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10621560&dopt=Abstract
•
Rising leukemia rates in Thailand: the possible role of benzene and related compounds in cigarette smoke. Author(s): Mitacek EJ, Brunnemann KD, Polednak AP, Limsila T, Bhothisuwan K, Hummel CF. Source: Oncol Rep. 2002 November-December; 9(6): 1399-403. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12375055&dopt=Abstract
•
Risk of premenopausal breast cancer in association with occupational exposure to polycyclic aromatic hydrocarbons and benzene. Author(s): Petralia SA, Vena JE, Freudenheim JL, Dosemeci M, Michalek A, Goldberg MS, Brasure J, Graham S. Source: Scand J Work Environ Health. 1999 June; 25(3): 215-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10450771&dopt=Abstract
•
Scientific update on benzene. Author(s): Rangan U, Snyder R. Source: Annals of the New York Academy of Sciences. 1997 December 26; 837: 105-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9472333&dopt=Abstract
84
Benzene
•
Self-assessment of exposure--a pilot study of assessment of exposure to benzene in tank truck drivers. Author(s): Liljelind IE, Stromback AE, Jarvholm BG, Levin JO, Strangert BL, Sunesson AL. Source: Applied Occupational and Environmental Hygiene. 2000 February; 15(2): 195202. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10675977&dopt=Abstract
•
Self-collected breath sampling for monitoring low-level benzene exposures among automobile mechanics. Author(s): Egeghy PP, Nylander-French L, Gwin KK, Hertz-Picciotto I, Rappaport SM. Source: The Annals of Occupational Hygiene. 2002 July; 46(5): 489-500. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12176763&dopt=Abstract
•
Significance of the renal effects of ethyl benzene in rodents for assessing human carcinogenic risk. Author(s): Hard GC. Source: Toxicological Sciences : an Official Journal of the Society of Toxicology. 2002 September; 69(1): 30-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12215658&dopt=Abstract
•
Simultaneous determination of benzene, toluene, ethylbenzene, and xylenes in urine by thermal desorption-gas chromatography. Author(s): Hung IF, Lee SA, Chen RK. Source: J Chromatogr B Biomed Sci Appl. 1998 March 20; 706(2): 352-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9551824&dopt=Abstract
•
Single strand DNA breaks in T- and B-lymphocytes and granulocytes in workers exposed to benzene. Author(s): Sul D, Lee D, Im H, Oh E, Kim J, Lee E. Source: Toxicology Letters. 2002 August 5; 134(1-3): 87-95. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12191865&dopt=Abstract
•
Species comparison of hepatic and pulmonary metabolism of benzene. Author(s): Powley MW, Carlson GP. Source: Toxicology. 1999 December 6; 139(3): 207-17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10647921&dopt=Abstract
•
Species differences in the metabolism of benzene. Author(s): Henderson RF. Source: Environmental Health Perspectives. 1996 December; 104 Suppl 6: 1173-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9118889&dopt=Abstract
Studies
85
•
Specific determination of benzene in urine using dynamic headspace and massselective detection. Author(s): Ljungkvist G, Larstad M, Mathiasson L. Source: J Chromatogr B Biomed Sci Appl. 1999 January 8; 721(1): 39-46. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10027635&dopt=Abstract
•
S-phenylcysteine in albumin as a benzene biomarker. Author(s): Bechtold WE, Strunk MR. Source: Environmental Health Perspectives. 1996 December; 104 Suppl 6: 1147-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9118885&dopt=Abstract
•
Structure and validation of a pharmacokinetic model for benzene. Author(s): Sinclair GC, Gray CN, Sherwood RJ. Source: American Industrial Hygiene Association Journal. 1999 March-April; 60(2): 24958. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10222576&dopt=Abstract
•
Structure-activity relationships in the induction of DNA-protein cross-links by hematotoxic ring-opened benzene metabolites and related compounds in HL60 cells. Author(s): Schoenfeld HA, Witz G. Source: Toxicology Letters. 2000 July 27; 116(1-2): 79-88. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10906425&dopt=Abstract
•
Studies on the antitumor 2,6-piperazinediones: synthesis of 2,3-diacetoxy-4carbomethoxy-(3',5'-dioxo-N4' substituted piperazinyl methyl) benzene. Author(s): Li Q, Shao HW, Jiang HL, Xie YY. Source: Pharmazie. 1995 July; 50(7): 447-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7675884&dopt=Abstract
•
Study of some immunological parameters in workers occupationally exposed to benzene. Author(s): Bogadi-Sare A, Zavalic M, Trosic I, Turk R, Kontosic I, Jelcic I. Source: International Archives of Occupational and Environmental Health. 2000 August; 73(6): 397-400. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11007343&dopt=Abstract
•
Suitability of S-phenyl mercapturic acid and trans-trans-muconic acid as biomarkers for exposure to low concentrations of benzene. Author(s): Boogaard PJ, van Sittert NJ. Source: Environmental Health Perspectives. 1996 December; 104 Suppl 6: 1151-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9118886&dopt=Abstract
86
Benzene
•
Suppression of apoptosis by Bcl-2 to enhance benzene metabolites-induced oxidative DNA damage and mutagenesis: A possible mechanism of carcinogenesis. Author(s): Kuo ML, Shiah SG, Wang CJ, Chuang SE. Source: Molecular Pharmacology. 1999 May; 55(5): 894-901. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10220568&dopt=Abstract
•
Synthesis and crystal structures of substituted benzenes and benzoquinones as tissue factor VIIa inhibitors. Author(s): Parlow JJ, Stevens AM, Stegeman RA, Stallings WC, Kurumbail RG, South MS. Source: Journal of Medicinal Chemistry. 2003 September 25; 46(20): 4297-312. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=13678408&dopt=Abstract
•
Synthesis of 1-(2-deoxy-beta-D-ribofuranosyl)-2,4-difluoro-5-substituted-benzene thymidine mimics, some related alpha-anomers, and their evaluation as antiviral and anticancer agents. Author(s): Wang ZX, Duan W, Wiebe LI, Balzarini J, De Clercq E, Knaus EE. Source: Nucleosides, Nucleotides & Nucleic Acids. 2001 January-February; 20(1-2): 1140. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11303557&dopt=Abstract
•
Synthesis of 1-(2-deoxy-beta-D-ribofuranosyl)-2,4-difluoro-5-substituted-benzenes: “thymine replacement” analogs of thymidine for evaluation as anticancer and antiviral agents. Author(s): Wang ZX, Duan W, Wiebe LI, Balzarini J, De Clercq E, Knaus EE. Source: Nucleosides, Nucleotides & Nucleic Acids. 2001 January-February; 20(1-2): 4158. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11303562&dopt=Abstract
•
Synthesis, antiviral and antiproliferative activity of some N-benzenesulphonyl-2(2- or 3-pyridylethyl)-benzimidazoles. Author(s): Garuti L, Roberti M, Rossi T, Cermelli C, Portolani M, Malagoli M, Castelli M. Source: Anti-Cancer Drug Design. 1998 July; 13(5): 397-406. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9702206&dopt=Abstract
•
Terrestrial risk assessment for linear alkyl benzene sulfonate (LAS) in sludgeamended soils. Author(s): de Wolf W, Feijtel T. Source: Chemosphere. 1998 March; 36(6): 1319-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9493328&dopt=Abstract
Studies
87
•
The absorption of benzene through human skin. Author(s): Hanke J, Dutkiewicz T, Piotrowski J. Source: International Journal of Occupational and Environmental Health : Official Journal of the International Commission on Occupational Health. 2000 April-June; 6(2): 104-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10828138&dopt=Abstract
•
The benzene metabolite, hydroquinone, selectively induces 5q31- and -7 in human CD34+CD19- bone marrow cells. Author(s): Stillman WS, Varella-Garcia M, Irons RD. Source: Experimental Hematology. 2000 February; 28(2): 169-76. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10706073&dopt=Abstract
•
The benzene metabolites hydroquinone and catechol act in synergy to induce dosedependent hypoploidy and -5q31 in a human cell line. Author(s): Stillman WS, Varella-Garcia M, Irons RD. Source: Leukemia & Lymphoma. 1999 October; 35(3-4): 269-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10706450&dopt=Abstract
•
The casual relation between benzene exposure and multiple myeloma. Author(s): Goldstein BD, Shalat SL. Source: Blood. 2000 February 15; 95(4): 1512-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10722282&dopt=Abstract
•
The contribution of benzene to smoking-induced leukemia. Author(s): Korte JE, Hertz-Picciotto I, Schulz MR, Ball LM, Duell EJ. Source: Environmental Health Perspectives. 2000 April; 108(4): 333-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10753092&dopt=Abstract
•
The effects of aliphatic (n-nonane), naphtenic (1,2, 4-trimethylcyclohexane), and aromatic (1,2,4-trimethylbenzene) hydrocarbons on respiratory burst in human neutrophil granulocytes. Author(s): Myhre O, Vestad TA, Sagstuen E, Aarnes H, Fonnum F. Source: Toxicology and Applied Pharmacology. 2000 September 15; 167(3): 222-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10986013&dopt=Abstract
•
The effects of benzene and hydroquinone on myeloid differentiation of HL-60 promyelocytic leukemia cells. Author(s): Kalf GF, O'Connor A. Source: Leukemia & Lymphoma. 1993 November; 11(5-6): 331-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8124204&dopt=Abstract
88
Benzene
•
The frontier orbital phase angles: novel QSAR descriptors for benzene derivatives, applied to phenylalkylamine hallucinogens. Author(s): Clare BW. Source: Journal of Medicinal Chemistry. 1998 September 24; 41(20): 3845-56. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9748359&dopt=Abstract
•
The National Exposure Registry: analyses of health outcomes from the benzene subregistry. Author(s): Burg JR, Gist GL. Source: Toxicology and Industrial Health. 1998 May-June; 14(3): 367-87. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9569445&dopt=Abstract
•
The nature of chromosomal aberrations detected in humans exposed to benzene. Author(s): Zhang L, Eastmond DA, Smith MT. Source: Critical Reviews in Toxicology. 2002 January; 32(1): 1-42. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11846214&dopt=Abstract
•
The putative benzene metabolite 2,3, 5-tris(glutathion-S-yl)hydroquinone depletes glutathione, stimulates sphingomyelin turnover, and induces apoptosis in HL-60 cells. Author(s): Bratton SB, Lau SS, Monks TJ. Source: Chemical Research in Toxicology. 2000 July; 13(7): 550-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10898586&dopt=Abstract
•
The role of metabolism and specific metabolites in benzene-induced toxicity: evidence and issues. Author(s): Ross D. Source: Journal of Toxicology and Environmental Health. Part A. 2000 November; 61(56): 357-72. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11086940&dopt=Abstract
•
The toxicology of benzene. Author(s): Snyder R, Witz G, Goldstein BD. Source: Environmental Health Perspectives. 1993 April; 100: 293-306. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8354177&dopt=Abstract
•
The use of non-tumor data in cancer risk assessment: reflections on butadiene, vinyl chloride, and benzene. Author(s): Albertini R, Clewell H, Himmelstein MW, Morinello E, Olin S, Preston J, Scarano L, Smith MT, Swenberg J, Tice R, Travis C. Source: Regulatory Toxicology and Pharmacology : Rtp. 2003 February; 37(1): 105-32. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12662914&dopt=Abstract
Studies
89
•
Time courses of sensory irritations due to 2-butanone and ethyl benzene exposure: influences of self-reported multiple chemical sensitivity (sMCS). Author(s): van Thriel C, Haumann K, Kiesswetter E, Blaszkewicz M, Seeber A. Source: International Journal of Hygiene and Environmental Health. 2002 February; 204(5-6): 367-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11885363&dopt=Abstract
•
Toxicokinetics of 1,2,4-trimethylbenzene in humans exposed to vapours of white spirit: comparison with exposure to 1,2,4-trimethylbenzene alone. Author(s): Jarnberg J, Johanson G, Lof A, Stahlbom B. Source: Archives of Toxicology. 1998 July-August; 72(8): 483-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9765063&dopt=Abstract
•
Trans,trans-muconic acid, a biological indicator to low levels of environmental benzene: some aspects of its specificity. Author(s): Pezzagno G, Maestri L, Fiorentino ML. Source: American Journal of Industrial Medicine. 1999 May; 35(5): 511-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10212704&dopt=Abstract
•
Trisubstituted benzene leukotriene B4 receptor antagonists: synthesis and structureactivity relationships. Author(s): Konno M, Nakae T, Sakuyama S, Odagaki Y, Nakai H, Hamanaka N. Source: Bioorganic & Medicinal Chemistry. 1997 August; 5(8): 1649-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9313868&dopt=Abstract
•
Urban benzene and population exposure. Author(s): Cocheo V, Sacco P, Boaretto C, De Saeger E, Ballesta PP, Skov H, Goelen E, Gonzalez N, Caracena AB. Source: Nature. 2000 March 9; 404(6774): 141-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10724154&dopt=Abstract
•
Urban benzene exposure and oxidative DNA damage: influence of genetic polymorphisms in metabolism genes. Author(s): Sorensen M, Skov H, Autrup H, Hertel O, Loft S. Source: The Science of the Total Environment. 2003 June 20; 309(1-3): 69-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12798093&dopt=Abstract
•
Urinary benzene as a biomarker of exposure among occupationally exposed and unexposed subjects. Author(s): Waidyanatha S, Rothman N, Fustinoni S, Smith MT, Hayes RB, Bechtold W, Dosemeci M, Guilan L, Yin S, Rappaport SM. Source: Carcinogenesis. 2001 February; 22(2): 279-86. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11181449&dopt=Abstract
90
Benzene
•
Urinary excretion of unmetabolized benzene as an indicator of benzene exposure. Author(s): Ghittori S, Fiorentino ML, Maestri L, Cordioli G, Imbriani M. Source: Journal of Toxicology and Environmental Health. 1993 March; 38(3): 233-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8450555&dopt=Abstract
•
Urinary phenylmercapturic acid as a marker of occupational exposure to benzene. Author(s): Inoue O, Kanno E, Kakizaki M, Watanabe T, Higashikawa K, Ikeda M. Source: Ind Health. 2000 April; 38(2): 195-204. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10812842&dopt=Abstract
•
Urinary trans,trans-muconic acid determined by liquid chromatography: application in biological monitoring of benzene exposure. Author(s): Lee BL, New AL, Kok PW, Ong HY, Shi CY, Ong CN. Source: Clinical Chemistry. 1993 September; 39(9): 1788-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8375048&dopt=Abstract
•
Urine trans,trans-muconic acid determination for monitoring of benzene exposure in mechanics. Author(s): Suwansaksri J, Wiwanitkit V. Source: Southeast Asian J Trop Med Public Health. 2000 September; 31(3): 587-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11289027&dopt=Abstract
•
Use of expert judgment in exposure assessment. Part I. Characterization of personal exposure to benzene. Author(s): Walker KD, Evans JS, MacIntosh D. Source: Journal of Exposure Analysis and Environmental Epidemiology. 2001 JulyAugust; 11(4): 308-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11571610&dopt=Abstract
•
Use of expert judgment in exposure assessment: part 2. Calibration of expert judgments about personal exposures to benzene. Author(s): Walker KD, Catalano P, Hammitt JK, Evans JS. Source: Journal of Exposure Analysis and Environmental Epidemiology. 2003 January; 13(1): 1-16. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12595879&dopt=Abstract
•
Utilization of breath analysis for exposure estimates of benzene associated with active smoking. Author(s): Jo WK, Pack KW. Source: Environmental Research. 2000 June; 83(2): 180-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10856191&dopt=Abstract
Studies
91
•
Validated method for quantitation of biomarkers for benzene and its alkylated analogues in urine. Author(s): Laurens JB, Mbianda XY, Spies JH, Ubbink JB, Vermaak WJ. Source: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 2002 July 15; 774(2): 173-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12076687&dopt=Abstract
•
Validation and evaluation of biomarkers in workers exposed to benzene in China. Author(s): Qu Q, Shore R, Li G, Jin X, Chen LC, Cohen B, Melikian AA, Eastmond D, Rappaport S, Li H, Rupa D, Waidyanatha S, Yin S, Yan H, Meng M, Winnik W, Kwok ES, Li Y, Mu R, Xu B, Zhang X, Li K. Source: Res Rep Health Eff Inst. 2003 June; (115): 1-72; Discussion 73-87. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12931845&dopt=Abstract
•
Validation of benzene exposure assessment. Author(s): Dosemeci M, Rothman N, Yin SN, Li GL, Linet M, Wacholder S, Chow WH, Hayes RB. Source: Annals of the New York Academy of Sciences. 1997 December 26; 837: 114-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9472334&dopt=Abstract
•
Validation of biomarkers in humans exposed to benzene: urine metabolites. Author(s): Qu Q, Melikian AA, Li G, Shore R, Chen L, Cohen B, Yin S, Kagan MR, Li H, Meng M, Jin X, Winnik W, Li Y, Mu R, Li K. Source: American Journal of Industrial Medicine. 2000 May; 37(5): 522-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10723046&dopt=Abstract
•
Validation of exposure estimation for benzene in the Australian petroleum industry. Author(s): Glass DC, Gray CN, Adams GG, Manuell RW, Bisby JA. Source: Toxicology and Industrial Health. 2001 May; 17(4): 113-27. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12479507&dopt=Abstract
•
Validity of biomarkers in environmental health studies: the case of PAHs and benzene. Author(s): Dor F, Dab W, Empereur-Bissonnet P, Zmirou D. Source: Critical Reviews in Toxicology. 1999 March; 29(2): 129-68. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10213110&dopt=Abstract
93
CHAPTER 2. NUTRITION AND BENZENE Overview In this chapter, we will show you how to find studies dedicated specifically to nutrition and benzene.
Finding Nutrition Studies on Benzene The National Institutes of Health’s Office of Dietary Supplements (ODS) offers a searchable bibliographic database called the IBIDS (International Bibliographic Information on Dietary Supplements; National Institutes of Health, Building 31, Room 1B29, 31 Center Drive, MSC 2086, Bethesda, Maryland 20892-2086, Tel: 301-435-2920, Fax: 301-480-1845, E-mail:
[email protected]). The IBIDS contains over 460,000 scientific citations and summaries about dietary supplements and nutrition as well as references to published international, scientific literature on dietary supplements such as vitamins, minerals, and botanicals.7 The IBIDS includes references and citations to both human and animal research studies. As a service of the ODS, access to the IBIDS database is available free of charge at the following Web address: http://ods.od.nih.gov/databases/ibids.html. After entering the search area, you have three choices: (1) IBIDS Consumer Database, (2) Full IBIDS Database, or (3) Peer Reviewed Citations Only. Now that you have selected a database, click on the “Advanced” tab. An advanced search allows you to retrieve up to 100 fully explained references in a comprehensive format. Type “benzene” (or synonyms) into the search box, and click “Go.” To narrow the search, you can also select the “Title” field.
7 Adapted from http://ods.od.nih.gov. IBIDS is produced by the Office of Dietary Supplements (ODS) at the National Institutes of Health to assist the public, healthcare providers, educators, and researchers in locating credible, scientific information on dietary supplements. IBIDS was developed and will be maintained through an interagency partnership with the Food and Nutrition Information Center of the National Agricultural Library, U.S. Department of Agriculture.
94
Benzene
The following information is typical of that found when using the “Full IBIDS Database” to search for “benzene” (or a synonym): •
Accumulation of low molecular weight (bleomycin detectable) iron in bone marrow cells of rats after benzene exposure. Author(s): Industrial Toxicology Research Centre, Lucknow, India. Source: Pandya, K P Rao, G S Khan, S Krishnamurthy, R Arch-Toxicol. 1990; 64(4): 33942 0340-5761
•
An online automatic sample cleanup system for the quantitative detection of the benzene exposure biomarker S-phenylmercapturic acid in human urine by electrospray ionization tandem mass spectrometry. Author(s): Department of Environmental and Occupational Health, National Cheng Kung University College of Medicine, Tainan, Taiwan.
[email protected] Source: Liao, P C Li, C M Lin, L C Hung, C W Shih, T S J-Anal-Toxicol. 2002 May-June; 26(4): 205-10 0146-4760
•
Benzene exposure in car mechanics and road tanker drivers. Author(s): Institut Medecine du Travail Languedoc Roussillon, Carcassonne, France. Source: Javelaud, B Vian, L Molle, R Allain, P Allemand, B Andre, B Barbier, F Churet, A M Dupuis, J Galand, M Millet, F Talmon, J Touron, C Vaissiere, M Vechambre, D Vieules, M Viver, D Int-Arch-Occup-Environ-Health. 1998 June; 71(4): 277-83 0340-0131
•
Benzene-extracted components are important for the major activity of diesel exhaust particles: effect on interleukin-8 gene expression in human bronchial epithelial cells. Author(s): Department of Respiratory Medicine, Graduate School of Medicine, University of Tokyo, Japan. Source: Kawasaki, S Takizawa, H Takami, K Desaki, M Okazaki, H Kasama, T Kobayashi, K Yamamoto, K Nakahara, K Tanaka, M Sagai, M Ohtoshi, T Am-J-RespirCell-Mol-Biol. 2001 April; 24(4): 419-26 1044-1549
•
Biofilter performance and characterization of a biocatalyst degrading alkylbenzene gases. Author(s): University of La Coruna, Department of Fundamental and Industrial Chemistry, Spain. Source: Veiga, M C Fraga, M Amor, L Kennes, C Biodegradation. 1999 June; 10(3): 169-76 0923-9820
•
Comparative studies of the in vitro metabolism and covalent binding of 14C-benzene by liver slices and microsomal fraction of mouse, rat, and human. Author(s): Department of Pharmacology, Mayo Clinic & Foundation, Rochester, MN 55905. Source: Brodfuehrer, J I Chapman, D E Wilke, T J Powis, G Drug-Metab-Dispos. 1990 Jan-February; 18(1): 20-7 0090-9556
•
Contraluminal para-aminohippurate (PAH) transport in the proximal tubule of the rat kidney. IV. Specificity: mono- and polysubstituted benzene analogs. Author(s): Max-Planck-Institut fur Biophysik, Frankfurt/Main, Federal Republic of Germany. Source: Ullrich, K J Rumrich, G Kloss, S Pflugers-Arch. 1988 December; 413(2): 134-46 0031-6768
•
Depletion of liver regulatory heme in benzene exposed rats. Author(s): Industrial Toxicology Research Centre, Lucknow, India. Source: Siddiqui, S M Rao, G S Pandya, K P Toxicology. 1988 March; 48(3): 245-51 0300483X
Nutrition
95
•
Determination of urinary t-t muconic acid as biomarker of environmental benzene intake and its interference factors. Author(s): Sez. Medicina del Lavoro, Universita degli Studi di Genova Largo R. Benzi 10, 16132 Genova.
[email protected] Source: Valente, T Medico, L Chiapperini, D Bonsignore, A D Ann-Chim. 2002 September; 92(9): 911-7 0003-4592
•
Development and validation of a competitive immunoassay for urinary Sphenylmercapturic acid and its application in benzene biological monitoring. Author(s): AB Biomonitoring Ltd, Cardiff Medicentre, Heath Park, Cardiff CF14 4UJ, UK.
[email protected] Source: Aston, J P Ball, R L Pople, J E Jones, K Cocker, J Biomarkers. 2002 Mar-April; 7(2): 103-12 1354-750X
•
Development of liquid chromatography-electrospray ionization-tandem mass spectrometry methods for determination of urinary metabolites of benzene in humans. Author(s): American Health Foundation, Valhalla, NY 10595, USA. Source: Melikian, A A Meng, M O'Connor, R Hu, P Thompson, S M Res-Rep-Health-EffInst. 1999 June; (87): 1-36: discussion 37-43 1041-5505
•
Feasibility of urinary trans, trans-muconic acid determination using high performance liquid chromatography for biological monitoring of benzene exposure. Author(s): Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Source: Wiwanitkit, V Suwansaksri, J Nasuan, P J-Med-Assoc-Thai. 2001 June; 84 Suppl 1: S263-8 0125-2208
•
Genetic polymorphisms influence variability in benzene metabolism in humans. Author(s): Pisa University, Department of Human and Environmental Sciences, Genetics and Environmental Mutagenesis, Italy.
[email protected] Source: Rossi, A M Guarnieri, C Rovesti, S Gobba, F Ghittori, S Vivoli, G Barale, R Pharmacogenetics. 1999 August; 9(4): 445-51 0960-314X
•
Hepatic and pulmonary microsomal benzene metabolism in CYP2E1 knockout mice. Author(s): School of Health Sciences, 1338 Civil Engineering Building, Purdue University, West Lafayette, IN 47907-1338, USA. Source: Powley, M W Carlson, G P Toxicology. 2001 December 28; 169(3): 187-94 0300483X
•
Hydrogen bonding NH/pi interactions between betacarboline and methyl benzene derivatives. Author(s): Departamento de Quimica Fisica, Facultad de Farmacia, Universidad de Sevilla, Spain. Source: Munoz, M A Sama, O Galan, M Guardado, P Carmona, C Balon, M SpectrochimActa-A-Mol-Biomol-Spectrosc. 2001 April; 57A(5): 1049-56 1386-1425
•
Identification of N-acetyl-S-(2,5-dihydroxyphenyl)-L-cysteine as a urinary metabolite of benzene, phenol, and hydroquinone. Author(s): Department of Pharmacology and Toxicology, University of Louisville, KY 40292. Source: Nerland, D E Pierce, W M Drug-Metab-Dispos. 1990 Nov-December; 18(6): 95861 0090-9556
96
Benzene
•
Improvement in HPLC analysis of urinary trans,trans-muconic acid, a promising substitute for phenol in the assessment of benzene exposure. Author(s): Institut National de Recherche et de Securite, Vandoeuvre, France. Source: Ducos, P Gaudin, R Robert, A Francin, J M Maire, C Int-Arch-Occup-EnvironHealth. 1990; 62(7): 529-34 0340-0131
•
In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Author(s): Department of Pharmacology and Toxicology, P.O. Box 5000, University of Oulu, FIN-90014 Finland.
[email protected] Source: Taavitsainen, P Juvonen, R Pelkonen, O Drug-Metab-Dispos. 2001 March; 29(3): 217-22 0090-9556
•
Investigation of the role of the 2',3'-epoxidation pathway in the bioactivation and genotoxicity of dietary allylbenzene analogs. Author(s): Department of Pharmacology, College of Medicine, University of Illinois at Chicago, 835 South Wolcott Avenue, Chicago, IL 60612, USA.
[email protected] Source: Guenthner, T M Luo, G Toxicology. 2001 March 7; 160(1-3): 47-58 0300-483X
•
Methodological issues in biomonitoring of low level exposure to benzene. Author(s): Istituto Superiore di Sanita, Rome, Italy.
[email protected] Source: Lagorio, S Crebelli, R Ricciarello, R Conti, L Iavarone, I Zona, A Ghittori, S Carere, A Occup-Med-(Lond). 1998 November; 48(8): 497-504 0962-7480
•
Muconic acid determinations in urine as a biological exposure index for workers occupationally exposed to benzene. Author(s): Inhalation Toxicology Research Institute, Albuquerque, NM 87185. Source: Bechtold, W E Lucier, G Birnbaum, L S Yin, S N Li, G L Henderson, R F Am-IndHyg-Assoc-J. 1991 November; 52(11): 473-8 0002-8894
•
Pharmacological evaluation of 1-(carboxymethyl)-3,5-diphenyl-2-methylbenzene, a novel arylacetic acid with potential anti-inflammatory properties. Author(s): Department of Pharmaceutical Sciences, Mercer University, Atlanta, GA 30341, USA. Source: Cutler, S J DeWitt Blanton, C Akin, D T Steinberg, F B Moore, A B Lott, J A Price, T C May, S W Pollock, S H Inflamm-Res. 1998 July; 47(7): 316-24 1023-3830
•
Retinoic acids repress constitutive active receptor-mediated induction by 1,4-bis[2(3,5-dichloropyridyloxy)]benzene of the CYP2B10 gene in mouse primary hepatocytes. Author(s): Pharmacogenetics Section, Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA.
[email protected] Source: Kakizaki, Satoru Karami, Sohrab Negishi, Masahiko Drug-Metab-Dispos. 2002 February; 30(2): 208-11 0090-9556
•
Reversible anti-fertility effect of benzene extract of Ocimum sanctum leaves on sperm parameters and fructose content in rats. Author(s): Department of Post-Graduate Studies in Zoology, Karnatak University, Dharwad, India. Source: Ahmed, M Ahamed, R N Aladakatti, R H Ghosesawar, M G J-Basic-ClinPhysiol-Pharmacol. 2002; 13(1): 51-9 0792-6855
•
Reversible azoospermia by oral administration of the benzene chromatographic fraction of the chloroform extract of the seeds of Carica papaya in rabbits. Author(s): Department of Zoology, University of Rajasthan, Jaipur, India.
Nutrition
97
Source: Lohiya, N K Mishra, P K Pathak, N Manivannan, B Jain, S C Adv-Contracept. 1999; 15(2): 141-61 0267-4874 •
SFE with GC and MS determination of safrole and related allylbenzenes in sassafras teas. Author(s): Total Diet Research Center, Food and Drug Administration, Lenexa, Kansas 66285-5905. Source: Heikes, D L J-Chromatogr-Sci. 1994 July; 32(7): 253-8 0021-9665
•
Sonolysis of chlorobenzene in Fenton-type aqueous systems. Author(s): Costin D. Nenitzescu Institute of Organic Chemistry, P.O. Box 15-254, 71141 Bucharest, Romania. Source: Stavarache, C Yim, B Vinatoru, M Maeda, Y Ultrason-Sonochem. 2002 November; 9(6): 291-6 1350-4177
•
Subclinical effects of groundwater contaminants. IV. Effects of repeated oral exposure to combinations of benzene and toluene on regional brain monoamine metabolism in mice. Source: Hsieh, G.C. Sharma, R.P. Parker, R.D.R. Arch-Toxicol. Berlin, W. Ger. : Springer. 1990. volume 64 (8) page 669-676. 0340-5761
•
The benzene metabolites hydroquinone and catechol act in synergy to induce dosedependent hypoploidy and -5q31 in a human cell line. Author(s): Molecular Toxicology and Environmental Health Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver 80262, USA. Source: Stillman, W S Varella Garcia, M Irons, R D Leuk-Lymphoma. 1999 October; 35(34): 269-81 1042-8194
•
The influence of benzene on the erythroid cell system in mice. Author(s): Institute for Occupational and Social Medicine, University of Ulm, FRG. Source: Seidel, H J Beyvers, G Pape, M Barthel, E Exp-Hematol. 1989 August; 17(7): 7604 0301-472X
•
Toxicokinetics of benzene, toluene and xylenes. Author(s): Department of Environmental Health, Medical University of Yamanashi, Yamanashi, Japan. Source: Sato, A IARC-Sci-Publ. 1988; (85): 47-64 0300-5038
•
trans,trans-Muconic acid, a reliable biological indicator for the detection of individual benzene exposure down to the ppm level. Author(s): Institut National de Recherche et de Securite, Vandoeuvre, France. Source: Ducos, P Gaudin, R Bel, J Maire, C Francin, J M Robert, A Wild, P Int-ArchOccup-Environ-Health. 1992; 64(5): 309-13 0340-0131
•
Tylophorine B benzene solvate. Author(s): Instrumental Analysis and Research Center, Lanzhou University, Gansu, People's Republic of China.
[email protected] Source: Wang, Q Xie, L Zhai, J Acta-Crystallogr-C. 2000 February; 56 ( Pt 2)197-8 01082701
•
Uptake by foods of tetrachloroethylene, trichloroethylene, toluene, and benzene from air. Author(s): Kantonales Labor, Zurich, Switzerland. Source: Grob, K Frauenfelder, C Artho, A Z-Lebensm-Unters-Forsch. 1990 December; 191(6): 435-41 0044-3026
98
Benzene
•
Urinary excretion of phenol, catechol, hydroquinone, and muconic acid by workers occupationally exposed to benzene. Author(s): Occupational Studies Branch, National Cancer Institute, Bethesda, MD, USA.
[email protected] Source: Rothman, N Bechtold, W E Yin, S N Dosemeci, M Li, G L Wang, Y Z Griffith, W C Smith, M T Hayes, R B Occup-Environ-Med. 1998 October; 55(10): 705-11 1351-0711
•
Urine trans,trans-muconic acid as a biomarker for benzene exposure in gas station attendants in Bangkok, Thailand. Author(s): Department of Laboratory Medicine, Medical Faculty, Chulalongkorn University, Bangkok, Thailand.
[email protected] Source: Wiwanitkit, V Suwansaksri, J Nasuan, P Ann-Clin-Lab-Sci. 2001 October; 31(4): 399-401 0091-7370
•
Uterotrophic and Hershberger assays for n-butylbenzene in rats. Author(s): Chemicals Assessment Center, Chemicals Evaluation and Research Institute, Hita, Oita, Japan.
[email protected] Source: Yamasaki, Kanji Sawaki, Masakuni Noda, Shuji Takatsuki, Mineo Arch-Toxicol. 2002 January; 75(11-12): 703-6 0340-5761
•
Validity of biomarkers in environmental health studies: the case of PAHs and benzene. Author(s): Agence De L'Environnement et de La Maitrise De L'Energie, Paris. Source: Dor, F Dab, W Empereur Bissonnet, P Zmirou, D Crit-Rev-Toxicol. 1999 March; 29(2): 129-68 1040-8444
Federal Resources on Nutrition In addition to the IBIDS, the United States Department of Health and Human Services (HHS) and the United States Department of Agriculture (USDA) provide many sources of information on general nutrition and health. Recommended resources include: •
healthfinder®, HHS’s gateway to health information, including diet and nutrition: http://www.healthfinder.gov/scripts/SearchContext.asp?topic=238&page=0
•
The United States Department of Agriculture’s Web site dedicated to nutrition information: www.nutrition.gov
•
The Food and Drug Administration’s Web site for federal food safety information: www.foodsafety.gov
•
The National Action Plan on Overweight and Obesity sponsored by the United States Surgeon General: http://www.surgeongeneral.gov/topics/obesity/
•
The Center for Food Safety and Applied Nutrition has an Internet site sponsored by the Food and Drug Administration and the Department of Health and Human Services: http://vm.cfsan.fda.gov/
•
Center for Nutrition Policy and Promotion sponsored by the United States Department of Agriculture: http://www.usda.gov/cnpp/
•
Food and Nutrition Information Center, National Agricultural Library sponsored by the United States Department of Agriculture: http://www.nal.usda.gov/fnic/
•
Food and Nutrition Service sponsored by the United States Department of Agriculture: http://www.fns.usda.gov/fns/
Nutrition
99
Additional Web Resources A number of additional Web sites offer encyclopedic information covering food and nutrition. The following is a representative sample: •
AOL: http://search.aol.com/cat.adp?id=174&layer=&from=subcats
•
Family Village: http://www.familyvillage.wisc.edu/med_nutrition.html
•
Google: http://directory.google.com/Top/Health/Nutrition/
•
Healthnotes: http://www.healthnotes.com/
•
Open Directory Project: http://dmoz.org/Health/Nutrition/
•
Yahoo.com: http://dir.yahoo.com/Health/Nutrition/
•
WebMD®Health: http://my.webmd.com/nutrition
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
The following is a specific Web list relating to benzene; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
Food and Diet Weight Loss and Obesity Source: Healthnotes, Inc.; www.healthnotes.com
101
CHAPTER 3. ALTERNATIVE MEDICINE AND BENZENE Overview In this chapter, we will begin by introducing you to official information sources on complementary and alternative medicine (CAM) relating to benzene. At the conclusion of this chapter, we will provide additional sources.
National Center for Complementary and Alternative Medicine The National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (http://nccam.nih.gov/) has created a link to the National Library of Medicine’s databases to facilitate research for articles that specifically relate to benzene and complementary medicine. To search the database, go to the following Web site: http://www.nlm.nih.gov/nccam/camonpubmed.html. Select “CAM on PubMed.” Enter “benzene” (or synonyms) into the search box. Click “Go.” The following references provide information on particular aspects of complementary and alternative medicine that are related to benzene: •
2-(2'-Hydroxyphenyl)benzene sulfinate desulfinase from the thermophilic desulfurizing bacterium Paenibacillus sp. strain A11-2: purification and characterization. Author(s): Konishi J, Maruhashi K. Source: Applied Microbiology and Biotechnology. 2003 September; 62(4): 356-61. Epub 2003 May 13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12743754&dopt=Abstract
•
Anti-fertility activity of a benzene extract of Hibiscus rosa-sinensis flowers on female albino rats. Author(s): Singh MP, Singh RH, Udupa KN. Source: Planta Medica. 1982 March; 44(3): 171-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7089096&dopt=Abstract
102
Benzene
•
Benzene exposure measurement in shoe and glue manufacturing: a study to validate biomarkers. Author(s): Qu Q, Cohen BS, Shore R, Chen LC, Li G, Jin X, Melikian AA, Yin S, Yan H, Xu B, Li Y, Mu R, Zhang X, Li K. Source: Applied Occupational and Environmental Hygiene. 2003 December; 18(12): 98898. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14612295&dopt=Abstract
•
Benzene metabolites antagonize etoposide-stabilized cleavable complexes of DNA topoisomerase IIalpha. Author(s): Baker RK, Kurz EU, Pyatt DW, Irons RD, Kroll DJ. Source: Blood. 2001 August 1; 98(3): 830-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11468185&dopt=Abstract
•
Benzene myeloclastogenicity: a function of its metabolism. Author(s): Gad-el-Karim MM, Ramanujam VM, Ahmed AE, Legator MS. Source: American Journal of Industrial Medicine. 1985; 7(5-6): 475-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4003406&dopt=Abstract
•
Comparative effectiveness of Tiron (4,5-dihydroxy benzene 1,3-disulphonic acid disodium salt) and CaNa2EDTA with time after beryllium poisoning. Author(s): Sharma P, Shukla S. Source: Indian J Exp Biol. 2000 August; 38(8): 785-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12557911&dopt=Abstract
•
Complexation of 1,2,4-benzenetriol with inorganic and ferritin-released iron in vitro. Author(s): Ahmad S, Rao GS. Source: Biochemical and Biophysical Research Communications. 1999 May 27; 259(1): 169-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10334934&dopt=Abstract
•
Correlation between the induction of micronuclei in bone marrow by benzene exposure and the excretion of metabolites in urine of CD-1 mice. Author(s): Gad-El Karim MM, Sadagopa Ramanujam VM, Legator MS. Source: Toxicology and Applied Pharmacology. 1986 September 30; 85(3): 464-77. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3764927&dopt=Abstract
•
Differential susceptibility of rats and guinea pigs to the ototoxic effects of ethyl benzene. Author(s): Cappaert NL, Klis SF, Muijser H, Kulig BM, Ravensberg LC, Smoorenburg GF.
Alternative Medicine 103
Source: Neurotoxicology and Teratology. 2002 July-August; 24(4): 503-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12127896&dopt=Abstract •
DNA breakage induced by 1,2,4-benzenetriol: relative contributions of oxygenderived active species and transition metal ions. Author(s): Li AS, Bandy B, Tsang S, Davison AJ. Source: Free Radical Biology & Medicine. 2001 May 1; 30(9): 943-56. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11316574&dopt=Abstract
•
Effect of benzene extract of Hibiscus rosa sinensis on the estrous cycle and ovarian activity in albino mice. Author(s): Murthy DR, Reddy CM, Patil SB. Source: Biological & Pharmaceutical Bulletin. 1997 July; 20(7): 756-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9255415&dopt=Abstract
•
Effects of Sheng-Mai injection on the PRPP synthetase activity in BFU-es and CFU-es from bone marrows of mice with benzene-induced aplastic anemia. Author(s): Liu LP, Liu JF, Lu YQ. Source: Life Sciences. 2001 August 10; 69(12): 1373-9. Erratum In: Life Sci 2001 October 12; 69(21): 2573. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11531161&dopt=Abstract
•
Efficiency of rice bran for removal of organochlorine compounds and benzene from industrial wastewater. Author(s): Adachi A, Ikeda C, Takagi S, Fukao N, Yoshie E, Okano T. Source: Journal of Agricultural and Food Chemistry. 2001 March; 49(3): 1309-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11312856&dopt=Abstract
•
Evaluation of daily dietary intake of dichloro-diphenyl-trichloroethane (DDT) and benzene hexachloride (BHC) in India. Author(s): Kashyap R, Iyer LR, Singh MM. Source: Archives of Environmental Health. 1994 January-February; 49(1): 63-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7509592&dopt=Abstract
•
Evaluation of the role of free hydroxyl radicals in the cytochrome P-450-catalyzed oxidation of benzene and cyclohexanol. Author(s): Gorsky LD, Coon MJ. Source: Drug Metabolism and Disposition: the Biological Fate of Chemicals. 1985 MarchApril; 13(2): 169-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2859164&dopt=Abstract
104
Benzene
•
Flowers of Hibiscus rosa-sinensis, a potential source of contragestative agent. III: Interceptive effect of benzene extract in mouse. Author(s): Pakrashi A, Bhattacharya K, Kabir SN, Pal AK. Source: Contraception. 1986 November; 34(5): 523-36. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3816235&dopt=Abstract
•
Flowers of Hibiscus rosa-sinensis, a potential source of contragestative agent: II. Possible mode of action with reference to anti-implantation effect of the benzene extract. Author(s): Pal AK, Bhattacharya K, Kabir SN, Pakrashi A. Source: Contraception. 1985 November; 32(5): 517-29. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4085250&dopt=Abstract
•
Gasoline-contaminated ground water as a source of residential benzene exposure: a case study. Author(s): Lindstrom AB, Highsmith VR, Buckley TJ, Pate WJ, Michael LC. Source: Journal of Exposure Analysis and Environmental Epidemiology. 1994 AprilJune; 4(2): 183-95. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7549473&dopt=Abstract
•
Induction of T-lymphocyte responses to a small molecular weight antigen. II. specific tolerance induced in azebenzenearsonate (ABA)-specific T cells in Guniea pigs by administration of low doses of an ABA conjugate of chloroacetyl tyrosine in incomplete Freund's adjuvant. Author(s): Bullock WW, Katz DH, Benacerraf B. Source: The Journal of Experimental Medicine. 1975 August 1; 142(2): 261-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=806648&dopt=Abstract
•
Inhibition of 1,2,4-benzenetriol-generated active oxygen species and induction of phase II enzymes by green tea polyphenols. Author(s): Lee SF, Liang YC, Lin JK. Source: Chemico-Biological Interactions. 1995 December 22; 98(3): 283-301. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8548865&dopt=Abstract
•
Iron-stimulated ring-opening of benzene in a mouse liver microsomal system. Mechanistic studies and formation of a new metabolite. Author(s): Zhang Z, Goldstein BD, Witz G. Source: Biochemical Pharmacology. 1995 November 9; 50(10): 1607-17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7503763&dopt=Abstract
•
Muconaldehyde formation from 14C-benzene in a hydroxyl radical generating system. Author(s): Latriano L, Zaccaria A, Goldstein BD, Witz G.
Alternative Medicine 105
Source: J Free Radic Biol Med. 1985; 1(5-6): 363-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3018062&dopt=Abstract •
Phenoxyl radical-induced thiol-dependent generation of reactive oxygen species: implications for benzene toxicity. Author(s): Stoyanovsky DA, Goldman R, Claycamp HG, Kagan VE. Source: Archives of Biochemistry and Biophysics. 1995 March 10; 317(2): 315-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7893144&dopt=Abstract
•
Reversible anti-fertility effect of benzene extract of Ocimum sanctum leaves on sperm parameters and fructose content in rats. Author(s): Ahmed M, Ahamed RN, Aladakatti RH, Ghosesawar MG. Source: J Basic Clin Physiol Pharmacol. 2002; 13(1): 51-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12099405&dopt=Abstract
•
Reversible azoospermia by oral administration of the benzene chromatographic fraction of the chloroform extract of the seeds of Carica papaya in rabbits. Author(s): Lohiya NK, Mishra PK, Pathak N, Manivannan B, Jain SC. Source: Advances in Contraception : the Official Journal of the Society for the Advancement of Contraception. 1999; 15(2): 141-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10997896&dopt=Abstract
•
Role of iron and copper during benzene toxicity. Author(s): Ahmad S, Murthy RC, Rao GS. Source: Indian J Exp Biol. 1998 March; 36(3): 283-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9754061&dopt=Abstract
•
Sterility due to inhibition of sperm motility by oral administration of benzene chromatographic fraction of the chloroform extract of the seeds of Carica papaya in rats. Author(s): Pathak N, Mishra PK, Manivannan B, Lohiya NK. Source: Phytomedicine : International Journal of Phytotherapy and Phytopharmacology. 2000 July; 7(4): 325-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10969727&dopt=Abstract
•
Studies on the metabolism of the benzene ring of tryptophan in mammalian tissues. ii. enzymic formation of alpha-aminomuconic acid from 3-hydroxyanthranilic acid. Author(s): ICHIYAMA A, NAKAMURA S, KAWAI H, HONJO T, NISHIZUKA Y, HAYAISHI O, SENOH S. Source: The Journal of Biological Chemistry. 1965 February; 240: 740-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14275130&dopt=Abstract
106
Benzene
•
Synthesis of spirodienones by intramolecular ipso-cyclization of N-methoxy-(4halogenophenyl)amides using [hydroxy(tosyloxy)iodo]benzene in trifluoroethanol. Author(s): Miyazawa E, Sakamoto T, Kikugawa Y. Source: The Journal of Organic Chemistry. 2003 June 27; 68(13): 5429-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12816516&dopt=Abstract
•
The biofiltration of indoor air: air flux and temperature influences the removal of toluene, ethylbenzene, and xylene. Author(s): Darlington AB, Dat JF, Dixon MA. Source: Environmental Science & Technology. 2001 January 1; 35(1): 240-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11352020&dopt=Abstract
•
The effect of iron overload on the development of hexachlorobenzene (HCB) porphyria. Author(s): Bach PH, Taljaard JT, Joubert SM, Shanley BC. Source: South African Medical Journal. Suid-Afrikaanse Tydskrif Vir Geneeskunde. 1971 September 25; : 75-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4113778&dopt=Abstract
•
The non-enzymic oxidation of NADH by nitrosobenzene. Author(s): Bernheim ML. Source: Biochemical and Biophysical Research Communications. 1972 February 25; 46(4): 1598-602. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4401357&dopt=Abstract
•
Transplacental genotoxicity of triethylenemelamine, benzene, and vinblastine in mice. Author(s): Xing SG, Shi X, Wu ZL, Chen JK, Wallace W, Whong WZ, Ong T. Source: Teratogenesis, Carcinogenesis, and Mutagenesis. 1992; 12(5): 223-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1363495&dopt=Abstract
Additional Web Resources •
AOL: http://search.aol.com/cat.adp?id=169&layer=&from=subcats
•
Chinese Medicine: http://www.newcenturynutrition.com/
•
drkoop.com®: http://www.drkoop.com/InteractiveMedicine/IndexC.html
•
Family Village: http://www.familyvillage.wisc.edu/med_altn.htm
•
Google: http://directory.google.com/Top/Health/Alternative/
•
Healthnotes: http://www.healthnotes.com/
•
MedWebPlus: http://medwebplus.com/subject/Alternative_and_Complementary_Medicine
Alternative Medicine 107
•
Open Directory Project: http://dmoz.org/Health/Alternative/
•
HealthGate: http://www.tnp.com/
•
WebMD®Health: http://my.webmd.com/drugs_and_herbs
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
•
Yahoo.com: http://dir.yahoo.com/Health/Alternative_Medicine/
The following is a specific Web list relating to benzene; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
General Overview Allergies and Sensitivities Source: Healthnotes, Inc.; www.healthnotes.com Bone Cancer Source: Integrative Medicine Communications; www.drkoop.com Bone Marrow Disorders Source: Integrative Medicine Communications; www.drkoop.com Chronic Myelogenous Leukemia Source: Integrative Medicine Communications; www.drkoop.com Hirsuitism Source: Integrative Medicine Communications; www.drkoop.com Leukemia Source: Integrative Medicine Communications; www.drkoop.com Myelofibrosis Source: Integrative Medicine Communications; www.drkoop.com Myeloproliferative Disorders Source: Integrative Medicine Communications; www.drkoop.com Polycythemia Vera Source: Integrative Medicine Communications; www.drkoop.com Thrombocytosis Source: Integrative Medicine Communications; www.drkoop.com
•
Herbs and Supplements Acorus Alternative names: Sweet Flag; Acorus calamus L. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org
108
Benzene
Dryopteris Alternative names: Male Fern; Dryopteris sp. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Guatteria Alternative names: Guatteria gaumeri Greenman Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Hibiscus Alternative names: Hibiscus, Roselle; Hibiscus sp. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Hydroxycitric Acid Source: Healthnotes, Inc.; www.healthnotes.com Hydroxycitric Acid Source: Prima Communications, Inc.www.personalhealthzone.com Liquorice Source: The Canadian Internet Directory for Holistic Help, WellNet, Health and Wellness Network; www.wellnet.ca Mentha Alternative names: Pennyroyal; Mentha/Hedeoma pulegium Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Pimpinella Alternative names: Anise; Pimpinella anisum (L) Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Piper Nigrum Alternative names: Black Pepper Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Pueraria Alternative names: Kudzu; Pueraria lobata Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Sassafras Alternative names: Sassafras albidum (Nuttall) Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Zizyphus Alternative names: Jujube; Ziziphus sp. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org
General References A good place to find general background information on CAM is the National Library of Medicine. It has prepared within the MEDLINEplus system an information topic page dedicated to complementary and alternative medicine. To access this page, go to the
Alternative Medicine 109
MEDLINEplus site at http://www.nlm.nih.gov/medlineplus/alternativemedicine.html. This Web site provides a general overview of various topics and can lead to a number of general sources.
111
CHAPTER 4. DISSERTATIONS ON BENZENE Overview In this chapter, we will give you a bibliography on recent dissertations relating to benzene. We will also provide you with information on how to use the Internet to stay current on dissertations. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical dissertations that use the generic term “benzene” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on benzene, we have not necessarily excluded non-medical dissertations in this bibliography.
Dissertations on Benzene ProQuest Digital Dissertations, the largest archive of academic dissertations available, is located at the following Web address: http://wwwlib.umi.com/dissertations. From this archive, we have compiled the following list covering dissertations devoted to benzene. You will see that the information provided includes the dissertation’s title, its author, and the institution with which the author is associated. The following covers recent dissertations found when using this search procedure: •
Benzene-Structure Controversies, 1865-1920. by Koeppel, Tonja A., PhD from University of Pennsylvania, 1973, 429 pages http://wwwlib.umi.com/dissertations/fullcit/7414092
•
Biodegradation of Benzene, Toluene, and Xylenes (BTX) under Denitrifying Conditions in Sand from a Shallow Aquifer a Microcosm Study by Major, David William; PhD from University of Waterloo (Canada), 1987 http://wwwlib.umi.com/dissertations/fullcit/NL38737
•
Chelate-Exchange Reactions of Beta-Diketonates of Zinc, Cadmium and Several Transition Metals in Benzene and Methanol : Thermodynamic Properties and Titrimetric Applications by D'Amboise, Marius; PhD from McGill University (Canada), 1973 http://wwwlib.umi.com/dissertations/fullcit/NK18134
112
Benzene
•
Cluster Ion Mobility, Structures, and Binding Energy: Application to the Benzene Cluster System by Rusyniak, Mark John, PhD from Virginia Commonwealth University, 2003, 159 pages http://wwwlib.umi.com/dissertations/fullcit/3082014
•
Dipole Moment and Spectroscopic Studies on Methyl-substituted BenzeneTetracyanoethylene Complexes by Liao, Shu-Chung; AdvDeg from The University of Western Ontario (Canada), 1970 http://wwwlib.umi.com/dissertations/fullcit/NK07223
•
Electrodeposition of Aluminum from Alkyl Benzene Electrolytes by Capuano, Guido A; PhD from McGill University (Canada), 1973 http://wwwlib.umi.com/dissertations/fullcit/NK15805
•
Factors Influencing the Biodegradation of Benzene, Toluene, Ethylbenzene, MXylene (BTEX), Naphthalene, and Phenanthrene in Subsurface Environments by D'Adamo, Peter Charles, PhD from The Johns Hopkins University, 2003, 258 pages http://wwwlib.umi.com/dissertations/fullcit/3080647
•
Goal Setting and Task Performance at the Organizational Level: Studies of Emissions Reduction Goals and Performance (Chemical Manufacturers Association, Benzene Emissions) by Milledge, Vicki Lynn, PhD from University of California, Berkeley, 1995, 165 pages http://wwwlib.umi.com/dissertations/fullcit/9621283
•
Novel Use of a Two-Phase Partitioning Bioreactor for the Removal and Destruction of Benzene and Toluene in a Gas Stream by Davidson, Colin Thomas, MSC(Eng) from Queen's University at Kingston (Canada), 2003, 103 pages http://wwwlib.umi.com/dissertations/fullcit/MQ74899
•
Stereospecific Long-Range Nuclear Spin-Spin Coupling Constants between the SideChain Carbon-13 Nucleus and Hydrogen,Carbon-13 and Fluorine-19 Nuclei in the Ring of Some Benzene Derivatives Conformational Applications by Penner, Glenn H; PhD from The University of Manitoba (Canada), 1987 http://wwwlib.umi.com/dissertations/fullcit/NL37208
•
Structural Determinations of Some Transition Metal Hydrido and Tris (Benzene-1,2Dithiolato) Complexes by Cowie, Martin; PhD from University of Alberta (Canada), 1974 http://wwwlib.umi.com/dissertations/fullcit/NK20988
•
The High Resolution Raman Spectrum of Gaseous Benzene and Benzene-D 6 by Hollinger, Allan Bernard; PhD from University of Toronto (Canada), 1977 http://wwwlib.umi.com/dissertations/fullcit/NK36693
•
The Tertiary Amide and Carbamoyloxy Groups in Aromatic Directed Metalation Synthesis of Polysubstituted Benzene and Pyridine Derivatives by Miah, M. A. J; PhD from University of Waterloo (Canada), 1986 http://wwwlib.umi.com/dissertations/fullcit/NL29580 http://wwwlib.umi.com/dissertations/fullcit/NK60767
Dissertations 113
Keeping Current Ask the medical librarian at your library if it has full and unlimited access to the ProQuest Digital Dissertations database. From the library, you should be able to do more complete searches via http://wwwlib.umi.com/dissertations.
115
CHAPTER 5. CLINICAL TRIALS AND BENZENE Overview In this chapter, we will show you how to keep informed of the latest clinical trials concerning benzene.
Recent Trials on Benzene The following is a list of recent trials dedicated to benzene.8 Further information on a trial is available at the Web site indicated. •
Biomarkers of Benzene Exposure in Inner City Residents Condition(s): Lung Disease; Cancer Study Status: This study is currently recruiting patients. Sponsor(s): National Institute of Environmental Health Sciences (NIEHS); Mickey Leland National Urban Air Toxics Research Center; Environmental Protection Agency (EPA) Purpose - Excerpt: This study compares air pollution exposures of residents in a South Baltimore community next to major industry with those in a comparison community with much less industry nearby. Parents and children as well as adults alone will be included. Air levels of 3 chemicals that have been found in increased amounts in the community as well as two urinary breakdown products of benzene will be measured. Participants will limit the amount of sorbate preserved foods they eat as this preservative interferes with one of the benzene breakdown products. Benzene air and urine exposure measurements will be compared in each community as well as between communities. By including children and parents we will gather exposure information on children who may be more sensitive that adults to these types of pollution. Lastly, by restricting the amount of food preserved with sorbates, we can decide if this improves the use of ttMA for people exposed to benzene from air pollution. Study Type: Observational Contact(s): see Web site below
8
These are listed at www.ClinicalTrials.gov.
116
Benzene
Web Site: http://clinicaltrials.gov/ct/show/NCT00014963 •
Modulation of Benzene Metabolism by Exposure to Environment Condition(s): Lung Diseases; Cancer Study Status: This study is completed. Sponsor(s): National Institute of Environmental Health Sciences (NIEHS) Purpose - Excerpt: The research is to evaluate benzene metabolism after exposure at levels that can be found in the environment, such as the higher end concentrations in the air inside cars and buses while being driven in heavy traffic and inside private and public parking garages. To do so breath, urine, and blood samples prior to, during and after being exposed to benzene as well as benzene levels and benzene metabolites present are measured. Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00041860
•
Protection Against Benzene Toxicity Condition(s): Leukemia; Aplastic Anemia Study Status: This study is completed. Sponsor(s): National Institute of Environmental Health Sciences (NIEHS) Purpose - Excerpt: We are investigating the role of an enzyme (NQO1) in protection against the bone marrow toxicity of the occupational and environmental toxicant benzene. All of the proposed studies involve use of human bone marrow cells in-vitro to define mechanisms of NQO1-mediated protection. Cells are obtained from healthy volunteers and protocols have undergone IRB review and approval. Study Type: Observational Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00011453
Keeping Current on Clinical Trials The U.S. National Institutes of Health, through the National Library of Medicine, has developed ClinicalTrials.gov to provide current information about clinical research across the broadest number of diseases and conditions. The site was launched in February 2000 and currently contains approximately 5,700 clinical studies in over 59,000 locations worldwide, with most studies being conducted in the United States. ClinicalTrials.gov receives about 2 million hits per month and hosts approximately 5,400 visitors daily. To access this database, simply go to the Web site at http://www.clinicaltrials.gov/ and search by “benzene” (or synonyms). While ClinicalTrials.gov is the most comprehensive listing of NIH-supported clinical trials available, not all trials are in the database. The database is updated regularly, so clinical
Clinical Trials 117
trials are continually being added. The following is a list of specialty databases affiliated with the National Institutes of Health that offer additional information on trials: •
For clinical studies at the Warren Grant Magnuson Clinical Center located in Bethesda, Maryland, visit their Web site: http://clinicalstudies.info.nih.gov/
•
For clinical studies conducted at the Bayview Campus in Baltimore, Maryland, visit their Web site: http://www.jhbmc.jhu.edu/studies/index.html
•
For cancer trials, visit the National Cancer Institute: http://cancertrials.nci.nih.gov/
•
For eye-related trials, visit and search the Web page of the National Eye Institute: http://www.nei.nih.gov/neitrials/index.htm
•
For heart, lung and blood trials, visit the Web page of the National Heart, Lung and Blood Institute: http://www.nhlbi.nih.gov/studies/index.htm
•
For trials on aging, visit and search the Web site of the National Institute on Aging: http://www.grc.nia.nih.gov/studies/index.htm
•
For rare diseases, visit and search the Web site sponsored by the Office of Rare Diseases: http://ord.aspensys.com/asp/resources/rsch_trials.asp
•
For alcoholism, visit the National Institute on Alcohol Abuse and Alcoholism: http://www.niaaa.nih.gov/intramural/Web_dicbr_hp/particip.htm
•
For trials on infectious, immune, and allergic diseases, visit the site of the National Institute of Allergy and Infectious Diseases: http://www.niaid.nih.gov/clintrials/
•
For trials on arthritis, musculoskeletal and skin diseases, visit newly revised site of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health: http://www.niams.nih.gov/hi/studies/index.htm
•
For hearing-related trials, visit the National Institute on Deafness and Other Communication Disorders: http://www.nidcd.nih.gov/health/clinical/index.htm
•
For trials on diseases of the digestive system and kidneys, and diabetes, visit the National Institute of Diabetes and Digestive and Kidney Diseases: http://www.niddk.nih.gov/patient/patient.htm
•
For drug abuse trials, visit and search the Web site sponsored by the National Institute on Drug Abuse: http://www.nida.nih.gov/CTN/Index.htm
•
For trials on mental disorders, visit and search the Web site of the National Institute of Mental Health: http://www.nimh.nih.gov/studies/index.cfm
•
For trials on neurological disorders and stroke, visit and search the Web site sponsored by the National Institute of Neurological Disorders and Stroke of the NIH: http://www.ninds.nih.gov/funding/funding_opportunities.htm#Clinical_Trials
119
CHAPTER 6. PATENTS ON BENZENE Overview Patents can be physical innovations (e.g. chemicals, pharmaceuticals, medical equipment) or processes (e.g. treatments or diagnostic procedures). The United States Patent and Trademark Office defines a patent as a grant of a property right to the inventor, issued by the Patent and Trademark Office.9 Patents, therefore, are intellectual property. For the United States, the term of a new patent is 20 years from the date when the patent application was filed. If the inventor wishes to receive economic benefits, it is likely that the invention will become commercially available within 20 years of the initial filing. It is important to understand, therefore, that an inventor’s patent does not indicate that a product or service is or will be commercially available. The patent implies only that the inventor has “the right to exclude others from making, using, offering for sale, or selling” the invention in the United States. While this relates to U.S. patents, similar rules govern foreign patents. In this chapter, we show you how to locate information on patents and their inventors. If you find a patent that is particularly interesting to you, contact the inventor or the assignee for further information. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical patents that use the generic term “benzene” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on benzene, we have not necessarily excluded non-medical patents in this bibliography.
Patents on Benzene By performing a patent search focusing on benzene, you can obtain information such as the title of the invention, the names of the inventor(s), the assignee(s) or the company that owns or controls the patent, a short abstract that summarizes the patent, and a few excerpts from the description of the patent. The abstract of a patent tends to be more technical in nature, while the description is often written for the public. Full patent descriptions contain much more information than is presented here (e.g. claims, references, figures, diagrams, etc.). We
9Adapted
from the United States Patent and Trademark Office: http://www.uspto.gov/web/offices/pac/doc/general/whatis.htm.
120
Benzene
will tell you how to obtain this information later in the chapter. The following is an example of the type of information that you can expect to obtain from a patent search on benzene: •
Catalysts for oxidative polymerization of fluorophenol, method of oxidative polymerization of fluorophenol, and poly(oxyfluorophenylene) derivative Inventor(s): Kumaki; Yosuke (Tokyo, JP), Oyaizu; Kenichi (Tokyo, JP), Saito; Kei (Tokyo, JP), Tsuchida; Eishun (Tokyo, JP) Assignee(s): Japan Science and Technology Corporation (saitama, Jp) Patent Number: 6,689,919 Date filed: September 7, 2001 Abstract: The synthesis of fluoropolyarylene ether with a high degree of polymerization is enabled, by using a copper complex catalyst with an oxidation potential in the range of -1V to 2V, for the oxidative polymerization of fluorophenols that contain at least one hydrogen atom as well as a fluorine atom bonded to the carbon atoms constituting the benzene ring. Excerpt(s): The present invention relates to catalysts for the oxidative polymerization of fluorophenols and a method for the oxidative polymerization of fluorophenols wherein such catalysts are used. More particularly, this invention relates to catalysts for the oxidative polymerization of fluorophenols useful for the synthesis of engineering plastics, such as fluoropolyarylene ether, with excellent heat resistance and flame resistance, as well as small friction factor, and a method for the oxidative polymerization of fluorophenols wherein such catalysts are used. Further, the present invention relates to poly(oxyfluorophenylene) compounds. More particularly, the present invention relates to soluble poly(oxyfluorophenylene) compounds with excellent heat resistance, membrane-formability and chemical stability. Polyarylene ethers are known as engineering plastics having characteristics such as excellent heat resistance, mechanical strength, drug resistance, dimensional stability, electric performance, and workability, and are used in various industrial fields, such as mechanical parts, gas separating membranes, conductive resins, and functional rubbers. Web site: http://www.delphion.com/details?pn=US06689919__
•
Epoxy resin composition and curing product thereof Inventor(s): Ogura; Ichiro (Chiba, JP), Takahashi; Yoshiyuki (Chiba, JP) Assignee(s): Dainippon Ink and Chemicals, Inc. (tokyo, Jp) Patent Number: 6,660,811 Date filed: January 30, 2002 Abstract: An epoxy resin composition comprising: (i) an epoxy resin having a melt viscosity of from 0.1 dPa to 5 dPa at 150.degree. C. and having two or more repeating units each comprising: a methylene bond substituted by at least an aromatic ring; and a benzene ring substituted by at least a glycidyloxy group, wherein said aromatic ring is at least one member selected from the group consisting of (a) condensed aromatic rings and (b) combinations of aromatic rings in which two or more aromatic monocycles or condensed aromatic rings are connected directly to each other via a single bond; and (ii) a curing agent.
Patents 121
Excerpt(s): The present invention relates to an epoxy resin composition which is excellent in flame retardance and which is suitably used as a semiconductor-sealing material or a printed circuit board material. An epoxy resin can be cured with various curing agents to form a cured product normally excellent in mechanical properties, humidity resistance, chemical resistance, heat resistance, electrical properties, etc. Thus, an epoxy resin finds wide application to electronic materials and molding materials. An epoxy resin to be used in the art of electronic materials such as printed wiring circuit board essentially comprises a halogen compound incorporated therein to render these materials flame retardant. In recent years, however, a halogen-based flame retardant has been considered problematic as a dioxin-producing factor from the standpoint of environmental protection. Thus, it has been keenly desired to provide a halogen-free flame retardant epoxy resin material. In the art of semiconductor-sealing material, as the semiconductor surface packaging process has spread, the solder crack resistance of the semiconductor package has become an important factor. A conventional semiconductorsealing material comprising a cresol-novolac type epoxy resin and a phenol-novolac resin in combination exhibits an excellent heat resistance but is disadvantageous in that it exhibits a poor humidity resistance and hence a deteriorated solder crack resistance. Referring to the method for solving these problems, Japanese Patent Laid-Open No. 2000-1524 discloses a technique involving the use of an epoxy resin having a specific molecular structure that meets the requirements for humidity resistance. The invention of the above cited Japanese Patent Laid-Open No. 2000-1524 can provide a cured product excellent in humidity resistance but is poor in flame retardance, which is required in the art of electronic material. Further, the epoxy resin described in Japanese Patent Laid-Open No. 2000-1524 is bifunctional and thus cannot increase in its crosslinking density. Thus, the foregoing epoxy resin exhibits a deteriorated heat resistance and leaves something to be desired in the improvement of solder crack resistance. Web site: http://www.delphion.com/details?pn=US06660811__ •
Fluorescent nucleoside analogs and combinatorial fluorophore arrays comprising same Inventor(s): Kool; Eric T. (Stanford, CA) Assignee(s): Research Corporation Technologies, Inc. (tucson, Az) Patent Number: 6,670,193 Date filed: April 19, 2002 Abstract: The present invention provides fluorescent nucleoside analogs which comprise a fluorescent cyclic compound joined to a carbon of a sugar molecule such as pentose, hexose, ribose or deoxyribose or analogs thereof in either an.alpha. or.beta. configuration. The subject compounds are useful as probes in the study of the structure and dynamics of nucleic acids and their complexes with proteins. In addition, the subject compounds are useful in any technique which uses labeled oligonucleotides for detection. Non-fluorescent spacer molecules in which a cyclohexane, cyclohexene, decalin, or benzene is joined to a carbon of a sugar moiety such as pentose, hexose, ribose or deoxyribose are also provided. Also provided are the 5' dimethoxytrityl-3'-Ophosphoramidite derivatives, suitable for incorporation into oligonucleotides by automated synthesizers. Combinatorial fluorophore array (CFA) libraries comprising oligomers of the subject nucleoside analogs attached to one or more solid supports are also provided as are methods of selecting fluorophores from the CFA libraries. The
122
Benzene
present invention also provides oligonucleotide analogs comprising one or more of the subject nucleoside analogs in place of a DNA or RNA base. Excerpt(s): Fluorescence methods are extremely widespread in chemistry and biology. The methods give useful information on structure, distance, orientation, complexation, and location for biomolecules [1]. In addition, time-resolved methods are increasingly used in measurements of dynamics and kinetics [2]. As a result, many strategies for fluorescence labeling of biomolecules, such as nucleic acids, have been developed [3]. In the case of DNA, one of the most convenient and useful methods for fluorescence labeling is to add a fluorescent moiety during the DNA synthesis itself. Addition of the fluorescent moiety during DNA synthesis avoids the extra steps required for postsynthesis labeling and purification. The majority of labels commonly used during DNA synthesis are attached to the DNA by tethers that are often 5 to 11 atoms long. These flexible tethers can at times be problematic, since they allow the dye to tumble independently of the DNA and make the location of the dye difficult to determine precisely [4]. There are very few examples of dye conjugates that hold the dye close to the DNA, thus avoiding these problems. Among the known dyes of this class are ethenodeoxyadenosine [5] and 2-aminopurinedeoxyriboside [6]. These latter two compounds have modified DNA bases that are themselves fluorescent, and have found much use as probes of enzymatic activities such as DNA synthesis, editing, and repair [7-9]. The present invention provides fluorescent labels for nucleic acids which, rather than modifying an existing nucleic acid base, replace one or more DNA or RNA bases with a fluorescent cyclic compound. Since the replacement fluorescent cyclic compound is also a flat cyclic structure, only small perturbations to the overall nucleic acid structure occur upon its use. The fluorescent label may be thought of as a nucleoside analog in which a known fluorescent cyclic compound is joined to a carbon atom of a sugar moiety. The subject nucleoside analogs allow for close interaction, including stacking, with a neighboring RNA or DNA helix. There are many known cyclic fluorophores which may be joined to a carbon atom of a sugar moiety to form the nucleoside analogs of the present invention. Many of the known cyclic fluorophores have high quantum yields with varied excitation and emission characteristics. Moreover, their lack of functional groups makes them relatively simple to work with in preparing conjugates. The literature has reported incorporation of 4-methylindole, naphthalene, phenanthrene, and pyrene fluorophores at the C1-position of deoxyribose [10, 11]. In a similar strategy, the substitution of a coumarin dye at the C1 position of deoxyribose has also been reported[12]. The methylindole derivative has recently found use as a fluorescent reporter of DNA repair activities [13]. In addition, the C1.alpha. pyrene derivative has been shown to be useful in DNA diagnostics strategies, where it efficiently forms excimers with neighboring pyrene labels [14]. The C1.beta. pyrene derivative stabilizes DNA helices markedly (due to its low polarity) [15, 16], and can be enzymatically incorporated into the DNA helix [17]. Thus, this new nucleic acid labeling strategy has many useful applications. Web site: http://www.delphion.com/details?pn=US06670193__ •
Low dielectric constant polymer and monomers used in their formation Inventor(s): Martin; Arthur (Glenham, NY), Tseng; Wei-Tsu (Hopewell Junction, NY) Assignee(s): International Business Machines Corporation (armonk, Ny) Patent Number: 6,660,820 Date filed: July 24, 2002
Patents 123
Abstract: A new class of fluorinated arylacetylene compounds useful as monomers in the formation of polymers having low dielectric constant. These polymers, which are the reaction products of one of the fluorinated arylacetylene compounds, a diphenyl oxide biscyclopentadienone and, optionally, 1,3,5-tris(phenylacetylene)benzene, are useful in insulating microelectric device. Excerpt(s): The present invention is directed to a new class of fluorinated aryl acetylenes useful as monomers in the polymerization of a low dielectric constant polymer which has excellent thermal stability. In addition, the present invention is directed to a polymeric reaction product of the new class of fluorinated aryl acetylenes, a diphenyloxide biscyclopentadienone and, optionally, 1,3,5tris(phenylacetylene)benzene. The continuing decrease in the size of integrated circuits has resulted in the development of dramatically decreased size integrated circuits wherein the spaces between individual devices or elements thereon are similarly diminished. This development has put increased insulative demand upon insulators, disposed between conductive paths, to prevent "cross-talk," shorts and other integrated circuit failures. A limiting factor in the development of these devices has been the inability to insulate between decreased conductive paths which these insulative layers separate. This problem has been addressed in the prior art by the development of fluorine silicate glass (FSG) films. However, these films, effective in the relatively large size integrated circuits of recent years, have proven inadequate insofar as the dielectric constant of these films has proven to be too high to prevent "cross talk," shorting and other manifestations of capacitance failure in the much smaller integrated circuits presently in use or under development. The insulating films currently employed in electrically insulating conductive layers of integrated circuits, which are usually metallic layers, particularly copper layers, include little or no fluorine. The most recent of these new films are polyphenylenes, as exemplified by U.S. Pat. No. 5,965,679, which is incorporated herein by reference. These polyphenylene films, which are polymerized from a monomeric reaction product, are characterized by lower dielectric constants compared to films heretofore employed in this application. Web site: http://www.delphion.com/details?pn=US06660820__ •
Low temperature chemical vapor deposition of thin film magnets Inventor(s): Miller; Joel S. (Salt Lake City, UT), Pokhodnya; Kostyantyn I. (Salt Lake City, UT) Assignee(s): University of Utah Research Foundation (salt Lake City, Ut) Patent Number: 6,660,375 Date filed: November 27, 2002 Abstract: A thin-film magnet formed from a gas-phase reaction of tetracyanoetheylene (TCNE) OR (TCNQ), 7,7,8,8-tetracyano-P-quinodimethane, and a vanadium-containing compound such as vanadium hexcarbonyl (V(CO).sub.6) and bis(benzene)vanalium (V(C.sub.6 H.sub.6).sub.2) and a process of forming a magnetic thin film upon at least one substrate by chemical vapor deposition (CVD) at a process temperature not exceeding approximately 90.degree. C. and in the absence of a solvent. The magnetic thin film is particularly suitable for being disposed upon rigid or flexible substrates at temperatures in the range of 40.degree. C. and 70.degree. C. The present invention exhibits air-stable characteristics and qualities and is particularly suitable for providing being disposed upon a wide variety of substrates.
124
Benzene
Excerpt(s): The present invention relates generally to thin-film magnets, or magnetic thin films, and more specifically relates to the composition of magnetic thin films produced from the reaction of a vanadium containing compound, tetracyanoethylene and a low-temperature chemical vapor deposition processes for depositing a vanadium containing thin-film upon a wide variety of supporting substrates. Thin films having certain magnetic, electrical, optical properties, low temperature processibility, insulating to semiconducting behavior, mechanical flexibility, solubility, and substrate compatibility properties, as well as other physical properties, are of interest and often times are essential in many applications. Of particular interest are magnetic thin films that may be deposited upon substrates comprised of materials such as plastics, glasses, metals, and ionic crystalline materials and in which the substrates are either rigid or flexible. For example, thin magnetic films are used extensively on magnetic tapes and media used in the storage and retrieval of computer generated data, magnetic shielding, as well as for providing extraction of magnetic substances. The use of chemical vapor deposition (CVD) techniques for applying various thin films onto a variety of substrates is generally well known. For example, CVD is used extensively in the semiconductor industry to apply thin films having various electrical and magnetic characteristics onto substrates constructed primarily or entirely of semiconductive material containing silicon, germanium, or gallium arsenide and other generally inorganic substrates. Normally CVD techniques used in the semiconductor industry are conducted at temperatures above 200.degree. C. Web site: http://www.delphion.com/details?pn=US06660375__ •
Magnetic recording medium containing specific binder in the magnetic layer and the lower non-magnetic layer Inventor(s): Hashimoto; Hiroshi (Kanagawa, JP), Meguro; Katsuhiko (Kanagawa, JP), Murayama; Yuichiro (Kanagawa, JP) Assignee(s): Fuji Photo Film Co., Ltd. (kanagawa, Jp) Patent Number: 6,686,073 Date filed: November 16, 2001 Abstract: A magnetic recording medium containing a support having provided thereon a lower layer containing a nonmagnetic powder and a binder and further provided thereon at least one magnetic layer containing a ferromagnetic powder and a binder. The lower layer can contain as a binder at least a monomer unit containing from 5 to 45% by weight of a (meth)acrylate unit containing a benzene ring and from 1 to 45% by weight of a radical polymerizable monomer unit containing a nitrogen atom, with these units making a total amount of 100% by weight. It can also contain an acrylic resin having a hydrophilic polar group. The magnetic recording medium may also contain a support having provided thereon at least one magnetic layer containing a ferromagnetic powder and a binder each in the dispersed state. The magnetic layer can contain at least a monomer unit comprising from 15 to 75% by weight of an alkyl (meth)acrylate as a binder and from 1 to 45% by weight of a radical polymerizable monomer unit containing nitrogen, with these units making a total amount of 100% by weight. It can also contain an acrylic resin having a hydrophilic polar group used in combination with a resin (A) defined herein; a resin (B) defined herein; or a resin (C) defined herein. Excerpt(s): The present invention relates to a magnetic recording medium having very excellent electromagnetic conversion characteristics (i.e., electromagnetic characteristics) and running durability. The magnetic recording medium commonly used is a recording
Patents 125
medium obtained by providing on a nonmagnetic support a magnetic layer comprising a binder having dispersed therein ferromagnetic powder particles. Recently, in the field of magnetic recording, digital recording is practically taking the place of conventional analog recording because of its less deterioration of recording. In the digital recording, a large number of signals must be generally recorded and moreover, the recording/reproducing apparatus and the recording medium used therefor are demanded to ensure high image quality and high sound quality and at the same time, realize downsizing and space saving. To cope with these requirements, still higher density recording is being demanded. For achieving higher density recording, recording signal with a short wavelength and recording locus in a narrow track are employed. As for the recording medium, more improvement in the electromagnetic conversion characteristics is demanded and for this purpose, various proposals have been proposed, such as improvement in the magnetic characteristics of ferromagnetic powder, formation of fine particles, high filling, or ultra-smoothing of the medium surface. These are, however, not satisfactory for the higher density recording demanded in recent years. Web site: http://www.delphion.com/details?pn=US06686073__ •
Method of manufacturing phenol by direct oxidation of benzene Inventor(s): Tsuruya; Shigeru (Hyogo-ken, JP) Assignee(s): President of Kobe University (kobe, Jp) Patent Number: 6,646,167 Date filed: September 25, 2001 Abstract: Benzene, ascorbic acid acting as a reducing agent, and a vanadium-supported alumina catalyst are placed in an aqueous solution of acetic acid used as a solvent, and the reaction is carried out under an oxygen gas atmosphere having a pressure of at least 0.3 MPa so as to directly oxidize benzene and, thus, to obtain phenol at a high yield of at least 8%. Excerpt(s): The present invention relates to a method of manufacturing phenol by a single stage direct oxidation of benzene. However, the cumene process, which involves three process steps, is not economical. Also, the phenol manufacture is dependent on the market price of acetone obtained as a by-product in the cumene process. Under the circumstances, the present inventor has conducted an extensive research on the method to obtain phenol by direct oxidation of benzene in the presence of a Cu-supported catalyst. However, the conventional method is not satisfactory in the phenol yield and leaves room for further improvement in the phenol manufacturing cost. Web site: http://www.delphion.com/details?pn=US06646167__
•
Optical resin composition comprising thiol-ene prepolymer Inventor(s): Herold; Robert D. (Monroeville, PA), Okoroafor; Michael O. (Export, PA), Smith; Robert A. (Murrysville, PA) Assignee(s): Ppc Industries Ohio, Inc. (cleveland, Oh) Patent Number: 6,669,873 Date filed: March 14, 2000
126
Benzene
Abstract: Described is a polymerizable organic composition comprising: (a) a radically polymerizable gel-free prepolymer of (i) at least one first polymerizable monomer having at least two radically polymerizable ethylenically unsaturated groups, e.g., divinyl benzene, and (ii) at least one first polythiol monomer having at least two thiol groups, e.g., thioglycerol bis(mercaptoacetate); and (b) at least one second polymerizable monomer having at least two radically polymerizable ethylenically unsaturated groups, e.g., divinyl benzene and/or methacrylic anhydride, the first and second radically polymerizable monomers each being substantially free of norbornene groups. The molar equivalent ratio of ethylenically unsaturated groups of (a)(i) to the thiol groups of (a)(ii) is no greater than 1:1. The described polymerizable composition has reduced shrinkage, and a polymerizate prepared therefrom has a refractive index of at least 1.57 and an Abbe number of at least 33. Excerpt(s): The present invention relates to polymerizable organic compositions having reduced shrinkage and solid polymerizates prepared therefrom having a refractive index of at least 1.57, and an Abbe number of at least 33. Particularly, the present invention relates to certain polymerizable organic compositions comprising a substantially gel-free liquid prepolymer of a first polyethylenically unsaturated monomer and a polythiol monomer, and a separate second polyethylenically unsaturated monomer. More particularly, the polymerizable compositions of the present invention have a percent shrinkage less than that of a corresponding polymerizable composition containing no prepolymer. Organic polymeric materials having refractive indices of at least 1.57 and low levels of chromatic dispersion have been developed recently as alternatives and replacements for high refractive index inorganic silica based glass for applications such as optical lenses. These polymeric materials can provide advantages relative to glass, including, shatter resistance, lighter weight for a given application, ease of molding and ease of dying. The chromatic dispersion of an optical lens is typically quantified with reference to Abbe numbers (also known as nu-values). Lower Abbe numbers are indicative of an increasing level of chromatic dispersion, which is typically manifested as an optical distortion at or near the rim of the lens. Values of Abbe numbers corresponding to desirably lower levels of chromatic dispersion are, for example, typically at least 33 and more typically at least 35. It is known that polymeric materials having high refractive indices, e.g., of at least 1.57, and low levels of chromatic dispersion, e.g., having Abbe numbers of at least 33, can be prepared from polymerizable compositions containing monomers having at least two thiol groups and monomers having two or more radically polymerizable ethylenically unsaturated groups. Such compositions, which are referred to in the art as thiol-ene compositions, are described in, for example, U.S. Pat. No. 5,484,972, and International Patent Publication No. WO 96/38486. Web site: http://www.delphion.com/details?pn=US06669873__ •
Oxidation bases containing a guanidine chain, process for preparing them, their use for the oxidation dyeing of keratin fibers, dye compositions and dyeing processes Inventor(s): Bordier; Thierry (Tremblay en France, FR), Philippe; Michel (Wissous, FR) Assignee(s): L'oreal S.a. (paris, Fr) Patent Number: 6,652,600 Date filed: January 29, 2001 Abstract: Novel oxidation bases comprising a benzene nucleus and a guanidine chain, a process for their preparation, their use for the oxidation dyeing of keratin fibers, dye
Patents 127
compositions containing them, and oxidation dyeing processes using them are described. Excerpt(s): The present invention relates to novel oxidation bases containing a benzene nucleus and comprising a guanidine chain, to a process for their preparation, to their use for the oxidation dyeing of keratin fibers, to dye compositions containing them and to oxidation dyeing processes using them. It is known practice to dye keratin fibers, and in particular human hair, with dye compositions containing oxidation dye precursors, in particular ortho-phenylenediamines, para-phenylenediamines, ortho-aminophenols or para-aminophenols and heterocyclic compounds, which are generally referred to as oxidation bases. The oxidation dye precursors, or oxidation bases, are colorless or weakly colored compounds which, when combined with oxidizing products, can give rise to colored compounds and dyes by a process of oxidative condensation. It is also known that the shades obtained with these oxidation bases can be varied by combining them with couplers or coloration modifiers, the latter being chosen in particular from aromatic meta-diamines, meta-aminophenols, meta-diphenols and certain heterocyclic compounds. Web site: http://www.delphion.com/details?pn=US06652600__ •
Paint containing surfactants for structuring non-aqueous liquid compositions Inventor(s): Broeckx; Walter August Maria (Zele, BE), Parry; Diane (Cincinnati, OH), Smerznak; Mark Allen (Cincinnati, OH), White, Jr.; Daniel Jerome (North Bend, OH) Assignee(s): The Procter & Gamble Company (cincinnati, Oh) Patent Number: 6,682,723 Date filed: December 13, 2001 Abstract: A paint containing a surfactant system capable of structuring a non-aqueous liquid composition, wherein the surfactant system comprises at least about 5% of a structuring particle. The surfactant system preferably further comprises a surfactant selected from the group consisting of anionic, nonionic, cationic, amphoteric surfactants and mixtures thereof. A well dispersed mixture of a non-aqueous liquid, for example, a nonionic surfactant, and at least about 25%, by weight of the surfactant system results in the mixture having a yield of at least about 2.0 Pa when measured at 20 sec.sup.-1 and 25.degree. C. Moreover, the surfactant system should exhibit a peak when measured by SAXS x-ray diffraction, wherein the peak's center is between about the 1.5 to 2.5 v positions on the 2 theta axis. The structuring particles are most preferably structuring particles of sulfate and linear alkyl benzene sulfonate. Excerpt(s): This invention is in the field of structuring particles. Specifically, surfactant systems comprising a sufficient concentration of a surfactant that can structure a nonaqueous liquid. Structured liquids, for example, gels and certain non-Newtonian fluids, have numerous applications and have gained great favor among consumers. For example, many paints are supplied as liquids that are structured in situ, that is, the structure is established in the container as the paint is mixed. Paint is typically structured in an attempt to evenly suspended fine, solid pigment particles in the liquid paint carrier. But as most consumers of paint products are well aware, more often than not when paint is purchased the pigment particles have settled to the bottom of the container. This occurs when the structure of the paint is broken down by the normal jostling during shipping and handling of the containerized paint. Once the structure is broken down it cannot be reestablished, and the paint must be shaken or stirred before
128
Benzene
each use to resuspend the pigment particles. The necessity of shaking or stirring, which is often a messy procedure, is the bane of painting. Among the most common structurants for liquid compositions are clay compounds. While clay provides good in situ structuring for certain liquid environments, clay structured systems are inherently unstable. Liquids structured with clay and other conventional structurants rely of a delicate balancing of particle forces that when disturbed cause the structure to break down. Specifically, two particles are often attracted due to natural forces such as van der Waals forces. But if brought too close together two particles will normally repel one another due to natural repulsive forces between particles. Also, entropy works to break down weakly structured systems. Hence, structured liquids are fragile and the structure is easily broken down. Web site: http://www.delphion.com/details?pn=US06682723__ •
Polyetherimide resin/polyester resin blends having improved visual clarity Inventor(s): Jin; Yimin (Newburgh, IN), Liao; Jun (Evansville, IN) Assignee(s): General Electric Company (pittsfield, Ma) Patent Number: 6,646,031 Date filed: March 26, 2002 Abstract: Transparent thermoplastic resin compositions include a polyetherimide resin, a polyester resin, sodium benzene phosphinate, and optionally 3,4-epoxy cyclohexylmethyl-3,4-epoxy cyclohexanecarboxylate and preferably comprising a first polyester resin and a second polyester resin and sodium benzene phosphinate, wherein from 50 to 100 mole percent of the structural units of the first polyester resin include an alicyclic hydrocarbon radical as the diol residue of the structural unit, and wherein less than 50 mole percent of the structural units of the second polyester include an alicyclic hydrocarbon radical as the diol residue of the structural unit, exhibit resistance to elevated temperature and improved impact properties. Excerpt(s): The disclosure relates to thermoplastic resin blends, more specifically to certain transparent blends of polyetherimide resins and polyester resins. Blends of polyetherimide resins and polyester resins derived predominantly from cyclohexanedimethanol and a carbocyclic dicarboxylic acid, such as, for example, a poly(cyclohexane-dimethanol terephthalate) resin that provide improved impact strength are disclosed in U.S. Pat. No. 5,439,987. Blends of polyetherimide resins and copolyesters of terephthalic acid and/or isoterephthalic acid, 1,4cyclohexanedimethanol and ethylene glycol, that is, certain poly(cyclohexane-1,4dimethylene-co-ethylene terephthalate) resins that are said to exhibit a high flexural modulus are disclosed in U.S. Pat. No. 5,439,987. Polyetherimide-polyester blends that exhibit transparency, resistance to elevated temperature, reduced processing temperatures, and further improvements are desired. Web site: http://www.delphion.com/details?pn=US06646031__
Patents 129
•
Porous part for refrigerators, and method of producing the same and refrigerator Inventor(s): Endou; Atsushi (Kusatsu, JP), Taira; Shigeharu (Kusatsu, JP) Assignee(s): Daikin Industries, Ltd. (osaka, Jp) Patent Number: 6,672,100 Date filed: June 7, 2002 Abstract: In this porous part producing method, a head part (11A, 11B) in the interior of a compressor, which is a sintered part, is subjected at least to vacuum substitution or heat blow cleaning, whereby after oils causing contamination and/sludge, such as rustpreventive oil, in the head part (11A, 11B) in the interior of the compressor is discharged therefrom, the head part (11A, 11B) is immersed in alkyl benzene type oil serving as refrigerator oil. Thereby, deterioration-inducing substances in the head part (11A, 11B) in the interior of the compressor is replaced with the refrigerator oil; thus, it is possible to produce a porous part which will not bring about contamination and/or sludge even if used as a component for refrigerators for a long time. Excerpt(s): This invention relates to a porous part for refrigerators, which is used as a component for a compressor, refrigerant piping, or the like. This invention also relates to a refrigerator having a material (e.g., a porous part) used as a component for a compressor, refrigerant piping, or the like. A sintered part as a porous part is inexpensive. However, because oils such as a processing oil, a form-rolling oil, a cutting oil and so on are used when processing the sintered part, these oils are contained in large quantities in the sintered part after the processing. When this sintered part is used, for example, as a component for a compressor of a refrigerator, repetition of operation/stop conditions causes variations in the pressure in the interior of the compressor. As a result, the oils such as the processing oil exude from the sintered part. Among these oils, rust-preventive oils, which are liable to deteriorate a refrigerator oil in a refrigerator, have a problem of easily causing contamination and/or sludge which are a cause of clogging. For that reason, it is conceivable to wash the sintered part with a cleaning device before it is incorporated into the refrigerator as a component thereof. However, since this requires new capital investment, there is a problem in that the cost increases. Web site: http://www.delphion.com/details?pn=US06672100__
•
Process for producing 1,3-bis(3-aminophenoxy)benzene Inventor(s): Hayashi; Hidetoshi (Omuta, JP), Nukii; Yasuhiro (Omuta, JP), Okazaki; Koju (Sodegaura, JP), Tomoshige; Naoki (Sodegaura, JP), Wada; Masaru (Omuta, JP) Assignee(s): Mitsui Chemicals, Inc. (tokyo, Jp) Patent Number: 6,664,425 Date filed: September 5, 2002 Abstract: 1,3-Bis(3-aminophenoxy)benzene effective, for example, as a raw material for highly heat-resistant polyimide is produced industrially at a high yield by a reaction between 1,3-difluorobenzene and an alkali metal salt of 3-aminophenol. Excerpt(s): The present invention relates to a process for producing 1,3-bis(3aminophenoxy)benzene which is useful as a raw material for especially adhesive polyimide resin, and polyether-polyamines useful as a raw material for heat-resistant polymer, especially polyimide, as well as to an intermediate used for production of 1,3-
130
Benzene
bis(3-aminophenoxy)benzene. As a process for producing 1,3-bis(3aminophenoxy)benzene, a reaction between 1,3-dibromobenzene and an alkali metal salt of 3-aminophenol is described in U.S. Pat. No. 4,222,962. In the process, however, the reactivity of the second step is inferior and the yield is low at 65%. Also in JP-A-03255058 is described a process which comprises reacting 1,3,5-trichlorobenzene with an alkali metal salt of 3-aminophenol to form two ether linkages and then conducting hydrogenolysis using a noble metal catalyst to eliminate the remaining chloro group. In the process described in the literature, however, trichlorobenzene into which electronattractive chloro group is introduced excessively, is used in order to enhance the reactivity of chloro group substitution. This requires two steps and the process has not been satisfactory as an industrial process. Web site: http://www.delphion.com/details?pn=US06664425__ •
Process for producing aromatic hydrocarbon compounds and liquefied petroleum gas from hydrocarbon feedstock Inventor(s): Choi; Sun (Eulsan, KR), Kim; Yong-Seung (Eulsan, KR), Lim; Beung-Soo (Eulsan, KR), Oh; Seung-Hoon (Taejon, KR), Seong; Kyeong-Hak (Taejon, KR) Assignee(s): SK Corporation (seoul, Kr) Patent Number: 6,635,792 Date filed: November 20, 2001 Abstract: Disclosed are a process for producing aromatic hydrocarbon compounds and liquefied petroleum gas (LPG) from a hydrocarbon feedstock having boiling points of 30-250.degree. C. and a catalyst useful therefor. In the presence of said catalyst, aromatic components in the hydrocarbon feedstock are converted to BTX-enriched components of liquid phase through hydrodealkylation and/or transalkylation, and non-aromatic components are converted to LPG-enriched gaseous materials through hydrocracking. The products of liquid phase may be separated as benzene, toluene, xylene, and C.sub.9 or higher aromatic compounds, respectively according to their different boiling points, while LPG is separated from the gaseous products, in a distillation tower. Excerpt(s): The present invention pertains, in general, to a process for producing aromatic hydrocarbon compounds of liquid phase and non-aromatic hydrocarbon compounds of gas phase, for instance, liquefied petroleum gas (LPG), from hydrocarbon feedstock, and a catalyst useful therefor. More specifically, the present invention pertains to a process for converting aromatic compounds in hydrocarbon feedstock having boiling points of 30-250.degree. C. to oil components including BTX (benzene, toluene and xylene) through dealkylation and/or transalkylation, and for converting non-aromatic compounds to LPG-rich gaseous components through hydrocracking; and a catalyst used in said process. Generally, aromatic hydrocarbons are separated from non-aromatic hydrocarbons by subjecting feedstocks abundantly containing aromatic compounds, such as reformate produced through a reforming process and pyrolysis gasoline obtained from a naphtha cracking process, to solvent extraction. The aromatic hydrocarbons obtained as above is separated as benzene, toluene, xylene, and C.sub.9 or higher aromatic compounds, according to their different boiling points, and thus used as fundamental materials of the petrochemical industry. Non-aromatic hydrocarbons are used as raw materials or fuel of the naphtha cracking process. In this regard, U.S. Pat. No. 4,058,454 refers to a solvent extraction process for separating and recovering polar hydrocarbons from hydrocarbon mixture including polar hydrocarbons and non-polar hydrocarbons. Such solvent extraction process uses
Patents 131
polarity of aromatic hydrocarbons to achieve separation. That is, when polar materialsdissolving solvents, such as sulfolane, are contacted with hydrocarbon mixture, polar aromatic hydrocarbons can be selectively dissolved and thus separated from non-polar non-aromatic hydrocarbons. Said process is advantageous in terms of obtaining high purity aromatic hydrocarbon mixture, while is disadvantageous in requiring additional solvent-extraction equipments and continuously feeding solvents during operation of equipment. Therefore, the methods for separating aromatic hydrocarbons and nonaromatic hydrocarbons from raw oils without additional solvent extraction process have been devised. Web site: http://www.delphion.com/details?pn=US06635792__ •
Process for reducing volatile organic compound content of refinery liquid waste streams using aqueous solutions containing microbes Inventor(s): Leonhardt; Gene (Texas City, TX) Assignee(s): Marathon Ashland Petroleum Llc (findlay, Oh) Patent Number: 6,653,120 Date filed: May 11, 2001 Abstract: A process and apparatus are provided for reducing volatile organic compound content, e.g., benzene content, of a hydrocarbon-containing gas stream, e.g., a refinery waste vapor stream by contacting the stream, preferably in a single pass, with an aqueous liquid medium containing volatile organic compound-metabolizing microbes, e.g., Bacillus subtilis, under volatile organic compound-metabolizing conditions. A treated stream results which contains volatile organic compound metabolization products of volatile organic compounds, e.g., water and carbon dioxide, and substantially reduced volatile organic compound content. Excerpt(s): The present invention relates generally to biodegrading volatile organic compounds found in refinery liquid waste streams and, in particular, to a process and apparatus for removing volatile organic compounds from refinery liquid waste streams. Processes for biodegrading hazardous organic waste are generally classified in U.S. Patent Office Class 435/262.5. Microbial degradation of oil dates back to at least 1942, when the American Petroleum Institute began to subsidize research in the field. Considerable basic knowledge about factors that affect natural biodegradation, about the kinds of hydrocarbons capable of being degraded, and about the species and distribution of the microorganisms involved in biodegradation had already been developed in the early 1970s. The Office of Naval Research sponsored more than a dozen basic and applied research projects in the late 1960s and early 1970s on oil biodegradation to control marine oil spills. Since this time, a large number of refineries, tank farms, and transfer stations now employ in situ bioremediation to restore land contaminated by accidental spills of fuel oil or other hydrocarbons. Web site: http://www.delphion.com/details?pn=US06653120__
132
•
Benzene
Process for the coproduction of benzene from refinery sources and ethylene by steam cracking Inventor(s): Netzer; David (7979 Westheimer Rd., Apt. 1408, Houston, TX 77063) Assignee(s): None Reported Patent Number: 6,677,496 Date filed: October 23, 2001 Abstract: A process for the coproduction of purified benzene and ethylene is provided. The method comprises providing a first mixture comprising benzene, toluene, and one or more C.sub.6 to C.sub.7 non-aromatics and separating the majority of the benzene and the one or more C.sub.6 to C.sub.7 non-aromatics from the majority of the toluene to form a second mixture containing benzene and at least a portion of the one or more C.sub.6 to C.sub.7 non-aromatics. Thereafter at least about 80% of the C.sub.6 to C.sub.7 non-aromatics in the second mixture are cracked while maintaining essentially no cracking of benzene to produce a cracked product containing ethylene, propylene and pyrolysis gasoline comprising olefins, di-olefins and benzene. The pyrolysis gasoline is preferably hydrotreated and then fractionated to form a purified benzene product comprising at least about 80 wt % benzene. The purified benzene can be used as a feed to a liquid phase or mixed phase alkylation and/or to produce ethylbenzene or cumene. Excerpt(s): About 50% of benzene consumption in the petrochemical industry is directed to the production of ethylbenzene, an additional about 25% is dedicated to the production of cumene, and another 15% goes toward the production of cyclohexane. About 4 to 5% of benzene is directed to the production of nitrated products. Ethylbenzene is a precursor for the production of styrene, which is a precursor for the production of polystyrene, and cumene is a precursor for the production of phenol. Benzene is obtained from various sources. Over 55% of all benzene is attained from to petroleum refining, mostly catalytic reforming of naphtha. Additionally, over 30% of all benzene is obtained from pyrolysis gasoline resulting from steam cracking in olefins production and under 15% is obtained from coke oven gas, originated from coal, as related to iron and steel production. All the above sources are coproducers of toluene, and a significant portion of toluene is converted to benzene by either hydrodealkylation or by coproduction of xylenes. Production of ethylene by gas crackers, mostly C2-C3 and some C4 feeds, amounts to about 40% of the world ethylene capacity. This results in a relatively small coproduction of benzene compared to benzene coproduced in naphtha and gas oil crackers, which account for 60% of the world's ethylene production capacity. A typical overall benzene yield from ethane cracking is on the order of 0.60 wt % of the ethane feed, and benzene yield from propane cracking is on the order of 3.0 wt % of the propane feed. Benzene yield resulting from naphtha cracking can range from 4 wt % to 10 wt % of the naphtha feed depending the on aromatic content of the naphtha and severity of cracking. The benzene coproduction in naphtha cracking is a coincidental production to ethylene, whereas in the present invention additional ethylene production is coincidental to benzene production. For C2/C3 cracking, any significant downstream alkylation process, such as for producing ethylbenzene, is likely to be deficient in benzene. Web site: http://www.delphion.com/details?pn=US06677496__
Patents 133
•
Quaternary ammonium salt and process for the preparation thereof Inventor(s): Harada; Katsuyoshi (Aichi, JP), Kourai; Hiroki (Tokushima, JP), Kume; Masayoshi (Aichi, JP), Shibata; Shigeyuki (Aichi, JP) Assignee(s): Toagosei Co., Ltd. (tokyo, Jp) Patent Number: 6,664,224 Date filed: May 15, 2001 Abstract: The novel quaternary ammonium salt according to the invention has two quaternary ammonium groups connected to a benzene ring, wherein two C.sub.4-12 alkyl groups and one C.sub.1-2 alkyl group are connected per one nitrogen atom constituting the quaternary ammonium. The compound is used as an antimicrobial agent, exhibits a high safety to human as compared with known antimicrobial agents, exerts an excellent sterilizing effect itself and exhibits a wide sterilizing spectrum. In particular, the compound is used as a presevative for eye drop. Excerpt(s): The present invention relates to a novel quaternary ammonium salt and a process for the preparation thereof. The compound according to the present invention is useful as an antimicrobial agent such as preservative for eye drop. A quaternary ammonium salt having an antimicrobial activity has long been known and is now widely used. However, conventional quaternary ammonium salts are normally disadvantageous in that they show deteriorated sterilizing power and antimicrobial power due to the effect of saccharides, protein and lipid or in an acid range having a low pH value and have no effect on cellular spore. As solutions to the foregoing problems, a compound having two structural units called quaternary ammonium per molecular has been proposed, which unit is capable of having four alkyl groups or other groups connected to one nitrogen atom, e.g., the antimicrobial agent comprising quaternary ammonium salt in JP-A-6-321902 (The term "JP-A" as used herein means an "unexamined published Japanese patent application") and JP-A-10-114604. The compound disclosed in these published applications has methyl or ethyl groups connected thereto in a proportion of 2 or more per one of nitrogen atoms constituting the quaternary ammonium. Accordingly, this compound has a high antimicrobial activity and thus is a good compound from the standpoint of antimicrobial properties. This compound has been actually used as an antimicrobial agent. This compound has a high antimicrobial activity but it has been desired to improve the safety of this compound to human. Web site: http://www.delphion.com/details?pn=US06664224__
•
Reactive distillation process for the alkylation of aromatic hydrocarbons Inventor(s): Brown; Mary J. (Cedar Park, TX), Howe; Richard C. (Round Rock, TX), Murray; Joy L. (Austin, TX), Schell; John R. (Austin, TX), Sorensen; Wayne L. (Austin, TX), Szura; Daniel P. (Georgetown, TX), Wharry; Donald L. (Austin, TX), Winder; J. Barry (Austin, TX) Assignee(s): Sasol North America Inc. (houston, Tx) Patent Number: 6,642,425 Date filed: March 5, 2002 Abstract: A unified process for reactive distillation under pressure for the alkylation of light aromatic hydrocarbons such as benzene and cumene with straight chain C.sub.6 -
134
Benzene
C.sub.18 olefins using a solid acid alkylation catalyst supported in the reflux zone of the distillation column. The process is continuous, using a reactive distillation configuration such that at least a portion of the olefin is injected below the benzene rectification zone at the top of the column. The aromatic hydrocarbon is injected continuously at a low rate above the rectification zone at the base of the column and above the reboiler. The alkylation reaction takes place primarily in the liquid phase on the solid acid catalyst and is characterized in that the molar ratio of aromatic hydrocarbon to olefin in the liquid phase may be adjusted. The molar ratio is adjustable up to about 100/1, through adjustment of the internal column operating pressure, the benzene reflux rate, the amount of benzene removed from the reflux condenser to storage or from the reboiler with the distillation column operated at or near total aromatic hydrocarbon reflux. The unexpectedly high liquid phase aromatic hydrocarbon to olefin molar ratios achieved in the reactive distillation column increases the selectivity to mono-alkylated aromatics and helps stabilize catalyst lifetime. Excerpt(s): This invention relates to an alkylation process. More particularly, this invention relates to the alkylation of aromatic hydrocarbons with olefins in a continuous, pressurized, reactive distillation process employing a solid alkylation catalyst system. Linear alkylated aromatic compounds have many uses of significant commercial value. For example, alkylated light aromatic compounds, such as benzene and cumene, have value as gasoline octane enhancers. Aromatic compounds alkylated with long chain (that is, having greater than about 10 carbon atoms) linear olefins are commonly sulfonated to produce surfactants suitable for use in detergent manufacture. The chemical reactions involving alkylation of aromatics with olefins have been studied for a long time. For example, U.S. Pat. No. 2,860,173 discloses the use of a solid phosphoric acid as a catalyst for the alkylation of benzene with propylene to produce cumene. More recently, the use of Friedel Crafts catalysts, especially aluminum chloride and certain natural zeolites and synthetic commercial sieves, as alkylation catalysts, has been taught. Web site: http://www.delphion.com/details?pn=US06642425__ •
Self-doped conductive polymer, monomer for synthesizing self-doped conductive polymer, and processes of producing the same Inventor(s): Kondo; Kuniyoshi (Nishikasugai-gun, JP), Sato; Makoto (Nishikasugai-gun, JP), Tanaka; Hiromitsu (Aichi-gun, JP), Usuki; Arimitsu (Aichi-gun, JP) Assignee(s): Toyoda Gosei Co., Ltd. (aichi-ken, Jp) Patent Number: 6,660,183 Date filed: June 13, 2002 Abstract: A process for producing an aromatic monomer for synthesizing a self-doped conductive polymer, the process comprising:introducing an alkoxysulfonic acid group as a self-doping group to a benzene or naphthalene derivative having a hydroxyl group bonded to an aromatic ring thereof by alkanesulfonation of the hydroxyl group;protecting the self-doping group by converting to an acid halide form by sulfonyl halogenation; andintroducing two chloromethyl groups as a polymerizable groups into the aromatic ring. Excerpt(s): This invention relates to a monomer for synthesizing a self-doped conductive polymer, a process of producing the monomer, a self-doped conductive polymer, and a process of producing a self-doped conductive polymer. The terminology "self-doped
Patents 135
conductive polymer" means a polymer having a functional group serving as a dopant covalently bonded to the backbone thereof either directly or via a spacer so as to have controlled conductivity. While the present invention will be described with particular reference to poly[(2,5-dipropoxysulfonic acid)phenylene-1,4-vinylene] as a self-doped conductive polymer (hereinafter referred to as a self-doped PPV), the present invention is not limited thereto. The present invention is applicable to synthesis of any aromatic monomer from a benzene or naphthalene derivative having a hydroxyl group bonded to its aromatic nucleus and self-doped conductive polymers obtained therefrom. Web site: http://www.delphion.com/details?pn=US06660183__ •
Thermographic recording material with improved image tone Inventor(s): Defieuw; Geert (Bonheiden, BE), Dooms; Philip (Oosteeklo, BE), Hoogmartens; Ivan (Wilrijk, BE) Assignee(s): Agfa-gevaert (be) Patent Number: 6,693,062 Date filed: June 27, 2002 Abstract: A monosheet black and white substantially light-insensitive thermographic recording material comprising a thermosensitive element and a support, the thermosensitive element containing one or more substantially light-insensitive organic silver salts, one or more reducing agents consisting of one or more 1,2dihydroxybenzene-compounds in thermal working relationship therewith and a binder, wherein the molar ratio of molar hydroxy-equivalents of the 1,2-dihydroxybenzene compounds to molar silver-equivalents of the substantially light-insensitive organic silver salts is between 1.2 and 6.0; the 1,2-dihydroxybenzene-compounds have a -(CH.dbd.CH).sub.n R group in the 4 position wherein n is zero or an integer and R is a substituent with a Hammett.sigma.sub.p constant >0.35 and <0.95 exclusive of a carboxy-group; and the benzene ring of the 1,2-dihydroxy-compounds is optionally further substituted with an entity selected from the group consisting of an alkyl, substituted alkyl, alkenyl, aryl, heteroaryl, alkoxy, thioalkyl, aryloxy, thioaryl, thioheteroaryl, acyloxy, thioacyl, amido, sulphonamido and halogen groups, an annelated aryl ring system and an annelated heteroaryl ring system; and a thermographic recording process therefor. Excerpt(s): The present invention relates to thermographic recording materials whose prints have improved image tone. Thermal imaging or thermography is a recording process wherein images are generated by the use of thermal energy. In direct thermal thermography a visible image pattern is formed by image-wise heating of a recording material. where R is --P(.dbd.O)R.sup.1 R.sup.2, --SO.sub.x R.sup.3, --CN, --NO.sub.2 or --CR.sup.4.dbd.NR.sup.5 when n is 0; R is --P(.dbd.O)R.sup.1 R.sup.2, --SO.sub.x R.sup.3, --CN, --NO.sub.2, --CR.sup.4.dbd.NR.sup.5 or --COR.sup.6 when n is an integer; R.sup.1 and R.sup.2 are independently an alkyl, a substituted alkyl, an aryl, a substituted aryl group, an alkoxy, a substituted alkoxy, an aryloxy, a substituted aryloxy, a hydroxy group, an amino group or a substituted amino group; R.sup.3 is an alkyl, a substituted alkyl, an aryl, a substituted aryl, an amino or a substituted amino group; R.sup.4 is an alkyl, a substituted alkyl, an aryl or a substituted aryl group or hydrogen; R.sup.5 is an alkyl, a substituted alkyl, an aryl, a substituted aryl, a hydroxy, an alkoxy, an aryloxy, an acyl, an amino or a substituted amino group; R.sup.6 is an alkyl, a substituted alkyl, an aryl, a substituted aryl, an alkoxy, a substituted alkoxy, an aryloxy, a substituted aryloxy, a hydroxy, an amino or a substituted amino group or
136
Benzene
hydrogen; x is 1, 2 or 3; and the benzene ring of the 1,2-dihydroxybenzene-compound represented by the formula (I) may be further substituted. Web site: http://www.delphion.com/details?pn=US06693062__ •
Thin lithium secondary cell Inventor(s): Izuchi; Syuichi (Takatsuki, JP), Nakagawa; Hiroe (Takatsuki, JP), Ochiai; Seijiro (Takatsuki, JP) Assignee(s): Yuasa Corporation (takatsuki, Jp) Patent Number: 6,673,496 Date filed: July 27, 1999 Abstract: A film-type lithium secondary battery in which at least one of a positive electrode (2), a negative electrode (3) and a separator (1) contains an electrolyte having a specified structure, the electrolyte having the above specified structure is composed of a liquid electrolyte and an organic polymer, the organic polymer is formed by polymerizing an organic monomer having a polymeric functional group at its molecular chain end, the organic polymer contains in its molecule a first chemical structure and a second chemical structure, the first chemical structure is at least one of an ethylene oxide structure and a propylene oxide structure, and the second chemical structure is at least one kind selected from among an alkyl structure, a fluoroalkyl structure, a benzene structure, an ether group and an ester group. Excerpt(s): This invention relates to a film-type lithium secondary battery, and in particular to an improvement in an electrolyte for use in an electrode or a separator. In recent years, portable devices such as a portable telephone, a PHS and a small personal computer etc. are undergoing remarkable development in fabrication into small-size and light-weight with a progress of electronics technology. Further, batteries serving as power supplies for use in these portable devices are also required to be built into smallsize and light-weight form. A lithium battery can be mentioned here as an example of a battery to be expected for use in such purpose. In addition to a lithium primary battery already put in practical use, studies have been made on the lithium secondary battery to be put it in practical use, and to achieve its high capacity and long service life. Web site: http://www.delphion.com/details?pn=US06673496__
Patent Applications on Benzene As of December 2000, U.S. patent applications are open to public viewing.10 Applications are patent requests which have yet to be granted. (The process to achieve a patent can take several years.) The following patent applications have been filed since December 2000 relating to benzene:
10
This has been a common practice outside the United States prior to December 2000.
Patents 137
•
1,3-Bis(trifluoromethyl)benzene derivatives Inventor(s): Nightingale, Peter David; (Stockport, GB), O'Neill, Reginald Barry; (Oldham, GB), Rhodes, Robert; (Chesterfield, GB) Correspondence: Notaro And Michalos; 100 Dutch Hill Road; Suite 110; Orangeburg; NY; 10962-2100; US Patent Application Number: 20040019243 Date filed: July 21, 2003 Abstract: A method of manufacture of 3,5-bis(trifluoromethyl)bromobenzene, comprising the addition of a brominating reagent to a mixture of 3,5bis(trifluoromethyl)benzene together with at least one of sulphuric acid or oleum in the absence of acetic acid. A method of production of 3,5-bis(trifluoromethyl)acetophenone comprising the reaction of 3,5-bis(trifluoromethyl)phenyl magnesium bromide with acetyl chloride in the presence of cuprous chloride. A method of production of 3,5bis(trifluoromethyl)acetophenone comprising the steps of reacting 3,5bis(trifluoromethyl)phenyl magnesium bromide with acetic anhydride, adding water, and recovering the product by azeotropic distillation. A method of removal of impurities including 3,5-bis(trifluoromethyl)acetate- , 4-bromobutyl acetate and 4chlorobutyl acetate from a preparation of 3,5-bis(trifluoromethyl)acetophenone, the method comprising heating the 3,5-bis(trifluoromethyl)acetophenone with a dilute solution of alkali. A method of production of 3,5-bis(trifluoromethyl)phenyl magnesium bromide comprising the reaction of 3,5-bis(trifluoromethyl)bromobenzene with magnesium in a solvent whilst maintaining the temperature of the reactants above 20.degree. C. and below the reflux temperature of the solvent. Excerpt(s): The present invention relates to a process of producing 1,3bis(trifluoromethyl)benzene derivatives substituted in the 5-position and, in particular, 3,5-bis(trifluoromethyl)bromobenzene and 3,5-bis(trifluoromethyl)acetophenone. These compounds are useful intermediates in pharmaceutical manufacture. 3,5bis(trifluoromethyl)brom- obenzene is a very versatile intermediate, but its use is restricted owing to problems in its manufacture. 1,3-bis(trifluoromethyl)benzene is a useful starting material in the manufacture of this compound and 3,5bis(trifluoromethyl)acetophenone in that it is readily available on a large scale. Bromination of 1,3-bis(trifluoromethyl)benzene is difficult owing to the relative unreactivity of the benzene nucleus to conventional bromination. In order to overcome this problem processes are known using expensive solvents such as trifluoroacetic acid. This material causes environmental problems on disposal. Bromination in sulphuric acid is also reported in which sulphuric acid is added to a mixture of 1,3-dibromo-5,5dimethylhydantoin in 1,3-bis(trifluoromethyl)benzene. This process is not suitable for industrial use owing to problems in mixing and heat transfer. Furthermore, solvent extraction is required to isolate the product and the use of the large amounts of solvent required on an industrial scale would be environmentally undesirable. It is further noted that the waste products of the reaction are environmentally unfavourable. The present invention seeks to provide an alternative method of producing 3,5bis(trifluoromethyl)bromobenzene which addresses these problems. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
138
•
Benzene
8-Azabicyclo(3,2,1)oct-2 ene and octane derivatives as cholinergic ligands at nicotinic ACh receptors Inventor(s): Nielsen, Elsebet Ostergaard; (Ballerup, DK), Nielsen, Simon Feldback; (Ballerup, DK), Olsen, Gunnar M.; (Ballerup, DK), Peters, Dan; (Arlov, SE) Correspondence: Birch, Stewart, Kolasch & Birch, Llp; P.O. Box 747; Falls Church; VA; 22040-0747; US Patent Application Number: 20040019207 Date filed: July 17, 2003 Abstract: The present invention discloses compounds of formula (1) any of its enantiomers or any mixture thereof, or a pharmaceutically acceptable salt thereof; wherein is a single or a double bond; R is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl; and R.sup.1 is (a), wherein R.sup.2 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, amino; or aryl which may be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl alkenyl, alkynyl, alkoxy, cycloalkoxy, thioalkoxy, thiocycloalkoxy, methylenedioxy, aryloxy, halogen, CF.sub.3, OCF.sub.3, CN, amino, aminoacyl, nitro, aryl and a monocyclic 5 to 6-membered heteroaryl group; a monocyclic 5 to 6-membered heteroaryl group which may be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl alkenyl, alkynyl, alkoxy, cycloalkoxy, thioalkoxy, thiocycloalkoxy, methylenedioxy, aryloxy, halogen, CF.sub.3, OCF.sub.3, CN, amino, nitro, aryl and a monocyclic 5 to 6membred lieteroaryl group; or a bicyclic heteroaryl group composed of a monocyclic 5 to 6 membered heteroaryl group fused to a benzene ring or fused to another monocyclic 5 to 6-membered heteroaryl, all of which may be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl cycloalkylalkyl alkenyl, alkynyl, alkoxy, cycloalkoxy, thioalkoxy, thiocycloalkoxy methylenedioxy, aryloxy, halogen, CF.sub.3, OCF.sub.3, CN, amino, nitro, aryl and a monocyclic 5 to 6membered heteroaryl group. The compounds of the invention are useful as nicotinic ACh receptor ligands. 1 Excerpt(s): The present invention relates to novel B-Azabicyclo[3.2.1]oct-2-ene and octane derivatives which are cholinergic ligands at nicotinic ACh receptors. The compounds of the invention are useful for the treatment of condition or disorders or diseases involving the cholinergic system of the central nervous system, pain, inflammatory diseases, diseases caused by smooth muscle contractions and as assistance in the cessation of chemical substance abuse. The endogenous cholinergic neurotransmitter, acetylcholine, exert its biological effect via two types of cholinergic receptors; the muscarinic ACh receptors and the nicotinic ACh receptors. As it is well established that muscarinic ACh receptors dominate quantitatively over nicotinic ACh receptors in the brain area important to memory and cognition, much research aimed at the development of agents for the treatment of memory related disorders have focused on the synthesis of muscarinic ACh receptor modulators. Recently, however, an interest in the development of nicotinic ACh receptor modulators has emerged. Several diseases are associated with degeneration of the cholinergic system i.e. senile dementia of the Alzheimer type, vascular dementia and cognitive impairment due to the organic brain damage disease related directly to alcoholism. Indeed several CNS disorders can be attributed to a cholinergic deficiency, a dopaminergic deficiency, an adrenergic deficiency or a serotonergic deficiency. Alzheimers disease is characterised by a profound loss of memory and cognitive functions caused by a severe depletion of cholinergic neurons, i.e. neurons that release acetylcholine. A reduction in the number of
Patents 139
nicotinic ACh ereceptors are also observed with the progression of Alzheimer's disease. It is believed that the neurons in the cortex that die with the progression of Alzheimer's disease do so because of lack of stimulation of the nicotinic ACh receptors. It is predicted that treatment of Alzheimer's patients with nicotinic ACh receptor modulators will not only improve the memory of patients but in addition act to keep these neurons alive. Smoking actually seems to protect individuals against neurodegeneration and compounds behaving on these receptor may very likely have a generally neuroprotective effect. However degeneration of the cholinergic system is not limited to individuals suffering from i.e. Alzheimers disease but is also seen in healthy aged adults and rats. Therefore it is suggested that the cholinergic system is involved and partly responsible for the memory disturbances seen in aged animals and humans. Nicotine receptor modulator may therefore be useful in the treatment of Alzheimer's disease, memory loss, memory dysfunction, AIDS-dementia, senile dementia or neurodegenerative disorders. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Amphiphile solid support for peptide synthesis, bioorganic and organic chemistry Inventor(s): Cote, Simon; (Quebec, CA) Correspondence: Ogilvy Renault; 1981 Mcgill College Avenue; Suite 1600; Montreal; QC; H3a2y3; CA Patent Application Number: 20040039126 Date filed: September 22, 2003 Abstract: The present invention fulfils desired specifications generally rarely encountered with existing solid supports such as highly amphiphile behaviour. The solid support described herein is a poly(ethylene or propylene)glycol based polymer that can be useful in solid and liquid phase synthesis, chromatography, scavenging purposes and immobilisation of proteins and reagents. More specifically, the solid support is a cross-linked polyether derived from a cross-linked polyester which is obtained by copolymerization of at least one monomer comprising (a) one-ended polymerizable vinyl or allyl ketone, ester, ether or mixtures thereof with at least one cross-linker having at least two polymerizable terminal end groups, with the exception of epoxy and oxetane end groups, or (b) divinyl benzene. The method for the preparation of the cross-linked polyether is also disclosed. Excerpt(s): This invention relates to a polymeric support for use in peptide synthesis, and in the field of bioorganic and organic chemistry. The invention also relates to a method of preparation thereof as well as to intermediates which can be used in such preparation. More particularly, the invention relates to a polyethylene or polypropylene glycol based polymer which can be used in the form of solid support in solid and liquid phase synthesis, chromatography, for scavenging purposes and immobilization of proteins and reagents. Since the pioneering work of Merrifield (Merrifield, R. B. (1963), J. Am. Chem. Soc., 85, 2149-2153) on polystyrene (2% divinylbenzene cross-linked) as solid support for peptide synthesis, several improvements on the nature of the solid support were brought about to meet special needs of new organic chemistry. Through the years, most of the work done in that field has been focused on peptide synthesis. Several polyamide resins (Kanda et al., (1991), Int. J. Peptide Protein Res., 38, 385-391) for solid phase peptide synthesis have been developed since the '80. The amide bonds of the polymer are the same as those found in peptides. Consequently, peptide chemistry can be performed in a polarity environment which is similar to that of peptides and that
140
Benzene
improves chemical yields and peptide purity. PEPSYN (Arshady et al., (1981), J. Chem. Soc. Perkin Trans., 529-537), PEPSYN K (Atherton et al., (1981), J. Chem. Soc. Chem. Commun., 1589-1591), can be mentioned as other types of solid supports for peptide chemistry which were developed during the period 1981-1989. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Azo dyes, a process for their preparation and their use in the production of coloured plastics or polymeric colour particles, and in the dyeing or printing of hydrophobic fibre materials Inventor(s): Andreoli, Anton; (Itingen, CH), Clement, Antoine; (Basel, CH), Lauk, Urs; (Zurich, CH), Tzikas, Athanassios; (Pratteln, CH) Correspondence: Ciba Specialty Chemicals Corporation; Patent Department; 540 White Plains RD; P O Box 2005; Tarrytown; NY; 10591-9005; US Patent Application Number: 20040031109 Date filed: July 23, 2003 Abstract: The present invention relates to an azo dye of formula wherein D is the radical of a diazo component of the benzene, naphthalene, diphenyl, thiophene, benzothiazole, benzisothiazole, thiadiazole, indazole, benzotriazole, pyrazole, anthraquinone, naphthalic acid imide, chromone, phthalimide or diphenylene oxide series, R.sub.1 is an unsubstituted or substituted aryl radical and R.sub.2 is an unsubstituted or substituted aryl radical, with the exception of the compounds of formulae (1a) and (1b) to a process for its preparation and to its use in a process for the production of mass-coloured plastics or polymeric colour particles, and in the dyeing or printing of semi-synthetic or synthetic hydrophobic fibre materials. Excerpt(s): The present invention relates to novel azo dyes, to a process for their preparation and to their use in a process for the production of mass-coloured plastics or polymeric colour particles, and in the dyeing or printing of semi-synthetic or synthetic hydrophobic fibre materials. Dyes, especially the dyes of the anthraquinone series, are known for the mass-colouration of plastics. It has been shown, however, that the dyes used hitherto do not always fully satisfy the highest demands, whether it be in respect of high-temperature light fastness or, especially, in respect of colour strength. There is therefore a need for new thermostable dyes that yield lightfast dyeings, especially hightemperature lightfast dyeings, having high colour strength and that exhibit good allround properties. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Bactericidal preparation Inventor(s): Boeck, Betty; (Wolongong, NSW, AU), Boeck, Harry; (Fairy Meadow, AU) Correspondence: Molins And CO.; Level 25 Chifley Tower; Sydney; 2000; AU Patent Application Number: 20040014818 Date filed: June 4, 2003 Abstract: A bactericidal preparation in the form of a solution, cream or ointment is disclosed. The preparation comprises a liquid compounded from photosynthesized
Patents 141
hydrocarbons, isolates from hydrocarbons, 2-hydroxy-1-isopropyl-4-methyl-benzene (thymol) and butylated hydroxytoluene. Excerpt(s): This invention relates to bactericidal preparations such as solutions and creams, in particular to topical solutions which may be applied to the skin and which exhibit penetrating action, whereby they are able to be absorbed into the skin to reach subdermal pathogens. In order to fight pathogenic organisms on the skin and particularly in the body, chemical compounds under the general heading of "antibiotics" are administered by mouth (ingestion) or by injection and sometimes are applied to the surface of the skin in the form of creams or ointments. Generally speaking, an antibiotic may be described as an organic substance which is produced by micro-organisms or has a molecular structure similar to naturally occurring substances and is capable at low concentration of inhibiting the growth of or destroying another micro-organism. Antibiotics have been isolated from numerous sources, but principally from bacteria (eg bacitracin, polymixin, gramicidan), actinomycetes (eg tetracycline, streptomycin, chloramphenicol) and fungi (eg penicillins, cephalosporins). Bacterial antibiotics are mostly polypeptides. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Benzoxazole compound, process for producing the same, and herbicide Inventor(s): Asahara, Takehiko; (Yamaguchi, JP), Fukuda, Shohei; (Yamaguchi, JP), Nakamura, Akira; (Yamaguchi, JP), Okada, Tatsuo; (Yamaguchi, JP), Oohida, Satoshi; (Yamaguchi, JP), Shimizu, Motohisa; (Yamaguchi, JP) Correspondence: Jordan And Hamburg Llp; 122 East 42nd Street; Suite 4000; New York; NY; 10168; US Patent Application Number: 20040014977 Date filed: January 6, 2003 Abstract: The present invention relates to benzoxazole compounds represented by the following formula (I): 1wherein R.sup.1 to R.sup.4 may be the same or different from each other, and each represent a hydrogen atom, alkyl group having 1 to 6 carbon atoms, alkoxy group having 1 to 4 carbon atoms, haloalkyl group having 1 to 4 carbon atoms, haloalkoxy group having 1 to 4 carbon atoms, halogen atom, nitro group, cyano group, R.sup.2S(O).sub.n, alkoxycarbonyl group having 1 to 4 carbon atoms, amino group, --NHCOR.sup.11 or carbonyl group, where R.sup.1 and R.sup.2 each represent an alkyl group having 1 to 6 carbon atoms, and n is an integer of 0 to 2,A represents a single bond, CHR.sup.5--Y, CR.sup.5.dbd.CR.sup.6, CR.sup.5R.sup.7--CHR.sup.6 or CHR.sup.5, where R.sup.5 represents a hydrogen atom, hydroxyl group, halogen atom or alkyl group, R.sup.6 and R.sup.7 each represent a hydrogen atom, hydroxyl group, alkyl group, halogen atom or substituted sulfonyloxy group,Y represents O, S or NH, andW represents a substituted or unsubstituted benzene ring or hetero ring,and processes for preparing the same. Excerpt(s): The present invention relates to a benzoxazole compound, a process for producing the same and a herbicide which comprises containing the same as effective ingredients. As a similar compound of that of the present invention, there may be mentioned an aniline compound described in Japanese Provisional Patent Publication No. 139767/1998. However, the compound of the present invention is clearly different from the above compound of the reference at least the structure connecting from the benzoxazole portion and a phenyl portion, and in a part of the embodiment of the
142
Benzene
present invention, the point of the aniline portion being replaced by a hetero ring is different. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Bituminous composition with improved "walk-on-ability" and its use in roofing applications Inventor(s): Heimerikx, Gerardus Wilhelmus Jozef; (Amsterdam, NL), Trommelen, Erik Adrianus Theunis; (Amsterdam, NL) Correspondence: Dean F Vance; Kraton Polymers U.S.; Intellectual Property; 3333 Highway 6 SOUTH. RM. Ca-108; Houston; TX; 77082; US Patent Application Number: 20040014846 Date filed: August 6, 2003 Abstract: The present invention concerns a bituminous composition which comprises a bituminous component (A), an elastomer component (B), preferably a block copolymer of a conjugated diene and a monovinylaromatic hydrocarbon, and an additive (C), wherein the additive is a compound of the general formula Ar--R--Ar (I) wherein each "A" independently is a benzene ring or fused aromatic ring system of 6 to 20 carbon atoms, substituted by at least one hydroxyl group, and "R" is an optionally substituted divalent radical comprising 6 to 20 atoms in the backbone and at least one amide and/or ester group in the backbone, and its use in roofing applications. Excerpt(s): The present invention concerns bituminous compositions having advantageous high and low temperature properties which are maintained over time giving an improved estimated service life when used in, for example, roofing applications. A major proportion of the roofing felts applied nowadays are made of modified bituminous compositions, e.g., bituminous compositions comprising a bitumen component and an elastomer component, typically a styrenic block copolymer such as SBS (polystyrene-polybutadiene-polystyre- ne) SEBS (polystyrenepoly[ethylene-butylene]-polystyrene); SIS (polystyrene-polyisoprene-polystyrene) and SEPS (polystyrene-poly[ethylen- e-propylene]-polystyrene) and the like. Advantages of modified bituminous compositions over traditional systems (blown bitumen) include: improved fatigue resistance (the accommodation of repeated thermal movements of the roof); improved flexibility (especially at low temperature, enabling contractors to lay felt under colder weather conditions than with conventional bitumen); improved strength (to allow a reduction in the number of plies of felt by replacing in whole or part the traditional blown bitumen coated system); improved resistance to (permanent) deformation at short and longer loading times (so-called `walk-on-ability`); and improved elasticity, resulting in a greater capacity to bridge movement of crack and joints. Although modified bituminous compositions satisfy all of the above requirements in as much as these materials having excellent high and low temperature properties (i.e. cold bending resistance at -30 to --25.degree. C. and flow resistance at 80 to 100.degree. C.), improvement is still desired. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Patents 143
•
Catalyst comprising at least one zeolite with structure type NES and rhenium, and its use for transalkylation of alkylaromatic hydrocarbons Inventor(s): Alario, Fabio; (Neuilly Sur Seine, FR), Ferrer, Nathalie; (Montesson, FR), Martin, Olivia; (Nanterre, FR), Merlen, Elisabeth; (Rueil-Malmaison, FR) Correspondence: Millen, White, Zelano & Branigan, P.C.; 2200 Clarendon BLVD.; Suite 1400; Arlington; VA; 22201; US Patent Application Number: 20030208094 Date filed: May 2, 2003 Abstract: The present invention concerns a catalyst which contain at least one zeolite with structure type NES, preferably NU-87, comprising silicon and at least one element T selected from the group formed by aluminium, iron, gallium and boron. Preferably, element T has been extracted so that the overall Si/T atomic ratio is more than 20. This zeolite is at least partially in its acid form. The binder is preferably alumina. The catalyst also contains at least one metal selected from the group formed by group VIIB, group VIB and iridium, preferably rhenium. Finally, the catalyst optionally also contains at least one metal selected from the group formed by elements from groups III and IV of the periodic table, preferably indium or tin. The present invention also concerns the use of the catalyst in a process for transalkylating alkylaromatic hydrocarbons such as toluene and alkylaromatic compounds containing at least 9 carbon atoms. In particular, this catalyst is highly effective in treating C9+ aromatic feeds containing more than 5% by weight of aromatic olefins containing 10 carbon atoms and more, this feed possibly also containing benzene. Excerpt(s): The present invention relates to a catalyst which can, for example, be used in aromatic hydrocarbon transformation reactions. More precisely, it concerns a catalyst for alkylaromatic hydrocarbon transalkylation, preferably transalkylation of toluene and aromatic compounds containing at least 9 carbon atoms, to produce xylenes. The present invention also relates to the preparation of said catalyst and to its use in an alkylaromatic hydrocarbon transalkylation process. A number of catalysts for dismutation and/or transalkylation have already been described in the prior art, and are based on mordenite (United States patents U.S. Pat. No. 3,506,731, U.S. Pat. No. 4,151,120, U.S. Pat. No. 4,180,693, U.S. Pat. No. 4,210,770, U.S. Pat. No. 3,281,483, U.S. Pat. No. 3,780,121 and U.S. Pat. No. 3,629,351) or based on omega zeolite (U.S. Pat. No. 5,210,356, U.S. Pat. No. 5,371,311). European patent EP-B1-0 378 916 describes NU-87 zeolite, a zeolite with structure type NES, and a method for its preparation in the presence of a salt of a polymethylene diammonium cation, for example decamethonium bromide. In that patent, rhenium is cited among numerous other elements for its hydrodehydrogenating properties. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Catalyst for aromatization of alkanes, process of making and using thereof Inventor(s): Juttu, Gopalakrishnan G.; (Sugar Land, TX), Smith, Robert Scott; (Houston, TX) Correspondence: Jim Wheelington; Sabic Americas, INC.; Sabic Technology Center; 1600 Industrial BLVD.; Sugar Land; TX; 77478; US Patent Application Number: 20040028584 Date filed: August 6, 2002
144
Benzene
Abstract: A catalyst, a process for making the catalyst and a process for using the catalyst in aromatization of alkanes to aromatics, specifically, aromatization of alkanes having two to six carbon atoms per molecule, such as propane, to aromatics, such as benzene, toluene and xylene. The catalyst is an aluminum-silicon-germanium zeolite on which platinum has been deposited. Germanium is in the framework of the crystalline zeolite. Platinum is deposited on the zeolite. The catalyst may be supported on magnesia, alumina, titania, zirconia, thoria, silica, boria or mixtures thereof. The catalyst may contain a sulfur compound on the surface of the catalyst. The sulfur compound may be added to the catalyst in a pretreatment process or introduced with the hydrocarbon feed to contact the catalyst during the aromatization process. Generally, the catalyst may be of the formula M[(SiO.sub.2)(XO.sub.2).sub.x(YO.sub.2).sub.y]Z.sup-.+.sub.y/n where M is a noble metal such as platinum or gold, X is titanium, germanium, tin or another tetravalent element, Y is boron, aluminum, gallium, indium, tellurium or another trivalent element, Z is a cation with a valence of n such as H.sup.+, Na.sup.+, K.sup.+, Rb.sup.+, Cs.sup.+, Ca.sup.2+, Mg.sup.2+, Sr.sup.2+ or Ba.sup.2+, x varies from 0-0.15 and y is 0-0.125. An example catalyst would be represented as.vertline.H.sup.+Pt.vertline.[Si.sub.91Ge.sub.4Al.sub.1O.sub.192]-MFI. Excerpt(s): This invention relates to a catalyst for the aromatization of alkanes to aromatics, specifically a zeolite, preferably a MFI-type structure, most preferably a ZSM5 MFI zeolite, catalyst for the aromatization of alkanes having two to six carbon atoms per molecule to aromatics, such as benzene, toluene and xylene. Zeolite is a crystalline hydrated aluminosilicate that may also contain other metals, such as sodium, calcium, barium, and potassium, and that has ion exchange properties (Encarta.RTM. World English Dictionary [North American Edition].COPYRGT. & (P) 2001 Microsoft Corporation). A method for preparing a zeolite comprises (a) preparing an aqueous mixture of silicon oxide and sources of oxides of aluminum; and (b) maintaining said aqueous mixture under crystallization conditions until crystals of said zeolite form. Much zeolite research has focused on the synthesis of zeolite frameworks containing elements other than silicon and aluminum. U.S. Pat. No. 6,160,191 discloses that the term "zeolite" includes not only aluminosilicates but substances in which the aluminum is replaced by gallium, titanium, iron or boron and substances in which silicon is replaced by germanium, tin and phosphorous. U.S. Pat. Nos. 3,329,480 and 3,329,481, both issued to D. A. Young, report the existence of crystalline zirconosilicate and titanosilicate zeolites. A zeolite having chromium in the tetrahedral positions has been described by Yermolenko et al at the Second Oil Union Conference on Zeolites, Leningrad, 1964, pages 171-8 (published 1965). However, D. W. Breck, in Zeolite Molecular Sieves, p. 322, John Wiley & Sons (1974) suggests that the chromium present was not present in a zeolite A structure and furthermore was present as an impurity in insoluble form. The impurity was said to be in the form of a chromium silicate as confirmed by the nature of the water vapor adsorption isotherm. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Patents 145
•
Composition for use in flexible polyurethane foams Inventor(s): Knickmeyer, Angela M.; (St. Charles, MO), Wiese, Kevin D.; (North Royalton, OH) Correspondence: Rankin, Hill, Porter & Clark, Llp; 700 Huntington Building; 925 Euclid Avenue, Suite 700; Cleveland; OH; 44115-1405; US Patent Application Number: 20040014830 Date filed: May 13, 2003 Abstract: A plasticizer with a crosslinking/chain extending agent is incorporated into a water-blown flexible polyurethane foam formulation to provide acceptable softness, openness, and tensile strength characteristics. The class of plastisizers is selected from the group consisting of alkyl benzyl phthalates, phosphate esters and benzoates. The aromatic polyhydroxy compounds are a preferred class of crosslinking/chain extending agents, particularly dihydroxyaromatic compounds, more particularly resorcinol. Other classes of preferred crosslinking/extending agents are saccharides, alkyl glycosides, and alkylene oxide adducts of aliphatic triols. Other preferred crosslinker/extenders include epoxidized soybean oil, polymeric 1,3,5-trimethyl, 2-hydroxy-benzene, selected phenolic resins, selected low molecular weight adducts of a polyfunctional aliphatic amines, and polyoxyalkylene polyols wherein the hydroxyl number is less than about 200 and the average number of hydroxyl groups range from about 3 to about 8. Excerpt(s): This application is a continuation of U.S. Non-Provisional application Ser. No. 09/585,839 filed Jun. 1, 2000 which claims the benefit of U.S. Provisional Application No. 60/136,884, filed Jun. 1, 1999. The invention relates to a method of manufacturing a flexible polyurethane foam manufactured with little solvent or other halo-carbon foaming agents, to the prepolymer used in the manufacture of the flexible polyurethane foam, and to the foam. In particular, this invention relates to combining a particular class of plasticizers with particular crosslinking or chain extending agents to make an additive, wherein said additive can be added to foam formulations in order to produce improved flexible polyurethane foam while using a combination of water and, optionally, a reduced quantity of a halogen-carbon foaming agent. The flexible polyurethane foam industry is being challenged by the EPA and OSHA to dramatically reduce the use of halo-carbon blowing agents, i.e., methylene chloride (MeCl.sub.2), as a process chemical and reduce employee exposure in the workplace. Environmental pressures, employee safety and ever-tightening governmental regulations have shifted the flexible slabstock polyurethane foam market away from the use of conventional blowing agents such as CFC-11, methylene chloride, 1,1,1-trichloroethane, and acetone. The industry responded by developing polyurethane foam made with higher-water based formulations. The physical blowing of such high-water polyurethane foam formulations occurs primarily from the carbon dioxide given off as a result of the reaction of water and isocyanate, and to a lesser extent from the vaporization of volatiles including water resulting from the reaction exotherm. This blowing replaces the traditional foam expansion derived from the volatilization of conventional blowing agents. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
146
•
Benzene
CONVERSION OF AROMATIC HYDROCARBONS Inventor(s): Butler, James R.; (Friendswood, TX), Xiao, Xin; (Houston, TX) Correspondence: David J. Alexander; Fina Technology, INC.; P.O. Box 674412; Houston; TX; 77267-4412; US Patent Application Number: 20030229258 Date filed: June 11, 2002 Abstract: A process for the transalkylation of an aromatic feedstock containing a benzene component and a polyalkylated aromatic component comprising at least one polyalkyl aromatic compound of at least nine carbon atoms. The feedstock is supplied to a reaction zone containing a metal modified zeolite transalkylation catalyst. The reaction zone is operated under conditions providing an equivalent conversion of pure toluene in the presence of the catalyst within the range of 40-55%, resulting in a transalkylated product with a reduced polyalkyl benzene content and an enhance monoalkyl benzene content relative to the transalkylation feedstock. In continued operation of the transalkylation reaction zone, at least one of the reaction conditions of temperature, pressure, and space velocity is adjusted in order to maintain a constant reaction severity to provide a desired equivalent conversion of toluene within a tolerance range of.+-.2%. Specifically, the temperature is progressively increased while continuing the operation of the transalkylation zone to maintain a condition of constant reaction severity. Excerpt(s): The present invention involves the operation of an aromatic conversion unit in a manner to provide for the transalkylation of aromatic hydrocarbons in conjunction with or in reference to a toluene disproportionation reaction. Various processes involving the disproportionation of aromatic hydrocarbons are utilized in petroleum refining operations. One commonly utilized refining process involves the disproportionation of toluene in a transalkylation reaction in which toluene is converted to benzene and xylene. The disproportionation reaction which typically takes place in the presence of molecular hydrogen supplied in addition to the toluene provides for a stoichiometric relationship in which two moles of toluene are converted to one mole of benzene and one mole of xylene. The disproportionation reaction may be carried out over a metal modified zeolite disproportionation catalyst, such as mordenite modified by the inclusion of a metal such as nickel or palladium. Another conversion reaction employed in petroleum refining operations involves the transalkylation of polyalkyl aromatic compounds with benzene to produce a transalkylation product having a diminished content of polyalkylated aromatics with an enhanced content of monoalkylated aromatic compounds. The resulting transalkylation product exhibits correspondingly reduced benzene content. Oftentimes, transalkylation reactions are carried out in an integrated process in which an aromatic substrate, such as benzene, is alkylated with an alkylating agent, such as ethylene or propylene, to produce ethylbenzene or propylbenzene together with polyalkylated aromatics, such as dialkyl and trialkyl benzenes. The polyalkyl aromatics are separated from the monoalkyl benzene recovered from the alkylation reactor and recycled to a downstream transalkylation reactor. Benzene is also supplied to the transalkylation reactor in order to produce a monoalkylated disproportionation product, along with other alkylated aromatic compounds. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Patents 147
•
Cyclocarbamate derivatives as progesterone receptor modulators Inventor(s): Edwards, James P.; (San Diego, CA), Fensome, Andrew; (Wayne, PA), Fletcher, Horace III; (Pottstown, PA), Jones, Todd K.; (Solana Beach, CA), Tegley, Christopher M.; (Thousand Oaks, CA), Terefenko, Eugene A.; (Quakertown, PA), Wrobel, Jay E.; (Lawrenceville, NJ), Zhang, Puwen; (Audubon, PA), Zhi, Lin; (San Diego, CA) Correspondence: Howson And Howson; One Spring House Corporation Center; Box 457; 321 Norristown Road; Spring House; PA; 19477; US Patent Application Number: 20030216388 Date filed: March 12, 2003 Abstract: This invention provides compounds of Formula (I): 1wherein R.sup.1 and R.sup.2 are independent substituents or are fused to form spirocyclic rings; R.sup.3, R.sup.C, and R.sup.4 are as defined herein; and R.sup.5 is a substituted benzene ring or a substituted five or six membered heterocyclic ring having in its backbone 1, 2, or 3 heteroatoms including O, S, SO, SO.sub.2 or NR.sup.6; or pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions and methods using the compounds as antagonists of the progesterone receptor. Excerpt(s): This application is a divisional of U.S. patent application Ser. No. 09/948,309, filed Sep. 6, 2001, which is a divisional of U.S. patent application Ser. No. 09/552,633, filed Apr. 19, 2002, now U.S. Pat. No. 6,509,334, which claims the benefit of the priority of U.S. Provisional Patent Application No. 60/183,012, filed May 4, 1999. Intracellular receptors (IR) form a class of structurally related gene regulators known as "ligand dependent transcription factors" (R. M. Evans, Science, 240, 889, 1988). The steroid receptor family is a subset of the IR family, including progesterone receptor (PR), estrogen receptor (ER), androgen receptor (AR), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR). The natural hormone, or ligand, for the PR is the steroid progesterone, but synthetic compounds, such as medroxyprogesterone acetate or levonorgestrel, have been made which also serve as ligands Once a ligand is present in the fluid surrounding a cell, it passes through the membrane via passive diffusion, and binds to the IR to create a receptor/ligand complex. This complex binds to specific gene promoters present in the cell's DNA. Once bound to the DNA the complex modulates the production of mRNA and protein encoded by that gene. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Display device Inventor(s): Fujiwara, Sayuri; (Nara-shi, JP), Kanbe, Makoto; (Sakurai-shi, JP), Tsuda, Kazuhiko; (Ikoma-gun, JP) Correspondence: Nixon & Vanderhye, PC; 1100 N Glebe Road; 8th Floor; Arlington; VA; 22201-4714; US Patent Application Number: 20040013822 Date filed: July 16, 2003 Abstract: A display device includes: a display medium layer; and a first electrode and a second electrode, which face each other with the display medium layer interposed between them. The first electrode includes: a first conductive layer; and a first polymer film, which covers the first conductive layer and which makes contact with the display
148
Benzene
medium layer. The second electrode includes: a second conductive layer; and a second polymer film, which covers the second conductive layer and which makes contact with the display medium layer. At least a portion of the first conductive layer has a different work function from the second conductive layer. The number of benzene rings included in each of the first and second polymer films is 0.4 or less for a molecular weight of 100. Excerpt(s): The present invention generally relates to a display device and more particularly relates to a display device in which two electrodes, arranged to face each other with a display medium layer interposed between them, include conductive layers with mutually different work functions. Various types of office automation (OA) equipment, such as personal computers with displays, have rapidly reduced their sizes and weights so significantly these days as to carry or move them to anywhere we like. But their manufacturing costs have not been successfully decreased as fast, or as significantly, as their sizes and weights. Accordingly, under the current circumstances, it is one of the most important and most pressing tasks to reduce the manufacturing cost of a display device. A display device normally has a configuration in which a pair of electrodes is arranged so as to face each other with a display medium layer, exhibiting electrooptical properties, interposed between them. Such a display device conducts a display operation by applying a voltage to the display medium layer (i.e., creating a potential difference between the electrodes). The display medium layer may be made of a liquid crystal material, an electroluminescent material, a plasma or an electrochromic material, for example. Among other things, liquid crystal displays (LCDs), using a liquid crystal material for the display medium layer, have been popularized faster and more extensively than any other type of display device, because LCDs can conduct a display operation at relatively low power consumption. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Enhanced polymerization reactions based on use of special methylaluminoxane compositions Inventor(s): Beard, William R.; (Baton Rouge, LA), Brantley, Noel H.; (Baton Rouge, LA), Stoll, Andrew Timothy; (Baton Rouge, LA) Correspondence: MR. Philip M. Pippenger; Patent & Trademark Division; Albemarle Corporation; 451 Florida Street; Baton Rouge; LA; 70801-1765; US Patent Application Number: 20030232936 Date filed: August 9, 2001 Abstract: Polymerization of olefin monomers is conducted using at least one d- or fblock metal-containing olefin polymerization catalyst compound or complex and a novel methylaluminoxane composition (MAOC) which is a solid at 25.degree. C. that has a total aluminum content of about 39 to 47 wt %. The MAOC is either free of aluminum as trimethylaluminum (TMA) or if TMA is present, not more than about 30 mole % of the total aluminum in the MAOC is TMA. In the solid state the MAOC contains no more than about 7500 ppm (wt/wt) of aromatic hydrocarbon. The cryoscopic number average molecular weight of MAOC as determined in benzene is at least about 1000 amu, and the MAOC has sufficient solubility in n-heptane at 25.degree. C. to provide a solution containing 4 to as high as 7.5 wt % or more of dissolved aluminum. By vacuum distilling a solution of ordinary MAO in aromatic hydrocarbon long enough under proper conditions, MOAC is formed.
Patents 149
Excerpt(s): This is a continuation-in-part of commonly-owned U.S. application Ser. No. 09/739,052, filed Dec. 15, 2000, all disclosure of which including the claims thereof is incorporated herein by reference. This invention relates to the provision of novel methylaluminoxane compositions, to especially useful solutions of such methylaluminoxanes in hydrocarbon solvents other than aromatic hydrocarbon solvents, to the preparation of such compositions and solutions, and to use of such methylaluminoxane compositions in catalytic polymerization reactions. In the ensuing description and in the claims hereof, reference is sometimes made to solubility in nheptane because this is a typical, representative saturated hydrocarbon which serves as a very convenient point of reference for comparisons of solubility. However, such references to n-heptane does not constitute a limitation or restriction on the scope of this invention as regards hydrocarbons used, as the invention produces methylaluminoxane compositions that have improved solubility in a variety of liquid aliphatic and cycloaliphatic hydrocarbons as compared to the solubility of previously reported methylaluminoxane in the same respective hydrocarbons. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Fused-benzene derivatives of thiouracil, herbicidal and desiccant compositions contaning them Inventor(s): Gupta, Sandeep; (Concord, OH), Pulman, David A.; (Mentor, OH), Roh, Taikyun; (Highland Heights, OH) Correspondence: Sughrue Mion, Pllc; 2100 Pennsylvania Avenue, NW; Washington; DC; 20037-3213; US Patent Application Number: 20040018941 Date filed: July 17, 2002 Abstract: The invention relates to certain substituted fused-benzene compounds (1), herbicidal compositions containing them, herbicidal methods of use and processes for preparing these compounds; 1wherein A, B, X, Y, R, R.sub.1, R.sub.2, and Z are as described herein, as well as salts thereof Excerpt(s): The present invention relates to novel fused benzene derivatives of thiouracils, their salts and compositions, intermediates, process for their production, and their use as herbicides. U.S. Pat. No. 4,859,229 discloses the herbicidal utility of uracil derivatives, in which the phenyl ring of the described compounds did not have any 2,6disubsutitutions. Recently WO97/08170 and WO97/08171 disclosed benzoxazole and benzothiazole derivatives which exhibit herbicidal activity. U.S. Pat. No. 5,169,431 disclosed benzofuran or benzothiophene type derivatives and WO97/29105 disclosed benzofuran derivatives. WO93/14073 described substituted dihydrobenzofuran type compounds, U.S. Pat. No. 5,521,147 disclosed dihydrobenzofuran and dihydrobenzofuran-3-one type derivatives, and WO95/33746 disclosed cyclic sulfonamide derivatives. U.S. Pat. No. 5,346,881 disclosed benzodioxin or benzodioxole derivatives with herbicidal activity and JP 09301973 disclosed 2H-chromene type derivatives. WO97/12886 disclosed benzisoxazole or benzisoxazolidinone derivatives as herbicides and WO97/42188 disclosed indole type compounds with herbicidal activity. Despite the broad coverage of these patents, the general structure of the present invention containing the thiouracil heterocycle has not been described. The specific fused-benzene compounds of the formula 1 mentioned below are not known and are novel. The compounds of present invention exhibit potent herbicidal activity when applied pre or postemergence. The invention delineates a method for the control of
150
Benzene
undesired vegetation in a plantation crop by the application to the locus of the crop an effective amount of a compound described herein. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Fused-benzene derivatives useful as herbicides Inventor(s): Gupta, Sandeep; (Concord, OH), Pulman, David A.; (Mentor, OH), Tsukamoto, Masamitsu; (Mayfield Heights, OH), Wu, Shao-Yong; (Fremont, CA), Ying, Bai-Ping; (Fishers, IN) Correspondence: Sughrue Mion, Pllc; 2100 Pennsylvania Avenue, NW; Washington; DC; 20037-3213; US Patent Application Number: 20040029734 Date filed: November 22, 2002 Abstract: A compound of the formula or its salt represented by the formula (Ia) or Ib) 1in which variables other than Q are described in the patent application and Q is selected from 2345in which the variables in Q.sub.1-Q.sub.19 are described in the patent application, provided when Q is Q.sub.1, Q.sub.3, Q.sub.4, Q.sub.13, Q.sub.18 or Q.sub.19, structure (Ib) is excluded; when Q is Q.sub.7, U is CR.sub.9, nitrogen, NR.sub.2, C(.dbd.O), C(.dbd.S) or C(.dbd.NR.sub.2); herbicidal compositions of said compounds, herbicidal processes using said compounds, defoliant processes using said compounds, and processes for preparing said compounds. Excerpt(s): The present invention relates to novel fused-benzene derivatives, their salts and compositions, intermediates, a process for producing them, and their use as herbicides. Q is uracil and D is either oxygen or sulfur. U.S. Pat. No. 5,169,431 disclosed benzofaran or benzothiophene type derivatives with Q as uracil and D is carbon. WO97/29105 disclosed benzofuran derivatives with Q as uracil and D is oxygen. WO93/14073 disclosed substituted dihydrobenzofuran type compounds with Q as uracil or triazine derivatives and D is carbon. U.S. Pat. No. 5,521,147 disclosed dihydrobenzofuran, dihydrobenzopyran and dihydrobenzofuran-3-one type derivatives with Q as uracil and D or M is oxygen. EP.0,271,170 disclosed dihydrobenzofuiran and dihydrobenzopyran derivatives where Q is many kinds of heterocycles and D or M is carbon. WO95/33746 disclosed cyclic sulfonamide derivatives where Q is many kinds of heterocycles including uracil and D is carbon. U.S. Pat. No. 5,346,881 disclosed benzodioxin or benzodioxole derivatives where Q is uracil, M is oxygen. JP 09301973 disclosed 2H-chromene type derivatives with Q is many kinds of heterocycles including uracil and M is oxygen. WO97/12886 disclosed benzisoxazole or benzisoxazolidinone derivatives where Q is many kinds of heterocycles including uracil and D is oxygen. WO97/42188 disclosed indole type derivatives with Q as uracil and D or U is nitrogen. Despite the broad coverage of these patents, the general structure of the present invention has not been described. The specific fused-benzene compounds of the formula (Ia) and (Ib) mentioned below are novel and can be used to effectively control a variety of broad or grassy leaf plant species. In the definitions given above, unless alkyl, alkenyl and halogen are defined or mentioned, the term alkyl used either alone or in compound words such as "haloalkyl" or "alkylcarbonyl" includes straight-chain or branched chains containing 1 to 6 carbon atoms. The terms of alkenyl and alkynyl include straight chain or branched alkenes and alkynes respectively containing 2 to 6 carbon atoms, and the term halogen either alone or in the compound words such as haloalkyl indicates fluorine, chlorine, bromine, or iodine. Further a haloalkyl is represented by an alkyl partially or fully substituted with halogen atoms which may be same or different. The
Patents 151
term or part of the term "aryl" or "heteroaryl" are defined as those monocyclic or fused bicyclic aromatic rings wherein at least one ring satisfy the Huckel rule and contain 0 to 4 heteroatoms, examples include: phenyl, furyl, furazanyl, thienyl, pyrrolyl, pyrazolyl, oxazolyl, oxadiazolyl, imidazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, quinolyl, isoquinolyl, quinoxalinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, isobenzofuranyl, benzothienyl, benzodioxolyl, chromanyl, indolinyl, isoindolyl, naphthyl, thienofuranyl and purinyl. These rings can attached through any available carbon or nitrogen, for example, when the aromatic ring system is furyl, it can be 2-furyl or 3-furyl, for pyrrolyl, the aromatic ring system is 1-pyrrolyl, 2-pyrrolyl or 3-pyrrolyl, for naphthyl, the carbobicyclic aromatic ring is 1-naphthyl or 2- naphthyl and for benzofuranyl, the aromatic ring system can be 2-, 3-, 4-, 5-, 6- or 7-benzofuranyl. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Hand dishwashing detergent composition and methods for manufacturing and using Inventor(s): Hodge, Charles A.; (Cottage Grove, MN), Levitt, Mark D.; (St. Paul, MN), Olson, Keith E.; (Apple Valley, MN), Sanders, Lisa M.; (Eagan, MN) Correspondence: Merchant & Gould PC; P.O. Box 2903; Minneapolis; MN; 55402-0903; US Patent Application Number: 20040029757 Date filed: November 18, 2002 Abstract: A hand dishwashing detergent composition as provided according to the invention. The hand dishwashing detergent composition includes an anionic surfactant blend, a betaine surfactant, and water. The anionic surfactant blend includes a first anionic surfactant component and a second anionic surfactant component. The first anionic surfactant component can include at least one of an alkyl aryl sulfonate wherein the alkyl group contains 10 to about 18 carbon atoms and the aryl group comprises at least one of benzene, toluene, xylene, and a secondary alkane sulfonate wherein the alkane group includes about 10 to about 18 carbon atoms. The second anionic surfactant component includes at least one of:an alkyl ether sulfate wherein the alkyl group contains 10 to about 18 carbon atoms;alkyl methyl sulfate wherein the alkyl group contains about 10 to about 18 carbon atoms;alkyl sulfate wherein the alkyl group contains about 10 to about 18 carbon atoms;and alpha olefin sulfonate wherein the alpha olefin contains about 10 to about 18 carbon atoms. The betaine surfactant can have the following formula: 1wherein:y is N, S or P. Methods for manufacturing and using the hand dishwashing composition are described. Excerpt(s): This application claims priority to U.S. Provisional Patent Application Serial No. 60/401,763 that was filed with the United States Patent and Trademark Office on Aug. 8, 2002. U.S. Provisional Patent Application Serial No. 60/401,763 is encorporated herein by reference. The invention relates to a hand dishwashing detergent composition, a method for manufacturing a hand dishwashing detergent composition, and a method for using a hand dishwashing detergent composition. In particular, the hand dishwashing detergent composition can be provided as a superconcentrate and diluted to form a concentrate detergent composition for sale to consumers. The concentrate detergent composition can be used to prepare a use solution for washing items in a sink including dishes, flatware, glasses, pots, pans, etc. Hand dishwashing detergent compositions are widely available for washing dishware, flatware, glasses, pots, and pans. In general, it is desirable for hand dishwashing detergent compositions to exhibit
152
Benzene
sudsing and grease removal properties. Hand dishwashing detergent compositions are often provided as a liquid, concentrate that is squirted into a sink containing water and items to be washed. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Keratinocyte growth inhibitors and hydroxamic acid derivatives Inventor(s): Hashimoto, Koji; (Ehime, JP), Higashiyama, Shigeki; (Osaka, JP), Yamamoto, Minoru; (Osaka, JP), Yoshiizumi, Kazuya; (Osaka, JP), Yoshino, Kohichiro; (Osaka, JP) Correspondence: William M Blackstone; Akzo Nobel Patent Department; Intervet Inc; 405 State Street; Millsboro; DE; 19966; US Patent Application Number: 20030229113 Date filed: February 19, 2003 Abstract: This invention relates to a keratinocyte-proliferation inhibitor comprising as active ingredient a compound having an activity of inhibiting the solubilization of heparin-binding EGF-like growth factor bound to cell membranes and a compound of the formula (I); 1or pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3 are hydrogen atom or alkyl and X is substituted benzene or the like. Excerpt(s): This invention relates to an inhibitor of proliferation of keratinocytes and hydroxamic acid derivatives which are an active ingredient of the inhibitor. More specifically, it relates to the inhibitor comprising as active ingredient a compound having an activity of inhibiting the solubilization of heparin-binding EGF-like growth factor (hereinafter referred to as "HB-EGF") bound to cell membranes. Furthermore, it relates to novel hydroxamic acid derivatives having an inhibitory activity on the solubilizing enzyme of HB-EGF. Keratinocytes occupying major portions of epidermal cell layers of skin play an important role in the barrier function of the skin. Excessive proliferation of keratinocytes is observed in dermatitis such as psoriasis, photogenic keratosis, ichthyosis, excrescence, seborrheic dermatitis or atopic dermatitis and skin diseases such as skin cancer. As a keratinocyte proliferation factor, epithelium growth factor (EGF), transforming growth factor-.alpha. (TGF-.alpha.), anphiregulin (AR), HBEGF, fibroblast growth factor-1 (FGF-1), FGF-2, FGF-7, hepatocyte growth factor, etc., have been reported (J. Invest. Dermatol., 115: 715-721 (1988)). It is known that factors of EGF family such as EGF, TGF-.alpha., AR and HB-EGF are synthesized as membranebound proteins which are broken into a soluble form by the action of metal enzymes (hereinafter referred to as "solubilizing enzymes") and that both membrane-bound and soluble forms bind to EGF receptor. (EMBO J., 17:7260-7272 (1998); Nature, 402:884-888 (1999); Proc. Natl. Acad. Sci. USA, 25:6235-6240 (1990)). Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Patents 153
•
Limiting the loss of tin through oxidation in tin or tin alloy electroplating bath solutions Inventor(s): Brown, Neil D.; (Merrick, NY), Chirafisi, Angelo; (Howard Beach, NY), Levey, Peter R.; (Bellmore, NY) Correspondence: C/o Edwards & Angell, Llp; Dike, Bronstein, Roberts & Cushman, IP Group; P.O. Box 9169; Boston; MA; 02209; US Patent Application Number: 20030226759 Date filed: March 5, 2003 Abstract: Provided for is a solution for use in the electroplating of tin and tin alloys comprising a basis solution comprising an acid, optionally a salt thereof, the acid selected from the group consisting of fluoboric acid, an organic sulfonic acid, a mineral acid, or a combination thereof; divalent tin ions; and an antioxidant comprising a hydroxy benzene sulfonic acid or salt thereof, in an amount effective to prevent the oxidation of divalent tin ions. Also provided for is a method for electroplating comprising electroplating a substrate using an electroplating solution comprising a hydroxy benzene sulfonic acid or salt thereof in an amount effective to decrease the oxidation of tin ions. Excerpt(s): This application claims the benefit under 35 U.S.C.sctn.119(e) of U.S. Provisional Application No. 60/361,858, filed Mar. 5, 2002, the entire contents of which are incorporated herein by reference. Electroplating baths containing divalent tin and acids such as mineral acids (e.g., sulfuric acid, hydrochloric acid, and hydrofluoric acid), phenol-sulfonic acid, fluoboric acid, and methane sulfonic acid are used in plating tin and tin alloys. A problem is the loss of available divalent tin (Sn.sup.2+) due to oxidation of the divalent tin to tetravalent tin (Sn.sup.4+). Tetravalent tin accumulates as stannic acid and eventually forms an insoluble sludge in the bath. In addition to removing the amount of divalent tin available for plating, sludge formation also causes equipment fouling and plugging, resulting in an inferior product, along with increased operational costs. Oxidation of divalent tin occurs at the anode of the electroplating cell, or can result from air introduced into the bath. For example, rapid pumping of plating solution required in the so called "high speed plating" processes result in the inclusion of substantial amounts of oxygen into the bath, which accelerates the oxidation of divalent tin. Accordingly, high-speed tin-plating worsens the sludge problem as compared to other non-high speed tin-plating applications. To prevent this oxidation and the corresponding formation of sludge, divalent tin should remain in solution, and/or be quickly converted back to divalent tin once oxidation has occurred. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Manufacture of xylenes using reformate Inventor(s): Abichandani, Jeevan S.; (Houston, TX), Buchanan, John Scott; (Lambertville, NJ), Crane, Robert A.; (Lumberton, TX), Dakka, Jihad M.; (Whitehouse Station, NJ), Feng, Xiaobing; (Houston, TX), Iaccino, Larry L.; (Seabrook, TX), Luo, Shifang L.; (Pittsford, NY), Mohr, Gary D.; (Houston, TX) Correspondence: Exxonmobil Chemical Company; Law Technology; P. O. Box 2149; Baytown; TX; 77522-2149; US Patent Application Number: 20040015027 Date filed: June 18, 2003
154
Benzene
Abstract: A process is provided for the production of xylenes from reformate. The process is carried out by methylating under conditions effective for the methylation, the benzene/toluene present in the reformate outside the reforming loop, to produce a resulting product having a higher xylenes content than the reformate. Greater than equilibrium amounts of para-xylene can be produced by the process. Excerpt(s): This application claims priority to U.S. Provisional Patent Application No. 60/389,977, filed Jun. 19, 2002, which is hereby incorporated by reference. This invention relates to a process for producing xylenes using reformate by methylating the benzene and/or toluene contained in the reformate to produce xylenes. Most aromatics production is based on the recovery of aromatics derived from catalytic reforming of naphtha. That process, using a feed containing a C.sub.6+ hydrocarbons, typically produces a reformate comprised of C.sub.6-C.sub.8 aromatics along with paraffins and heavier aromatics. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Metal-doped organic gels and method thereof Inventor(s): Baumann, Theodore F.; (Tracy, CA), Satcher, Joe H. JR.; (Patterson, CA) Correspondence: Ann M. Lee; Assistant Laboratory Counsel; Lawrence Livermore National Laboratory; P.O. Box 808, L-703; Livermore; CA; 94551; US Patent Application Number: 20030216482 Date filed: June 9, 2003 Abstract: Disclosed herein is a sol-gel polymerization process for synthesizing metaldoped organic gels. The process polymerizes metal salts of hydroxylated benzenes or hydroxylated benzene derivatives with alkyl or aryl aldehydes to form metal-doped, wet, organic gels. The gels can then be dried by supercritical solvent extraction to form metal-doped aerogels or by evaporation to form metal-doped xerogels. The aerogels and xerogels can then be pyrolyzed. Excerpt(s): This application is a Divisional of Ser. No. 10/132,783 filed Apr. 24, 2002 and claims priority in provisional application filed on Nov. 28, 2001, entitled "Metal-doped Organic Aerogels and Method Thereof" serial No. 60/334,023, by inventor(s) Theodore F. Baumann and Joseph H. Satcher. Aerogels are a special class of open-cell foams derived from highly cross-linked inorganic or organic gels that are dried using special techniques to preserve the tenuous solid network. These materials have ultra fine cell/pore sizes, continuous porosity, high surface area, and a microstructure composed of interconnected colloidal-like particles or polymeric chains with characteristic diameters of 100.ANG. This microstructure is responsible for the unusual optical, acoustical, thermal, and mechanical properties of aerogels. These materials are prepared through the sol-gel process and can be either granular or monolithic. Other researchers have synthesized carbon aerogels containing transition metals for the purpose of catalyzing graphitization reactions producing unique carbon structures. For example, Maldonado-Hodar et al in a recent article in Langmuir 2000, 16, 4367-4373, describe a method to synthesize Cr-, Fe-, Co-, and Ni-containing carbon aerogels by dissolving resorcinol and formaldehyde in water and adding either chromium nitrate, iron acetate, cobalt acetate or nickel acetate to the solution. The metal content of these carbon aerogels ranged from 1.4 to 5.4%. See Maldonado-Hodar et al, pg. 4368, Table 2. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Patents 155
•
Methods for preparing ruthenium and osmium compounds and films Inventor(s): Uhlenbrock, Stefan; (Boise, ID), Vaartstra, Brian A.; (Nampa, ID) Correspondence: Mueting, Raasch & Gebhardt, P.A.; P.O. Box 581415; Minneapolis; MN; 55458; US Patent Application Number: 20030212285 Date filed: April 21, 2003 Abstract: The present invention provides methods for the preparation of compounds of the formula (Formula I):L.sub.yM(CO).sub.zwherein M is Ru or Os, each L is independently a neutral ligand, y=1-4, and z=1-5. These methods involve the reaction of Ru.sub.3(CO).sub.12 or Os.sub.3(CO).sub.12 with a neutral ligand in a solvent system having a boiling point higher than that of benzene at atmospheric pressure. Excerpt(s): This invention relates to the preparation of ruthenium and osmium compounds, which are particularly useful as chemical vapor deposition precursors. Films of metals and metal oxides, particularly ruthenium and osmium films and oxides thereof, are becoming important for a variety of electronic and electrochemical applications. For example, high quality RuO.sub.2 thin films deposited on silicon wafers have recently gained interest for use in ferroelectric memories. Ruthenium and osmium films are generally unreactive to silicon and metal oxides, resistant to diffusion of oxygen and silicon, and are good conductors. Oxides of these metals also possess these properties, although perhaps to a different extent. Thus, films of ruthenium and osmium and oxides thereof have suitable properties for a variety of uses in integrated circuits. For example, they can be used in integrated circuits for electrical contacts. They are particularly suitable for use as barrier layers between the dielectric material and the silicon substrate in memory devices, such as ferroelectric memories. Furthermore, they may even be suitable as the plate (i.e., electrode) itself in capacitors. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Methods for treating hyperactive gastric motility Inventor(s): Argentieri, Thomas M.; (Yardley, PA) Correspondence: Wyeth; Patent Law Group; Five Giralda Farms; Madison; NJ; 07940; US Patent Application Number: 20040029949 Date filed: August 6, 2003 Abstract: This invention provides methods and pharmaceutical compositions for treating, inhibiting or preventing hyperactive gastric motility in a mammal utilizing agonists of KCNQ potassium channels, including KCNQ2, KCNQ3, KCNQ4 and KCNQ5 potassium channels, alone or in combination. The hyperactive gastric motility may be associated with maladies including, colitis, irritable bowel syndrome and Crohn's disease. Compounds useful in these methods include the 1,2,4-triaminobenzene derivatives described in U.S. Pat. No. 5,384,330 (Dieter et al.) and the substituted 3-phenyl oxindole compounds described in U.S. Pat. No. 5,565,483 (Hewawasam et al.). Excerpt(s): This application is a divisional of U.S. application Ser. No. 10/114,148 filed on Apr. 2, 2002, pending, which in turn claims the benefit of U.S. Provisional application Serial No. 60/281,471, filed Apr. 4, 2001. The entire disclosures of the Ser. Nos.
156
Benzene
60/281,471 and 10/114,148 applications are hereby incorporated by reference. This invention relates to novel methods for modulating gastric tissues utilizing compounds which modulate the KCNQ family of potassium channels, particularly compounds which open or agonize the channels. The methods of this invention include the treatment, prevention, inhibition and amelioration of hyperactive gastric motility, including that associated with colitis, Irritable Bowel Syndrome and Crohn's Disease. and their properties as anti-epileptic, muscle relaxing, fever-reducing and peripheral analgesic agents. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
N-(heterocyclyl)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants Inventor(s): Altenburger, Jean-Michel; (Saint Remy-Les-Chevreuse, FR), Cremer, Gerard; (Morangis, FR), Lassalle, Gilbert; (Les Molieres, FR), Matrougui, Mostafa; (Palaiseau, FR) Correspondence: Sanofi-synthelabo INC.; 9 Great Valley Parkway; P.O. Box 3026; Malvern; PA; 19355; US Patent Application Number: 20030207920 Date filed: September 12, 2002 Abstract: Compounds of formula [I] 1in which:W may represent a --(CH.sub.2).sub.2--, -(CH.sub.2).sub.3--, --CH.sub.2--C.ident.C-- or --CH.sub.2--CH.dbd.CH-- group,R.sub.2 may in particular represent a piperidyl group, an optionally substituted 1,2,3,6tetrahydropyridyl group, a hexahydro-1H-azepinyl group, an optionally substituted piperazinyl group or a morpholinyl group,R.sub.3 may in particular represent a group -COR.sub.1,A may in particular represent an optionally substituted phenyl group, a heterocycle or a cyclopentyl group, andB may in particular represent a pyridyl group, an aminopyrazinyl group, an aminopyridazinyl group, a pyrimidinyl group optionally substituted with an amino group, piperidyl group or an aminopyridyl group optionally substituted on the pyridine with a (C.sub.1-C.sub.4)alkyl or (C.sub.1-C.sub.4)alkoxy group, the amino group possibly also being substituted with a (C.sub.1-C.sub.4)alkyl group,their preparation and their therapeutic application. Excerpt(s): The present invention relates to N-(heterocyclyl)benzene- or pyridinesulphonamide derivatives, to their preparation and to their therapeutic application. or an aminophenyl group, the amino group possibly being substituted with a (C.sub.1-C.sub.4)alkyl group and the phenyl group possibly being substituted with a (C.sub.1-C.sub.4)alkyl group or a halogen atom. a halogen atom is a chlorine, bromine, iodine or fluorine atom. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Negative resist composition Inventor(s): Shirakawa, Koji; (Shizuoka, JP), Yasunami, Shoichiro; (Shizuoka, JP) Correspondence: Sughrue Mion, Pllc; 2100 Pennsylvania Avenue, N.W.; Washington; DC; 20037; US Patent Application Number: 20040033441 Date filed: August 18, 2003
Patents 157
Abstract: A negative resist composition of the present invention comprises: (A) an alkalisoluble resin; (B-1) a cross-linking agent capable of cross-linking with the alkali-soluble resin (A) by the action of an acid, in which the cross-linking agent is a phenol compound containing: in the molecule one or more benzene rings; and at least two cross-linking groups bonded to any of the benzene rings, the cross-linking group being a group selected from the group consisting of a hydroxymethyl group, an alkoxymethyl group and an acyloxymethyl group; (B-2) a cross-linking agent capable of cross-linking with the alkali-soluble resin (A) by the action of an acid, in which the cross-linking agent contains at least two specific groups; and (C) a compound capable of generating an acid upon irradiation with an actinic ray or radiation. Excerpt(s): The present invention relates to a negative resist composition suitable for use in ultramicro-lithographic processes for manufacturing VLSI chips and high-capacity microchips, and in other photofabrication processes. More specifically, the invention is concerned with a negative resist composition capable of forming finer patterns by using electron beams or X-rays in particular. Hitherto, fine patterning by lithography using photoresist compositions has been performed in processes of manufacturing semiconductor devices, such as ICs and LSI. In recent years, increasing need for larger packing densities of integrated circuits has come to entail superfine patterning in the submicron or quatermicron region. In response to such a requirement, the light sources used in photolithography are showing a tendency to have shorter wavelengths. Actually, the exposure light used has been changed from g-ray to i-ray, and further to KrF excimer laser beam. And nowadays the development of lithographic processes using not only excimer laser beams but also electron beams and X-rays is proceeding. Electron-beam lithography in particular is placed as a next-generation patterning technology or a generation-after-next patterning technology, and it is desired to develop negative resist highly sensitive to electron beams and capable of forming highly resolved patterns. Enhancement of resist sensitivity is a very important problem in pursuing reduction of wafer processing time. As to the electron-beam negative resist, however, pursuit of increased sensitivity causes a worsening of line edge roughness in addition to reduction of resolution and deterioration in pattern profile, thereby resulting in a problem of greatly reducing yield rates of devices. Therefore, it is strongly desired to develop resist compositions satisfying those quality requirements at the same time. The term "line edge roughness" as used here in means rough appearance the patternsubstrate interface edge has when resist patterns are viewed from right above, wherein the roughness of the pattern-substrate interface edge arises from irregular fluctuation in a direction perpendicular to the line direction that is attributed to resist properties. Transfer of this roughness occurs in the etching process using the resist as a mask and gives rise to deterioration in electric properties and decrease in yield rate. High sensitivity bears a trade-off relation to high resolution, pattern profiles of good quality and satisfactory line edge roughness, and so how to satisfy these properties at the same time is a very important problem. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
158
•
Benzene
Nonaqueous electrolytic solution with improved safety and lithium battery employing the same Inventor(s): Choy, Sang-Hoon; (Daeloon-city, KR), Kim, Ho-Sung; (Suwon-city, KR), Kim, Jun-Ho; (Aagn-city, KR), Lee, Ha-Young; (Choonan-city, KR) Correspondence: Staas & Halsey Llp; Suite 700; 1201 New York Avenue, N.W.; Washington; DC; 20005; US Patent Application Number: 20040029018 Date filed: August 11, 2003 Abstract: A nonaqueous electrolytic solution and a lithium battery employing the same include a lithium salt, an organic solvent, and a halogenated benzene compound. The use of the nonaqueous electrolytic solution causes formation of a polymer by oxidative decomposition of the electrolytic solution even if a sharp voltage increase occurs due to overcharging of the battery, leading to consumption of an overcharge current, thus protecting the battery. Excerpt(s): This application claims the benefit of Korean Application No. 2002-47510, filed Aug. 12, 2002, in the Korean Intellectual Property Office, the disclosure of which is incorporated herein by reference. The present invention relates to a nonaqueous electrolytic solution with improved safety and a lithium battery employing the same, and more particularly, to a nonaqueous electrolytic solution with improved safety when the battery is overcharged, and a lithium battery employing the polymer electrolyte. A lithium battery includes a cathode, an anode and an electrolytic solution providing a movement path of lithium ions between the cathode and the anode, and generates electric energy by oxidation and reduction when the lithium ions are intercalated into/deintercalated from the cathode and anode. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Novel cyclic diamine compounds and medicine containing the same Inventor(s): Edano, Toshiyuki; (Saitama, JP), Hirata, Mitsuteru; (Saitama, JP), Kawamine, Katsumi; (Saitama, JP), Miura, Toru; (Tokyo, JP), Ohgiya, Tadaaki; (Saitama, JP), Ozaki, Chiyoka; (Tokyo, JP), Sato, Yukihiro; (Tokyo, JP), Shibuya, Kimiyuki; (Saitama, JP) Correspondence: Dike, Bronstein, Roberts & Cushman; Intellectual Property Practice Group; Edwards & Angell, Llp; P.O. Box 9169; Boston; MA; 02209; US Patent Application Number: 20040038987 Date filed: February 20, 2003 Abstract: The present invention offers novel cyclic diamine compounds and a pharmaceutical composition containing the same.The present invention relates to a compound represented by the formula (I) or salt(s) or solvate(s) thereof. 1(In the formula, 2is an optionally substituted divalent residue of benzene, pyridine, cyclohexane or naphthalene or is a vinylene group whereAr is an optionally substituted aryl group;X is --NH--, oxygen atom or sulfur atom;Y is --NR.sub.1--, oxygen atom, sulfur atom, sulfoxide or sulfone;Z is a single bond or --NR.sub.2--;R.sub.1 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group;R.sub.2 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally
Patents 159
substituted silyl lower alkyl group;l is an integer of from 0 to 15;m is an integer of 2 or 3; andn is an integer of from 0 to 3).The compound of the present invention is useful as a pharmaceutical composition, particuarly as an inhibitor of acyl coenzyme A cholesterol acyltransferase (ACAT). Excerpt(s): n is an integer of from 0 to 3). In recent years, as a result of an increase in persons of advanced age and also of changes in daily eating habits to the food of European and American style containing high calories and high cholesterol due to upgrade of the standard of living, there has been a rapid increase in hyperlipemia and arteriosclerotic diseases caused thereby and that is one of the social problems. The pharmacotherapy for hyperlipemia and arteriosclerosis up to now has mostly given its priority to reduce the lipid content in blood which is a cause thereof and has not been a therapy where arteriosclerotic focus per se is a target. Acyl coenzyme A cholesterol acyltransferase (ACAT) is an enzyme which catalyzes the synthesis of cholesterol ester from cholesterol and plays an important role in metabolism and absorption in digestive organs of cholesterol. It is believed that inhibition of ACAT enzyme which esterifies free cholesterol in epithelial cells of small intestine results in inhibition of absorption of cholesterol from intestinal tract, that inhibition of production of cholesterol ester in liver due to ACAT inhibition suppresses the secretion of very low-density lipoprotein (VLDL) from liver into blood and that, as a result thereof, a decrease in cholesterol in blood is resulted. Many of ACAT inhibitors until now have been those which act the ACAT enzyme in small intestine and liver whereby a decrease in cholesterol in blood is expected as antihyperlipemic agents. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Oxidant/catalyst nanoparticles to reduce tobacco smoke constituents such as carbon monoxide Inventor(s): Hajaligol, Mohammad; (Midlothian, VA), Li, Ping; (Richmond, VA), Rasouli, Firooz; (Midlothian, VA), Shin, Eun-Jae; (Midlothian, VA) Correspondence: Burns, Doane, Swecker & Mathis, L.L.P.; P.O. Box 1404; Alexandria; VA; 22313-1404; US Patent Application Number: 20040025895 Date filed: June 13, 2003 Abstract: Cut filler compositions, cigarettes, methods for making cigarettes and methods for smoking cigarettes are provided, which involve the use of nanoparticle additives capable of reducing amounts of at least one constituent from mainstream and/or sidestream tobacco smoke, the at least one constituent being selected from the group consisting of aldehyde, carbon monoxide, 1,3-butadiene, isoprene, acrolein, acrylonitrile, hydrogen cyanide, o-toluidine, 2-naphtylamine, nitrogen oxide, benzene, Nnitrosonornicotine, phenol, catechol, benz(a)anthracene, benzo(a)pyrene, and mixtures thereof. Preferably, the nanoparticle additives are effective as an oxidant for the conversion of carbon monoxide to carbon dioxide and/or as a catalyst for the conversion of carbon monoxide to carbon dioxide and/or catalyst for conversion of aldehydes such as acetaldehyde and acrolein, hydrocarbons such as isoprene and/or phenolic compounds such as catechol to carbon dioxide and water vapor. Excerpt(s): This application is a continuation-in-part of application Ser. No. 10/286,968, filed Nov. 4, 2002 which is a continuation-in-part of application Ser. No. 09/942,881, filed Aug. 31, 2001. The invention relates generally to methods for reducing constituents
160
Benzene
such as carbon monoxide in the mainstream smoke of a cigarette during smoking. More specifically, the invention relates to cut filler compositions, cigarettes, methods for making cigarettes and methods for smoking cigarettes, which involve the use of nanoparticle additives capable of reducing the amounts of various constituents in tobacco smoke. Various methods for reducing the amount of carbon monoxide in the mainstream smoke of a cigarette during smoking have been proposed. For example, British Patent No. 863,287 describes methods for treating tobacco prior to the manufacture of tobacco articles, such that incomplete combustion products are removed or modified during smoking of the tobacco article. This is said to be accomplished by adding a calcium oxide or a calcium oxide precursor to the tobacco. Iron oxide is also mentioned as an additive to the tobacco. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Polycarbonate composition having excellent releasability from mold Inventor(s): Funakoshi, Wataru; (Yamaguchi, JP), Hirata, Masumi; (Yamaguchi, JP), Kageyama, Yuichi; (Yamaguchi, JP), Sasaki, Katsushi; (Yamaguchi, JP), Yamoshi, Takanori; (Yamaguchi, JP) Correspondence: Sughrue Mion, Pllc; 2100 Pennsylvania Avenue, N.W.; Washington; DC; 20037; US Patent Application Number: 20040034130 Date filed: June 2, 2003 Abstract: An aromatic polycarbonate composition which is suitable for use in the production of an optical molded article such as an optical disk or lens and has excellent heat stability and releasability at the time of molding. This composition comprises 100 parts by weight of an aromatic polycarbonate obtained by reacting an aromatic dihydroxy compound with a carbonic acid diester in the presence of at least one ester exchange catalyst selected from the group consisting of an alkali metal compound and an alkali earth metal compound, 0.0001 to 0.3 part by weight of an epoxy compound and 0.015 to 0.3 part by weight of an aromatic compound having at least four benzene rings in the molecule. Excerpt(s): The present invention relates to a polycarbonate composition having excellent mold releasability, a process for producing an injection molded article, a critical surface tension modifier for use in the injection molded process, a substrate for an optical recording medium and an optical recording medium. A polycarbonate is an engineering plastic which is excellent in terms of color, transparency and mechanical strength. In recent years, the application of the polycarbonate has been diversified and the polycarbonate has been processed into various molded articles. As it has excellent mechanical strength in particular, it is used in large quantities as a material for thin molded articles having a high surface area ratio, such as optical disk substrates and housings for electric appliances. The molded articles are generally formed by injection molding using a metal mold. In this molding method, it has been apprehended that when the mold releasability of a molded article is poor in the step of removing the molded article, the production efficiency is reduced, which is a serious problem when the production scale is large. Particularly in the case of an optical disk substrate, the flowability of a resin is generally improved by increasing the cylinder temperature of an injection molding machine to 350 to 400.degree. C. in order to transfer a signal carved on a stamper to a polycarbonate substrate accurately. Therefore, the temperature of a metal mold to which the stamper is mounted must be set to a high temperature of 80 to
Patents 161
120.degree. C. However, when the temperature of the metal mold is high, there arise such problems as a reduction in the mold releasability of a polycarbonate molded article, nonuniform release and poor transferability. To prevent these, the metal mold must be fully cooled before the molded article is removed from the metal mold. If the metal mold is fully cooled, the molding cycle will be long and productivity will be low. For the above reason, the development of a polycarbonate having excellent mold releasability in injection molding has been strongly desired in recent years. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade Inventor(s): Parlow, John J; (Arnold, MO), South, Michael S; (St Louis, MO) Correspondence: Senniger Powers Leavitt And Roedel; One Metropolitan Square; 16th Floor; ST Louis; MO; 63102; US Patent Application Number: 20030236231 Date filed: November 13, 2002 Abstract: The invention relates to polycyclic aryl and heteroaryl substituted benzene compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases. Excerpt(s): This invention is in the field of anticoagulant therapy, and specifically relates to compounds, compositions and methods for preventing and treating thrombotic conditions such as coronary artery and cerebrovascular disease. More particularly, the invention relates to polycyclic aryl and heteroaryl substituted benzene compounds that inhibit serine proteases of the coagulation cascade. Physiological systems control the fluidity of blood in mammals [Majerus, P. W. et al: Anticoagulant, Thrombolytic, and Antiplatelet Drugs. In Hardman, J. G. and Limbird, L. E., editors: Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th edition. New York, McGraw-Hill Book Co., 1996, pp. 1341-1343]. Blood must remain fluid within the vascular systems and yet be able to undergo hemostasis, cessation of blood loss from a damaged vessel, quickly. Hemostasis or clotting begins when platelets first adhere to macromolecules in subendothelian regions of an injured and/or damaged vessels. These platelets aggregate to form the primary hemostatic plug and stimulate local activation of plasma coagulation factors leading to generation of a fibrin clot that reinforces the aggregated platelets. Plasma coagulation factors include factors II, V, VII, VIII, IX, X, XI, and XII; these are also called protease zymogens. These coagulation factors or protease zymogens are activated by serine proteases leading to coagulation in a so called "coagulation cascade" or chain reaction [Handin, R. I.: Bleeding and Thrombosis. In Wilson, J., et al. editors: Harrison's Principles of Internal Medicine. 12th Edition, New York, McGraw-Hill Book Co., 1991,p.350]. Coagulation or clotting occurs in two ways through different pathways. An intrinsic or contact pathway leads from XII to XIIa to XIa to IXa and to the conversion of X to Xa. Xa with factor Va converts prothrombin (II) to thrombin (IIa) leading to conversion of fibrinogen to fibrin. Polymerization of fibrin leads to a fibrin clot. An extrinsic pathway is initiated by the conversion of coagulation factor VII to VIIa by Xa. The presence of Tissue Factor and VIIa accelerates formation of Xa in the presence of calcium ion and phospholipids. Formation of Xa leads to thrombin, fibrin, and a fibrin clot as described above. The presence of one or more of these many
162
Benzene
different coagulation factors and two distinct pathways of clotting could enable the efficacious, selective control and better understanding of parts of the coagulation or clotting process. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
PREPARATION OF ORGANOSILICON INTERMEDIATE DERIVATIVES IN A NOVEL GRIGNARD PROCESS
AND
THEIR
Inventor(s): Nguyen, Binh T.; (Midland, MI) Correspondence: Mckellar Stevens & Hill Pllc; Poseyville Professional Complex; 784 South Poseyville Road; Midland; MI; 48640; US Patent Application Number: 20030233005 Date filed: June 13, 2002 Abstract: A one-step process for the preparation of organosilicon intermediates. The organosilicon intermediates comprise a group which includes such intermediates as 1,4bis(dimethylsilyl)benzene, 1,4-bis(dimethylchlorosil- yl)benzene, and their derivatives. The process comprises: combining a dihalobenzene with magnesium metal in a cosolvent mixture of an ether and an organic solvent and reacting them with an organosilicon compound of the general formula, R2bHcSiXd. The resulting mixture is allowed to react to completion. The resulting mixture is passed through a filtration device. The liquid, now free of solid magnesium halide, is subjected to a separation technique to recover the subject organosilicon intermediates and their derivatives. Excerpt(s): The present invention is directed to a one step Grignard-type process for preparation of an organosilane. The process comprises contacting a mixture of an organic halide in a co-solvent mixture of an ether and an organic solvent with magnesium metal in an ether and an organic solvent, and reacting this mixture with an organohalosilane. The present inventors have found that the presence of the co-solvent mixture of an ether and an organic solvent provides for a product slurry that stirs and flows easily. These characteristics of the product slurry improve mass transfer and heat transfer during the process and allows for easier separation of the organosilane from the product slurry. Conduct of the present process in the co-solvent provides for improved ratios of the desired organosilane to byproducts and improved recovery of the product from the resultant slurry. Furthermore, the use of the co-solvent allows the process to be run as a continuous process. The process can be self-initiating when it is run with the cosolvent. The process is particularly useful for making bisorganosilylbenzene intermediates. The reaction of organic halides with magnesium metal in the presence of oxygenated solvents such as dialkyl ethers to form reactive complexes, typically referred to as Grignard reagents, is well known. The production and reactions of Grignard reagents has been the subject of books and numerous review articles. Such reviews are provided, for example, in Coates, et al., ORGANOMETALLIC COMPOUNDS, vol. 1, p. 76-103, (1967), Methuen and Co., LTD, London, U.K., and Kirk and Othmer, ENCYCLOPEDIA CHEMICAL, vol. 10, p. 721-734 (1966), The Interscience Encyclopedia, Inc., New York, N.Y. The structure of the Grignard reagent has not been determined with certainty, however, it is generally believed that the Grignard reagent exists as a complex in solution and that solvent can play a critical role in such complex formation. The unpredictable effect of solvent on the formation and reactivity of the Grignard reagents is discussed in the above cited review articles. The preparations of organosilicon compounds using a Grignard reagent as an intermediate are known. However, nowhere in the art is there shown the preparation of organosilicon
Patents 163
intermediates from a group which includes such intermediates as 1,4bis(dimethylsilyl)benzene, 1,4-bis(dimethylchlorosilyl)benzene, and their derivatives. Turk et al., Organic Synthesis, vol. 27, 7-8, 1947, teach a process for preparing organic intermediates in anhydrous ether with magnesium turnings. Turk et al. teach that this reaction results in the formation of a thick slurry that becomes unstirrable. This unstirrable slurry is then treated with a hydrochloric acid solution until the magnesium chloride byproduct is in solution and the slurry becomes sufficiently fluid to be stirred. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Process for eliminating sulphur from a feed containing hydrogen sulfide and benzene, toluene and/or xylenes Inventor(s): Chapat, Jean-Francois; (Salindres, FR), Nedez, Christophe; (Salindres, FR), Ray, Jean-Louis; (Neuilly Sur Seine, FR) Correspondence: Millen, White, Zelano & Branigan, P.C.; 2200 Clarendon BLVD.; Suite 1400; Arlington; VA; 22201; US Patent Application Number: 20040033192 Date filed: June 3, 2003 Abstract: A process is described for eliminating sulphur from a feed containing hydrogen sulphide, sulphur dioxide, carbon oxysulphide and/or carbon sulphide and a minimal quantity of benzene, toluene and/or xylenes in at least one reaction zone containing a catalyst, and recovering elemental sulphur and an effluent that is at least partially free of sulphur, the process being characterized in that the catalyst used is at least one catalyst containing a support comprising at least one compound selected from de group formed by alumina, titanium oxide and zirconia, the support further comprising at least one doping element selected from the group formed by iron, cobalt, nickel, copper and vanadium. Excerpt(s): The invention relates to a process for eliminating sulphur from a feed containing hydrogen sulphide and minimal traces of benzene, toluene and/or xylenes (BTX). In particular, it is applicable to feeds containing up to 50000 ppm (volume) of BTX and preferably between 50 and 5000 ppm. Natural gas, refinery gases, gases from coal transformation etc can contain H.sub.2S in varying quantities. For environmental and safety reasons, it is usually necessary to transform the H.sub.2S into an inert compound that also has added value, for example elemental sulphur. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Process for preparation of optically active halogeno hydroxypropyl compound and glycidyl compound Inventor(s): Furukawa, Yoshiro; (Osaka-shi, JP), Yaegashi, Keisuke; (Osaka-shi, JP) Correspondence: Wenderoth, Lind & Ponack, L.L.P.; 2033 K Street N. W.; Suite 800; Washington; DC; 20006-1021; US Patent Application Number: 20040024254 Date filed: July 30, 2003 Abstract: A process for preparing regioselectively an optically active 1-halogeno-2hydroxypropyl compound of the following formula; 1wherein X is halogen atom and
164
Benzene
Nu is a heteroatom having a substituent,and an optically active glycidyl compound of the formula; 2which comprises reacting an optically active epihalohydrin of the formula; 3with a neucleophilic agent,in the presence of a metal complex of the formula; 4wherein n is an integer of 0, 1 or 2, Y.sup.1, Y.sup.2 and Y.sup.3 are hydrogen atom, etc., and Y.sup.2 and Y.sup.3 may form a ring such as benzene, A is a counterion and M is a metal ion, and further subjecting the compound (4) to reaction with a base to prepare the optically active glycidyl compound (5). Excerpt(s): The present invention relates to a novel process for preparation of an optically active 1-halogeno-2-hydroxypropyl compound and an optically active glycidyl compound useful as an intermediate for synthesis of medicines or agrochemicals. The preparation methods for a glycidyl compound via a 1-halogeno-2-hydroxypropyl compound were reported in many documents from of old. wherein X' is halogen atom and Nu' is a residue of neucleophilic substance. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Process for producing fluorinated methyl-benzyl alcohol Inventor(s): Miura, Motoo; (Tokyo, JP), Morikawa, Kohei; (Kanagawa, JP), Suyama, Yuseki; (Kanagawa, JP) Correspondence: Sughrue Mion, Pllc; 2100 Pennsylvania Avenue, N.W.; Washington; DC; 20037; US Patent Application Number: 20040010167 Date filed: March 11, 2003 Abstract: An object of the present invention is to provide a process for producing a fluorinated methyl-benzyl alcohol, which process is industrially practicable.A process for producing a fluorinated methyl-benzyl alcohol according to the present invention comprises hydrogenolysis of one hydroxyl group in fluorinated benzene dimethanol. Excerpt(s): This application is an application filed under 35 U.S.C.sctn.111(a) claiming benefit pursuant to 35 U.S.C.sctn.119(e) of the filing date of Provisional Application No. 60/256,918 filed on Dec. 21, 2000, pursuant to 35 U.S.C.sctn.111(b). The present invention relates to a process for producing fluorinated methyl-benzyl alcohols by hydrogenolysis of one hydroxyl group in a fluorinated benzene dimethanol, particularly by hydrogenolysis in a solvent in the presence of a catalyst. Fluorinated methyl-benzyl alcohols are useful as a starting material or an intermediate of medical and pharmaceutical products, agricultural chemicals or other organic compounds. For example, JP-B-1-20143/1989 discloses that fluorinated methyl-benzyl alcohols are reacted with cyclopropane carboxylic acids to obtain ethers having high insecticidal activities. For example, the following processes are proposed as the process for producing fluorinated methyl-benzyl alcohols. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Patents 165
•
PROCESS FOR THE RECOVERY OF PHENOL AND BIPHENOLS Inventor(s): Bianchi, Daniele; (Arese, IT), Bortolo, Rossella; (Novara, IT), Carnelli, Lino; (Carbonate, IT), Moscotti, Daniele; (Brugherio, IT) Correspondence: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.; 1940 Duke Street; Alexandria; VA; 22314; US Patent Application Number: 20030221948 Date filed: May 21, 2003 Abstract: A process is described for the recovery of phenol and biphenols from their homogeneous mixtures containing benzene, sulfolane and water, which is based on the use of an alkaline solution and benzene for the separation of biphenols from sulfolane, after removing the benzene, H.sub.2O and phenol contained in the reaction effluent.The process allows the recovery of phenol and biphenol by-products dissolved in sulfolane, directly obtaining the purified solvent containing the benzene necessary for the feeding to the reactor for the direct oxidation of benzene, as well as the biphenols dissolved in water and pure phenol. Excerpt(s): The present invention relates to a process for the recovery of phenol and biphenol by-products from solutions containing them. In particular, the present invention relates to a process for the recovery of phenol and biphenol by-products from their homogeneous mixtures containing benzene, sulfolane and water. Phenol is a useful product in the preparation of synthetic resins, insecticides and antioxidants. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Process for vapor phase nitration of benzene using nitric acid over molybdenum silica catalyst Inventor(s): Dongare, Mohan Keraba; (Pune, IN), Malshe, Kusum Madhukar; (Pune, IN), Patil, Pratap Tukaram; (Pune, IN) Correspondence: Ladas & Parry; 26 West 61st Street; New York; NY; 10023; US Patent Application Number: 20040024267 Date filed: May 30, 2003 Abstract: Nitration of benzene is an important reaction for the production of nitro benzene, which is an important intermediate in chemical and pharmaceutical industries. Conventionally nitrobenzene is produced by liquid phase reactions employing mixed acids. A sulfuric acid/nitric acid mixture is the most commonly used nitrating agent. Generation of large amount dilute sulfuric acid, organic wastes and products of their neutralization makes the benzene nitration a environmentally harmful process. The present process enables the preparation of nitrobenzene by vapor phase nitration of benzene over solid acid catalyst, MoO.sub.3/SiO.sub.2 using nitric acid. This process is a clean and environment friendly process without use of sulphuric acid. Excerpt(s): The present invention relates to a process for vapor phase nitration of benzene using nitric acid over molybdenum silica catalyst. The invention particularly relates to a process for the preparation of mono-nitrobenzene wherein the nitration of benzene is carried out in vapor phase using molybdenum silica catalyst and nitric acid. By the process of present invention nitrobenzene has been prepared in high yield in a continuous process without any waste byproduct formation making it an environment friendly process. Major part of nitrobenzene (95% or more) produced is converted to
166
Benzene
aniline, which has hundreds of downstream products. Nitrobenzene also is used as a processing solvent in specific chemical reactions. Conventionally nitrobenzene is produced by liquid phase reactions employing mixed acids. A sulfuric acid/nitric acid mixture is the most commonly used nitrating agent. Generation of large amount dilute sulfuric acid, organic wastes and products of their neutralization makes the benzene nitration one of the most environmentally harmful processes. Vapor-phase nitration of benzene to nitrobenzene over zeolite is expected to be a clean process without sulfuric acid waste. A number of heterogeneous catalysts have been proposed for this process. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Processes for preparing substituted aryl boronic acids Inventor(s): Caron, Stephane; (Groton, CT), Nowakowski, Jolanta; (Old Saybrook, CT) Correspondence: Pfizer Inc; 150 East 42nd Street; 5th Floor - Stop 49; New York; NY; 10017-5612; US Patent Application Number: 20040038940 Date filed: June 3, 2003 Abstract: The invention relates to processes for preparing a compound of the formula (V) 1and alkyl boronic esters thereof wherein R.sup.1 is attached at the 2 or 3 position of the benzene ring, R.sup.2 is attached at the 5 or 6 position, and R.sup.1, R.sup.2 and G are as defined herein. Said compound is a key synthetic intermediate in the preparation of 2-amino-6-(substituted-4-phe- noxy)-substituted-pyridines useful as nitric oxide synthase (NOS) inhibitors in a mammal. Excerpt(s): This application claims priority under 35 USC 119 of U.S. Provisional 60/393,501, filed Jul. 3, 2002. This invention relates to a new route for the preparation of substituted-aryl boronic acid derivatives which are useful intermediates in the preparation of 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyr- idines that exhibit activity as nitric oxide synthase (NOS) inhibitors. Examples of 2-amino-6-(2-substituted4-phenoxy)-substituted-pyridines that are prepared from substituted-aryl boronic acid derivatives are disclosed in PCT international application publication number WO 98/34919, published Aug. 13, 1998, and incorporated herein by reference in its entirety. The 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines disclosed in WO 98/34919 as nitric oxide synthase (NOS) inhibitors are useful in the treatment of migraine inflammatory diseases, stroke, acute and chronic pain, hypovolemic shock, traumatic shock, reperfusion injury, Crohn's disease, ulcerative colitis, septic shock, multiple sclerosis, AIDS associated dementia, neurodegenerative diseases, neuron toxicity, Alzheimer's disease, chemical dependencies and addictions, emesis, epilepsy, anxiety, psychosis, head trauma, adult respiratory distress syndrome (ARDS), morphine induced tolerance and withdrawal symptoms; inflammatory bowel disease, osteoarthritis, rheumatoid arthritis, ovulation, dilated cardiomyopathy, acute spinal cord injury, Huntington's disease, Parkinson's disease, glaucoma, macular degeneration, diabetic neuropathy, diabetic nephsopathy and cancer in a mammal. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Patents 167
•
Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells Inventor(s): Miyamoto, Masaomi; (Hyogo, JP), Okawa, Shigenori; (Osaka, JP), Okura, Masahiro; (Osaka, JP) Correspondence: Takeda Pharmaceuticals North America, Inc; Intellectual Property Department; 475 Half Day Road; Suite 500; Lincolnshire; IL; 60069; US Patent Application Number: 20040034049 Date filed: April 1, 2003 Abstract: An agent for promoting the proliferation or differentiation of a stem cell and/or neural progenitor cell, comprising a compound represented by Formula: 1wherein each of R.sup.1 and R.sup.2 is H, a hydrocarbon group or a heterocyclic group, or taken together with the adjacent carbon atom to form a ring, R.sup.3 is H, a hydrocarbon group or a heterocyclic group, W is a group represented by Formula: 2wherein Ring A is an optionally substituted benzene ring, Ring B is an optionally substituted 5- to 7-membered nitrogen-containing heterocyclic ring, R.sup.4 is an acyl group having an aliphatic hydrocarbon group, which is substituted by an aromatic group and may have a further substitutent, or aromatic group, R.sup.5 is H, C.sub.1-6 alkyl or acyl, R.sup.4c is an aromatic group, an aliphatic hydrocarbon group or acyl, andX is O or S;Y is O, S or NH, Ring C is an optionally substituted benzene ring, or a salt or prodrug thereof is provided. Excerpt(s): The present invention relates to an agent for promoting the proliferation or differentiation of a stem cell and/or neural progenitor cell comprising a benzofuran derivative. A neurodegenerative disease is a disease in which a selective neuronal death takes place progressively, and major known neurodegenerative diseases are Alzheimer's disease, Perkinson's disease, amyotropic lateral sclerosis (ALS) and Huntington's disease. A current medication therapy mainly employs a substitution therapy that compensates for the depletion of neurotransmitters accompanying neurodegeneration. A dopaminergic agent such as L-dopa which is a precursor of dopamine is employed to treat Parkinson's disease, while an acetylcholine decomposition enzyme inhibitor is employed to treat Alzheimer's disease, the both being used as a substitution therapy agent or a symptomatic therapy agent. However, such a substitution therapy agent or a symptomatic therapy agent does not suppress the progress of neurodegeneration, and its effect becomes attenuated gradually with progression of the disease. Accordingly, the development of an agent that suppresses the progress of neurodegeneration and promotes the regeneration of the remaining nerve ending is desired. However, currently no agent having such effects has been identified. In addition, it is believed that most of neurocytes have been degenerated at the time of the onset of a neurodegenerative disease, and thus a sufficient functional regeneration is not considered to be achieved only by suppression of degeneration or by promotion of nerve ending regeneration. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
168
•
Benzene
Quinoline and quinazoline compounds useful in therapy Inventor(s): Collis, Alan John; (Sandwich, GB), Fox, David Nathan Abraham; (Sandwich, GB), Newman, Julie; (Sandwich, GB) Correspondence: Pfizer INC.; Patent Department, Ms8260-1611; Eastern Point Road; Groton; CT; 06340; US Patent Application Number: 20030220332 Date filed: June 4, 2003 Abstract: The invention provides compounds of formula (I), 1wherein R.sup.1 represents C.sub.1-4 alkoxy optionally substituted by one or more fluorine atoms; R.sup.2 represents H or C.sub.1-6 alkoxy optionally substituted by one or more fluorine atoms; R.sup.3 represents one or more groups independently selected from H, halogen, C.sub.1-4 alkoxy and CF.sub.3; in addition, R.sup.2 and one R.sup.3 group may together represent --OCH.sub.2--, the methylene group being attached to the ortho-position of the pendant phenyl ring; R.sup.4 represents a 4-, 5- or 6-membered heterocyclic ring containing 1 or 2 heteroatoms selected from N, O and S, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring containing 1 or 2 heteroatoms selected from N, O and S, the ring system as a whole being optionally substituted; X represents CH or N; and L is absent or represents a cyclic group or an open chain group; and the pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful in the treatment of inter alia benign prostatic hyperplasia. Excerpt(s): This invention relates to novel compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia. International Patent Application WO 89/05297 discloses a number of substituted quinazoline compounds which are indicated as inhibitors of gastric acid secretion. or a pharmaceutically acceptable salt thereof (referred to together herein as "the compounds of the invention"). Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Quinoline and quinazoline compounds useful in therapy Inventor(s): Collis, Alan John; (Sandwich, GB), Fox, David Nathan; (New York, NY) Correspondence: Pfizer INC.; Patent Department, Ms8260-1611; Eastern Point Road; Groton; CT; 06340; US Patent Application Number: 20040034032 Date filed: August 13, 2003 Abstract: Compounds of formula I, 1whereinR.sup.1 represents C.sub.1-4 alkoxy optionally substituted by one or more fluorine atoms;R.sup.2 represents an aryl group or a heteroaryl group, optionally substituted by C.sub.1-4 alkyl or SO.sub.2NH.sub.2;R.sup.3 represents a 4-, 5-, 6-, or 7-membered heterocyclic ring containing at least one heteroatom selected from N, O and S, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring containing at least one heteroatom selected from N, O and S, the ring system as, a whole being optionally substituted;X represents CH or N; andL is absent, or represents a cyclic group of formula Ia, 2or represents a chain of formula Ib, 3and pharmaceutically acceptable salts thereof, are useful in the treatment of a variety of disorders including benign prostatic hyperplasia.
Patents 169
Excerpt(s): This application claims priority to U.S. Ser. No. 10/252,852, filed Sep. 23, 2002, now allowed, which is a continuation of U.S. Ser. No. 09/591,195, filed Jun. 9, 2000, now abandoned, which is a continuation of U.S. Ser. No. 09/067,608, filed Apr. 28, 1998, now abandoned, which claims priority to British Application Serial No. GB 9708917.1, filed May 1, 1997. This invention relates to novel compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia. International Patent Application WO 89/05297 discloses a number of substituted quinazoline compounds that are indicated as inhibitors of gastric acid secretion. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Selective hydrogenation of acetylenes and dienes in a hydrocarbon stream Inventor(s): Gelbein, Abraham P.; (Falls Church, VA), Smith, Lawrence A. JR.; (Houston, TX) Correspondence: Kenneth H. Johson; P.O. Box 630708; Houston; TX; 77263; US Patent Application Number: 20030233017 Date filed: March 12, 2003 Abstract: Acetylenes and dienes in a stream containing hydrogen, methane, C.sub.2C.sub.6 olefins and paraffins, C.sub.2-C.sub.6 acetylenes and dienes, benzene, toluene, xylenes, and other C.sub.6+ components are hydrogenated in a downflow boiling point reactor wherein the heat of reaction is absorbed by the liquid in the reactor which produces a vapor. Besides the feed to the reactor there is a recirculating stream which is fed at a rate sufficient to ensure that the catalyst particles within the reactor are wetted. A third stream, which is taken from a downstream distillation column, is fed to provide the make up mass corresponding to the mass evaporated in the reactor. The composition of the this third stream controls the steady state composition of the liquid flowing through the reactor. Excerpt(s): The present invention relates to a process for selectively hydrogenating acetylenes and dienes in a hydrocarbon stream. More particularly the invention relates to the selective hydrogenation of acetylenes and dienes in a hydrocarbon stream containing hydrogen, olefins and smaller amounts of acetylenes and dienes using a downflow boiling point reactor. The vapor product stream from the quench system of a hydrocarbon steam cracker typically consists mainly of hydrogen, methane, C.sub.2C.sub.6 olefins and paraffins, C.sub.2-C.sub.6 acetylenes and dienes, benzene, toluene, xylenes, and other C.sub.6+ components. Separation and recovery of the products according to carbon number is generally accomplished in a sequential distillation system after the first separation of hydrogen from the methane in a high pressure cold box system. The design of the distillation system is complicated by the fact that the differences in relative volatility of the olefins, acetylenes, and dienes of the same carbon number are small making it difficult to produce the pure olefin products. One method of circumventing this problem is to first separate the carbon number fractions and then to selectively hydrotreat each fraction to convert the acetylene and/or diene to its corresponding olefin or paraffin. This so called "back end" approach requires a separate hydrotreating system for each carbon number fraction as well as the addition of a requisite amount of hydrogen to each system. An alternative method is to hydrotreat the feed stream before separation using the contained hydrogen as the source of hydrogen for the conversion. This so-called "front end" approach has the advantage of removing a significant portion of the hydrogen from the feed stream to the cold box thereby reducing the size and refrigeration requirements of the cold box. The present invention
170
Benzene
provides a "front end" hydrotreating system that allows for effective control of the temperature within a bed of catalyst which is hydrogenating acetylenes and dienes in a stream containing hydrogen, methane, C.sub.2-C.sub.6 olefins and paraffins, C.sub.2C.sub.6 acetylenes and dienes, benzene, toluene, xylenes, and other C.sub.6+ components. The invention utilizes a downflow boiling point reactor wherein the heat of reaction is absorbed by the liquid in the reactor which produces a vapor. Besides the feed to the reactor there is a recirculating stream which is fed at a rate sufficient to ensure that the catalyst particles within the reactor are wetted. A third stream, which is taken from a downstream distillation column, is fed to provide the make up mass corresponding to the mass evaporated in the reactor. The composition of the this third stream controls the steady state composition of the liquid flowing through the reactor. The composition of this stream may be controlled by selecting the point from the downstream distillation column from which the stream is drawn. The lower the draw point is in the column, the higher the boiling point of the components in the third stream. The steady state composition of the liquid flowing through the reactor along with the pressure determines the reactor temperature profile. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Silver halide photographic material Inventor(s): Nakamura, Tetsuo; (Kanagawa, JP) Correspondence: Sughrue Mion, Pllc; 2100 Pennsylvania Avenue, N.W.; Washington; DC; 20037; US Patent Application Number: 20040038159 Date filed: September 23, 2002 Abstract: A silver halide photographic material comprising at least one methine dye of formula (I) and at least one coupler of formula (X): 1wherein X.sup.1 and X.sup.2 each represents O, S, Se, Te, N or C; Y.sup.1 represents a furan, pyrrole or thiophene ring which may be condensed and substituted with the specific ring; Y.sup.2 represents an atomic group necessary for forming a benzene ring or a 5- or 6-membered unsaturated heterocycle; R.sup.1 and R.sup.2 each represents a substituted or unsubstituted alkyl, aryl or heterocyclic group; L.sup.1, L.sup.2 and L.sup.3 each represents a methine group; n.sup.1 represents 0 or 1; M.sup.1 represents a counter ion; and m.sup.1 represents a number of 0 or more necessary for neutralizing a charge in a molecule; 2wherein Z.sup.1 and Z.sup.2 each represents --C(Q3).dbd. or --N.dbd.; Q.sup.1 and Q.sup.3 each represents a hydrogen atom or a monovalent substituent group; Q.sup.2 represents a hydrogen atom or a coupling release group. Excerpt(s): The present invention relates to a silver halide photographic material, and particularly to a silver halide photographic material having high sensitivity, decreased residual colors after processing and minor fluctuations in photographic characteristics after continuous processing. Much effort has hitherto been made to enhance sensitivity of silver halide photographic materials and to decrease residual colors after processing. It has been known that sensitizing dyes used for spectral sensitization greatly affect properties of the silver halide photographic materials. In the sensitizing dyes, the slight difference in structure greatly affects the photographic properties such as sensitivity, fog, storage stability and residual coloration (residual colors), and the use of two or more of the sensitizing dyes in combination also greatly affects the photographic properties. However, it is difficult to predict its effect beforehand. Accordingly, many researchers have hitherto made effort to synthesize many sensitizing dyes and to study
Patents 171
the use of many sensitizing dyes in combination, thereby examining their photographic properties. However, it is still impossible to predict the photographic properties in the present circumstances. For the above-mentioned reason, a technique for spectrally sensitizing the silver halide photographic materials at high sensitivity without adverse effects such as fog and residual colors has been desired. When it is desired that the absorption maximum of the sensitizing dye is shifted to the long wavelength side, a naphthazole nucleus has hitherto been widely used in which a benzene ring is further condensed with a benzazole nucleus. However, a recent strong demand toward enhancement in sensitivity increases the amount of the dye added, while a reduction in a processing waste solution for complying with rapid photographic processing and environmental problems must be complied with. A highly hydrophobic dye such as the naphthazole nucleus-containing dye becomes difficult to meet such demands. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Soluble beta amyloid precursor protein secretion promoters Inventor(s): Kakihana, Mitsuru; (Kobe-shi, JP), Kato, Kaneyoshi; (Kawanishi-shi, JP), Mori, Masaaki; (Tsukuba-shi, JP), Yamashita, Toshiro; (Tsukuba-shi, JP) Correspondence: Takeda Pharmaceuticals North America, Inc; Intellectual Property Department; 475 Half Day Road; Suite 500; Lincolnshire; IL; 60069; US Patent Application Number: 20030216398 Date filed: October 4, 2002 Abstract: According to the present invention, there are provided compounds represented by formula (I): 1[wherein R.sup.1 and R.sup.2 represent hydrogen atom, a lower alkyl group, etc.; ring A is an optionally substituted benzene ring, X is oxygen atom, etc.; and Y represents CH or N] or salts thereof, or prodrugs thereof, and use thereof as well as processes of manufacturing these compounds. The compounds of the present invention and the like possess a potent soluble beta amyloid precursor protein secretion promoting activity and suppress the functional disorders or apoptosis of cells, in particular neurons, mediated by the secreted soluble beta amyloid precursor proteins having a neurotrophic factor like property. Excerpt(s): The present invention relates to pharmaceuticals, in particular, soluble beta amyloid precursor protein secretion promoters, which are useful for the treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Down's syndrome, amyotrophic lateral sclerosis, prion disease (Creutzfeldt-Jakob's disease), Huntington's disease, neuropathy (preferably, diabetic neuropathy, etc.), etc., and further neuronal injuries associated with cerebrovascular disorders, as well as pharmaceutical compositions having both soluble beta amyloid precursor protein secretion promoting and apoptosis inhibiting activities, and the like. Drugs that prevent nerve cell death in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, etc. to arrest the diseases have not been developed. Alzheimer's disease is a neurodegenerative disease, which is characterized by the degeneration and loss of neuronal cells accompanied by the formation of senile plaques and neurofibrillary tangles. Senile plaques that are the most characteristic pathological finding of the brain in Alzheimer's disease are extracellular deposits of.beta. amyloid proteins (hereinafter sometimes referred to as A.beta.), which are metabolites of.beta. amyloid precursor proteins (hereinafter sometimes referred to as.beta.APP) (Biochem. Biophys. Res. Commun., 122, 1311 (1984); Proc. Natl. Acad. Sci. USA, 82, 4245 (1985); J. Neurochem., 46,1820 (1986); Neuron, 6, 487 (1991)). It is known that Ap comprised of 40 or 42 amino
172
Benzene
acids is toxic to neurons (Science, 250, 279 (1990); Brain Res., 563, 311 (1991); J. Neurosci. 12, 376 (1992)) and induces neurofibrillary changes (Proc. Natl. Acad. Sci. USA, 90, 77897793 (1993)). Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Sterilizing composition and method for sterilizing using the same Inventor(s): Hiraguri, Katsuko; (Fukushima, JP), Sato, Jun; (Saitama, JP) Correspondence: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.; 1940 Duke Street; Alexandria; VA; 22314; US Patent Application Number: 20030234382 Date filed: December 24, 2002 Abstract: A sterilizing composition for a food-packing material which comprises the following components (1) and (2):(1) an aqueous solution containing peracetic acid, hydrogen peroxide and acetic acid, and(2) a peracetic acid sterilizing power-improving agent comprising one or two or more compounds selected from the group consisting of esters obtained from a C.sub.2-C.sub.8 aliphatic acid and a C.sub.2-C.sub.8 aliphatic alcohol, C.sub.2-C.sub.8 aliphatic alcohols and aliphatic alcohols having a benzene ring. Excerpt(s): The present invention relates to a sterilizing composition usable for sterilizing a food-packing material such as a polyethylene terephthalate packing material, and also relates to a sterilizing method using the same. Examples of an industrial sterilizing method for a polyethylene terephthalate packing material, particularly a polyethylene terephthalate bottle (PET bottle), include a hot packing method and an aseptic packing method. The hot packing method comprises a system of sterilizing a packed content at an ultra-high temperature (UHT) and then packing the content into a container at 85 to 87.degree. C., and examples of pollutant bacteria include bacteria spores derived from a production line or a container. On the other hand, the aseptic packing method comprises a system of sterilizing a packed content at UHT and then packing the sterilized content into a chemically sterilized container under an aseptic environment (NASA Standard Class 100), and examples of pollutant bacteria include chemically tolerable mold or bacteria spores. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Surface coating agents Inventor(s): Swan, Dale G.; (St. Louis Park, MN) Correspondence: Intellectual Property Group; Fredrikson & Byron, P.A.; 4000 Pillsbury Center; 200 South Sixth Street; Minneapolis; MN; 55402; US Patent Application Number: 20040030159 Date filed: July 14, 2003 Abstract: Compounds useful as surface coating agents, including compounds of the formula: 1wherein X.sub.1 comprises a first photoreactive species; X.sub.2 comprises a second photoreactive species; Y comprises a nonpolymeric core molecule comprising an aromatic group; and Z comprises at least one charged group. The Y core can include an aromatic group such as a benzene radical, the charged groups Z can be independently selected from the organic acids that include sulfonic acid, carboxylic acid, and
Patents 173
phosphoric acid, and the photoreactive species of X.sub.1 and X.sub.2 can independently be aryl ketones, such as those selected from the group acetophenone, benzophenone, anthraquinone, anthrone, and anthrone-like heterocycles, and their substituted derivatives. Examples of such coating agents include 4,5-bis(4benzoylphenylmethyleneoxy) benzene-1,3-disulfonic acid di(potassium and/or sodium) salt, 2,5-bis(4-benzoylphenylmethyleneoxy) benzene-1,4-disulfonic acid di(potassium and/or sodium) salt (Compound II), and 2,5-bis(4-benzoylphenylmethyleneoxy) benzene-1-sulfonic acid monopotassium and/or monosodium salt. Excerpt(s): The present application is a continuation of U.S. patent application Ser. No. filed Jun. 25, 2001 and assigned Ser. No. 09/888,709, which is a continuation of U.S. patent application filed Dec. 14, 1999 and assigned Ser. No. 09/460,551, the entire disclosure of which is incorporated herein by reference. The present invention relates to chemical compounds providing both charged groups as well as photoreactive species. In a related aspect, the invention relates to chemical compounds for use as surface coating agents. The chemical modification of surfaces to achieve desired chemical and/or physical characteristics has been previously described. For example, U.S. Pat. Nos. 4,722,906; 4,973,493; 4,979,959; 5,002,582; and 5,512,329 (each of which is commonly owned by the assignee of the invention described herein, and the disclosure of each is incorporated herein by reference), relate to surface modification by the use of latent reactive groups to achieve covalent coupling of reagents such as biomolecules and synthetic polymers to various substrates. The preferred latent reactive group is typically described as a photochemically reactive functional group ("photoreactive species"). When exposed to an appropriate energy source, a photoreactive species undergoes a transformation from an inactive state (i.e., ground state) to a reactive intermediate capable of forming covalent bonds with appropriate materials. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Synthesis for quinacridone compounds Inventor(s): Cosimbescu, Lelia; (Rochester, NY), Shi, Jianmin; (Webster, NY) Correspondence: Paul A. Leipold; Patent Legal Staff; Eastman Kodak Company; 343 State Street; Rochester; NY; 14650-2201; US Patent Application Number: 20040002605 Date filed: June 27, 2002 Abstract: Disclosed is a process for forming a N,N'-diarylquinacridone compound comprising the step of reacting a 1,4-dialkylcarboxylate-2,5-bis(N -arylamino) benzene with an iodoaryl compound to form the corresponding 2,5 -bis(N-diarylamino) compound. The process is versatile and provides high yields and purity for the synthesis of N,N'-diarylquinacridone compounds. Excerpt(s): This invention relates to the field of organic syntheses and to a process for forming a N,N'-diarylquinacridone compound comprising the step of reacting a 1,4dialkylcarboxylate-2,5-bis(N-arylamino) benzene with an iodoaryl compound to form the corresponding 2,5-bis(N-diarylamino) compound. N,N'-diarylquinacridones have become useful materials and have necessitated synthetic methods for preparing them. In U.S. Pat. No. 6,376,107, Heuer et al disclose the preparation of N,N'dialkylquinacridones by contacting unsubstituted quinacridones and alkyl halides with a base such as sodium hydride, in a solvent such as dimethylacetamide or dimethylformamide. This is however not extended to the case of aryl halides. Radl et al,
174
Benzene
in a series of disclosures (Czech patents 262587, and 261338), disclose the reaction of 4oxodihydroquinolines with nitroaryl halides with a base such as sodium hydride in a solvent such as dimethylformamide. The disclosure only teaches the use of aryl halides including nitro groups, and those skilled in the art will realize that aryl halides with other substituents, or no substituents at all, will not react as efficiently in this way. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Toner, and process cartridge Inventor(s): Iida, Hideto; (Shizuoka, JP), Kasuya, Takashige; (Shizuoka, JP), Moribe, Shuhei; (Shizuoka, JP), Ogawa, Yoshihiro; (Shizuoka, JP), Tanikawa, Hirohide; (Shizuoka, JP), Yamazaki, Katsuhisa; (Shizuoka, JP), Yusa, Hiroshi; (Tokyo, JP) Correspondence: Fitzpatrick Cella Harper & Scinto; 30 Rockefeller Plaza; New York; NY; 10112; US Patent Application Number: 20040005509 Date filed: March 20, 2003 Abstract: In a toner having a polyester resin as a binder resin component, and a colorant, the toner contains (a) in the binder resin component, from 20.0% by weight to 65.0% by weight of a tetrahydrofuran-insoluble matter A1 in 6-hour extraction and from 35.0% by weight to 80.0% by weight of a tetrahydrofuran-soluble matter A2 in 6-hour extraction, (b) in the binder resin component, from 10.0% by weight to 30.0% by weight of a tetrahydrofuran-insoluble matter B1 in 16-hour extraction and from 70.0% by weight to 90.0% by weight of a tetrahydrofuran-soluble matter B2 in 16-hour extraction, and (c) in the binder resin component, from 0.5% by weight to 3.0% by weight of an orthodichlorobenzene-insoluble matter C1 in 6-hour extraction at 185.degree. C. and from 97.0% by weight to 99.5% by weight of an orthodichlorobenzene-soluble matter C2 in 6-hour extraction at 185.degree. C. The proportion of C1 to B1, C1/B1, is from 0.06 to 0.15, and the A1, B1 and C1 satisfy the following expression (1):A1>B1>C1. Expression (1)A process cartridge makes use of this toner. Excerpt(s): This invention relates to a toner used in electrophotography, electrostatic recording, toner jet recording and the like, and a process cartridge making use of the toner. Conventionally, as resins for toners, vinyl copolymers (such as styrene resins) and polyester resins are chiefly used. The vinyl copolymers such as styrene resins show superior pulverizability when toners are produced, and have superior high-temperature anti-offset properties because they can be made to have high molecular weight with ease. However, in an attempt to lower molecular weight in order to improve lowtemperature fixing performance, anti-blocking properties and developing performance may come poor. As for the polyester resins, though having high glass transition temperatures, they can readily provide resins having low softening points, and, when melted by heating, have so good wettability to fixing sheets such as paper that the fixing can sufficiently be performed at lower temperatures. On the other hand, however, the polyester resins simultaneously have a disadvantage that they tend to cause a phenomenon of high-temperature offset. For the purpose of providing resistance to such offset, a large number of proposals have been made, e.g., on making molecular weight distribution double-peak, on a polyester resin containing chloroform-insoluble matter as disclosed in Japanese Patent Publication No. 63-60904, and on a polyester resin having THF-insoluble matter as disclosed in Japanese Patent Application Laid-open Nos. 3269542 and No. 4-70765.
Patents 175
Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Transalkylation of aromatic fluids Inventor(s): Benitez, Francisco M.; (Houston, TX), Helton, Terry Eugene; (Bethlehem, PA), Mozeleski, Edmund John; (Califon, NJ), Schlosberg, Richard Henry; (Bridgewater, TX), Silverberg, Steven E.; (Seabrook, TX) Correspondence: Exxonmobil Chemical Company; Law Technology; P.O. Box 2149; Baytown; TX; 77522-2149; US Patent Application Number: 20040006251 Date filed: April 16, 2003 Abstract: A process for making an ethylated polycyclic aromatic compound in a mixed aromatic fluid, the process comprising contacting the mixed aromatic fluid containing a polycyclic aromatic compound and a monocyclic aromatic compound having an ethyl substituent in the presence of an acid catalyst under conditions sufficient to effect transalkylation to form the ethylated polycyclic compound and a de-ethylated monocyclic aromatic compound and removal of the de-ethylated monocyclic aromatic compound. A process for decreasing naphthalene concentration in a naphthalenecontaining aromatic fluid by acid catalyzed transalkylation of an alkylbenzene and naphthalene to form benzene and an alkylnaphthalene. Excerpt(s): The present invention relates to transalkylation of alkylated mononuclear aromatic compounds in the presence of polycyclic aromatic compounds. More particularly, the present invention relates to the selective transalkylation of a mixture of mononuclear aromatic compounds in the presence of a bicyclic aromatic compound. Large-scale refinery production separates crude oil into many fractions one of which is known as virgin naphtha. Virgin naphtha is often reformed to make aromatic naphtha or reformate for motor gasoline blending and chemicals recovery. The fractionation process is often a complex distillation that primarily relies on the difference in the boiling points of the components of the reformate for separation into various fractions. Many of these fractions may contain naphthalene. Consequently, there exists a need for aromatic fluids having a reduced naphthalene concentration and a process for producing aromatic fluids having a reduced concentration of naphthalene. These processes permit naphthalene-containing aromatic fluid and ethylbenzene-containing fluid to be converted into products with enhanced value and to recover by-products for recycling. Additionally, some of the refinery fractions contain a mixture of xylene and ethylbenzene. The xylene comprises at least one of 1,2-dimethylbenzene, 1,3dimethylbenzene and 1,4-dimethylbenzene. Removal of the ethylbenzene from the xylene is desirable, but complicated by the similar boiling points of the xylene and ethylbenzene. The problems of removing naphthalene from aromatic fluids and ethylbenzene from a mixture of xylene and ethylbenzene can be solved by transalkylation of the naphthalene containing aromatic fluid with a mixture of xylene and ethylbenzene under conditions for the selective de-ethylation of ethylbenzene and the ethylation of naphthalene. This results in increased value for a naphthalene-depleted aromatic fluid and for ethylbenzene-deplete xylene. Also this permits the recovery of benzene for recycle into higher value products. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
176
Benzene
Keeping Current In order to stay informed about patents and patent applications dealing with benzene, you can access the U.S. Patent Office archive via the Internet at the following Web address: http://www.uspto.gov/patft/index.html. You will see two broad options: (1) Issued Patent, and (2) Published Applications. To see a list of issued patents, perform the following steps: Under “Issued Patents,” click “Quick Search.” Then, type “benzene” (or synonyms) into the “Term 1” box. After clicking on the search button, scroll down to see the various patents which have been granted to date on benzene. You can also use this procedure to view pending patent applications concerning benzene. Simply go back to http://www.uspto.gov/patft/index.html. Select “Quick Search” under “Published Applications.” Then proceed with the steps listed above.
177
CHAPTER 7. BOOKS ON BENZENE Overview This chapter provides bibliographic book references relating to benzene. In addition to online booksellers such as www.amazon.com and www.bn.com, excellent sources for book titles on benzene include the Combined Health Information Database and the National Library of Medicine. Your local medical library also may have these titles available for loan.
Book Summaries: Online Booksellers Commercial Internet-based booksellers, such as Amazon.com and Barnes&Noble.com, offer summaries which have been supplied by each title’s publisher. Some summaries also include customer reviews. Your local bookseller may have access to in-house and commercial databases that index all published books (e.g. Books in Print®). IMPORTANT NOTE: Online booksellers typically produce search results for medical and non-medical books. When searching for “benzene” at online booksellers’ Web sites, you may discover non-medical books that use the generic term “benzene” (